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The role of adiponectin, a cytokine produced in adipose tissue and its relationship to 
risk factors for the metabolic syndrome, and dietary influences on its production are 
reviewed. The thesis examines the hypothesis that the amount and type of fatty acids in 
the diet affect serum adiponectin concentrations. The effects of ADIPOQ gene locus on 
serum adiponectin concentrations were examined in participants of the RISCK study at 
baseline and following dietary intervention. Major effects of age, BMI, gender and 
ethnicity on serum adiponectin were found. At baseline the ADIPOQ +276 G/T T-allele 
was associated with higher serum adiponectin. The ADIPOQ -10066 G/A A-allele was 
associated with lower serum adiponectin. No influences were observed for the other 
SNPs -7734 C/A or -11391. Participants with the -10066 GG genotype showed a 3.8% 
increase and -10066 A-allele carriers showed a 2.6% decrease in adiponectin (n=360; 
P=0.006) after a high mononounsaturated fat diet. In-10066 GG homozygotes, 
adiponectin increased progressively with age after a high monounsaturated fatty acid 
diet but decreased after a low fat diet. A randomised single-blind parallel study in 
healthy males (n=48) was conducted to investigate the effects on serum adiponectin 
concentration of two formulations of DHA and EPA (3 g/d each) versus placebo 
(refined olive oil) for 6 weeks. Compared to the placebo, neither EPA nor DHA 
changed serum adiponectin concentration. It was concluded that a high 
monounsaturated fatty acid diet has a moderate effect on adiponectin concentration and 
that dietary supplements of long-chain n-3 polyunsaturated fatty acids in healthy 
subjects have no effect on adiponectin concentration. 
. 
Further investigations were conducted to examine the interaction of dietary fatty acid 
intake with peroxisome proliferator-activated receptor (PPAR) genes. A significant 
interaction was found between the habitual dietary polyunsaturated/saturated fatty acid 
ratio and PPARG Pro12Ala genotype on total and LDL cholesterol and plasma 
triacylglycerol concentrations. After a high monounsaturated fat diet, carriages of both 
PPARA Val162 and PPARG Ala12 alleles were associated with a greater reduction in 
plasma LDL-C and its proportion as small dense LDL, than after low fat diet. A 
significant interactions between n-3 LCP treatment and genotypes of PPARA 
Leu162Val SNP were found among 310 participants in the MARINA trial. These 
contributed to a reduction in plasma triacylglycerol concentration with n-3 treatment in 
subjects homozygous for the more transcriptionally active Leu162 allele. The findings 
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4-AA  4-amino-antipyrine  
AA  Arachidonic acid  
ACAT  Acyl:cholesterol acyl transferase   
ACC  Acetyl coenzyme A carboxylase  
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CHO  Carbohydrate  
CI  Confidence interval  
COX1  Cyclo-oxygenases type 1  
COX2  Cyclo-oxygenases type 2 
CPT-1  Carnitine palmitoyl transferase-1  
CV  Coefficients of variance  
CVD  Cardiovascular disease  
DHA  Docosahexaenoic acid  
DHLA  Dihomo-gammalinolenic acid  
DINO  Diet in Nutrients out 
DNA  Deoxyribonucleic acid 
DNTP  Deoxynucleotide triphosphates  
DPA  Docosapentaenoic acid  
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EPA  Eicosapentaenoic acid  
FAS  Fatty-acid synthase 
FATP  Fatty acid transport proteins  
FMD  Flow mediated diameter  
Fox01a  Forkhead box protein 01A  
G6Pase  Gucose-6-phosphatase 
GLUT4  Glucose transporter type 4   
GLUT1  Glucose transporter type 1   
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GM  Geometric mean  
GSK-3  Glycogen synthase kinase 3  
HbA1c  Haemoglobin A1C 
HDL  High density lipoprotein  
HM  High-MUFA  
HMW  High molecular weight adiponectin  
HOMA-IR  Homeostatic model assessment of insulin resistance  
HS  High saturated fat 
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MgCl2  Magnesium chloride 
MUFA  Monounsaturated fatty acid 
NCBI  National Centre for Biotechnology Information  
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NFKB  Nuclear factor-KB 
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PDK  Phosphoinositide-dependent Kinase  
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PI3K  Phosphatidylinositol 3-kinase  
PKB  Protein kinase B 
PKC  Protein kinase C  
PLA2   Phospholipase A2 
PPARα  Peroxisome proliferator-activated receptor alpha   
PPARγ  Peroxisome proliferator-activated receptor gamma 
PPi  Pyrophosphate  
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Adiponectin is a 244 amino acid plasma protein secreted exclusively by adipocytes. 
Adiponectin gene expression is modulated by nuclear peroxysome proliferator receptor 
gamma (PPARγ). Lipids are the physiological ligands for the PPAR family (Xu et al, 
1999). Adiponectin is an insulin sensitising compound with anti-atherogenic, anti-
diabetic, anti-inflammatory functions (Oh et al, 2007). In healthy individuals, 
adiponectin circulates at a high concentration in serum (7.9-11.7 µg/ml) (Liu et al, 
2010). The aim of this thesis was to examine the influence of dietary lipids on 
adiponectin concentrations and variations in the ADIPOQ gene on serum adiponectin 
concentrations. Adiponectin concentrations are negatively associated with human 
obesity and are associated with the development of insulin resistance and the metabolic 
syndrome (Isobe et al 2005; Brochu-Gaudreau et al, 2010). Consequently, the following 
section will describe the metabolic syndrome and its definitions. 
 
 
 1.1 Metabolic syndrome 
The term ‘metabolic syndrome’ was first coined by Reaven in his Banting lecture in 
1988 to describe a cluster of features characterised by obesity (particularly central 
obesity, raised fasting glucose/hyperinsulinaemia, elevated plasma triacylglycerol 
(TAG) and low high density lipoprotein cholesterol (HDL-C) concentrations, 
hypertension, microalbuminuria and gout associated with an increased risk of 
cardiovascular disease (CVD). Most patients with Type 2 diabetes (T2D) have the 
metabolic syndrome and it is often referred to as a prediabetic state. Other clinical 
features associated with metabolic syndrome are impaired fibrinolysis, increased 
procoagulant activity and impaired endothelial function. The current definition of 
metabolic syndrome by the International Diabetes Federation (IDF) has evolved as a 
means of diagnosing people likely to have metabolic syndrome rather than the clinical 
importance of the component features. The earlier definitions by the World Health 
Organization (WHO) (1999) included measures of urinary microalbumin excretion and 
insulin concentrations. The current definition has been simplified and uses lower cut-
offs for blood pressure (BP) and blood glucose (Table 1.1) and includes a measure of 





 and two of the following features: impaired fasting glucose (>5.6 
mmol/L), hypertension or dyslipidaemia (low HDL-C or raised fasting TAG). Obesity, 
physical inactivity and aging are the major factors contributing to the development of 
the metabolic syndrome. However, the risk of developing of metabolic syndrome may 
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be inherited or influenced by early life events particularly the pattern of growth in utero 
and in early postnatal life. 
 
Table 1.1 Definitions of metabolic syndrome; WHO, National Cholesterol Education 
Program’s Adult Treatment Panel (NCEP ATP III) and IDF. From (Alberti et al, 2006) 
 
 
Table 1.2 Ethnic-specific values for waist circumference. From (IDF, 2006) 
Country Ethnic group waist circumference (cm) 
 Men  Women  
Europeans  ≥ 94 ≥ 80 
South Asians  ≥ 90 ≥ 80 
Chinese  ≥ 90 ≥ 80 
Japanese  ≥ 80 ≥ 90 
Ethnic South and Central Americans Use South Asian recommendations until more 
specific data are available 
Sub-Saharan Africans Use European data until more specific data are  
available 
Eastern Mediterranean and Middle East 
(Arab) Populations 
Use European data until more specific data are 
available 
  
WHO, 1999 NCEP ATP III, 
2001 
 IDF, 2005 
Diabetes or IGT or IR, plus two or 
more of the following: 
Three or more of the 
following:  
Central obesity  plus any 
two of the following:  
Obesity: BMI >30 or WHR 
>0.9(M)>0.85(F) 
BMI> 30 or waist 
circumference>102 
cm (M), >88 cm (F) 
Hypertriglyceridemia: 
TAG ≥1.7 mmol/L or 
medication. 
Dyslipidemia: TAG ≥1.7 mmol/L or 
HDL-C <0.9 mmol/L (M), <1.0 mmol/L 
(F) 
Hypertriglyceridemia: 
TAG ≥1.7 mmol/L  
Low HDL-C: <1.03 (M) 
and <1.29 mmol/L (F) or 
medication 
Hypertension: ≥140/90 mmHg or 
medication 
Low HDL-C: <1.03 
mmol/L (M), <1.29 
mmol/L (F) 
High blood pressure: 
≥130/85 mmHg or 
medication 
Microalbuminuria: Albumin excretion 
≥20μg/min or albumin/creatine ratio ≥30 
mg/g 
High BP: ≥130/85 
mmHg.  
High fasting glucose: FPG 
≥ 5.6 mmol/L or previous 
diagnosed diabetes.  
 High fasting glucose: 




1.1.1 Clinical significance and prevalence of metabolic syndrome 
The major health risk of metabolic syndrome is the development of T2D and its 
complications, notably CVD (Zimmet et al, 2001). It is also linked to an increased risk 
of some cancers (WCRF, 2007). 
 
The prevalence of metabolic syndrome in the European population is estimated to range 
between one quarter to one third of the adult male population and between a fifth and a 
quarter of women (Qiao, 2006). Using the NCEP-III definition, the prevalence was 
estimated to be 6.7% among subjects aged 20 through 29 years and 43.5% for 
participants aged 60 through 69 years (Ford & Li, 2008). The prevalence of metabolic 
syndrome has increased markedly with the increase in the prevalence of obesity, as has 
T2D. 
 
It has been predicted that there will be a global epidemic of T2D particularly affecting 
Asia with increasing levels of affluence (Zimmett et al, 2001). All the indices appear to 
indicate that this is occurring (IDF and CDC). 
[http://www.cdc.gov/diabetes/pubs/factsheet11.htm accessed 26/09/2011]. 
 
 
1.1.2 The role of diet in the causation of metabolic syndrome 
Insulin resistance is the central feature of the metabolic syndrome, although not 
necessary for its definition. It appears to arise when excess amounts of fat is stored in 
the wrong place i.e. in muscle or the liver. Obesity, particularly central obesity, is 
strongly related to the risk of developing metabolic syndrome, but not all obese people 
exhibit signs of metabolic syndrome. Regular physical activity appears to be protective. 
Among environmental factors, there is convincing evidence that maintaining a healthy 
weight by balancing energy intake with energy expenditure is central to the prevention 
and treatment of metabolic syndrome (Costacou & Mayer-Davis, 2003). There is 
considerably less certainty regarding the sources of macronutrients, dietary fibre, type 
of fat, added sugars and glycaemic index. 
 
Prospective cohort studies show no consistent association between the source of 
macronutrients and weight gain or weight loss. Neither do intervention trials (Pirozzo et 
al, 2003). The Women’s Health Study noted minimal differences in body weight and the 
risk of heart disease among postmenopausal women given intensive dietary advice to 
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decrease fat intake, as compared with those given no advice over 7.5 years of follow-up 
(Howard et al, 2006). However among participants who lost weight and did not regain 
it, there were improvements in features associated with metabolic syndrome and a 
reduced incidence of T2D. Currently, there is a debate as to whether high carbohydrate 
diets may exacerbate metabolic syndrome by increasing very low density lipoprotein 
(VLDL), TAG synthesis and lowering HDL-C. This is one of the reasons for the 
increased popularity of low carbohydrate diets. Some, but not all, prospective cohort 
studies show carbohydrate intake to be associated with an increased risk of metabolic 
syndrome (Mozaffarian et al, 2011). 
 
Insulin resistance is a condition where normal amounts of insulin are inadequate to 
produce a normal insulin response (Sheng & Yang, 2008). The development of T2D 
initiated by insulin resistance is a multistep process with strong environmental and 
genetic influences (Schinner et al, 2005). The type of fat in experimental animals 
appears to influence insulin resistance, with saturated fatty acids (SFA) increasing 
insulin resistance and long chain n-3 polyunsaturated fatty acids (PUFA) decreasing it. 
The role of monounsaturated fat (MUFA) is less clear. It is believed that fatty acids may 
exert their effects by acting as ligands for nuclear hormone receptors or influencing the 
metabolism of nuclear transcription factors.  
 
Several large randomised controlled trials have evaluated the effects of replacing SFA 
with MUFA on insulin resistance. The Kanwu study (Vessby et al, 2001) was a 
multicentre study comparing a SFA rich diet with a MUFA rich diet on insulin 
sensitivity (Si) using an intravenous glucose tolerance test (IVGTT). It reported a 
modest impairment of insulin sensitivity with the SFA rich diet and no change on the 
MUFA diet; the difference between treatments was of borderline significance 
(P=0.053). The LIPGENE study also used an IVGTT, reported no effect of reducing 
SFA on Si in weight-stable obese subjects with metabolic syndrome (Tierney et al, 
2011). Replacing a high SFA diet (19% of energy) with a high MUFA (20% of energy) 
or a Mediterranean diet (21% of energy) for 8 weeks did not affect insulin sensitivity 
(Bos et al, 2010) using the euglycemic clamp method. The RISCK study, which was a 
multicentre six month dietary intervention study comparing isoenergetic replacement of 
SFA with MUFA in participants judged as being at risk of metabolic syndrome (mainly 
on the basis of waist circumference and fasting insulin) did not influence insulin 
sensitivity measured by IVGTT (Jebb et al, 2010). Consequently, the evidence from 
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dietary intervention studies does not support the superiority of MUFA versus. SFA on 
insulin resistance in healthy and non-diabetic participants.  
 
The evidence with regard to PUFAs and insulin resistance is less clear, particularly with 
regard to dietary sources of EPA and DHA. Some prospective cohort studies (Kaushik 
et al, 2009; Djousse et al, 2011) have found that fish consumption and the intake of 
long-chain n-3 PUFA (LCP)  is associated with an increased risk of T2D. However, the 
LIPGENE study suggests an improvement in metabolic syndrome with supplementation 
with LCP (Paniagua et al, 2011). This is in contrast to the Kanwu (Vessby et al, 2001) 
and OPTILIP studies (Griffin et al, 2006) where no effect on insulin sensitivity was 
seen. 
 
Adiponectin appears to play a key role in the regulation of lipid and carbohydrate 
metabolism and may also have a role in regulating blood flow. Individuals with low 
plasma adiponectin concentrations are at increased risk of developing metabolic 
syndrome and T2D (Oh et al, 2007). The glitazone class of drugs, which are agonists for 
the PPARγ nuclear hormone receptor, promote the synthesis of adiponectin and are able 
to suppress the release of non-esterified fatty acids (NEFA) from adipose tissue, thus 
decreasing hepatic TAG synthesis as well as increasing sensitivity to insulin (Belfort et 
al, 2006). Some derivatives of PUFAs, such as prostaglandin J2, are ligands for PPARγ 
and it is believed that certain fatty acids are the normal biological ligands for PPAR 
receptors (Itoh et al, 2008). The influence of different PUFAs on adiponectin is of much 
interest and the following section describes PUFAs metabolism. 
 
 
1.2 Polyunsaturated fatty acid metabolism 
PUFAs are carboxylic fatty acids with two or more double bonds (Figure 1.1). The 
major dietary source of PUFA is vegetable oil but significant amounts can be provided 
by marine lipids (Figure 1.2). Virtually all of the PUFA in human diets consist of 
linoleic acid (18:2n-6; LA) and alpha-linolenic acid (18:3n-3; ALA) and their longer 
chain derivatives. Plants, but not animals have the ability to insert methylene interrupted 
double at positions 3 and 6 from the terminal methyl group.  Although animals are 
unable to synthesise linoleic and linolenic acid, they can convert them into longer chain 
polyunsaturated fatty acids, typically of 20-22 carbon chain length. These C20-22 LCPs 




Linoleic acid is abundant in main seed oils whereas ALA is less widely distributed. 
Linoleic acid is converted via dihomo-gammalinolenic acid (20:3n-6; DHLA) mainly to 
arachidonic acid (20:4n-6; AA) through alternating desaturation and chain elongation 
reactions. AA and DHLA have important roles as a membrane component as well as 
being a precursor for the major family of eicosanoids (prostaglandins, leukotrienes, 
thromboxanes, prostacyclins) which have regulatory functions both within and between 
cells. AA also gives rise to anandamides which are ligands for the endocanniboid 
receptors, which may interact with the PPAR receptors (Hansen & Artmann, 2008). 
Linoleic acid, however, does have a specific function in maintaining the water 
permeability barrier of the skin as part of acylglycosylceramines and is the preferred 
substrate for making cholesteryl esters used to transport cholesterol in blood (Sanders, 
1988). The minimum requirement for linoleic acid is about 1% of the dietary energy 
intake but optimal amounts are probably closer to 4-5%. Human diets typically provide 
contain 10-15 g of linoleic acid daily about 4-5% of the dietary energy (FAO/WHO, 
2010; EFSA 2010). 
 
The essential role of the n-3 series is less well established but hinges on the conversion 
of ALA to docosahexaenoic acid (22:6n-3; DHA) which is a major component of retinal 
and synaptic membranes. ALA is found in high concentrations of chloroplasts in plants. 
Soybean oil and rapeseed oil are the major dietary sources of ALA but small amounts 
are also provided by milk fat and some nuts. ALA can be converted into 
eicosapentaenoic acid (20:5 n-3; EPA) and DHA in man. The liver is believed to the 
main site of conversion (Burdge & Calder, 2005) but there is evidence that conversion 
occurs within the brain and other tissues i.e. testis. Fish oils are rich in dietary EPA and 
DHA and the consumption of these preformed LCPs has different effects on lipid 
metabolism from ALA (Sanders & Emery, 2003). Requirements for n-3 fatty acids are 
in the range of 0.2%-0.5% of the energy intake provided as ALA is about 0.5 -1 g/d. 
Some recent dietary recommendations have suggested a population intake of 0.25g n-3 
LCP (FAO/WHO 2010; EFSA 2010). 
 
AA, EPA and DHA are transferred preferentially into the sn-2 position of phospholipids 
(Flachs et al, 2009; Kopecky et al, 2009). Different phospholipid species have 
specificity for different PUFA. For example, AA is the dominant PUFA in phosphatidyl 
inositol and DHA is the dominant fatty acid in retinal ethanolamine phosphoglycerides. 
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Phospholipids, besides being important membrane components, act as a substrate for 
chemical messengers, such as eicosanoids C20 LCP cleaved by phospholipase A2 
(PLA2) (Flachs et al, 2009) available for conversion to eicosanoids. AA is the normal 
substrate for cyclo-oxygenases type 1 and 2 (COX-1 and COX-2). EPA does give rise to 
a series of metabolites that are either less active or inactive compared with those derived 
from AA. DHA does not form prostaglandins but like EPA does competitively inhibit 
the formation of prostaglandins from AA.  Eicosanoids derived from n-6 PUFA are 
essential for normal housekeeping functions and are usually synthesised by COX-1 but 
excessive eicosanoid production can be induced in response to inflammation and injury 
via activation of COX-2. In animals, the partial replacement of AA with EPA and DHA 
in membrane lipids decreases the production of eicosanoids and this can modulate 
processes involved in thrombosis and inflammation. Recently discovered metabolites 
called resolvins and neuroprotectins derived from EPA and DHA may possess an anti-
inflammatory effect and provide protection against tissue damage (Flachs et al, 2009; 


































1.2.1 EPA and DHA: effect on lipid metabolism  
EPA and DHA, but not ALA, lower fasting and postprandial TAG concentrations. This 
effect is more marked among individuals with raised plasma TAG associated with 
elevation of VLDL particles by the liver (Harris et al, 2008). One meta-analysis 
reported that the intake of 4g/d of marine omega-3 fatty acids caused a 25-30% 
reduction in TAG, an increase of 5 - 10 % of low density lipoprotein (LDL-C) and a 1 - 
3% increase in HDL-C (Harris, 1997). Both EPA and DHA contribute to the TAG 
lowering effect. Variable effects have been found on LDL-C with a tendency for LDL 
to increase in patients with initially elevated TAG (Sanders, 2009). The mechanism 
which involves EPA and DHA exhibiting their effects on TAG concentrations is mainly 
explained by inhibiting hepatic VLDL-TAG secretion rates and decreasing TAG 
synthesis (Harris et al, 2008). Reduced VLDL-TAG secretion may be due to decreased 
expression of sterol regulatory element-binding protein-1(SREBP-1), which is a 
transcriptional factor involved in hepatic lipogenesis where the synthesis of acetyl-CoA 
carboxylase-1 (ACC1) and fatty-acid synthase (FAS) is stimulated. PUFAs found to 
suppress SREBP-1 expression are mediated through competition with oxysterols to bind 
to LXR, thereby inhibiting the binding of the LXR/retinoid X receptor (RXR) 
hetrodimer (which regulates the expression of SREBP-1) to the LXREs in the SREBP-
1c promoter (Yoshikawa et al, 2002). Competing with LXR will also inhibit the 
expression of SREBP-2, which regulates the genes involved in cholesterol synthesis 
(Davidson, 2006). 
 
Physiological ligands for peroxisome proliferator-activated receptor alpha (PPARα) 
include branched chain and C20-22 fatty acids. Both EPA and DHA are ligands for 
PPARα and this may explain why these fatty acids plasma TAG concentrations 
(Deckelbaum et al, 2006). Activation of PPARα enhances fatty acid metabolism, 
transport and β-oxidation, and suppresses TAG synthesis (Davidson, 2006). Both EPA 
and DHA induce acyl-CoA oxidase gene expression in a PPARα dependent manner in 
rat hepatocytes, (Harris et al, 2008) and suppress phosphatidic acid phosphohydrolase 
(PAP) and acyl-CoA: diacylglycerol hydrolase, which are key enzymes in TAG 
biosynthesis (Harris & Bulchandani, 2006). Fatty acids are weaker ligands for PPARγ 
(Xu et al, 1999). In human adipocytes, EPA and DHA increase lipoprotein lipase (LPL) 
expression possibly as a consequence of PPARγ induction (Khan et al, 2002). A study 
on mice has suggested that DHA, but not EPA may increase circulating adiponectin 
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(Vemuri et al, 2007). However, the effect of DHA versus. EPA on adiponectin 




1.3 Adiponectin  
Adiponectin belongs structurally to the collagen superfamily and is composed of an 
NH2-terminal collagen region and a COOH-terminal C1q-like globular domain 
(Radjainia et al, 2008). In the circulation, adiponectin is present in three oligomeric 
complexes, which have been shown to act though distinct signalling pathways and 
therefore have different biological functions (Figure 1.3).  The trimeric adiponectin, the 
basic building block of adiponectin is also called the low molecular weight adiponectin 
(LMW) isoform (Oh et al, 2007; Tsao et al, 2003). The hexametric adiponectin 
(medium- molecular-mass) isoform is formed through the disulfide bond-mediated self- 
association of two homotrimers. The high molecular weight adiponectin (HMW) is the 
critical form for the biological activity of adiponectin (Oh et al, 2007). 
 
As reviewed by Wang et al. (2008), both in vitro and animal- based studies support the 
role of the HMW as the major active form in mediating the metabolic action of 
adiponectin. It has been established that the HMW adiponectin possesses anti-diabetic 
and anti-atherogenic functions in humans and mice (Kobayashi et al, 2004). It has been 
found that coronary artery disease (CAD) is associated with a reduction in the HMW 
isoform, with either no change or an increase in the hexamer and trimer forms 
(Kobayashi et al, 2004). In 3T3-L1 adipocytes activation of AMPK significantly 
increases the concentrations of HMW adiponectin (Li et al, 2011). Animal studies 
showed that the HMW/total adiponectin correlated closely to hepatic insulin sensitivity 
(Pajvani et al, 2004). Significant weight reduction was also associated with an increase 
in HMW adiponectin, with no changes to the hexamer and trimer forms (Kobayashi et 
al, 2004). In recent studies, HMW adiponectin was associated with TAG/HDL-C, 
TC/HDL-C, LDL-C/HDL-C (Kawamoto et al, 2011), and administering 
thiazolidinediones (TZDs) to diabetic patients increased the serum HMW adiponectin , 





Figure1.3 Schematic model of adiponectin multimerisation. From (Oh et al, 2007) 
 
 
1.3.1 Adiponectin and gender and age 
The sexual differences in adiponectin concentrations has been well reported in humans, 
animals and cultured cells, with males having significantly lower plasma concentrations 
than females (Wang et al, 2008). In male mice, adiponectin concentrations increase 4- 
fold during sexual maturation compared to a 10-fold increase in females (Combs et al, 
2003). The gender differences in plasma concentrations have been attributed primarily 
to the inhibitory effect of testosterone on adiponectin production (Liu & Liu, 2010; 
Wang et al, 2008). In cultured 3T3-L1 adipocytes, testosterone suppresses the secretion 
of adiponectin into the culture media (Nishizawa et al, 2002). Some studies have 
suggested that testosterone maybe involved in the post-transcriptional regulation of 
adiponectin (Combs et al, 2003; Nishizawa et al, 2002). Adiponectin concentrations 
generally increase with age, which may be explained by the changes of sex hormones 
associated with aging (Isobe et al, 2005; Adamczak et al, 2005). As insulin sensitivity 
declines with age, the increase in adiponectin associated with aging may reflect 






1.3.2 Adiponectin receptors 
Adiponectin is involved in the regulation of energy homeostasis and glucose and lipid 
metabolism through acting on two receptors; adiponectin receptor 1 (AdipoR1) and 
adiponectin receptor 2 (AdipoR2). AdipoR1 is the receptor for global and full length 
adiponectin, and almost all is expressed in skeletal muscle. However, AdipoR2 is more 
abundant in the liver and is the receptor for full length adiponectin (Kadowaki & 
Yamauchi, 2005).  
 
Figure1.4 Adiponectin mechanism of action. From (Kadowaki & Yamauchi, 2005)  
 
Adiponectin can activate AMP-activated protein kinase (AMPK), which is a key energy 
sensor that maintains cellular energy homeostasis and PPARα in the liver and skeletal 
muscle (Figure 1.4). In the liver, full fragment adiponectin activates AMPK and 
PPARα via the AdipoR2. AMPK is activated by an increase in the intracellular 
AMP/adenosine triphosphate (ATP) ratio. This down-regulates the enzymes involved in 
gluconeogenesis including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-
6-phosphatase (G6Pase). It also increases the inhibitory phosphorylation of ACC, 
promoting fatty acid oxidation, and inhibits the action of other genes such as SREBP-1 
required for fatty acid synthesis. The activation of PPARα by AMPK decreases the 
TAG content in the liver by stimulating fatty acid oxidation (Kadowaki & Yamauchi, 
2005). In muscle, both full length and globular adiponectin act via the AdipoR1 receptor 
to stimulate fatty acid oxidation and glucose utilisation. AdipoR1 targets genes such as 
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CD36 involved in fatty acid transport, acyl coenzyme A oxidase (ACOD), which is 
involved in fatty acid oxidation, and uncoupling protein-2 (UCP-2) which is involved in 
energy dissipation as heat (Kadowaki & Yamauchi, 2005).  
 
Therefore, as adiponectin increases fatty acid oxidation in the liver and muscles, it leads 
to a reduction in adipose tissue content and a decrease in pro-inflammatory cytokines, 
resulting in insulin signalling no longer being compromised. Insulin not only stimulates 
the production of adiponectin, but in turn, adiponectin sensitises tissues to insulin. The 
following section reviews the metabolic effect of adiponectin.  
 
 
1.3.3 Adiponectin metabolic effects  
1.3.3.1 Insulin sensitivity 
Low adiponectin concentrations are associated with insulin resistance and obesity 
(Whitehead et al, 2006). Insulin resistance may explain its association with low 
adiponectin concentrations, or insulin resistance could be the consequence of a lack of 
adiponectin. The reduction of adiponectin concentration associated with insulin 
resistance could be caused by the disruption of the phosphatidylinositol 3-kinase (PI3K) 
insulin signalling pathway (Figure 1.5), as insulin stimulates adiponectin expression 




Figure1.5 Schematic representation of insulin signalling cascade. Insulin binds to the 
insulin receptors (IR) that activate PI3K through IRS. PI3K activates 
phosphoinositide-dependent Kinase (PDK) that will then mediate the activation of 
both protein kinase C (PKC) and protein kinase B (PKB). PKC can then activate and 
translocate glucose transporter type 4 (GLUT4) which regulates glucose uptake to 
the plasma membrane. PKB can also regulate the latest pathway and the 
transcription of target genes via glycogen synthase kinase 3 (GSK-3) or Forkhead 
box protein 01A (Fox01a). From (Schinner et al, 2005) 
 
Pereira & Draznin (2005) have investigated the effects of insulin on adiponectin 
production. In this study 3T3-L1 mouse adipocytes were treated with increasing 
concentration of insulin. The insulin signalling pathways involved in the regulation of 
adiponectin production were examined by the inhibitors of PI3K and mitogen-activated 
protein kinase (MAPK) pathways. The study revealed that insulin stimulates 
adiponectin secretion in a dose-dependent manner and proceeds via the PI3K-dependant 
signalling pathway, but not via the MAPK pathway. Therefore, low adiponectin 
concentrations in insulin resistance may be explained by the blockage of the PI3K 
dependant pathway observed in insulin resistant states. This is supported by the work of 
Bogan & Lodish (1999), which showed that insulin-stimulated enhancement of 
adiponectin secretion, was blocked by pharmacological PI3K inhibitors. Foxo1 is a 
member of the forkhead transcription factor family and is involved in adipocyte 
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differentiation (Liu &Liu, 2010). Studies have shown that Foxo1-C/enhance binding 
protein (EBP) transcription complex which is enhanced by SIRT1, is critical in 
controlling adiponectin promoter activation and gene expression (Qiao & Shoa, 2006). 
 
Alternatively, increased adiponectin secretion could be the normal physiological 
response to improved insulin sensitivity with increasing adiposity. Adiponectin 
treatment improved insulin resistance in lipotrophic mice (Yamauchi et al, 2001) and 
enhanced insulin sensitivity in male Wistar rats (Satoh et al, 2005). A recent meta-
analysis of human studies showed that higher adiponectin concentrations are linked to a 
lower risk of developing T2D (Li et al, 2009).  
 
Interactions between adiponectin and AdipoR1 increase the activation of PPARα, 
AMPK and p38 MAPK (Yamauchi et al, 2003). APPL1 is recognised as a key player in 
the regulation of insulin sensitivity through the activation of the adiponectin signal 
cascade, and acts as a positive regulator of adiponectin signalling (Deepa & Dong, 
2009). Studies have shown that over-expression of APPL1 increases the 
phosphorylation of AMPK and p38 MAPK by binding to AdipoR1 (Mao et al, 2006). In 
vitro, Wang et al. (2007) provided a molecular mechanism by which adiponectin 
functions as an insulin sensitizer. They reported that adiponectin activates AMPK 
pathways by binding to its membrane receptor AdipoR1 and AdipoR2. This leads to the 
recruitment of the adaptor protein APPL1 and the activation of AMPK signally 
pathway. Activation of AMPK signalling reduces serine phosphorylation of IRS protein 
leading to enhanced IRS tyrosine phosphorylation and insulin signalling (Wang et al, 
2007; Nishida et al, 2007). Adiponectin may also attenuate tumur necrosis factor-α 
(TNF-α) expression and inflammation in adipose tissue, therefore improving overall 
insulin sensitivity (Maury & Brichard, 2010). The following section describes the role 




Obesity is associated with a reduction in serum adiponectin in many, but not all, 
subjects; this phenomenon has been partly attributed to the influence of inflammatory 
cytokines (Behre, 2007). Obesity, particularly which associated with T2D, is also 
characterised by an increased production of a wide range of inflammatory molecules, 
TNFα and interleukin-6 (IL-6) (Ouchi & Walsh, 2007). Butner et al. (2010) have 
suggested that adiponectin is a key mediator of inflammation in adipose tissue. 
 
Attenuation of insulin signalling by pro-inflammatory cytokines would reduce the 
stimulation of adiponectin expression by insulin, leading to low concentrations of 
adiponectin associated with obesity and insulin resistance. Two transcription factor-
signalling pathways have been linked to the pro-inflammatory effects of insulin 
resistance and obesity; c-Jun NH2-terminal kinase (JNK) and nuclear factor- κB (NF- 
κB). These pathways are activated by cytokonase such as TNF-α (Shoelson, 2007). 
TNF-α induced insulin resistance induces the expression of protein tyrosine phosphatase 
(PTP)-1B and mediates serine phosphorylation of the insulin receptor substrate-1 (IRS-
1), which inhibits normal tyrosine phosphoration of IRS-1 and down regulates insulin 
signalling (Chuang et al, 2011), and inhibits insulin stimulated GLUT4 translocation 
(Nohara et al, 2011). Furthermore, this has been shown to phosphorylate PPARγ and 
decrease its deoxyribonucleic acid (DNA) binding activity (Liu & Liu, 2010). 
Adiponectin suppresses TNF-α induced IkBα-NFKB activation through a cAMP– 
dependant pathway (Ouchi et al, 2000). Mitochondrial dysfunction activates ER stress 
and JNK in adipose tissue, which may also explain decreased plasma adiponectin 
concentrations associated with obesity (Koh et al, 2007). 
 
Elevated plasma NEFA, which occurs when body fat is mobilised, produces a defect in 
insulin-stimulated glucose transport and/or phosphorylation caused by a defect in 
insulin signalling (Boden & Chen, 1995). There is no simple relationship between the 
size of body fat stores and plasma NEFA concentrations. There is substantial variation 
between individuals with similar fat stores in their capacity to release NEFA and 
currently there is a limited understanding of the mechanisms that lead to the regulation 
of adipose tissue lipases. Epinephrine, glucagon and adrenocorticotrophic hormones 
stimulate lipolysis whereas insulin appears to suppress hormone sensitive lipase by 
changing is phosphorylation status (Frayn, 2003). Elevated plasma NEFA concentration 
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will lead to the accumulation of acetyl CoA and diacylglycerol, and the activation of 
PKC in liver, skeletal muscle and vascular endothelial cells. This interrupts insulin 
signalling by serine phosphorylation of IRS, resulting in a decrease in tyrosine 
phosphorylation of IRS (Boden, 2008). NEFA also inhibits the GLUT4 translocation to 
the cell membrane, thus disrupting insulin-mediated glucose uptake into skeletal 
muscle. In the liver, NEFA inhibits the insulin-induced suppression of glycogenolysis 
and gluconeogenesis (Gallagher et al, 2010). Therefore, attenuation of insulin signalling 
by elevated NEFA, inflammatory cytokines and mitochondrial dysfunction may 
contribute to the reduction in adiponectin concentrations associated with obesity and 
insulin resistance.  
 
A 5-year follow-up study concluded that changes in body weight are inversely 
correlated with changes in adiponectin concentration (Arawaka et al, 2006). Treatment 
of obesity by either calorie restriction or bariatric surgery increases adiponectin 
concentrations (Yang et al 2001; Appachi et al, 2011). Marked weight-loss induced 
decrease in TNF-α (Dandona et al, 1998), improved insulin sensitivity (Agueda et al, 
2010) and induced adiponectin gene expression (Coughlin et al, 2007). The following 




1.3.3.3 Plasma lipid profile 
It has been reported that adiponectin is negatively correlated with TAG concentrations 
(Hotta et al, 2000) and positively correlated to HDL-C and Apo-A1 (Matsubara et al, 
2002). The mechanism underlying the association between plasma adiponectin and 
dyslipidaemia may be a direct effect of adiponectin on inhibiting hormone sensitive 
lipase rather than an indirect caused by insulin resistance. Insulin is a well-known 
stimulator of adipose tissue LPL activity but is an inhibitor of hormone sensitive lipase 
(Schittmaye & Birner-Gruenberger, 2009). LPL plays a role in lipid metabolism and the 
storage of fat by catalysing the rate-limiting step in the hydrolysis of the TAG 
component present in circulating VLDL and chylomicrons. This reaction provides 
NEFA and 2-monoacylglycerol for tissue utilisation. Decreased adipose tissue LPL 
activity is seen in insulin resistant subjects (Kern, 1997). However, the 
hypertriglyceridaemia associated with metabolic syndrome is due to overproduction of 
VLDL TAG rather than impaired LPL activity, although in some cases i.e. type V 
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hyperlipoproteinaemia, impaired lipolysis is present (Thompson, 2004). The main 
driver for TAG synthesis in the liver is the flux of NEFA from adipose tissue which is a 
consequence of a failure of adipose tissue to suppress lipolysis. The glitazone class of 
drugs which are PPARγ agonists suppress the outflow of NEFA from adipose tissue and 
lower plasma TAG (Belfort et al, 2006). This suggests that adiponectin may have a role 
in regulating adipose tissue lipase. 
 
 
1.4 ADIPOQ gene  
Adiponectin is encoded by the ADIPOQ gene which is located on chromosome 3q27. It 
encodes a protein with similarity to collagens X and VIII and complement factor C1q. 
This gene is exclusively expressed in adipose tissue. It contains 2 introns and 3 exons 
within the region of 17 kb. It is estimated that genetic factors account for 30 to 70% of 
the variability of serum adiponectin concentrations (Menzaghi et al, 2002). The 
translation start point is located in exon 2. The promoter region from −676 to +41 has 
found to be sufficient for basal transcriptional activity, in which there are two elements; 
SREBP and CCAAT/enhancer binding (Gu, 2009), as shown in Figure 1.6.  
  




1.4.1 ADIPOQ polymorphisms 
The ADIPOQ gene is very polymorphic; several single nucleotide polymorphisms 
(SNPs) have been detected. From the known polymorphisms in the National Centre for 
Biotechnology Information (NCBI) and in the literature, 53 SNPs of ADIPOQ have 
been identified (Heid et al, 2006). Some of these polymorphisms have been associated 
with the expression of adiponectin, suggesting their determination of circulating 
concentrations (Yang & Chuang, 2006). Associations were found between +276 G-
allele and lower adiponectin concentrations in the Spanish population, healthy 
Caucasians, nondiabetic Koreans and obese Japanese subjects (Gonzalez-Sanchez et al, 
2005; Mackevics et al 2006; Jang et al, 2005; Hara et al, 2002). An association was also 
reported in healthy young Finnish subjects where the +276 T-allele was associated with 
elevated adiponectin concentrations (Mousavinasab et al, 2006).  
 
Woo et al. (2006) showed a significant association between SNP alleles -11391A, 
+267T and -10066G with higher adiponectin concentrations in White Americans. A 
similar association with -11391 A and +267 T-alleles was found in African Americans. 
They also showed that three SNP haplotypes +45, +276 and +349 T/T/A and T/G/G 
were significantly associated with higher adiponectin in White American, but not 
Africans.  In the same study the strongest association with serum adiponectin was found 
with haplotypes from the promoter through to the second intron SNPs -11391 to +349 in 
White Americans and SNPs -11391 to + 45 in African Americans (Woo et al, 2006). In 
a more recent study, SNP association with adiponectin was tested in two independent 
populations of Caucasian females. In the Chingford cohort (n = 808), the common allele 
of -10066 G/A and the rare alleles of 11391 G/A, -7734 C/A, +276 G/T and +3228 C/T 
were significantly associated with higher adiponectin concentrations. In the Twins UK 
cohort (n = 2718), the same association was found with all SNPs except for +3228 C/T 
(Kyriakou et al, 2008). In the CARDIA study, -10066 G/A, -11391 G/A and +276 G/T 
were strongly associated with serum adiponectin concentrations in White subjects, with 
dose – response relationship of mean adiponectin concentrations across genotypes. This 
study also reported that only -11391 G/A was significantly associated with serum 
adiponectin in African Americans (Wassel et al, 2010) similar association was reported 




Association between ADIPOQ gene variants with metabolic syndrome risk factors has 
been established in many studies. Jang et al. (2005) for example, reported that carriage 
of the +276 G-allele could be a significant contributor to higher CVD risk in Koreans. 
This result seems to contradict an Italian study which reported an increased risk of CAD 
in the carriers of the +276 T-allele (Filippi et al, 2004). More recent studies suggested 
that the +276 T-allele appeared to protect from myocardial infarction and T2D 
(Chiodini et al, 2010) and is associated with a decreased risk of CAD in T2D patients 
(Esteghamati et al, 2011) and +276 G-allele with the presence of hypertension (Leu et 
al, 2011). 
 
Some polymorphisms in the ADIPOQ gene have been shown to be associated with 
some risk factors, such as insulin resistance and glucose intolerance. In a Spanish cross 
sectional study, the G276G genotype was associated with increased risk of impaired 
glucose tolerance (Gonzalez-Sanchez et al, 2005). In a cross sectional study of 413 
healthy Caucasians, +276 T-allele was significantly associated with a lower homeostatic 
model assessment of insulin resistance (HOMA-IR) (Menzaghi et al, 2002). However, 
an adverse effect of +276 T-allele on insulin resistance was found in non-diabetic Greek 
women, who exhibited higher fasting insulin levels and thus higher HOMA-IR 
(Melistas et al, 2009). The +276 G-allele was significantly associated with higher 
HOMA-IR in Koreans (Jang et al, 2005), non-diabetic Italian subjects (Menzaghi et al, 
2002) and Japanese subjects (Hara et al, 2002). Others reported no association between 
ADIPOQ variants and insulin resistance indexes (Vasseur et al, 2002). Some other 
associations with HDL-C, LDL-C and diastolic BP were also reported. Carriers of the 
+276 T-allele have been associated with LDL-C and lower HDL-C concentrations 
(Berthier et al, 2005), elevated diastolic BP (Mousavinasab et al, 2006) and lower 
systolic BP (Menzaghi et al, 2002). Carriers of +276 G-allele were found to have 
significantly higher concentration of TAG (Jang et al, 2005). 
 
Association studies have also demonstrated significant interaction between ADIPOQ 
gene variants and quantitative measurements of obesity. Significant but inconsistent 
associations were found with BMI: the +276 G-allele was associated with higher BMI 
in Italian subjects (Menzaghi et al, 2002) but with lower BMI in Swedish women and 
African Americans (Ukkola et al, 2003; Beebe-Dimmer et al, 2010). A recent meta-
analysis, suggested that the ADIPOQ G276T is associated with obesity susceptibility 
43 
 
(Yu et al, 2011). Higher WHR was found in carriers of the -11391 A-allele (Dolley et 
al, 2008). 
 
The inconsistencies in the results may be attributed partly to differences of the racial 
composition of the populations; differences in the frequencies of SNPs between races 
could be due to different patterns of Linkage disequilibrium (LD) (Wassel et al, 2010). 
The presence of co-morbidities in the study populations could largely explain such 
controversy. Age and environmental factors (food intake, fatty acid composition of the 
diet), may differ significantly between study populations, thus leading to this 
inconsistency (Ntalla et al, 2009). Therefore, the following section reviews the effect of 
diet on adiponectin concentrations. 
 
 
1.4.2 Adiponectin, ADIPOQ polymorphisms and diet 
1.4.2.1 Adiponectin concentration and diet  
A study on Japanese men has reported that adiponectin concentrations are 
independently related to dietary factors, smoking and physical activity (Tsukinoki et al, 
2005). Diets low in glycaemic load and high in fibre have been significantly associated 
with high adiponectin concentrations in diabetic men (Qi et al, 2005) and healthy 
women (Yannakoulia et al, 2008). Pischon et al. (2005) also reported that high 
glycaemic load is associated with lower adiponectin concentrations whereas moderate 
intake of alcohol was found to be associated with high adiponectin concentrations. 
Following a high saturated fat diet Van Dijk et al. (2009) reported that ADIPOQ 
expression and serum adiponectin concentrations were significantly decreased. 
Adherence to the Mediterranean diet for 2 years along with increasing physical activity 
decreased BMI and increased adiponectin concentrations in postmenopausal obese 
women (Esposito et al, 2003), diabetic women (Mantzoros et al, 2006) and in healthy 
adults (Fragopoulou et al, 2010). Women from the Nurse’s Health Study, with the 
highest adherence to healthy eating patterns had 23% higher adiponectin concentrations 
than those with the lowest adherence (Fargnoli et al, 2008). Other reported a negative 
correlation between adiponectin concentrations and the consumption of trans fatty acids 
and a positive correlation with vegetable consumption (Cassidy et al, 2009).  
 
EPA and DHA have been reported to increase plasma adiponectin concentrations 
through stimulation of ADIPOQ gene expression in adipocytesin mice (Flachs et al, 
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2006). Similarly, Todoric et al. (2006) reported that 6 weeks of omega-3 
supplementation significantly increased adiponectin concentrations in diabetics and 
non-diabetics rats. Human studies have shown that 24 weeks supplementation of a low-
fat/high carbohydrate diet with EPA + DHA in overweight insulin-resistant women  
resulted in beneficial effects on improved risk factors associated with CVD and 
improved adiponectin concentrations (Krebs et al, 2006). Many animal studies have 
demonstrated that EPA and DHA intake result in a significant increase in adiponectin 
concentrations (Hassanali et al, 2010; Kuda et al 2009; Duda et al, 2009; Higuchi et al, 
2008). EPA alone increases adiponectin concentrations in patients with coronary 
stenoses (Rasmussen et al, 2009) and in obese Japanese (Satoh et al, 2009).  
 
In vitro, the independent action of EPA and DHA in 3T3-L1 adipocytes was 
investigated. Both EPA and DHA increased adiponectin secretion, however, this 
increase was 40% more with DHA treatment compared to EPA. Only DHA enhanced 
PPARγ and adiponectin mRNA expression compared with the control (Oster et al, 
2010). The same group later reported that the effect of EPA on adiponectin does not 
appear to be entirely PPARγ mediated. In their study, they cultured human adipocytes 
with DHA or EPA. Both these significantly increased adiponectin concentrations by 88 
% and 47 %, respectively. However, PPARγ antagonism fully abolishes the DHA-effect 
on increased adiponectin secretion, but only partially attenuated the EPA-mediated 
response (Tishinsky et al, 2011). Furthermore, DHA but not EPA may reduce insulin 
resistance in mice, which may be mediated through an increase in circulating 
adiponectin through PPARγ activation (Vemuri et al, 2007). As far as could be 
ascertained, no studies have compared the effects of supplementation with EPA versus. 
DHA on adiponectin concentrations 
 
 
1.4.2.2 ADIPOQ polymorphisms and diet 
Some studies have explored the influence of ADIPOQ gene polymorphisms on serum 
adiponectin in response to dietary factors. In a population of healthy Greek children, the 
+276 G/T x fibre interaction was significantly associated with adiponectin 
concentrations. The +276 G/G homozygotes subjects had significantly higher 
adiponectin concentrations compared to +276 T-allele carriers under conditions of low 
fibre intake (Ntalla et al, 2009). Chang et al. (2009) determined the effect of +276 G/T 
on adiponectin concentrations and HOMA-IR after 12 weeks intervention (replacement 
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of refined rice with whole grains, a high intake of vegetables and regular exercise) in 
overweight-obese patients with impaired fasting glucose or newly diagnosed T2D. After 
a 12-week trial, both serum glucose and HOMA-IR were reduced in G-allele carriers of 
+276, however, no differences were found in adiponectin concentration.  
 
A study in US Whites, demonstrated that in the highest 50
th
 percentile of MUFA intake, 
carriers of the minor allele at the ADIPOQ -11391 G/A had a lower BMI and a 48% 
reduction in the risk of obesity compared with G/G homozygotes. No interaction was 
found in the lowest 50
th
 percentile of MUFA intake (Warodomwichit et al, 2009). 
Perez-Martinez et al. (2008) found on a high MUFA diet, the C/C homozygous men for 
the -11377 were significantly less insulin resistant, compared to a high SFA diet. No 
dietary interactions were found with the -11391 G/A, +45 T/G and +276 G/T variants in 
determining other variables. In a recent study, an interaction between ADIPOQ -11377 
C/G genotype with SFA, but not MUFA or PUFA, significantly affected HOMA-IR. 
However, there were no significant effects on serum adiponectin concentration 
(Ferguson et al, 2010). There is still a limited number of studies looking at the diet-gene 
interaction with ADIPOQ variants. The ADIPOQ expression is induced by PPARγ 





1.5 Peroxisome proliferator-activated receptor γ 
The peroxisome-proliferator activated receptors (PPARs) are transcriptional regulators 
of cellular differentiation, development and lipid metabolism, activated by unsaturated 
fatty acids (Walczak & Tontonoz, 2002). One of the most studied isoforms of the PPAR 
family is PPARγ. It is a transcription factor that is a member of the nuclear hormone 
receptor superfamily (Lehrke & Lazar, 2005), which has been of particular interest 
because of its dominant role in the control of the expression of genes related to 
inflammation, adipose cell differentiation, atherosclerosis, metabolism and cancer 
(Costa et al, 2010).  
 
PPARγ controls biological functions by controlling the expression of specific genes, 
mainly in a ligand-dependant manner (Lehrke & Lazar, 2005). Ligands occur either 
naturally or in synthetic form. Natural ligands include linolenic, EPA, DHA and AA, as 
well as prostaglandin (Xu et al, 1999). The synthetic ligands include TZD, non-steroid 
and anti-inflammatory drugs (Lehrke & Lazar, 2005). 
 
 
1.5.1 Role in adipogenesis 
PPARγ2 regulates adipocytes differentiation and may serve to link the process of 
adipocytes differentiation to systemic lipid metabolism (Tontonoz & Spiegelman, 
1994). PPARγ2 deficient mice have exhibited a reduction in white adipose tissue 
(WAT), decreased expression of adipogenic genes and lower lipid accumulation in 
adipose tissue, while insulin sensitivity has also been found to be  dramatically impaired 
(Zhang et al, 2004). Meanwhile, the expression of IRS-1 in PPARγ2 deficient mice was 
significantly reduced in WAT, liver and skeletal muscle. Moreover, in these mice, the 
expression level of GLUT4 in skeletal muscle was also dramatically decreased (Zhang 
et al, 2004).  
 
As reviewed by Lowell (1999). One of the adipocyte-specific genes is adipocyte-
specific fatty acid–binding protein gene (ap2), which has binding sites for the two major 
adipogenic transcription factors: CCAAT/enhancer binding protein-α (C/EBPα) and 
PPARγ. During the early stages of adipocytes differentiation, C/EBPβ and C/EBPδ are 
induced and thought to in turn induce expression of PPARγ and C/EBPα, culminating in 
the terminal differentiation of adipocytes (Lowell, 1999; Walczak & Tontonoz, 2002). 
PPARγ activity will further increase through ligands such as PUFA. This will further 
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induce C/EBPα and also increase its own expression (Lowell, 1999). Another 
transcription factor associated with adipocyte differentiation and cholesterol 
homeostasis is adipocyte differentiation and determination factor 1/SREBP-1 (ADD-
1/SREBP-1), found to induce PPARγ mRNA levels  in 3T3 –L1 and HepG2 cells and 
therefore regulate different pathways of lipid metabolism (Fajas et al, 1999). 
 
 
1.5.2 Role in insulin sensitivity 
Activation of PPARγ increases GLUT1 and GLUT4 expression and lowers NEFA 
levels. It also enhances insulin signalling pathway by upregulating protein levels of IRS 
(Smith, 2001) and increasing the expression of c-Cbl-associated protein (CAP) which is 
a signalling protein that may be involved in the insulin-stimulated tyrosine 
phosphorylation of c-Cbl (Ribon et al, 1998; Gurnell, 2003). Incubating human 
adipocytes with rosiglitazone significantly increased the p85 subunit of PI3K, which is a 
major component of insulin action and UCP-2 mRNA levels and enhanced GLUT4 
expression (Rieusset et al, 1999; Gurnell, 2003). On the other hand, treating 3T3-L1 
cells with artepillin C, a PPARγ ligand had no effect on the insulin signalling cascade, 
but enhanced the expression and plasma membrane translocation of GLUT1 and 
GLUT4 and adipocyte differentiation (Choi et al, 2011). 
 
 
1.5.3 Role in lipid homeostasis 
PPARγ can modulate lipid homeostasis through the regulation of genes, including 
acyl:cholesterol acyl transferase  (ACAT), LPL, phospholipiase A (PLA), aP2, and the 
fatty acid transport proteins (FATP) and CD36 (Walczak & Tontonoz, 2002). The TZD 
class of drugs, which are PPARγ agonists, decrease plasma NEFA and TAG and 
increasing HDL-C (Boyle et al, 2002; Belfort et al, 2006, Komatsu & Node. 2010) 




1.6 PPARG gene 
The human PPARG gene is located on chromosome 3 at position 3p25 (Ackert-
Bicknell& Rosen, 2006). The PPARG gene includes 9 exons and exceeds 100 kb in 
length. It measures 146,483 base pairs in length, translating into 476 amino acids. Four 
different subtypes of PPARγ mRNA (-γ1,-γ2,-γ3 and -γ4) transcribed from four 
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different promoters have been identified, which give rise to two different PPARγ 
proteins (Zieleniak et al, 2008) as shown in Figure 1.7. The transcription from promoter 
– γ1, - γ3 and- γ4 mRNA results in a PPAR- γ1 protein of 477 amino acids. The PPAR- 
γ2 protein of 505 amino acids is produced by transcription from promoter γ2 (Zieleniak 
et al, 2008), exclusively expressed in adipose tissue (Lehrke & Lazar, 2005). 
 
 
Figure1.7 Scheme of the genomic structure of the human PPARG gene and the 
structures of the PPARγ protein isoforms. From (Zieleniak et al, 2008) 
 
 
1.6.1 PPARG Pro12Ala polymorphism 
Since PPARγ is involved in the regulation of several genes in many tissues, genetic 
variation of the PPARG gene is likely to be associated with an alteration of the 
expression levels of target genes (Costa et al, 2010). The most widely studied SNP 
amongst the PPARG genes is Pro12Ala, which occurs in the PPARγ2 isoform and is 
located in codon 12 of exon 3. It involves a C-to-G base substitution, resulting in a mis-
sense mutation in which proline is replaced by alanine (Tellechea et al, 2009). This 
polymorphism was first identified in 1997, with rare allele frequencies of 12% in 
Caucasians, 4 % in Japanese and 1 % in Chinese (Stumvoll & Haring, 2002). The 
frequency of the minor allele is 0.076 in Europeans (http://www.ncbi.nlm.nih.gov/snp; 




Numerous studies have investigated the association of this polymorphism and the risk 
of obesity and diabetes; however, the results are still very controversial. A recent meta-
analysis of 41 studies, including 30,612 subjects, reported a protective effect of the 
Ala12-allele against T2D. This study found a significant association between the Ala12- 
allele and the lowest risk of T2D, greater insulin sensitivity and lower serum insulin in 
overweight Caucasians, however no association was found in non-Caucasians 
(Huguenin & Rosa, 2010). Similarly, Radha et al. (2006) found that the Ala12-allele did 
not protect against T2D in South Asians but did protect Caucasians. Altshuler et al, 
(2000) reported a significant 1.25 fold increase in diabetes risk associated with the more 
common allele Pro12 in Caucasians and Asians. A protective effect of the Ala12-allele, 
lowering the risk of T2D, was also reported in non-obese Type 2 diabetic patients (Deeb 
et al, 1998) and in normoglycaemic and Type 2 diabetic subjects (Chistiakov et al, 
2010; Ereqat et al, 2009; Meshkani et al, 2007). However, a meta-analysis of 57 cohorts 
in subjects with normal or impaired glucose tolerance suggested no significant effect of 
the Pro12Ala on diabetes-related traits across all studies; this meta-analysis reported a 
protective effect of the Ala12-allele carriers and insulin sensitivity only on selected 
subgroups, such as Caucasians and obese subjects (Tonjes et al, 2006).  
 
Since PPARγ plays a key role in adipocyte differentiation, the influence of the Pro12Ala 
on obesity measures has been of major interest, despite being extremely subtle. In lean 
individuals, the Ala12-allele has been associated with reduced risk of obesity (Deeb et 
al, 1998) but with increased risk of weight gain in a large cohort of White obese British 
(Masud & Ye, 2003). This was supported by Tonjes’s meta-analysis, where amongst 
Caucasians, Ala12-allele carriers had greater BMI (Tonjes et al, 2006). This association 
was also found in the Québec Family Study, where Ala12-allele carriers had higher 
BMI, waist circumference and fat mass (Robitaille et al, 2003). A recent meta-analysis 
suggested that the interaction is greatly influenced by ethnic background as Pro12Ala 
polymorphism frequency is known to vary with ethnicity, with Caucasians having a 
higher frequency of the Ala12-allele compared with various types of Asian population 
(Gouda et al, 2010). Other influences could be the interaction with environmental 
factors, such as diet and genetic background, i.e., the interaction effect of the Pro12Ala 
polymorphism with Trp64Arg polymorphism in the β3-adrenegic receptor, which has 




Some studies have investigated the association between Pro12Ala and adiponectin 
concentrations. Yamamoto et al. (2002) reported that serum adiponectin concentrations 
were significantly increased in subjects with the Pro/Ala genotype compared with the 
Pro/Pro genotype in Japanese subjects. This association was also reported in Finnish 
men, in which the Ala12-allele variant was associated with elevated adiponectin 
concentrations (Mousavinasab et al, 2005). In contrast, Takata et al. (2004) found that 
Pro12Ala substitution is associated with reduced serum adiponectin concentrations in 
young Japanese men. There was no such association reported in healthy Europeans, 
Asian Indians, healthy women or women with polycystic ovary syndrome (Thamer et 
al, 2003; Radha et al, 2007; Orio et al, 2004).  
 
A recent meta-analysis investigated the association of Pro12Ala polymorphism with 
TC, LDL-C, HDL-C and TAG (Huang et al, 2011). The results of this suggested that 
Ala12-allele carriers have significantly increased total cholesterol (TC) in males and 
increased HDL-C in healthy subjects. They also found that Ala/Ala homozygote 
Caucasians have lower blood TAG compared with Pro/Pro homozygotes, which 
supports findings in the Spanish population, where a protective effect of the Ala12-
allele in lowering total TAG concentrations (Gonzalez Sanchez et al, 2002). Conflicting 
results were reported by Beamer et al. (1998), who found a protective effect of the 
Pro12-allele in lowering TAG and increasing HDL-C concentrations in male subjects. 
Similarly Hamada et al. (2007), reported significantly higher serum TAG concentrations 
and a large area in small dense LDL (sdLDL) in Ala12-allele carriers, compared with 
Pro/Pro homozygotes. Ereqat et al. (2009) and Mori et al. (2001) also reported an 
increase in TC in Ala12-allele carriers. Other studies have reported no association 
between Pro12Ala and plasma lipids concentrations (Ringel et al, 1999; Meshkani et al, 
2007). In a recent case control study, Ala12-allele was associated with reduced risk of 
CAD in Italian population (Galgani et al, 2010)  
 
The direct effect of this polymorphism was reported in functional studies, which have 
stated that Ala12-allele variants present a decreased binding affinity to peroxisome 
proliferator response element (PPRE) and thus reduced transactivation ability both in 
TZD-induced adipogenesis and a luciferase reporter gene assay (Masugi et al, 2000; 
Deeb et al, 1998). Both reports suggest that Ala variants may contribute to the 
variability in adipose tissue formation and insulin sensitivity in the general population. 
The following section will review the influence of dietary ligands on PPARG Pro12Ala. 
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1.6.2 PPARG Pro12Ala polymorphism and diet 
As previously mentioned, PPARγ-2 is a ligand-dependant nuclear receptor, which 
promotes adipocyte differentiation and TAG storage. Fatty acids are known natural 
ligands of PPARγ. However, their affinity depends largely on their chain length and 
degree of saturation (Xu et al, 1999). Thus the metabolic impact of this polymorphism 
is potentially dependent on gene-environmental interactions. 
 
Results from the Québec Family Study have indicated that total fat intake was positively 
associated with increased waist circumference in Pro/Pro homozygotes but not in 
Ala12-allele carriers (Robitaille et al, 2003). Similar observations were observed with 
BMI and total fat intake in Pro/Pro homozygotes but not in Ala12-allele carriers 
(Memisoglu et al, 2003). Luan et al. (2001), examined the interaction between 
polyunsaturated: saturated fat (P:S) and Pro12Ala polymorphism in 592 non-diabetic 
Caucasians. No significant association between either fasting insulin or BMI and the 
Pro12Ala polymorphism was found when dietary fat intake was not considered. 
However, when the P:S ratio was considered, a negative association was found between 
both fasting insulin and BMI and the P:S ratio in Ala12-allele carriers, but not in 
Pro/Pro homozygotes. Heikkinen et al. (2009) generated a knock-in mouse model for 
this variant. They demonstrated that on a chow diet, Ala/Ala mice are leaner, have 
improved plasma lipid profiles and insulin sensitivity, together with a longer life span 
than Pro/Pro mice. A three-month course of fish oil supplements (3.6g of n-3 LCP) 
significantly decreased serum TAG in healthy Ala12-allele carrier subjects but not in 
Pro/Pro homozygotes. This study found no difference in heparin plasma LPL activity 
following fish oil supplementation (Lindi et al, 2003). 
 
The Pro12Ala polymorphism responses were compared in a three year longitudinal trial 
of 522 subjects with impaired glucose tolerance randomized to either an intensive diet 
(lowering intake of dietary fat) and exercise group or control group. In the intervention 
group, individuals with the Ala/Ala lost more weight than Pro/Pro (Lindi et al, 2002). In 
a more recent study, the effect of Pro12Ala polymorphism in relation to adiposity was 
investigated in 774 high risk subjects on a Mediterranean diet over two years. After two 
years, the Ala12-allele carriers in the control group had higher waist circumference. 
However, this adverse effect was reversed among Ala12-allele carriers allocated to the 
Mediterranean diet (Razquin et al, 2009). The same effect was reported by a prospective 
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cohort study of 3,075 older adults, investigating the association between Pro12Ala, food 
patterns and body composition. Food intake was assessed with a semi-quantitative food 
frequency questionnaire: participants following a healthy diet characterised by a higher 
intake of low-fat dairy products, whole grains, fruit, vegetables, poultry and fish have 
significantly lower levels of adiposity in male Ala12-allele carriers but this was not the 
case for Pro/Pro homozygotes (Anderson et al, 2010). These studies suggest that Ala12-




1.6.3 ADIPOQ and PPARγ  
PPARγ agonists such as TZD have been clearly shown to increase serum adiponectin 
concentrations in both human and rodents (Iwaki et al, 2003). Both natural ligands such 
as PUFAs and artificial ligands such as TZDs enhanced the expression of adiponectin 
mRNA in adipose tissue and dramatically increased the plasma concentration of 
adiponectin (Maeda et al, 2001). The mechanism involves a functional PPRE and a 
responsive element of liver receptor homolog-1 (LRH-1) both located in the human 
adiponectin promoter (Iwaki et al, 2003). ADIPOQ gene expression is induced by 
PPARγ ligands via the direct binding to PPARγ/RXR heterodimer to the PPRE in 
adiponectin promoter. LRH-1 also binds to LRH-R, enhancing the transactivation of 
adiponectin promoter, thus enhancing the production and secretion of adiponectin from 




1.7 Peroxisome proliferator-activated receptor α 
PPARα is another member of the group of nuclear receptors that regulate key proteins 
involved in inflammation, fatty acid oxidation, lipoprotein metabolism (Vallim & Salter, 
2010), extracellular lipid metabolism and haemostasis (Yoon, 2009). It is mostly 
expressed in tissues with high levels of fatty acid oxidation, such as liver and muscle 
(Auboeuf et al, 1997), and it regulates target genes involved in the transportation and 
oxidation of fatty acids (Aoyama et al, 1998). The cytochrome P450 system, which is 
induced to metabolise foreign compounds including some lipids, is capable of producing 
PPARα ligands (Ng et al, 2007). PPARα ligands include exogenous lipid-lowering drugs 
such as clofibrate, fenofibrate and endogenous fatty acids, which include branched chain 
saturated (such as phytanic acid) and C20-22 unsaturated fatty acids (such as erucic acid 
22:1n-9) (Yoon, 2009; Corton et al, 2000). In the case of erucic acid, peroxysomes are 
induced to enable the microsomal chain shortening of erucic acid to 18:1 so that it can 
form carnitine esters and be translocated into the mitochondria for beta-oxidation (Clouet 
et al, 1982).  
 
Like PPARγ, ligand-activated PPARα heterodimerises with RXR-α before binding to 
target gene promoters (Zieleniak et al, 2008), which usually contain one or more PPREs 
(Chu et al, 1995). In addition, PPARα transactivation is modulated by cofactors or 
corepressors (Yoon, 2009), which in the absence of a ligand inhibit its activity (Pyper et 
al, 2010). Studies have also found that PPARα can modulate its own expression (Corton 
et al, 2000; Pyper et al, 2010; Pineda et al, 2002) and transcriptional activity is also 
regulated by phosphorylation, which stabilizes its binding to the PPRE (Yoon, 2009). 
Studies in mice have shown that PPARα deficiency results in late-onset obesity (Costet et 
al, 1998) and the disruption of lipid metabolism (Djouadi et al, 1998). 
 
 
1.7.1 Role in lipid homeostasis 
In the liver, fibrate agonists of PPARα enhance FATP and acyl coenzyme synthetase 
(ACS) which generates fatty acyl-CoA, carnitine palmitoyl transferase-1 (CPT-1) 
essential for facilitating the entry of fatty acyl carnitine into mitochondria, and genes 
involved in mitochondrial β-oxidation (Staels et al, 1998). Other genes involved in 
peroxisomal (Coleman et al, 2002, Jia et al, 2003) and microsomal β-oxidation (Reddy 
& Hashimoto, 2001) are tightly regulated by PPARα.  
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Clofibrate (an amphipathic carboxylic acid) was one of the first drugs to be shown to be 
a ligand for the PPARα receptor. PPARα activates cytochome P450 enzymes mainly in 
the liver that are able to adapt to oxidize fatty acids that are unable to be oxidized within 
the mitochondria. The cytochrome P450 enzymes clusters generated hydrogen 
peroxides and so were called peroxysomes (Wray et al, 2009). Prior to the discovery of 
PPAR receptors, clofibrate had been shown using radioisotope tracer studies in man to 
decrease hepatic TAG synthesis and VLDL secretion, thus lowering TC and TAG. Its 
use as a drug fell out of favour when it was shown to have toxic side effects on the liver. 
Other fibrate compounds have been developed that do not show this hepatotoxic effects 
and their lipid lowering effects have been reviewed by Shah et al. (2010). Some of these 
had effects on stimulating LPL and apoC-III expression (Lemieux et al, 2003). PPARα 
induces LPL gene transcription (Vallim & Salter, 2010; Staels et al, 1998) and represses 
the expression of apoC-III, a natural inhibitor of LPL activity (Lemieux et al, 2003), 
which further enhances LPL-mediated catabolism of VLDL production (Staels et al, 
1998). PPARα activation decreases mRNA concentration of fatty acid synthase (FASN), 
resulting in reduced synthesis of TAG (Jia et al, 2011). Hogue et al. (2008) reports that 
fibrate increases triacylglycerol rich lipoprotein (TRL) Apo B-48 as well as VLDL Apo 
B-100 clearance in T2D mellitus men with marked hypertriglyceridemia.  
 
The FIELD study showed that in T2D subjects, fibrate treatment enhanced the 
transcription of Apo A-1, leading to increased Apo A-1 production (Taskinen et al, 
2009). Therefore, PPARα activation by fibrates and other ligands, evokes a 
normolipidaemic response by reducing TRL, LDL-C and VLDL production, increasing 




1.8 PPARA gene 
The human PPARA gene has been mapped to the chromosomal region 22q12-q13.1. It 
spans 83.7 kb and is composed of 8 exons. The PPARA gene is highly polymorphic and 
contains 15 coding SNPs (http://www.ncbi.nlm.nih.gov/snp; build 132 accessed 
15/12/10). PPARA1 and PPARA2 are two isoforms of the PPARA gene and both are 
expressed in human tissue (Golembesky et al, 2008). PPARA1 encodes the entire 
region, whereas PPARA2 is truncated at exon 6 and lacks at least 200 base pairs. This 
results in a frame shift introducing a premature stop codon 3’ of the deletion 
(Golembesky et al, 2008; Gervois et al, 1999). This truncation leads to the absence of 
the DNA-binding domains and parts of the hinge region, which prevents activation by 
the ligand (Gervois et al, 1999). Therefore, all studies have investigated the PPARA1 
isoform because of its known protein activity (Golembesky et al, 2008). 
 
 
1.8.1 PPARA Leu162Val polymorphism 
Several polymorphisms have been found in the human PPARA gene, one of which 
being a C→G transversion in axon 5 at position 484 which leads to a substitution of 
valine for leucine at codon 162 (Leu162Val) (Tai et al, 2002). The frequency of the 
minor allele (Val162) is 0.042 in Europeans (http://www.ncbi.nlm.nih.gov/snp; build 
132 accessed 15/12/10). 
 
Many studies have examined the role of PPARA Leu162Val polymorphism in the 
variability of lipids and apolipoprotein concentrations. The minor allele Val162 has 
been associated with higher concentrations of Apo B and LDL-C (Vohl et al, 2000; Tai 
et al, 2002;Tanaka et al, 2007); HDL-C; Apo A1 (Flavell et al, 2000); apoC-III (Tai et 
al, 2002); higher serum TAG; lower HDL-C concentration, and higher subcutaneous fat 
volume in White males (Uthurralt et al, 2007), with lower BMI in subjects with T2D 
and healthy controls (Evans et al, 2001). The Val162 has also been associated with 
higher TC: HDL-C, and TAG: HDL ratios (Manresa et al, 2006); higher TAG and 
apoC-III in African Americans, but not Caucasians (Shin et al, 2008) and with lower 
TAG concentrations (Nielsen et al, 2003). The Val162Val homozygotes have 
significantly higher TC and TAG concentrations compared to Leu162 carriers (Sparsø 
et al, 2007). However, the Leu162Val SNP has not been associated with any of the lipid 
profiles (Pishva et al, 2009), BMI, body fat composition, insulin sensitivity, or insulin 
secretion in three European cohorts: TULIP, TUEF and the LURIC (Silbernagel et al, 
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2009). Furthermore, it is not linked with the lipid profiles of patients with T2D in the 
Go-DARTS study (Doney et al, 2005).  
 
In a study population in which subgroups with or without T2D were compared, carriage 
of the Val162-allele was associated with reduced concentrations of HDL-C and a 
reduced risk of CVD in the DM group. Only in Val162 carriers is fibrate treatment in 
the DM group associated with a reduced risk of CVD and a significantly increased CVD 
risk in the absence of DM (Tai et al, 2006). This may suggest that the beneficial effect 
of the Val162-allele in subjects receiving fibrate treatment depends on ligand 




1.8.2 PPARA Leu162Val polymorphism and diet  
A similar concentration-dependent effect was reported for endogenous ligands by Tai et 
al. (2005). When PUFA intake was less than 4%, carriers of Val162-allele had higher 
levels of plasma TAG in comparison with Leu/Leu homozygotes. However, when 
PUFA intake was more than 8%, Val162-allele carriers had lower concentrations of 
plasma TAG than Leu/Leu homozygotes (Tai et al, 2005).  
 
Carriers of the Val162-allele have been characterised by higher plasma Apo B and TAG 
concentrations (Robitaille et al, 2004). This study also reported a significant gene-diet 
interaction between the PPARA Leu162Val genotype and total fat intake in determining 
waist circumference. They reported that in Leu/Leu homozygotes, waist circumference 
increased with a higher intake of dietary fat, but no significant interaction was found in 
determining TC, LDL-C, HDL-C or Apo B concentrations. A study by Caron-Dorval et 
al. (2008), examined whether n-3 PUFA induced changes in CVD risk factors are 
influenced by PPARA Leu162Val polymorphism. This study reported that carriers of 
the Val162-allele exhibited an increase in the C-reactive protein (CRP), while a 
decrease CRP was reported in Leu126-allele carriers with n-3 PUFA supplementation. 
The ARIC study reported a significant genotype and n-6 PUFA intake in White 
subjects, with a reduction in TC and LDL-C in Val162Val subjects. Similar genotype-
phenotype association was reported in African-Americans but with n-3 PUFA intake in 
determining LDL-C and TC (Volcik et al, 2008). In healthy men, following a high P:S 
diet, Val162-allele carriers had lower Apo A1 concentrations, compared to Leu/Leu 
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homozygotes (Paradis et al, 2005). These findings suggest that associations of the lipid 
profile with the PPARA Leu126Val can be modulated by dietary intake of fat. Reports 
of the relative activities of the Leu162 and Val162 PPARα isoforms in vitro have been 
contradictory, possibly owing to dependence on ligand concentration. Sapone et al. 
(2000) found Val162 allele had greater activity than Leu162 at high, but lower activity 
at low ligand concentration. Flavell et al. (2000)
 
originally found Val162 showed 
greater transactivation in a reporter construct. However, recently Rudkowska et al. 
(2010) found transcription to be higher in Leu162- than Val162-constructs containing 
the LPL PPRE, after n-3 fatty acid transactivation. They also found an inverse 
correlation between LPL activities and plasma TAG levels in Leu162 homozygotes but 
not in Val162 carriers (Rudkowska et al, 2009), suggesting that Val162 has lower 





1.9 Hypothesis  
Understanding the nature of multiple gene-gene interaction and gene-environment 
interactions is pivotal in understanding the causes and progression of metabolic 
syndrome and its management (Roche et al, 2005). As outlined in the introductory 
paragraph the aim of this thesis was to examine the influence of dietary lipids and 
variations in ADIPQQ gene on serum adiponectin concentrations. As adiponectin 
expression could be modulated by PPARs it was decided to include PPARA and PPARG 
genotypes in the study. 
 
It was hypothesised that the type and amount of fatty acids in the diet would influence 
adiponectin concentrations and that this may be modulated by common polymorphisms 









Chapter 2  
 




2.1 Intervention studies  
2.1.1 RISCK 
2.1.1.2 Subjects 
The RISCK (Reading, Imperial, Surrey, Cambridge, King’s) study aimed to test the 
influence of specific dietary changes on cardiovascular risk factors associated with 
metabolic syndrome, among subjects at risk of metabolic syndrome. RISCK tests the 
impact of four different diets on CVD risk, with a change in insulin resistance as the 
primary outcome. The four treatments were diets high in MUFA or low fat, each 
subdivided into a high or low glycaemic index group. The principle investigators are Dr. 
Susan Jebb (Medical Research Council Human Nutrition Research Centre, Cambridge), 
Prof. Gary Frost (Imperial College London), Prof. Tom Sanders (King’s College 
London), Dr. Julie Lovegrove (University of Reading), and Dr. Bruce Griffin 
(University of Surrey). Recruitment onto the trial commenced in August 2004 and was 
completed in November 2006. 
 
Men and women (age range: 30-70 years) recruited from the general population, 
through media advertisements, attended a clinic in a fasting state at the participating 
centres (University of Reading, Imperial College London, University of Surrey and the 
Medical Research Council Human Nutrition Research Centre [MRC-HNR], University 
of Cambridge and King’s College London). Eligibility for entry to the study was 
assessed by a point system and implementation of exclusion criteria described 
previously (Jebb et al, 2010). 47.5% of the subjects had the metabolic syndrome 
according to the criteria of the IDF (Alberti et al, 2006). 548 subjects completed the 





2.1.1.3 Study design  
A parallel 2 × 2 factorial design compared with a control intervention was used. 
Subjects were randomly assigned to treatments using a computer-based minimization 
procedure to balance assignment by age, sex, waist, and HDL-C as described previously 
(Jebb et al, 2010). Power calculations were based on 113 subjects per group completing 
the study to give 80% power to detect a difference in means of 1 (×10
−4
 mL · μU−1 
min
−1
) in the index of Si at P = 0.005.  The final sample size, allowing for dropout of 
15%, was 130 per treatment group with equal numbers recruited at each of the five 
centres. The intervention diets were planned to provide similar intakes of dietary 
energy, but to vary in the amount and type of fats and carbohydrates. At screening, 
unweighed 4-d food diaries (3 weekdays and 1 weekend day) were collected to record 
the habitual diet. Nutrient intakes were estimated by using the food-composition 
database software Diet in Nutrients out (DINO) as described previously (Moore et al, 
2009). All participants followed a 4-week run-in period during which they consumed a 
high-saturated fat ‘reference diet’ before being randomised to the reference diet or one 
of four isoenergetic dietary interventions designed to lower saturated fat.  
 
For the purposes of the genetic investigation studies the dietary intervention groups 
differing in carbohydrate quality were combined to focus the analyses on the 
manipulation of dietary fat, from which the impact on adiponectin concentrations, 
insulin sensitivity and lipid profile was expected to be greater. The resulting three 
dietary groups were:  high saturated fat ‘reference diet’ (HS) designed to reflect 
saturated fat intake in a ‘Western’ diet, ‘high-MUFA diet’ ;(HM) in which SFA was 
reduced and replaced with MUFA and ‘low-fat diet’ (LF), in which SFA was reduced 
through replacement of total fat with carbohydrate. The target intake for total fat was 
38% of energy in the HS and HM diets and 28% of energy in the LF diets, with 
carbohydrate intakes of 45% and 55% of energy respectively. The HM and LF diets 
were designed to reduce dietary SFAs to 10% of energy with a planned MUFA intake of 
20% of energy in the HM diets and 12% of energy in the LF and HS reference diet. 
Measurements made after the run-in diet are referred to as ‘baseline’. All participants 
followed their randomly prescribed diets for 24 weeks, after which a further blood 
sample was collected and anthropometry measured. Ethical approval for the RISCK 
study (ISRCTN29111298) was granted from the National Research Ethics Service and 
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MARINA (Modulation of Atherosclerosis Risk by Increasing dose of N-3 fatty Acids) 
study was designed to determine the effect of  intakes of (n-3) LCP, equivalent to 
intakes provided by 1, 2 and 4 portions of oily fish per week, on endothelial function 
and established predictors of risk of CVD. The principal investigators are Prof. Tom 
Sanders, Dr. Wendy Hall, Dr. Fiona Lewis, Dr. Paul Chowienczyk and Dr. Zoe Maniou. 
The study commenced in May 2008 and was completed in July 2009. 
 
Participants in the MARINA study were non-smoking men and women aged between 
45-70 years, recruited through media advertisements. Potentially eligible subjects were 
screened to obtain measures of BP, height, weight, % body fat and waist circumference. 
Exclusion criteria included history of CVD, stroke, cancer, type 1 diabetes, chronic 
renal, liver or bowel disease, smoking, excess alcohol intake, pregnancy, weight change 
of > 3 kg in the preceding 2 months, BMI < 20 and > 35 kg/m
2
, untreated high BP or 
raised cholesterol. Sample size calculations were based on flow mediated diameter 
(FMD) as the primary outcome. In order to detect a 20% change in mean FMD, a 
sample size of 72 subjects/group was required for 90% power. The significance level 
was set at 0.01%. Hence the final sample size, allowing for a dropout rate of 20%, was 
90 per treatment group. The aim was therefore to recruit 360 subjects to allow for a non-
completion rate of 20% (292 completing) (Sanders et al, 2011). 
 
 
2.1.2.2 Study design  
The MARINA study is a randomised double-blind parallel design to test the effects of 
three dose levels of DHA and EPA versus placebo primarily on endothelial function. 
Secondary outcomes include lipid variables associated with risk of CVD: plasma TC, 
LDL-C and HDL-C and TAG concentrations. Each treatment comprised an initial run-
in period of 4 weeks, taking olive oil (British Pharmacopoeia specification) placebo 
capsules whilst following dietary advice to restrict oily fish intake. Baseline 
measurements of outcome variables were made at the end of the run-in period. 
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Participants were then randomly allocated to one of the four treatments using age, 
gender and ethnicity. The 12 months dietary intervention phase involved 
supplementation with encapsulated (n-3) PUFA, EPA and DHA, at three different doses 
(0.45, 0.9 and 1.8 g/d), compared with placebo. The lowest level of intake is based on 
the Scientific Advisory Committee on Nutrition Recommendation to consume two 
portions of fish per week, one of which should be an oily fish, which provides an intake 
of 3.2 g/week or 0.45 g/d. Further measurements of the outcome variables were made 
after 6 months and at the end of the 12 months intervention. Compliance to the dietary 
intervention was assessed from capsule counts and by measuring changes in the 
proportions of EPA and DHA in erythrocyte lipids. Details on the supplements used in 
the can be found in Appendix 2.1.The study received NHS R&D approval from the 
Guy’s and St Thomas’ Hospitals Foundation Trust (ISRCTN66664610).  
 
The design and recruitment to the RISCK and MARINA studies were conducted by the 
study group. The author’s role was to extract the DNA for both studies and preformed 





2.2.1 DNA extraction: 
DNA was extracted from the buffy coats using the Illustra blood genomicprep spin kit, 
(GE Healthcare, UK). 
2.2.1.1 Materials for DNA extraction 
Item  Supplier  
Proteinase K GE Healthcare, UK 
Lysis buffer GE Healthcare, UK 
Wash buffer GE Healthcare, UK 
Elusion buffer GE Healthcare, UK 
Illustra blood mini column GE Healthcare, UK 
Collection tubes GE Healthcare, UK 
96-well microplates Qiagen, Crawley, Surrey, UK 
Sterile plate covers Qiagen, Crawley, Surrey, UK 
 
2.2.1.2 Equipment 
Item  Supplier  
Microcentrifuge that accommodates 1.5 ml 
microcentrifuge tubes 
DJB Labcare Ltd, 
Buckinghamshire, UK 
Water bath or heat-block for 70
o
C incubation  
Vortex mixer 
Grant Operation 




2.2.2 Polymerase Chain Reaction (PCR)  
2.2.2.1 Reagents and chemicals 
Item  Supplier  
10 x PCR Buffer without MgCl2 Sigma-Aldrich, Gillingham, UK 
Nucleotides dATP, dCTP, dGTP, dTTP Invitrogen Ltd, Paisley, UK 
Primers Sigma-Aldrich, Gillingham, UK 
MgCl2 Sigma-Aldrich, Gillingham, UK 
RedTaq Genomic DNA Polymerase without MgCl2 Sigma-Aldrich, Gillingham, UK 
 
2.2.1.2 Equipment and materials  
Item  Supplier  
DNA Engine TETRADTM2 Peltier thermocycler Bio-Rad Laboratories 
96-wells (8x12) microplates ABGene, Thermo Fisher scientific 
Rubber sealing mats ABGene, Thermo Fisher scientific 
 
2.2.3 Electrophoresis and gel imaging 
2.2.3.1 Reagents 
Item  Supplier  
Agarose Sigma-Aldrich, Gillingham, UK 
10XTBE Buffer Invitrogen Ltd, Paisley, UK 
Ethidium bromide Sigma-Aldrich, Gillingham, UK 
Loading dye Sigma-Aldrich, Gillingham, UK 
100 bp ladder Invitrogen Ltd, Paisley, UK 
 
2.2.3.2 Equipment 
Item  Supplier  
Small horizontal electrophoresis tank Fisherbrand, Fisher Scientific, UK 
GeneGenius Imaging System Syngene, Cambridge, UK 
GeneSnap software Syngene, Cambridge, UK 





2.2.4 Pyrosequencing  
2.2.4.1 Reagents 
Item  Supplier  
Ultrapure water (18mΩ), Invitrogen Paisley, UK 
70% ethanol Invitrogen Paisley, UK 
Denaturating solution Invitrogen Paisley, UK 
10 x washing buffer Biotage, Uppsala, Sweden 
Binding buffer Biotage, Uppsala, Sweden 
Annealing buffer Biotage, Uppsala, Sweden 
Sepharose-streptavidin beads GE Healthcare, UK 
Sequencing primer Sigma-Aldrich, Gillingham, UK 
Reagent kit 50x96 (enzyme, substrate and dNTPs) Biotage, Uppsala, Sweden 
 
2.2.4.2 Equipment 
Item  Supplier  
Pyrosequencer PSQ HS 96 Biotage, Uppsala, Sweden 
Pyrosequencing vacuum preparation tool Biotage, Uppsala, Sweden 
Filter probes Biotage, Uppsala, Sweden 
Pyrosequencing PSQ HS 96 plate Biotage, Uppsala, Sweden 
PSQ HS CDT dispensing tip holder Biotage, Uppsala, Sweden 
PSQ HS reagent dispensing tips Biotage, Uppsala, Sweden 
Barnstead Thermolyne Hot block Thermo Fisher Scientific, UK 




2.3.1 Blood analytic methods 
Blood samples for analysis were drawn after a minimum 8-hour overnight fast and 
serum was stored at -45 °C until analysed. The author was not involved in analysing any 
of these variables. 
 
 
2.3.1.1 Adiponectin (RISCK study)  
Serum adiponectin analysis was carried out by Duncan Talbot at Unilever (Sharnbrook, 
UK) using AutoDELFIA-time-resolved-fluorescence based immunoassay (Perkin 
Elmer, Cambridge, UK). Tests of intra- and inter-assay coefficients of variance (CV) 
were performed in replicates of 25. Intra- and inter-assay % CV respectively were as 
follows: 0.95 μg/ml human adiponectin: 7.2, 8.8; 2.88 μg/ml: 7.5, 8.2; 8.60 μg/ml: 5.0, 




2.3.1.2 Blood lipids  
Analyses of TC, HDL-C and TAG were carried out by Dr Roy Sherwood at the 
Department of Clinical Biochemistry, King’s College Hospital. TC was determined 
using an enzymatic method using cholesterol esterase, cholesterol oxidase and 
peroxidase in a chemiluminescent reaction to produce a red quinoneimine dye. The 
increase in absorbance was measured as an endpoint reaction at 505/694 nm. For 
RISCK samples, inter-assay CVs were 1.1, 1.5 and 1.0 at 3.9, 5.2 and 5.7 mmol/L 
respectively. For MARINA samples inter-assay CVs were 1.1, 1.5 and 1.0 % at 3.9, 5.1 
and 5.7 mmol/L respectively. HDL-C was analysed using a two-step automated 
procedure (Bayer Advia Direct HDL-C method). For RISCK samples CVs were 2.2, 2.1 
and 2.5 at 0.91, 1.39 and 1.95 mmol/L respectively and for MARINA samples CVs 
were 2.2, 2.1 and 2.5 % at concentrations of 0.91, 1.39 and 1.95 mmol/L respectively. 
TAG was measured using an enzymatic assay (The Bayer Advia method). For RISCK 
samples, CVs were 2.5 and 1.5 at 1.32 and 2.36 mmol/L respectively and for MARINA 
samples CVs were 2.5 and 1.5 % at concentrations of 1.32 and 2.36 mmol/L 
respectively. LDL-C was calculated using the Friedwald formula if fasting plasma TG 
concentrations were < 4.49 mmol/L. The formula used was: LDL-C = TC - HDL-C - 
(TAG / 2.2) (Friedewald et al, 1972). 
 
For RISCK samples, plasma Apo B and Apo A1 were measured at the University of 
Surrey using commercially available kits (Randox, UK) that employ immuno-
turbidimetric assays. The proportion of small dense LDL was measured by 
ultracentrifugation of the LDL fraction on an iodixanol gradient at the University of 
Surrey. Fasted plasma phospholipid fatty acids were measured by GC at the University 
of Reading as described by (Moore et al, 2009).  
 
For MARINA samples, erythrocyte membrane phospholipid fatty acid composition 
measured using capillary gas liquid chromatography as described by Sanders et al. 




2.3.1.3 Insulin sensitivity (RISCK study) 
Insulin sensitivity was measured by the intravenous glucose tolerance test (IVGTT) and 
insulin was measured at the Nutritional Biochemistry Laboratory at MRC HNR. 
Glucose was measured by the hexokinase-glucose-6- phosphate dehydrogenase method, 
using the Dimension® clinical chemistry system (Dade Behring, Milton Keynes, UK). 
Typical inter-assay CV was 2.4%. Insulin samples were assayed on a Roche Elecsys 
analyser using an electrochemiluminescence immunoassay (Roche, Indianapolis, USA). 
Inter-assay CVs were 4.5% at 169ρmol/L and 3.6% at 552ρmol/L. Insulin resistance 
was indirectly assessed by estimated HOMA2-IR using software from the Diabetes 
Trials Unit, University of Oxford (Internet: http://www.dtu.ox.ac.uk/homa). More 
detailed methods can be found in Appendix 2.3.  
 
 
2.3.2 Anthropometry  
Weight was measured after an overnight fast to the nearest 0.1 kg using digital scales. 
Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. Waist 
circumference was measured to the nearest 0.1 using a measuring tape. Body 
composition was assessed using a Tanita BC-418 segmental body composition analyser 
(Tanita Corporation of America, Inc., Illinois USA). More detailed methods can be 
found in Appendix 2.4.  
 
 
2.3.3 Seated blood pressure  
Blood pressure and heart rate was taken using an OMRON 705CPII or equivalent auto 




2.3.4 DNA extraction  
DNA extraction from buffy coats of 466 RISCK subjects and 310 MARINA subjects 
was carried out using an Illustra blood genomic prep mini spin kit (GE healthcare, UK). 
Buffy coats in EDTA had been frozen since preparation of blood samples. Genomic 
DNA was purified from 200 μl buffy coat. This process was carried out according to 
manufacturer’s instructions. This includes the below steps: 
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1- Blood cell lysis: 20 μl of Proteinase K was added into the bottom of a 1.5 ml 
microcentrifuge tube. This digests protein, removing contamination and 
inactivating nucleases that might otherwise degrade the DNA during purification. 
This was followed by adding 200 μl of the buffy coat and then 400 μl lysis buffer 
into the same tube. The tube was mixed well for 15 seconds and incubated at 
room temperature for 10 minutes. 
2- Genomic DNA binding: a mini column was assembled in a collection tube. The 
sample was loaded on to the centre of the column and was centrifuged. The flow 
through in the collection tube was discarded. The column was placed back inside 
the collection tube.  
3- Wash: to ensure complete cell lysis and to denature any residual protein; 500 μl 
of lysis buffer was added to the column and centrifuged. And again, flowthrough 
in the collection tube was discarded.  
4- Wash and dry: into the column, 500 μl of wash buffer was added. This was 
centrifuged for 3 minutes. The collection tube and flow through were discarded.   
5- Elution: the purification column was transferred into a fresh DNAse- free 
microcentrifuge tube. Followed by adding 200 μl of 70 oC preheated elusion 
buffer on the centre of the column. This was centrifuged for 1 minute. Purified 





2.3.4.1 Quantitation of DNA samples 
The quality of the DNA samples was checked by NanoDrop (DNA quality analyses). 
NanoDrop accurately measures dsDNA samples up to 3700 ng/µl without dilution. It 
automatically detects the high concentration and utilizes the 0.2mm path length to 
calculate the absorbance as shown in Table 2.1. For NanoDrop spectrophotometry, 1.0 
µl of sample was used to quantify DNA concentration. A blank of nuclease-free water, 
was used to optimise the instrument. Sample pedestals were first cleaned with nuclease-




Table 2.1 Sample of DNA quality analyser  
 
260/280: the ratio of absorbance at 260 and 280 nm is used to assess the purity of DNA. 
A ratio of 1.8 is accepted as pure for DNA. If the ratio is lower, it may indicate the 
presence of contaminants such as protein or phenol that absorb strongly at or near to 
280 nm.  
 
After checking the quality of the extracted DNA, samples were diluted to 10 ng/µl. The 
high quality, intact genomic DNA from the buffy coat fraction of the RISCK subjects 
was frozen and stored in 5 x 94 wells and 1 x 60 on 96 well DNA plates, and 3 x 94 
wells and 1 x 55 wells on 96 well DNA plates for MARINA subjects. Samples were 
defrosted as needed for analysis.  
 
 
2.3.5 Polymerase chain reaction   
PCR is a technique where a specific sequence of DNA is amplified within the genome. 
Two oligonucleotide primers are required to bind to the target DNA segment which will 
allow the selective amplification of the target sequence. PCR was used to generate the 
template for SNP genotyping by Pyrosequencing.  
 
There are three cycles in the PCR which are needed to be carried out at different 
temperature: PCR stages 
1- Denaturation separates the DNA chains in the double helix. 
2- Annealing was optimized for each DNA to allow the designed primers bind to the 
ends of the DNA strands. 
3- DNA synthesis to allow the Taq polymerase to make a complete copy of the 
templates in the presence of deoxynucleotide triphosphates (dNTPs) dATP, dCTP, 
dGTP, dTTP. 




2.3.5.1 Primers selection  
Primers for the PPARA Leu162Val (rs1800206) were selected by entering 
approximately 200 base pair (bp) of 5’ and 3’ flanking sequence 
(http://www.ncbi.nlm.nih.gov/snp; build 132 accessed 15/12/10) in to the 
Pyrosequencing assay design software program (PSQHS96 Machine SNP Analysis, 
Program 1.2.1). Suitable primer options were generated with quality scores up to 100. 
The primer set selected for PPARA Leu162Val scored 97 as shown in Table 2.2. The 
primer set represented high quality and neither set overlapped with any other SNP 
located in the flanking sequence.  
 
Table 2.2 Pyrosequencing assay design analysis for PPARA L162V  
 
Primer Set 1 
Score:97 
Quality: High 




PCR  F1 GCCAGTATTGTCGATTTCACAAGT 24 70.4 41.7 
PCR  R1 TTACCTACCGTTGTGTGACATCC 23 69.9 47.8 
Sequencing  S1 TCGATTTCACAAGTGC 16 50.7 43.8 
 
ADIPOQ SNPs primers were those previously selected for a previous study in this 
laboratory (Kyriakou et al 2008). The relative positions of tSNPs with respect to the 
first coding base in exon 2 are shown in parentheses: rs17300539 (-11391 G/A), 





PPARA L162V Created by RMWO46586301\Sandra 
Assay Type Genotyping Created date 03/04/2009 12:25 
Direction Forward Changed date 03/04/2009 12:26 
Description  
Notes  
Target Polymorphisms  Position1 
Sequence to Analyse [C/G]TTTCT GTCGGGATGT CACACAACGG 
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Table 2.3 ADIPOQ SNPs primers 
dbSNP Alleles Template PCR primers  
rs17300539 -11391 G/A F: 5’-biotin-CTGGGGTCGTAATTTAATTCATCA-3’ 
  R: 5’-TTCTTGGCACGCTCATGTT 
  S: 5’-GGGCAGGATCTGAGC-3’ 
rs182052 -10066 G/A F: 5'-biotin- GTAGTGTGGGAGTGGATACAGGT-3'             
  R: 5'-AATCGAATTGGACTTCATCTGTG-3' 
  S:5'-CTGCTACAGAGCGAACT-3' 
rs16861209 -7734 C/A F: 5’-biotin-TGTGTTGGGCATGGAGATATT-3’  
  R: 5’-GAGGTTGCAGTGAGCTGAGAT-3’  
  S: 5’-TGGCAGTTTCACACG-3’ 
rs1501299 +276 G/T F: 5’-biotin-GGCCTCTTTCATCACAGACCT-3’ 
  R: 5’-GCTTTGCTTTCTCCCTGTGTCT-3’ 
  S: 5’-GGCCTTAGTTAATAATGAAT-3’ 
 
 
2.3.5.2 PCR optimization: 
Determination of the optimal temperature is crucial, as high temperatures prohibit the 
primers from annealing to the DNA strands. Optimizing the magnesium chloride 
(MgCl2) concentration is necessary to ensure primer annealing specificity. A deficient 
of MgCl2 can result in an inadequate yield of PCR product, however poor primer 
specificity may result from an excess of MgCl2. 
 
Using the selected primers, and pooled control DNA, the optimum annealing 
temperature and MgCl2 concentration were determined for each of the SNPs. This was 
done by setting up MgCl2 titration on a block with a temperature gradient facility for the 
annealing cycle. The ADIPOQ SNP PCR was optimized previously by Ms Laura 
Collins (Kyriakou et al, 2008). PPARA Leu162Val PCR was optimised as follows: 
 
In a PCR plate, 1 µl of pooled DNA (10ng/µl) was added into columns 1, 4, 5, 6, 7 and 
8 of the first three rows. Each column was labelled with one of the annealing 
temperatures, and each of the rows with one of the three MgCl2 concentrations as shown 




Figure 2.1 Representing the labelling of the PCR plate PPARA Leu162Val 
For optimization, the PCR mixture was made up in a single 500μl Eppendorf tube 
without MgCl2 to yield a total of 270μl (Table 2.4). The PCR volume was split equally 
into three separate 500μl Eppendorf tubes (90μl per tube). 
Table 2.4 PCR reagents and their volumes without MgCl2 
PCR reagent Volumes (μL) 
Sterile water 229.2 
10x PCR buffer 30 
dNTP mix ACGT 2.4 
Forward primer 1.2 
Reverse primer 1.2 
RedTaq polymerase 6.0 
Total 270 
 
Into each of the three tubes a 10μl MgCl2 solution of varying concentrations was 
inserted; this was achieved by adding different proportions of sterile water and 25mM 
MgCl2 to produce the relevant MgCl2concentration Table 2.5. This addition of MgCl2 
raised the total volume of PCR mixture to the final volume of 100μl. 
  
          50°C                      52.°C   54.°C   56°C    58°C   60°C                         
  1.5                    
  2.5                       
  2.0                       
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Table 2.5 Volume of reagents used for the various MgCl2 concentrations 
Concentration of MgCl2 (mM) 25 mM MgCl2 (μL) Sterile water (μL) 
1.5 6 4 
2 8 2 
2.5 10 0 
 
The PCR mixture was thoroughly mixed and then aliquoted into the required wells in 
the PCR plate, 10μl was added per well (preloaded with DNA). A rubber mat was used 
to seal the PCR plate and it was placed into the Tetrad thermocycler. Once completed 
the plate was stored at 4˚C while preparations were made for gel electrophoresis 
 
 
2.3.6 Electrophoresis and Gel Imaging: 
Following PCR optimisation, gel electrophoresis was used to determine the length of 
the DNA fragments. Small 1% agarose gels (135x156mm) were made up to run the 
sample of each optimization array. The gel was prepared by adding 0.7g agarose 
powder to 100ml 1 X Tris/Borate/EDTA (TBE) buffer; the mixture was then heated in 
the microwave for about 10 minutes until the agarose powder was fully dissolved. After 
the gel was cooled down, 10 μl of ethidium bromide was added. The gel was then 
poured into the gel tray (sealed with autoclaving tape). Two combs were inserted into 
the apparatus in order to create two rows of 16 wells. The gel was left to set for about 
30 minutes at room temperature. Once solidified, the combs were gently removed and 
the gel was placed into an electrophoresis tank. This was followed by pouring 1x TBE 
buffer into the tank, facilitating immersion of the gel.  
 
Into the first well of each row, 5μl of DNA ladder was inserted.  2μl of loading dye was 
added to the 10μl of PCR product present in each well of the PCR plate. They were then 
extracted from the PCR plate and inserted into the respective well of the gel. Loading 
buffer helps to stain the DNA fragments and enable the PCR product/loading dye mix to 
sink into the wells.  
 
On completion the gel was carefully removed from the tank and placed in the gel 
documentation apparatus for visualization and recording of the image. The image was 
photographed and bands of DNA fragments examined to determine at which 
temperature and MgCl2 concentration the brightest band was produced i.e. the PCR 
conditions at which the greatest number of DNA fragments were amplified. 
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After the electrophoresis, the gel was taken to the gel documentation apparatus for 
visualization under an ultraviolet (UV) illuminator. The image was photographed and 
printed out. Bands of DNA fragments were examined to determine at which temperature 




After optimizing the annealing temperature and the MgCl2 concentration, micro plates 
were prepared for the template PCRs for each SNP. A total volume of 1000 μL of PCR 
mix was prepared for 96 well micro plates for each SNP as following: 
 





















ADIPOQ - 10066 G/A 804.0 100 8.0 4.0 4.0 60.0 20.0 
ADIPOQ - 7734 C/A 784.0 100 8.0 4.0 4.0 80.0 20.0 
ADIPOQ  - 11391 G/A 784.0 100 8.0 4.0 4.0 80.0 20.0 
ADIPOQ + 276 G/T 804.0 100 8.0 4.0 4.0 60.0 20.0 
PPARA Leu162Val 804.0 100 8.0 4.0 4.0 60.0 20.0 
 
Into each well of the PCR plate, 10 μl of PCR mix was pipetted. This was followed by 
pipating 1.5 μl of the DNA sample into the appropriate well.  The plate was then 
covered and placed into Tetrad Thermocycler and programmed for the specific 
conditions required for the SNP.  
 
Table 2.7 PCR conditions for the selected SNPs  
SNP PCR cycling conditions 
ADIPOQ -10066 G/A 
and -7734 C/A 
1 cycle at 94 °C for 6 minutes; 50 cycles at 94°C for 1 minute; 61 °C for 
30 seconds; 72°C for 30 seconds; 1 cycle at 72°C for 10 minutes. 
ADIPOQ -11391 G/A 
and + 276 G/T 
1 cycle at 94 °C for 6 minutes; 50 cycles at 94°C for 1 minute; 59 °C for 
30 seconds; 72°C for 30 seconds; 1 cycle at 72°C for 10 minutes. 
PPARA Leu162Val 
 
1 cycle at 94 °C for 6 minutes; 50 cycles at 94°C for 1 minute; 54.0 °C for 
45 seconds; 72°C for 1 minutes ; 1 cycle at 72°C for 10 minutes. 
 
The completed PCR was the removed and stored in a 4
0






2.3.8 SNP genotyping by Pyrosequencing: 
Pyrosequencing is a real time sequencing strategy based on the release of pyrophosphate 
(PPi) during enzymatic DNA synthesis (Ronaghi, 2001). The general principal of the 
Pyrosequencer is that a polymerase catalyses incorporation of nucleotide(s) into a 
nucleic acid chain. This incorporation will cause the release of PPi molecule (s) and 
subsequently the conversion of ATP by ATP sulfurylase. As a result of this, light is 
produced in the luciferase reaction, during which a luciferin molecule is oxidized. 
 
A pyrosequencing instrument was used for the selected SNPs. This is an automated, 
highly sensitive and quantitative genetic analysis system that is based on 
pyrosequencing technology. The Pyrosequencer high sensitivity light detection system 
enables a small DNA sample (10 μl of PCR product) to be analysed. 
 
 
2.3.7.1 Principle of Pyrosequencing 
A sequencing primer is hybridised to a single strand, PCR amplified, DNA template, 
and incubated with the enzymes (DNA polymerase, ATP sulfurylase, luciferase and 
apyrase) and the substrates, adenosine 5’phosphosulfate (APS) and luciferin (Ronaghi, 
2001). 
 
After the addition of the first four deoxynucleotide triphosphates (dNTP), DNA 
polymerase catalyses the incorporation of the dNTP into the DNA stand if it is 
complementary to the base in the template strand. Each incorporation events is 
accompanied by the release of (PPi) in an equal quantity to the amount of incorporated 
nucleotide (Ronaghi, 2001). PPi is then converted to ATP via ATP sulfurylase, in the 
presence of APS. ATP will then drive the conversion of luciferin to oxyluceferin via 
luciferase that generates visible light in amounts that are proportional to the amount of 
ATP. This light is detected by a charge coupled device (CCD) camera and seen as a 
peak in a program. The height of each peak is proportional to the number of nucleotides 
incorporated. Apyrase will continuously degrade ATP and incorporated dNTPs. This 
switches off the light and regenerates the reaction solution (Ronaghi, 2001). 
 
The addition of dNTPs is performed one at a time. As the process continues, the 
complementary DNA strand is built up and the nucleotide sequence is determined from 





2.3.7.2 Cleaning up the PCR products and preparation for sequencing: 
After preparing the reagents and the equipment, a streptavidin- sepharose bead/binding 
buffer mix is prepared. For 100 samples, the mix was made with 220 μl sepharose 
beads, 4000 μl binding buffer and 3300 water. 70 μl of the bead/binding buffer was 
added and mixed into each the PCR products in the PCR plate; plates were shaken for 5 
minutes at room temperature. 
 
This was followed by preparing the primer/annealing buffer mix. For 100 samples, the 
mix was made by mixing 1540 μl of the annealing buffer with 6.6 μl of the sequencing 
primer. This buffer mix was then pipetted into 96 wells of pyrosequencing plate. 
 
For strand separation, beads containing immobilised PCR templates were captured on 
filtered probes by lowering a vacuum prep tool in the PCR plate. Samples were then 
washed in 70% ethanol, denaturizing solution and washing buffer before being 
transferred to a Pyrosequencer plate pre-filled with the primer/annealing buffer (12 μl 
per well). The primers were then annealed at 80
o
C for two minutes before running the 
samples in the Pyrosequencer. The volumes of the substrate, enzyme and dNTPs of the 
dispensing cartridge had already been calculated by the Pyrosequencer software were 
prepared and placed into the Pyrosequencer. The volumes varied for each of the SNP 
assays as shown in the table below. 
 
Table 2.8 Volumes of enzyme, substrate and dNTPs for pyrosequencing: 
SNP assay E (μl) S(μl) A(μl) C(μl) G(μl) T(μl) 
ADIPOQ-10066 G/A 182 182 47 42 42 42 
ADIPOQ -7734 C/A 182 182 42 47 42 42 
ADIPOQ -11391 G/A 182 182 36 47 42 47 
ADIPOQ +276 C/A 182 182 42 42 42 47 
PPARA L162V 182 182 42 42 42 47 
 
The PSQ HS96 was tested before each run to ensure functionality of all dispensing tips. 
At least four DNA samples from each plate were repeated to confirm consistency and 




After completion of the pyrosequencing run, the genotype results for each 
pyrosequencing well were analysed; a blue well indicated a pass; red wells a fail and the 
yellow wells had to be manually checked to decide upon whether they were a pass or 
fail. The analysed results were saved on the Pyrosequencer computer. The genotypes 
were then transferred to an Excel spreadsheet.  
 
 
2.3.9 PPARG Pro12Ala SNP genotyping  
Unsuccessful attempts were made to genotype PPARG Pro12Ala by pyrosequencing. 
When the sequence was run through the Pyrosequencing design software, the top two 
primer sets scored 85 %, which is medium quality as shown in Table 2.9. The melting 
temperature (Tm) of the sequencing primer is 51 ºC, which requires a low (<50 ºC) 
annealing temperature for the sequencing primer to anneal to the DNA strand. At low 
temperatures, a primer is likely to anneal non-specifically. Optimisation of the template 
PCR using different anneal temperatures and Mg concentrations was unsuccessful, so 
the SNP was genotyped commercially by an alternative method.   
  
Table 2. 9: Pyrosequencing assay design analysis for PPARG Pro12Ala 
Primer Set 1 
Score: 85 
Quality: Medium 
Primer Id Sequence Bp Tm, ºC %GC 
PCR  F1 ATTACAGCAAACCCCTATTCCATG 24 71.1 41.7 
PCR  R1 GTATCAGTGAAGGAATCGCTTTCT 24 68.9 41.7 
Sequencing  S1 AAGGAATCGCTTTCTG 16 51.0 43.8 
 
This SNP was genotyped in RISCK and MARINA subjects by KBiosciences 









Chapter 3  
 
 
The Influence of SNPs at the ADIPOQ Gene Locus and 






The metabolic syndrome is a complex disorder characterized
 
by abdominal obesity, 
insulin resistance, hypertension, dyslipidaemia
 
and inflammation (Tan et al, 2004). 
Observational evidence
 
and intervention studies indicate that saturated fat worsens 
insulin sensitivity (Vessby et al, 2001), whereas the effects of monounsaturated and 
polyunsaturated
 
fats on insulin sensitivity are inconsistent (Vessby et al, 2001; Djousse 
et al, 2011). However, individuals
 
show varying responses to dietary intervention, 
suggesting that significant gene x dietary
 
interaction occurs (Roche, 2005).
  
 
Associations with adiponectin concentration and/or the metabolic syndrome have been 
reported for genetic variants at the ADIPOQ gene locus in many studies (Vasseur et al, 
2002; Jang et al, 2005). However, some of these associations could not be confirmed by 
others (Filippi et al, 2004). These inconsistencies may relate to interaction between the 
gene and environmental influences, such as dietary intake and age. Such interaction may 
also underpin varied individual responses to diet in general.  
 
Adiponectin concentrations generally increase with age (Isobe et al, 2005). Results from 
observational or weight loss studies have suggested that diets low in carbohydrate 
(Pischon et al, 2005) and high in unsaturated fat (Esposito et al, 2003) might increase 
adiponectin concentrations. Unsaturated fatty acids are ligands for the transcription 
factor PPARγ (Maeda et al, 2001), which upregulates ADIPOQ gene expression (Iwaki 
et al, 2003) and directly increases serum adiponectin concentration (Maeda et al, 2001).  
 
 
3.1.1 Selected SNPs  
The four selected SNPs are located in the regulatory and intronic regions of the 
ADIPOQ gene as shown in Figure 3.1. They are all tagging SNPs, i.e. representative of 
a cluster of other SNPs whose alleles are on a single chromosome that are inherited 
together. These SNPs showed the strongest replicated associations with serum 
adiponectin in two cohorts previously investigated in this laboratory, using a set of 8 
tagSNPs that predicted remaining SNPs in the ADIPOQ gene with a minimum r
2
 of 0.85 
(Kyriakou et al 2008).  
 
SNP -10066 G/A (rs182052) and -7734 C/A (rs16861209) are both located in intron 1. 
According to NCBI dbSNP data (Internet: http://www.ncbi.nlm.nih.gov/snp build 132 
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accessed 15/02/11) the frequency of the common allele (G) and the rare allele (A) of 
SNP -10066 is 0.647 and 0.353 respectively, and for -7734 is 0.913 for the common 
allele (C) and 0.087 for the rare allele (A). SNP-11391 G/A (rs17300539) is located in 
the promoter region, the frequencies in the European population is 0.917 for the 
common allele (G) and 0.083 for the rare allele (A).  The commonly studied SNP + 276 
G/T (rs 1501299) which is found in intron 2 had a frequency of 0.733 for (G) the 
common allele and 0.267 of the rare allele (T).  
 
 
Figure 3.1 Location of the 4 selected SNPs in the ADIPOQ gene (underlined). Their 
relative positions with respect to the first coding base in exon 2 are shown. From 
(Kyriakou et al, 2008) 
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3.1.2 Hypothesis  
We hypothesised that variants in ADIPOQ could interact with dietary intake of 
unsaturated fat and age to influence serum adiponectin in the absence of significant 




There is still a very limited number of studies looking at the diet-gene interaction with 
ADIPOQ variants. In view of the active role of adiponectin in the regulation of energy 
homeostasis, glucose and lipid metabolism, and the influence of dietary fat intake on its 
involvement in insulin resistance, we aimed to investigate: 
1-  The association between adiponectin concentrations and age, gender, BMI and 
ethnicity. 
2- The correlation between serum adiponectin concentrations and risk factors for 
the metabolic syndrome. 
3- Whether modulation of fat in a diet while maintaining stable weight would 
increase serum adiponectin concentrations 
4- The association of 4 SNPs in the ADIPOQ gene (-10066 G/A, -7734 C/A and 
+276 G/T) and promoter (-11391 G/A) with circulating adiponectin and 
metabolic syndrome risk phenotypes at baseline in 366 White European 
subjects. 
5- The influence of dietary intake of fats on the associations of these variants with 
serum adiponectin and insulin sensitivity. 
6- The interaction of SNP genotypes with age and gender in the determination of 
serum adiponectin concentration and insulin sensitivity measures after 24 weeks 
of dietary intervention. 
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3.2 Subjects and Methods 
3.2.1 Subjects  
This work is based on the participants of the RISCK study. Refer to Section 2.1.1 for 
details of RISCK study participants. 
 
 
3.2.2 Study design  
Refer to Section 2.1.1 for description of RISCK study design. 
 
 
3.2.3 Blood analytic methods and anthropometry measurements:  
For serum adiponectin, plasma lipids, insulin sensitivity and anthropometric 
measurements; refer to Sections 2.3.1.1, 2.3.1.2, 2.3.1.3 and 2.3.2 respectively.  
 
 
3.2.4 DNA extraction and SNP genotyping  
Details on methods for DNA extraction from buffy coats are given in Section 2.3.4. 
Four SNPs
 
at the ADIPOQ gene locus were genotyped [-11391 G/A (rs17300539), -
10066 G/A (rs182052), -7734 C/A (rs16861209) and +276 G/T (rs1501299)]. Their 
relative positions with respect to the first coding base in exon 2 are indicated. 
Genotyping by Pyrosequencing (Qiagen, Crawley, Surrey, UK) was performed in the 
448 participants for whom DNA was available and who had consented to genetic 
analysis. Primers and PCR conditions for genotyping can be found in Section 2.3.7. We 
used internal controls
 
and accuracy, as assessed by inclusion of duplicates in the arrays, 
was 98%. Genotyping success rates were 98.1, 83.5, 84.9 and 92.1%.respectively.  
 
 
3.2.5 Statistical analyses  
All genotype distributions were tested for deviation from the Hardy-Weinberg 
equilibrium by a χ2 test with 1 df (P > 0.05). Statistical analyses were carried out using 
the SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
 
Insulin, Si, 
HOMA2-IR, adiponectin, TAG and HDL-C variables were log transformed to obtain 
better approximations of the normal distribution prior to analysis.  Data were analysed 
by using analysis of covariance (ANCOVA); regressing on % change or follow-up 
measures against baseline measures with age, change in BMI and gender as covariates 
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and genotype and diet as fixed factors. Outliers were excluded from the ANCOVA and 
were defined as points > 2.5 times the interquartile range from the median on the 
transformed scale at baseline, follow-up, or change from baseline. All data presented in 
text and tables are expressed
 
as means or geometric means (GM) ± standard deviation 
(SD) or 95% confidence interval (CI).
 
Correlations are presented as Spearman's r. 
Statistical significance was taken at P < 0.05. Figures were drawn using Prism version 5 
(GraphPad software, Inc., California, and USA). 
 
 
3.3 Results  
3.3.1 Baseline characteristics of subjects 
A total of 548 subjects completed the RISCK study; the characteristics of the RISCK 
complete cohort at baseline are presented in the Table 3.1. The ethnic mix of subjects 
was typical of England and predominantly White, with about one-fifth of subjects from 
ethnic minorities. Based on self-reported ethnicity, individuals of White (80%), South 
and South East (S, SE) Asian (9.5%); Black African (8%) and ‘other’ (2.5%) ancestry 
were distinguished. After 4-week run-in on the HS diet, there were significant 
differences between males and females in fasting glucose, waist circumference, TAG, 
systolic and diastolic BP (higher in males), HDL-C, adiponectin, insulin sensitivity and 
body fat percentage (lower in males). The 448 individuals for whom DNA samples 
were available are the subjects of this study, from which participants in the ‘other’ 
ethnic subgroup were excluded. Their characteristics at baseline with respect to 
ethnicity, age, obesity measures, insulin homeostatic variables, adiponectin, lipid profile 




Table 3.1 Characteristics of RISCK study subjects at baseline  
 Phenotype  All               Women             Men    P 
 (n = 548) ( n = 318) (n = 230 )   
Ethnicity
1
     
    South Asia (n) 52(9.5) 31(9.8) 21(9.1 )  
    Black African (n) 40(7.3) 28(8.8) 12(5.2 )  
    White European (n) 437(79.7) 247(77.7) 190(82.6)  
    Others  19(3.5) 12(3.7) 7(3.1)  
Age (years) 52.4 ± 9.8 51.8 ± 9.4 53.2 ± 10.3  0.13 
BMI (kg/m
2
) 28.7 ± 4.8 28.8 ± 5.3 28.5 ± 3.8  0.42 
Waist circumference (cm) 97.6 ± 12.3 94.3 ± 12.4 102.3 ± 10.4 <0.001 
Body fat % 33.8 ± 8.5 38.9 ± 6.4 26.6 ± 5.1 <0.001 
Fasting insulin (pmol/L)
2 
60.6 ± 49.5 58.7 ± 55.1 63.3 ± 40.5  0.11 
Fasting glucose (mmol/L) 5.7 ± 0.8 5.5 ± 0.7 5.8 ± 0.8 <0.001 
Insulin sensitivity IVGTT)((mU/L)-1 min-1)
2 
2.7 ± 2.6 2.9 ± 3.0 2.5 ± 1.9  0.001 
HOMA2-IR
2
 1.3  ± 0.7 1.3 ± 0.7 1.3  ± 0.8  0.44 
Adiponectin (μg/mL) 2 9.4 ± 5.7 11.1 ± 6.2 7.5 ± 4.1 <0.001 
TAG (mmol/L)
 2
 1.5 ± 0.7 1.4 ± 0.6 1.6 ± 0.8 <0.001 
TC (mmol/L) 5.6 ± 1.0 5.6 ± 1.0 5.6 ± 1.0  0.88 
HDL-C (mmol/L)
 2
 1.4 ± 0.3 1.5 ± 0.3 1.3 ± 0.3 <0.001 
Apo A1 (g/L) 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.2 <0.001 
LDL-C (mmol/L) 3.6 ± 0.8 3.5 ± 0.8 3.6 ± 0.8  0.11 
Apo B (g/L) 0.99 ± 0.29 0.97 ± 0.28 1.00 ± 0.31  0.27 
Systolic BP (mm Hg) 129 ± 15.7 126 ± 15.1 134 ± 15.0 <0.001 
Diastolic BP (mm Hg) 80 ± 9.4 77 ± 9.0 83 ± 9.0 <0.001 
Data is presented for all subjects who completed the study (n = 548). Mean ± SD, or 
2
GM 
± SD. All variables were measured at baseline after 4-week runs-in on reference HS diet. 
1
Self-reported ethnicity. Significance of differences between women and men was 
determined by T-test. 
 
 
3.3.2 Serum adiponectin with respect to age, BMI and ethnicity 
Regression analysis showed that adiponectin positively correlated with age (beta = 
0.217, P <0.001) and negatively correlated with BMI (beta = - 0.161, P < 0.001). Table 
3.2 shows that there was a significant increase in geometric mean serum adiponectin 
concentration with age, after adjustment for BMI, gender and ethnicity. Serum 
adiponectin decreased with increasing BMI, after adjustment for age, gender and 
ethnicity. There were highly significant differences with respect to ethnicity after 
adjustment for BMI, age and gender. Adiponectin was significantly higher in White 
Europeans than in S. Asians (P = 0.001) and Black Africans (P = 0.001). Serum 
adiponectin concentrations were significantly higher in females (11.1± 6.2 μg/mL) than 
in males (8.5 ± 4.1 μg/mL) (P < 0.001). However, there were no significant interactions 
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between gender x age (P = 0.69), gender x BMI (P = 0.14) or gender x ethnicity (P = 




Table 3.2 Serum adiponectin concentrations at baseline stratified by age, BMI and ethnicity 
Age  BMI  Ethnicity
1 
Age group (y)  n GM adiponectin 
(95% CI)  
 BMI group (kg/m
2
) n GM adiponectin 
(95% CI) 
 Ethnic group n GM adiponectin 
(95% CI) 
<40  63 8.5 (7.5,9.7)  <25 88 11.4 (10.2,12.6)  South Asian 44 7.5 (6.5,8.7) 
41-50  129 8.4 (7.7,9.2)  25-29 210 9.6 (8.9,10.2)  Black 38 6.8 (5.8,8.0) 
51-60  148 10.1 (9.3,11.0)  30-35 107 8.7 (7.9,9.5)  White 366 10.2 (9.7,10.8) 
61-70  108 11.2 (10.2,12.4)  >35 43 8.9 (7.6,10.3)     
P-value  <0.001  P-value  0.002  P-value  <0.001 
P-value adjusted
2
   <0.001  P-value adjusted
3
   <0.001  P-value adjusted
4
    <0.001 
Data is presented for subjects for whom DNA samples and serum adiponectin measurements were available (n = 448). GM (μg/mL); 95% CI. All 
variables were measured at baseline after 4-week run-in on reference HS diet. 
1
Self reported ethnicity. 
2
P-values adjusted for BMI, gender and ethnicity; 
3
P-values adjusted for age, gender and ethnicity; 
4
P-values adjusted for age, BMI and gender. Significance of differences between age, BMI and ethnic 
groups was determined by ANOVA (P values without adjustments) or ANCOVA (P-values with adjustments).  
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3.3.3 Correlation of serum adiponectin with insulin sensitivity measures, measures 
of obesity and lipid profile 
 
To establish any relationship between serum adiponectin concentrations and insulin 
resistance, BMI, body fat %, and lipid profile in RISCK subjects, we tested the 
correlation between geometric mean adiponectin and insulin homeostatic, obesity 
measures and lipid profile variables in all subjects at baseline. Serum adiponectin was 
negatively correlated with HOMA2-IR (r = -0.38; P < 0.001) and positively correlated 
with Si, measured by IVGTT (r = 0.37; P < 0.001). Serum adiponectin was negatively 
correlated with BMI (r = -0.17; P < 0.001) and positively correlated with body fat % (r 
= 0.16; P < 0.001). Serum adiponectin was also negatively correlated with TAG (r = -
0.26; P < 0.001) and positively correlated with HDL-C (r = 0.52; P < 0.001), Apo A1 (r 
= 0.32; P < 0.001), NEFA (r = 0.25; P < 0.001) and TC (r = 0.11; P =0.01). No 
significant correlation was found between serum adiponectin and LDL-C or Apo B. 
 
We also found the partial correlation coefficient, adjusting for BMI, age, gender and 
ethnicity. The correlation was decreased, but remained significant: partial r for 
HOMA2-IR = -0.279 (P < 0.001); partial r for Si = 0.323 (P < 0.001); partial r for TAG 
= -0.23 (P < 0.001); partial r for HDL-C = 0.46 (P < 0.001) and partial r for Apo A1 = 
0.32 (P < 0.001). After adjusting for age, gender and ethnicity, partial r for BMI = -
0.214 (P < 0.001) and partial r for body fat % = 0.187 (P = 0.001). After adjusting for 





3.3.4 Genotyping by Pyrosequencing 
Pyrograms for the ADIPOQ -10066 G/A genotypes are shown below (Figure 3.2). (For 
explanation of methodology see Section 2.3.8. More results can be found Appendix 3.2 
 
Figure 3.2  Pyrograms for -10066 G/A genotypes. Yellow blocks indicate the peaks for 
the analysed SNP. 
 
 
3.3.5 SNP minor allele and genotype frequencies 
Table 3.3 shows the minor allele frequency (MAF) and genotype frequencies of the four 
SNPs typed at the ADIPOQ locus in 466 subjects stratified by ethnic group. Genotype 
distributions for each SNP did not deviate from Hardy-Weinberg expectations. Allele 
frequencies were compared with those listed on the NCBI SNP database (Internet: 
http://www.ncbi.nlm.nih.gov/snp accessed 15/02/11). MAF in White Europeans were as 
follows: -11391 G/A: 0.09; -10066 G/A 0.38; -7734 C/A 0.02; +276 G/T 0.24. -11391 
G/A was not expected to be present in Blacks, -10066 G/A was not as frequent as 
expected in Blacks (0.40 HapMap- Yoruba in Ibadan, Nigeria (YRI)) and -7734 C/A 
frequency was lower than expected in Europeans and Blacks (respectively 0.09 
HapMap- Utah subjects of European descent (CEU) and 0.13 HapMap-YRI). +276 G/T 




Table 3.3 ADIPOQ SNP allele and genotype frequencies 
SNP  Ethnic group
1
 
   South Asian Black African White Others  All 
      (n=44; 9%) (n=38; 8%) (n=367; 79%) (n=17; 4%) (n=466) 
-11391G/A MAF  0.06 0.02 0.09 0.00 0.08 
 11  (n=32; 14%) (n=29; 76%) (n=266; 72%) (n=12; 7%) (n=339; 73%) 
 12  (n=4; 9%) (n=1; 9%) (n=58; 16%) (n=0; 0%) (n=63; 13%) 
 22  (n=0; 0%) (n=0; 0%) (n=0; 0%) (n=0; 0%) (n=0; 0%) 
        
-10066G/A MAF  0.37 0.32 0.38 0.38 0.38 
 11  (n=17; 39%) (n=17; 45%) (n=132; 36%) (n=8; 47%) (n=174; 37%) 
 12  (n=19; 20%) (n=15; 39%) (n=181; 49%) (n=5; 29%) (n=220; 47%) 
 22  (n=6; 14%) (n=4; 10%) (n=47; 13%) (n=4; 23%) (n=61; 13%) 
        
-7734 C/A MAF  0.00 0.05 0.02 0.00 0.02 
 11  (n=38; 86%) (n=30; 79%) (n=280; 76%) (n=14; 82%) (n=362; 78%) 
 12  (n=0; 0%) (n=3; 9%) (n=12; 3%) (n=0; 0%) (n=15; 3%) 
 22  (n=0; 0%) (n=0; 0%) (n=0; 0%) (n=0; 0%) (n=0; 0%) 
        
+276 G/T MAF  0.29 0.35 0.24 0.19 0.25 
 11  (n=20; 45%) (n=14; 37%) (n=196; 53%) (n=11; 65%) (n=241; 52%) 
 12  (n=15; 34%) (n=20; 53%) (n=126; 32%) (n=4; 23%) (n=165; 35%) 
  22   (n=4; 9%) (n=3; 8%) (n=18; 5%) (n=1; 6%) (n=26; 6%) 
Data for all subjects with available DNA samples are shown (n = 466). n (%) refers to 
number of each ethnic group genotyped, as % of total.  For each SNP, n (%) refers to 
number of each genotype obtained, with % frequency. 
 1
Self-reported ethnicity. 11 refers to 
subjects homozygous for the common allele; 12 refers to heterozygote subjects, and 22 refer 
to subjects homozygous for the minor allele. 
 
 
3.3.6 ADIPOQ SNP genotype associations with serum adiponectin, obesity 
measures, insulin homeostatic variables and lipid profile at baseline 
 
In view of the small sample size of the S. Asian and Black subgroups, we chose to focus 
our genetic investigation on the majority White subjects (n = 366). One subject did not 
have values for baseline or follow-up adiponectin concentrations, so we decided to 
exclude him. Tables 3.4 and 3.5 show measurements of serum adiponectin, BMI, body 
fat %, fasting insulin, fasting glucose insulin sensitivity measured by IVGTT, HOMA2-
IR, NEFA, TC, TAG, HDL-C, Apo A1, LDL and Apo B at baseline (after the 4-week 
run-in on HS diet), with respect to -11391 G/A, -10066 G/A, -7734 C/A and +276 G/T 
genotype groups. ANCOVA was used to test the association between genotypes and 
phenotypic values adjusted for BMI, age and gender, based on a dominant model. +276 
T allele carriers had significantly higher mean serum adiponectin concentration at 
baseline than non-carriers (P = 0.006) and -10066 A-allele carriers had significantly 
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lower concentration than non-carriers (P = 0.03) before correction for multiple testing. 
After correction using 4-way ANOVA, the association of serum adiponectin with -
10066 G/A genotype remained significant (P = 0.03), but not with +276 G/T genotype 
(P > 0.05). No other phenotypes were significantly associated with -10066 G/A or +276 
G/T SNP genotypes at baseline (P > 0.05). No phenotypes were significantly associated 
with -11391 G/A or -7734 C/A SNP genotypes at baseline (P > 0.05). Neither +276 G/T 
nor -10066 G/A genotypes significantly interacted with age in determination of serum 
adiponectin concentration at baseline (P > 0.05).  
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Table 3.4 Serum adiponectin concentration, obesity measures, insulin homeostatic variables and lipid profile by ADIPOQ -11391 G/A and -
10666 G/A genotypes in White Europeans 
 
Data is presented for White European subjects for whom DNA samples were available (n = 366). Mean (95% CI) values stratified by genotype are 
shown for each SNP. Association was tested by ANCOVA based on a dominant model. 
2
P-values derived from the GM values at baseline are 
presented. P-values in bold when nominally significant (< 0.05), adjusted for BMI, age and gender, 
1
P-values are adjusted for gender and age. 
  
  -11391 G/A   -10066 G/A 
Phenotype GG GA+AA P   GG GA+AA P 
Male/female 125/141 17/ 41   57/ 75 95/133  
Adiponectin (μg/mL)2 9.9 (9.4,10.5) 10.7 (9.6,11.9) 0.24  10.9 (10.2,11.8) 9.9 (9.3,10.4) 0.03 
BMI (kg/m2)
1 
28.9 (28.3,29.5) 28.8 (27.6,30.1) 0.92  29.4 (28.6,30.2) 28.4 (27.8,29.0) 0.06 
Body fat %
1 
33.5 (32.8,34.3) 34.3 (32.7,35.8) 0.41  33.8 (32.8,34.9) 33.8 (33.0,34.6) 0.93 
Fasting insulin (pmol/L)
2 
59.4 (56.3,62.7) 57.5 (51.2,64.6) 0.62  56.0 (51.9,60.4) 59.6 (56.3,63.2) 0.20 
Fasting glucose (mmol/L) 5.7 (5.6,5.8) 5.8 (5.6,5.9) 0.45  5.7 (5.5,5.8) 5.7 (5.6,5.8) 0.52 






2.8 (2.6,2.9) 2.6 (2.3,3.0) 0.51  2.9 (2.7,3.2) 2.7 (2.5,2.9) 0.22 
HOMA2-IR
2 
2.2 (2.0,2.3) 2.1 (1.8,2.4) 0.72  2.0 (1.8,2.2) 2.2 (2.1,2.4) 0.11 
NEFA (μmol/L) 695.8 (666.4,725.2) 667.6 (604.2,731.0) 0.43  686.3 (644.6,728.1) 701.1 (669.4,732.8) 0.58 
TC (mmol/L) 5.7 (5.6,5.8) 5.6 (5.4,5.9) 0.72  5.7 (5.6,5.9) 5.7 (5.6,5.8) 0.65 
TAG (mmol/L)
2 
1.5 (1.5,1.6) 1.5 (1.3,1.7) 0.86  1.5 (1.4,1.6) 1.5 (1.5,1.6) 0.30 
HDL-C (mmol/L)
2 
1.4 (1.4,1.4) 1.4 (1.3,1.5) 0.92  1.4 (1.4,1.5) 1.4 (1.4,1.4) 0.37 
Apo A1 (g/L) 1.2 (1.2,1.3) 1.2 (1.1,1.3) 0.48  1.3 (1.2,1.3) 1.2 (1.2,1.3) 0.25 
LDL-C (mmol/L) 3.6 (3.5,3.7) 3.5 (3.3,3.7) 0.68  3.6 (3.5,3.8) 3.6 (3.5,3.7) 0.55 
Apo B (g/L) 0.99 (0.96,1.03) 0.92 (0.84,0.99) 0.08   1.00 (0.95,1.05) 0.97 (0.94,1.01) 0.40 
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Table 3.5 Serum adiponectin concentration, obesity measures, insulin homeostatic variables and lipid profile by ADIPOQ -7734 C/A and +276 
G/T genotypes in White European 
 -7734 C/A  +276 G/T 
Phenotype CC CA+AA P   GG GT+TT P 
Male/female 128/152 3/9   87/109 55/89  
Adiponectin (μg/mL)2 10.4 (9.9,10.9) 10.8 (8.5,13.8) 0.73  9.6 (9.1,10.2) 11.0 (10.2,11.8) 0.006 
BMI (kg/m2)
1 
28.7 (28.2,29.3) 28.8 (26.1,31.5) 0.96  28.9 (28.2,29.6) 28.5 (27.7,29.3) 0.48 
Body fat %
1 
33.5 (32.8,34.2) 33.4 (30.1,36.8) 0.98  34.2 (33.3,35.0) 33.3 (32.3,34.3) 0.18 
Fasting insulin (pmol/L)
2 
58.4 (55.4,61.5) 54.2 (42.2,69.6) 0.57  60.9 (57.3,64.8) 55.6 (51.7,59.8) 0.06 







2.8 (2.6,3.0) 2.5 (1.8,3.3) 0.45  2.7 (2.5,2.9) 2.9 (2.6,3.1) 0.17 
HOMA2-IR
2 
1.3 (1.2,1.4) 1.1 (0.9,1.4) 0.28  1.3 (1.3,1.4) 1.2 (1.1,1.3) 0.07 
NEFA (μmol/L) 693.2 (665.4,721.1) 685.0 (549.9,820.0) 0.91  701.8 (667.2,736.4) 694.5 (654.1,734.9) 0.79 
TC (mmol/L) 5.7 (5.6,5.8) 6.1 (5.5,6.6) 0.21  5.7 (5.6,5.8) 5.6 (5.5,5.8) 0.31 
TAG (mmol/L)
2 
1.5 (1.4,1.6) 1.8 (1.5,2.2) 0.08  1.6 (1.5,1.7) 1.5 (1.3,1.6) 0.13 
HDL-C (mmol/L)
2 
1.4 (1.4,1.4) 1.4 (1.3,1.6) 0.80  1.4 (1.4,1.4) 1.4 (1.4,1.5) 0.87 
Apo A1 (g/L)
 
1.2 (1.2,1.3) 1.3 (1.2,1.4) 0.36  1.2 (1.2,1.3) 1.2 (1.2,1.3) 0.46 
LDL-C (mmol/L) 3.6 (3.5,3.7) 3.8 (3.4,4.3) 0.44  3.6 (3.5,3.7) 3.5 (3.4,3.7) 0.46 
Apo B (g/L)
 
0.99 (0.96,1.03) 1.15 (0.98,1.32) 0.07   0.98 (0.94,1.03) 0.97 (0.92,1.01) 0.59 
Data is presented for White European subjects for whom DNA samples were available (n = 366). Mean (95% CI) values stratified by genotype are 
shown for each SNP. Association was tested by ANCOVA based on a dominant model. P-values derived from the GM values at baseline are 
presented. P-values in bold when nominally significant (< 0.05), adjusted for BMI, age and gender, 
1
P-values are adjusted for gender and age.  
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3.3.7 Change in measured variables after dietary intervention 
The RISCK study was designed to address the effects of diets with different 
macronutrient composition but similar energy intake, in order to measure changes in the 
absence of significant alteration in weight. Subjects were randomly assigned to 
continuation on the HS reference diet, or 24 weeks on an isoenergetic diet in which 
saturated fat was replaced with either HM diet or carbohydrate (LF diet). Diet during 
the run-in was monitored by weighed intake. There was no significant difference in 
intake of saturated fat between subjects who continued on the HS reference diet or were 
later assigned to the HM and LF diets (Moore et al, 2009). Body weight was relatively 
stable. Further information is provided elsewhere (Jebb et al, 2010; Moore et al, 2009). 
The changes in % SF and % MUFA differed between the diets over the 24 weeks of 
intervention. The HM group had significantly lower plasma phospholipid % SF than the 
LF group and higher % MUFA, but other fatty acid classes [(n-3) PUFA, (n-6) PUFA 
and trans FA] were not affected (Moore et al, 2009). Mean serum adiponectin 
concentration was not significantly different between the diet groups: after reference HS 
diet (n = 85) mean concentration = 9.2 (95% CI: 8.2, 10.3) μg/mL, after HM diet (n = 
227) mean concentration = 9.3 (95% CI: 8.7, 10.0) μg/mL and after LF diet (n = 235) 
mean concentration = 9.6 (95% CI: 9.0, 10.2) μg/mL, with P = 0.44 after adjustment for 
BMI, age, gender and ethnicity. Dietary interventions had no significant effect on Si, 
unaltered after adjustment for change in weight. TC and LDL-C concentrations were 
significantly lower with the HM and LF than the HS diet (P < 0.001 and P < 0.001). 
Apo B concentrations differed between treatment groups (P < 0.001) and were lower 
with the HM and LF diets than with the HS diet. HDL-C concentrations were lower 
with the LF than with the HS or HM diets (P < 0.001 and P = 0.002, respectively). 
There were no significant changes in concentration of plasma TAG following 
interventions (Jebb et al, 2010). 
 
 
3.3.8 Change in adiponectin concentrations after dietary intervention with respect 
to ADIPOQ SNP genotype 
 
-10066 G/A and +276 G/T genotypes were significantly associated with serum 
adiponectin concentration at baseline in White subjects (Tables 3.4 and 3.5). We then 
investigated the significance of any changes in adiponectin concentration after the HM 
and LF diets, with respect to -10066 G/A, +276 G/T, -11391 G/A and -7734 C/A 
genotypes Table 3.6. There was no significant difference in change after HM or LF 
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diets with respect to +276 G/T, -11391 G/A or -7734 C/A genotypes, and none after the 
LF diet with respect to -10066 G/A genotype. However, after the HM diet there was a 
significant difference in change in serum adiponectin concentration between -10066 
G/A genotype groups. Geometric mean concentration (95% CI) at baseline in G/G 
subjects (n = 57) was 10.4 (9.3, 11.6) μg/mL and in G/A+A/A (n = 94) 9.6 (8.8, 10.4) 
μg/mL. Geometric mean adiponectin concentration (95% CI) at follow up in G/G 
subjects was 10.8 (9.7, 12.1) μg/mL and in G/A+A/A was 9.3 (8.6, 10.2) μg/mL. - 
10066 G/G subjects showed an increase of 3.8 (-0.1, 7.7) % and G/A+A/A subjects a 
decrease of -2.6 (-5.6, 0.4) % after the HM diet. The difference in % change between 
G/G homozygotes and carriers of the A-allele was significant (P = 0.006) after 
adjustment for change in BMI, age and gender. However, gene x diet interaction in 
determination of serum adiponectin was not significant (P = 0.12) after adjustment for 
change in BMI, age and gender. We then analysed the data by excluding the subjects 
homozygous for the minor allele (n = 14), to ensure that they did not skew results when 
added to the heterozygote group. The interaction between -10066 G/A and diet 
remained insignificant. However, GG subjects still demonstrated significantly higher 
serum adiponectin concentration after HM, compared with the GA subjects (P = 0.01). 
 
We also investigated possible -10066 G/A x diet interaction in determination of BMI, 
body fat %, fasting insulin, fasting glucose, Si, HOMA2-IR, NEFA, TC, TAG, HDL-C, 
Apo A1, LDL-C and Apo B were not significant (P >0.05) after adjustment for change 
in BMI, age and gender. Similarly no significant interaction between diet and +276 G/T 
, -11391 G/A or -7734 C/A was found in determining any of the phenotypes (P >0.05). 
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Table 3.6 Effect of high-MUFA and low-fat diets on adiponectin concentration with respect to ADIPOQ -11391 G/A, -10666 G/A, -7734 C/A 
and +276 G/T SNP genotypes in white European subjects  
  HM   LF     
  Baseline Follow-up Percentage 
change 
 Baseline Follow-up Percentage 
change 
 diet x 
gene  
Adiponectin (μg/ml)  GM  (95%CI) GM  (95%CI) GM  (95%CI) P GM  (95%CI) GM  (95%CI) GM  (95%CI) P P 
10066 GG 10.4 (9.3,11.6) 10.8 (9.7,12.1) 3.8 (-0.1,7.7) 0.006 11.7 (10.4,13.1) 11.6 (10.3,13.1) -0.5 (-4.8,3.8) 0.857 0.12 
10066 GA+AA 9.6 (8.8,10.4) 9.4 (8.6,10.2) -2.6 (-5.6,0.4)  9.9 (9.1,10.9) 9.8 (9.0,10.7) -1.1 (-4.2,2.1)    
           
276 GG 9.1 (8.4,10.0) 9.1 (8.4,10.0) -0.1 (-3.3,3.0) 0.841 9.9 (8.9,11.0) 10.1 (9.1,11.2) 1.7 (-1.9,5.4) 0.107 0.24 
276 GT+TT 11.2 (10.1,12.5) 11.3 (10.1,12.6)  0.4 (-3.6,4.4)  10.7 (9.6,12.0) 10.5 (9.4,11.7) -2.5 (-6.2,1.2)    
           
7734 CC 10.1 (9.4,10.8) 9.9 (9.2,10.7) -1.4 (-4.3,1.5) 0.51 10.7 (9.8,11.6) 10.5 (9.7,11.4) -1.5 (-4.2,1.3) 0.11 0.07 
7734 CA+AA 10.2 (7.9,13.4) 9.7 (7.4,12.9) -5.2 (-16.2,5.7)  11.7 (7.4,18.5) 13.2 (8.3,21.0) 11.3 (-4.2,26.9)    
           
11391 GG 9.8 (9.1,10.5) 9.7 (9.0,10.4) -0.9 (-3.8,1.9) 0.22 9.9 (9.1,10.8) 9.9 (9.1,10.8) -0.3 (-3.2,2.5) 0.95 0.51 
11391 GA+AA 10.1 (8.6,11.8) 10.4 (8.9,12.1)   3.3 (-2.8,9.3)  11.6 (9.6,14.1) 11.6 (9.6,14.0) -0.6 (-6.9,5.8)     
Mean baseline, follow-up and percentage change in GM of adiponectin (95% CI) values stratified by genotype and diet (HM or LF) are shown for each 
SNP. Association was tested by ANCOVA on a dominant model. P-values derived from the % change in GM of adiponectin. P-values in bold when  
nominally significant (< 0.05), adjusted for change in BMI, age and gender. 
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3.3.9 Change in adiponectin concentrations after dietary intervention with respect 
to age and -10066 G/A genotype 
 
We were interested to determine whether the significant increase in serum adiponectin 
concentration with age that we observed at baseline (Table 3.2) was modified by 
dietary intervention. After dietary treatment, interaction between diet x age was not 
significant in determining the change in concentration (P = 0.83) adjusted for change in 
BMI and gender. We then proceeded to determine whether age and -10066 G/A 
genotype interacted to influence the change in adiponectin concentrations after dietary 
intervention. Figure 3.3 compares the effect of HM and LF diets on % change in serum 
adiponectin concentration in White -10066 G/G homozygotes and A-allele carriers. 
Although there were inconsistent effects in the smallest number of subjects in the 35-40 
years age group (n = 41), general trends were evident across the 10 years categories 
from age 41-70 years. In G/G homozygotes over 40 years of age, adiponectin 
concentration increased progressively after the HM diet, and decreased after the LF diet 
(Figure 3.3A). The difference in % change in serum adiponectin between G/G subjects 
on HM and LF diets in the oldest 61-70 years age group was significant (P = 0.003). In 
A-allele carriers there was little change in serum adiponectin concentration compared to 
baseline with increasing age, after HM or LF diets (Figure 3.3B). Interaction between 
gene x age x diet in determination of change in serum adiponectin concentration 
approached significance after adjustment for gender and change in BMI (n = 303; P = 
0.07) and remained insignificant after correction for multiple testing. However, the 
interaction between gene x age x diet x gender was not significant (P = 0.67) after 





Figure 3.3 Effect of HM and LF diets on adiponectin concentration with respect to -
10066 G/A genotype and age in White subjects. % changes (95% CI) in GM 
adiponectin concentration adjusted for change in BMI and gender are shown in each age 
group, after subjects consumed HM (n = 151) or LF (n = 152) diets. (A) -10066 G/G 
subjects (n = 111) and (B) -10066 G/A+A/A subjects (n = 192). Interaction between 
gene x age x diet in determination of change in serum adiponectin concentration 
determined by ANCOVA, was not significant after adjustment for change in BMI and 
gender (n = 303; P = 0.07). *Denotes significant difference in % change in serum 
adiponectin between G/G subjects on HM and LF diets (P = 0.003). (A) -10066 G/G 
subjects; age 30-40, 41-50, 51-60 and 61-70 y on HM diet (n = 6, 18, 13 and 20 
respectively) and LF diet (n =9, 8, 21 and 16 respectively). (B) -10066 G/A+A/A 
subjects; 30-40, 41-50, 51-60 and 61-70 y on HM diet (n = 13, 22, 30 and 29 





In this cohort of mainly overweight men and women, we have shown significant effects 
of age, BMI and ethnicity on serum adiponectin concentration. We have demonstrated a 
novel influence of ADIPOQ -10066 G/A genotype dependent on age and diet. After the 
HM diet, G/G homozygotes showed a progressive increase in serum adiponectin 
concentrations between 41-70 years of age, whereas after the LF diet there was a 
progressive decline.  
 
 
3.4.1 Influence of body mass index, ethnicity, age and gender 
The significant increase in serum adiponectin concentration that we found with age, 
after adjustment for BMI, is in agreement with previous reports (Adamczak et al, 2005). 
As insulin sensitivity declines with age, this may reflect development of resistance or 
survival in those with higher concentrations. The inverse relationship that we found 
with BMI is well known (Isobe et al, 2005). Serum adiponectin was found to be 
significantly higher in White Europeans than in S. Asians and Black Africans after 
adjustments for age, BMI and gender. Similarly, Cohen et al. (2011) reported that Black 
subjects had significantly lower adiponectin concentrations than White subjects. They 
also reported inconsistent correlations of adiponectin with BMI and age in White and 
Black women (Cohen et al, 2011). Moreover, Hulver et al. (2004) have suggested that 
BMI, insulin, and HOMA correlated significantly with adiponectin concentrations only 
in Caucasian women but not in African-American women. These studies suggest that 
relationships with obesity and insulin sensitivity may not be generalisable to all ethnic 
groups. We focused our genetic investigation on the White Europeans. We also found 
significant, substantially higher serum adiponectin in women compared to men, as 
reported previously (Marques-Vidal et al, 2010) and those differences persisted after 
adjusting for age or fat mass. This was contrary to some studies that reported no gender 
differences in adiponectin concentration (Kuo & Halpern, 2011). Our data indicate that 
gender differences in adiponectin cannot be accounted for solely by differences in body 
fat between genders. Other factors might thus intervene, such as diet (Pischon et al, 
2005) or physical activity levels (Tsukinoki et al, 2005).  
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3.4.2 Correlation between adiponectin and metabolic risk factors 
We found a significant negative correlation between adiponectin and BMI, HOMA2-IR, 
and TAG. This is in line with the findings of other studies (Isobe et al, 2005; Brochu-
Gaudreau et al, 2010; Hotta et al, 2000; Meilleur et al, 2010; Cassidy et al, 2009). 
Others reported a negative correlation between adiponectin and BMI, insulin and 
HOMA (Hulver et al, 2004). We also found a positive correlation with Si, body fat %, 
HDL-C, Apo A1 and TC. Similarly, Park et al (2010) reported a significant association 
with HDL-C and suggested that in postmenopausal women, this may have a protective 
effect on atherosclerosis. A positive correlation with HDL-C and TC after adjusting for 
age, gender and BMI was found in West African populations (Meilleur et al, 2010).  
 
 
3.4.3 SNP associations at baseline 
Previously in our laboratory, Kyriakou et al. (2008) observed strong associations
 
of the 
four SNPs with serum adiponectin concentrations in two much larger cohorts of healthy 
White women. In White European subjects from the RISCK study, at risk of 
development of the metabolic syndrome we found significantly higher mean serum 
adiponectin at baseline in variant +276 T-allele carriers than non-carriers. In agreement 
with our findings, association of elevated adiponectin with +276T has been reported in 
several studies (Menzaghi et al, 2002; Hara et al, 2002). We found that carriage of the 
variant -10066 A-allele was associated with significantly lower serum adiponectin at 
baseline than non-carriers; this remained significant after correction for multiple 
comparisons, in agreement with previous reports (Woo et al, 2006; Kyriakou et al, 
2008). The remainder of our study centres on this SNP. Although the association of 
elevated adiponectin with the -11391 A-allele has been reported widely (Vasseur et al, 
2002; Woo et al, 2006; Heid et al, 2006; Bouatia-Naji et al, 2006), in our study 
population -11391, A-allele has a tendency towards higher adiponectin. However, the 
difference did not reach significance levels (P=0.24). While another group found lower 
adiponectin in-11391 G-allele carriers (Petrone et al, 2006). Furthermore, there are 
several reports of increased risk of insulin resistance and T2D associated with the -
11391 GG genotype (Vasseur et al, 2002; Petrone et al, 2006). We found the same 
trends in RISCK -11391 GG White subjects with higher fasting insulin and HOMA2-IR 
but greater insulin sensitivity measured by Si. However, these associations did not reach 
significant levels. We did not replicate the previous association of the -7734 A-allele 
with elevated adiponectin (Kyriakou et al, 2008) in the RISCK subjects; however we 
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found a trend for 7734 A-allele carriers to have elevated adiponectin. Some studies 
reported associations between ADIPOQ SNPs, BMI and blood lipids. For example, 
+276G was associated with higher BMI in Italian subjects (Menzaghi et al, 2002) but 
with lower BMI in Swedish and African Americans (Ukkola et al, 2003; Beebe-Dimmer 
et al, 2010) and higher concentration of TAG (Jang et al, 2005). We found no 




3.4.4 Dietary intervention  
Epidemiological evidence and intervention studies strongly suggest that the quality of 
dietary fat influences insulin
 
sensitivity in humans (Vessby et al, 2001).
 
However, in the 
full RISCK cohort, replacement of SFA by isoenergetic MUFA or carbohydrate diets 
for 24 weeks did not significantly improve adiponectin concentration. Previously Jebb 
et al. (2010) reported no significant effect on insulin sensitivity following this dietary 
regimen. Small changes in adiponectin concentration after dietary intervention may not 
have been sufficient to affect insulin sensitivity, or the intervention period may not have 
been long enough to produce an effect. This is consistent with other reports, where no 
association of total energy or macronutrient intake with serum adiponectin is evident in 
young subjects (Yannakoulia et al, 2003), or on the impact of hypocaloric diets on 
adiponectin concentrations in obese women
 
(Arvidsson et al, 2004), or else following a 
high-fat, low-carbohydrate
 
meal (Peake et al, 2003). Long term effects were seen only 
after a 10 year Mediterranean diet in diabetic women
 
(Mantzoros et al, 2006) and 
postmenopausal obese women (Esposito et al, 2003). These data suggest that 
adiponectin concentrations
 
are unlikely to be affected by relatively short term dietary 
changes, but rather
 
reflect intakes over longer time periods (Pischon et al, 2005).  
 
 
3.4.5 SNP associations after dietary intervention 
In a recent study, an interaction between ADIPOQ rs266729 (-11377 C/G) genotype 
with SFA, but not MUFA or PUFA, significantly affected HOMA-IR. However, there 
were no significant effects on serum adiponectin concentration, suggesting that insulin 
resistance did not reflect changes in ADIPOQ gene expression elicited by the diet 
(Ferguson et al, 2010). We hypothesised that stratification by genotype might uncover 
influential interaction between diet and ADIPOQ variants. There were no significant 
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differences in the change in serum adiponectin concentration after HM or LF diets with 
respect to +276 G/T, 11391 G/A or -7734 C/A genotypes and none after the LF diet 
with respect to -10066 G/A. However, after the HM diet, G/G subjects showed an 
increase of 3.8 % and G/A+A/A subjects a decrease of 2.6%. Although the difference in 
change was highly significant, gene x diet interaction was not a significant determinant 
of serum adiponectin. Activation of PPARγ by unsaturated fatty acids increases with 
chain length and degree of unsaturation (Sanderson et al, 2008). The switch from SFA 
to MUFA could lead to increased expression of the ADIPOQ gene and serum 
adiponectin concentration through increased availability of PPARγ-activating ligands. 
The PPRE is 250 bp upstream of exon 1 (Iwaki et al, 2003) and lies in a 1.3 kb LD 
block bounded 5’ by -11377 G/C in the promoter and 3’ by -10066 G/A in intron 1 
(Heid et al, 2006). If the rare -10066 A-allele was in linkage disequilibrium with a 
variant in the PPRE, reducing affinity for the receptor, this could account for higher 
serum adiponectin in response to MUFA in G/G homozygotes, and the lower 
concentration in A-allele carriers. It is worth noting that -11391 G/A, which was not 
associated with adiponectin concentration in RISCK subjects, lies upstream of the LD 
block containing the PPRE (Heid et al, 2006).  
 
 
3.4.6 SNP associations after dietary intervention and interaction with age 
We had previously shown that adiponectin increased with age in males and females, but 
age did not interact with +276 G/T or -10066 G/A genotypes in determining adiponectin 
concentrations in White subjects at baseline. We were interested to discover whether the 
strong relationship between adiponectin concentration and age seen at baseline was 
modified by diet. We looked at whether age x genotype interaction was influential after 
dietary intervention.  
 
After the HM diet, -10066 G/G homozygotes showed a progressive increase in serum 
adiponectin between 41-70 years of age, culminating in a highly significant difference 
in the oldest age group. However, after the LF diet, G/G homozygotes showed a 
progressive fall. Both diets produced little effect in A-allele carriers. Serum adiponectin 
might be expected to be lower in G/G subjects after the LF diet, in which carbohydrate 
replaces SFA, than after the HM diet. In A-allele carriers, substitution of SFA for 
MUFA or carbohydrate would have little effect if reduced affinity of the PPRE, rather 
than ligand activation were to be the rate-limiting step. This scenario would be 
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compatible with other reports of lower serum adiponectin after high carbohydrate 
(Pischon et al, 2005; Esposito et al, 2003) and higher serum adiponectin with a diet rich 
in MUFA, compared with a carbohydrate or protein rich diet (Yeung et al, 2010). If 
aging is associated with the development of adiponectin resistance, the change in 
adiponectin concentrations may reflect a capability of responding by increasing 
production after HM, but not LF, diets.  
 
Few studies have explored the relationship between dietary factors
 
and adiponectin 
concentrations or gene-nutrient interactions involving
 
SNPs at the ADIPOQ locus. In a 
larger study (n = 1083), there was no interaction between dietary fat and -11391
 
G/A 
genotype in determination of serum adiponectin concentration, but A-allele carriers had 
lower BMI than non-carriers when MUFA comprised >13% total energy intake 
(Warodomwichit et al, 2009). Nelson et al. (2007) have indicated reduced
 
adiponectin 
concentrations after α-linolenic acid supplementation in overweight individuals (n = 57) 
independent of two ADIPOQ
 
SNPs (+276 G/T and +45 T/G), which have no effect. 
Perez-Martinez et al. (2008) have studied 59 healthy young men and women on dietary 
regimes similar to RISCK: an initially SFA-enriched diet, followed by a MUFA-rich or 
carbohydrate-rich
 
(LF) diet for 28 days in a randomised, crossover design. They found 
no interaction between another ADIPOQ promoter, SNP –11377 C/G, and diet-affecting 
plasma
 
adiponectin concentration in all subjects, but male C/C homozygotes had lower 
adiponectin than C/C women independently of the dietary fat. C/C homozygous men 
were less insulin after MUFA-rich and low-fat diets, than after SFA-rich diet. SNPs 
residing outside the coding region of the gene may have functional significance, or 
simply be linkage disequilibrium markers. 
 
 
3.5 Limitations and conclusion 
Limitations include a relatively small sample size and changes in serum adiponectin 
concentration. We measured total adiponectin, rather than the most bioactive HMW 
form, but a strong correlation has been shown between the two measures, regardless of 
obesity status or dietary period (Yeung et al, 2010). Wide inter-individual variation at 
baseline and in response to diets could have limited the significance of some outcomes. 
Replication in other cohorts is the most reliable method to distinguish true from false-
positive associations. If substantiated in a larger sample, a recommendation to -10066 
G/G homozygotes to substitute SFA with MUFA to maintain adiponectin 
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concentrations with advancing years would be justified. Elucidation of the effects of 
common SNPs in modifying the outcome of dietary intervention studies should help in 
the
 
















Chapter 4  
 
The Influence of PPAR-γ2 Gene Pro12Ala SNP and Dietary 






PPARγ is one of three PPARs and a member of the nuclear hormone receptor 
superfamily (Desvergne & Wahli, 1999). The major natural ligands are PUFAs and 
prostanoids (Xu et al, 1999), suggesting a role in transducing nutritional to metabolic 
signals (Semple et al, 2006). An increase in PPARγ mRNA in adipose tissue of mice 
exposed to a high fat diet (Vidal-Puig et al, 1996) suggested that dietary modulation 
might influence adipogenesis induced by PPARγ in response to raised plasma 
concentration of fatty acid ligands.  
 
Variants of the PPARγ2 gene PPARG could alter transcriptional activity of the activator 
through DNA- and/or ligand-binding affinity. Previous studies have investigated 
PPARG Pro12Ala genotype associations with risk of obesity and diabetes, with 
equivocal results (Altshuler et al, 2000; Tonjes et al, 2006; Masud & Ye, 2003) 
suggesting that environmental influences such as dietary intake may be involved. Luan 
et al. (2001) found BMI and fasting insulin in Ala12-allele carriers but not Pro/Pro 
homozygotes, was influenced by ratio of habitual dietary P:S intake. Others showed a 
relationship between intake of total fat and BMI (Memisoglu et al, 2003) or waist 
circumference (Robitaille et al, 2003) in common Pro/Pro homozygotes, but not in 
Ala12-allele carriers. However, when MUFA rather than total fat was examined, intake 
was found to be inversely
 
associated with BMI in Ala12-allele carriers and not in 
Pro/Pro homozygotes (Memisoglu et al, 2003). In vitro, the PPARγ2 Ala-variant 
exhibits reduced binding to DNA and modest impairment of transcriptional activation 
following treatment with pharmacological ligand TZDs (Deeb et al, 1998, Masugi et al, 
2000). This raised the possibility that differential responses by Pro/Pro homozygotes 
and Ala12-allele carriers to unsaturated fatty acid ligands of PPARγ might influence 
adipogenesis. 
 
PPARγ target genes include several involved in adipogenesis (Tontonoz & Spiegelman, 
1994), insulin sensitivity (Gurnell, 2003) and lipid metabolism  (Walczak & Tontonoz, 
2002) We hypothesised that dietary intake of unsaturated fats might interact with 
PPARG Pro12Ala genotype to influence concentration of adiponectin, plasma lipids,  




We aimed to test  
1- The association of genotype with plasma lipids, BMI, waist circumference, 
fasting insulin, and glucose and HOMA-IR at recruitment screening (habitual 
diet) and after 4 weeks on a HS diet in White subjects at risk of the metabolic 
syndrome. 
2- Whether habitual P: S ratio modulates the effect of PPARG Pro12Ala on markers 
of metabolic syndrome. 
3-  Interaction between genotype and dietary fat intake after the intervention  in 




4.2 Subjects and Methods 
4.2.1 Subjects  
This work was based on the participants of the RISCK study. Refer to Section 2.1.1 for 
details of RISCK study participants.  
 
 
4.2.2 Study design  
Refer to Section 2.1.1 for description of RISCK study design. 
 
 
4.2.3 Blood analytic methods and anthropometry measurements:  
For serum adiponectin, blood lipids, insulin sensitivity and anthropometric 
measurements; refer to Sections 2.3.1.1, 2.3.1.2, 2.3.1.3 and 2.3.2 respectively.  
 
 
4.2.4 DNA extraction and SNP genotyping 
Details on methods for DNA extraction from buffy coats are given in Section 2.3.4. The 
PPARG Pro12Ala SNP was genotyped by KBiosciences (Hoddesdon, UK) for 466 
subjects who had consented to genetic analysis using the Kaspar system. Genotype 
accuracy as assessed by inclusion of duplicates in the array was 98% and negative 
controls (water blanks) were included on each plate. Genotyping success rate was 89%. 
 
 
4.2.5 Statistical analyses  
PPARG Pro12Ala genotype distributions were tested for deviation from the Hardy-
Weinberg equilibrium by a χ2 test with 1 df (P > 0.05). Statistical analyses were carried 
out using the SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
 
Values 
for Si, HOMA2-IR, HOMA-IR, insulin, adiponectin, TAG and HDL-C were log 
transformed to obtain better approximations of the normal distribution prior to analysis.  
Data were analysed by ANCOVA with BMI, age, gender and diet as covariates. 
Outliers were excluded from the ANCOVA and were defined as points >2.5 times the 
interquartile range from the median on the transformed scale at recruitment or after HS 
diet. All data presented in text and tables are expressed
 
as means or geometric means ± 
SD or 95% CI. Statistical significance was taken at P < 0.05. ANCOVA was used to test 
the interaction between genotypes and habitual P:S quartiles or intervention diets. In 
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this model, the dependant variable was the analysed plasma lipid (TAG, LDL-C or TC) 
and fixed factors were the genotypes and P:S quartiles or dietary intake of fat (HS,LF 
and HM). BMI, age and gender were the covariates. Figures were drawn using Prism 
version 5 (GraphPad software, Inc., California, and USA). 
 
 
4.3. Results  
4.3.1 Characteristics of subjects 
Refer to Section 3.3.1 and Table 3.1 for the characteristics of subjects who completed 
the study. The 466 individuals for whom DNA samples were available are the subjects 
of this study. Their characteristics at baseline with respect to ethnicity, age, obesity 
measures, insulin homeostatic variables, adiponectin, lipid profile and BP are presented 
in Table 4.1. After 4-week run-in on the HS diet, there were significant differences 
between males and females in fasting glucose and  insulin, waist circumference, TAG, 
systolic and diastolic BP (higher in males), HDL-C, adiponectin, Si and body fat % 
(lower in males). 
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Table 4.1 Characteristics of RISCK study subjects at baseline  
 Phenotype All  Males  Females  p  
(n =  466) (n = 191) (n = 275) 
Ethnicity
1
     
    South Asia (n) 44 19 25  
    Black African (n) 38 10 28  
    White European (n) 367 155 212  
    Others  17 7 10  
Age (years) 52.4± 9.9 53.5± 10.3 51.6± 9.5 0.042 
Height (m) 1.7± 0.1 1.8± 0.1 1.6± 0.1 <0.001 
Weight (kg) 81.8± 15.7 88.8± 13.1 77.0± 15.5 <0.001 
BMI (kg/m
2
) 28.7± 4.7 28.6± 3.9 28.8± 5.2 0.559 
Waist circumference (cm) 98.0± 12.3 103.0± 10.4 94.7± 12.4 <0.001 
Body fat (%) 34.0± 8.4 26.7± 5.1 39.0± 6.3 <0.001 
Systolic BP (mm Hg) 129.5± 15.9 135.1± 15.2 125.6± 15.3 <0.001 
Diastolic BP (mm Hg) 79.5± 9.5 83.0± 9.0 77.1± 9.1 <0.001 
Fasting insulin (pmol/L)
2 
61.2± 246.6 65.8 ±  378.7 58.1± 57.8 0.024 
Fasting glucose (mmol/L) 5.7± 0.8 5.9± 0.9 5.5± 0.6 <0.001 
Insulin sensitivity (IVGTT)((mU/L)-1 min-1)
2
 2.6 ± 5.8 2.2±  1.9 2.9± 7.3 <0.001 
HOMA2-IR
2
 1.3± 0.7 1.3± 0.8 1.3± 0.7 0.451 
TAG (mmol/L)
2
 1.5± 0.7 1.7± 0.8 1.4± 0.6 <0.001 
TC (mmol/L) 5.6± 1.0 5.6± 1.0 5.6± 1.0 0.57 
HDL-C (mmol/L)
2
 1.4± 0.3 1.3± 0.3 1.5± 0.3 <0.001 
Apo A1 (mg/dL) 1.2± 0.3 1.2± 0.2 1.3± 0.2 <0.001 
LDL-C (mmol/L) 3.5± 0.8 3.6± 0.8 3.5± 0.8 0.143 
Apo B (mg/dL) 0.97± 0.3 1.00± 0.3 0.955± 0.3 0.089 
Adiponectin (μg/mL)2 9.5± 5.9 7.7± 4.2 11.1± 6.4 <0.001 
Data is presented for subjects which DNA samples were available (n = 466). Mean ± SD, 
or 
2
GM ± SD. All variables were measured at baseline after 4-week run-in on reference HS 
diet. 
1
Self-reported ethnicity. Significance of differences between women and men was 
determined by T-test. 
 
In view of the small sample size of the S. Asian and other ancestries and absence of the 
PPARG Pro12Ala in Blacks, we chose to focus our genetic investigation on the White 
subjects only. The characteristics at recruitment of the White participants (n = 367) who 




Table 4.2 Characteristics of White RISCK study subjects at recruitment screening 
Phenotype Male 
(n = 155 ) 
Female 
(n = 212) 
Age (years) 54±10 53±10 
Waist circumference (cm) 103.1±10.7  95.4±12.6 
BMI (kg/m
2




TC (mmol/L) 5.6±0.8 5.7±1.0 




 Data measured at recruitment is presented for all White subjects who 
 completed the study and for whom DNA samples were available 
 (n = 367). Values are mean or 
1
GM ± SD. 
 
 
4.3.2 PPARG Pro12Ala allele and genotype frequencies 
All available DNA samples were genotyped (n = 466) and data was obtained for 415 
subjects. Table 4.3 shows the allele and genotype frequencies for PPARG Pro12Ala in 
subjects stratified by ethnic group. Genotype distributions did not deviate from Hardy-
Weinberg
 
expectations. The MAFs were similar to those listed on the NCBI SNP 
database (http://www.ncbi.nlm.nih.gov/snp; build 132 accessed 15/12/10). The Ala12-
allele was more frequent than expected in White Europeans (0.10 in RISCK compared 
to 0.076 in HapMap-CEU (European)) and absent in Black Africans, as in Hap-Map 
trios (HapMap- YRI (Sub-Saharan African)). There are no comparative data available 
for S. Asians. 
 
Table 4.3 PPARG Pro12Ala genotype allele and genotype frequencies 
All subjects for whom DNA samples were available were genotyped (n = 466); n (%) is 
number of each ethnic group genotyped, as % of total.  Total with genotype data (n = 




  Ethnic group
1
 
 S. Asian Black African        White European       Other All 
[n (%)] [n (%)]  [n (%)] [n (%)] [n (%)] 
  44 (9) 38 (8) 367 (79) 17 (4) 466 (100) 
MAF 0.07 0 0.1 0.1 0.09 
Pro/Pro 36 (86) 36 (100) 258 (80) 12 (80) 342 (82) 
Pro/Ala 6 (14) 0 (0) 61 (19) 3 (20) 70 (17) 
Ala/Ala 0 (0) 0 (0) 3 (1) 0 (0) 3 (1) 
Total  42 (100) 36 (100) 322 (100) 15 (100) 415 (100) 
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4.3.3 PPARG Pro12Ala genotype associations with phenotypes at recruitment 
screening 
 
Table 4.4 shows anthropometry, plasma lipid concentrations, fasting glucose and 
insulin and HOMA-IR values in White subjects at recruitment (screening) with respect 
to PPARG Pro12Ala genotype. There were no significant associations between PPARG 
Pro12Ala genotype and these variables in White subjects at recruitment, after 
adjustment for BMI, gender and age (P > 0.05). Pro/Pro homozygotes had higher BMI, 
waist circumference and % of body fat compared to Ala12-allele carriers. However the 
differences did not reach a level of significance (P > 0.05).  
Table 4.4 Associations between PPARG Pro12Ala genotypes and phenotypes at 
recruitment in White subjects  
Phenotype PPARG Pro12Ala genotype    P 
  Pro/Pro Pro/Ala + Ala/Ala   
Males n(%) 102(74%) 35(26%)  





 29.0 (28.4,29.5) 27.8 (26.7,29.0) 0.08 
Waist circumference (cm)
1
 98.9 (97.4,100.4) 97.4 (94.3,100.5) 0.10 
Body fat (%)
1
 34.5 (33.3,35.7) 31.4 (29.1,33.6) 0.24 
Fasting insulin (pmol/L)
2
  58.6 (55.6,61.8) 54.6 (48.9,60.8) 0.46 
Fasting glucose (mmol/L) 5.4 (5.3,5.5) 5.4 (5.3,5.6) 0.87 
HOMA-IR
2
 2.2 (2.1,2.4) 2.0 (1.8,2.3) 0.43 
TC (mmol/L) 5.6 (5.5,5.7) 5.7 (5.5,5.9) 0.42 
TAG (mmol/L)
2
 1.3 (1.2,1.3) 1.3 (1.1,1.4) 0.96 
HDL-C (mmol/L)
2
 1.4 (1.4,1.4) 1.4 (1.3,1.4) 0.54 
LDL-C (mmol/L) 3.5 (3.4,3.6) 3.6 (3.4,3.8) 0.54 
Data is presented for subjects for whom genotypic and phenotypic data was available 
(n = 322). Mean (95% CI), or 
2
GM mean (95% CI) values, stratified by genotype are 
shown at recruitment. Association was tested by ANCOVA based on a dominant 
model. P-values adjusted for BMI, age and gender 
1




4.3.4 Interaction between PPARG Pro12Ala genotype and habitual dietary P:S 
ratio 
 
The full cohort was divided into quartiles of P:S, regardless of their genotypes. 
However, because of some missing genotyping results, when looking at the P:S 
interaction with Pro12Ala, the numbers of the subjects in each quartile were not equal.  
There was a significant interaction between dietary P:S ratio and genotype as 
determinants of plasma TC (P = 0.02), LDL-C (P = 0.002), and TAG (P = 0.02) 
concentrations after adjustment for BMI, age and gender in White subjects. Table 4.5 
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shows plasma TC, LDL-C and TAG concentrations with respect to genotype in quartiles 
of habitual P:S intake. When the P:S ratio was low (≤ 0.33), mean  plasma TC 
concentration in Ala12-allele carriers was significantly higher than in non-carriers (P = 
0.003). In the remaining quartiles, as P:S increased,  the concentration of TC fell by 10 
%. The trend in reduction as the ratio increased from ≤ 0.33 to >0.65 was significant (P 
= 0.02). The same pattern was seen in the concentration of LDL-C, with a significant 
difference in concentration between carriers and non-carriers in the lowest P:S quartile 
(P = 0.0001). As P:S increased in remaining quartiles, the concentration of LDL-C fell 
by 19.5% in Ala12-allele carriers, but here the trend was not significant (P > 0.05). 
There were no significant differences in plasma TAG concentrations between carriers 
and non-carriers of the Ala12-allele in any P:S quartile, however, there was a significant 
trend in reduction of plasma TAG concentration in Ala12-allele carriers as the P:S ratio 
increased from 0.34 to >0.65, in which concentration fell by 50.0% (P = 0.002). Plasma 
TAG concentration stratified by genotype and P:S quartile is shown in Figure 4.1. No 
significant interaction was found with dietary P:S ratio and genotype as determinants of 
BMI, waist circumference, body fat %, fasting insulin and glucose, HOMA-IR, or TC 
and HDL-C (P > 0.05). We then analysed the data by excluding the subjects 
homozygous for the minor allele (n = 3), to ensure they did not skew the results when 
added to the heterozygote subjects. The interaction between Pro12Ala and P:S remained 
significant for LDL-C, TC and TAG (P= 0.006, 0.04 and 0.03, respectively). 
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Table 4.5 Plasma lipid concentrations with respect to Pro12Ala genotype and quartiles of habitual dietary P:S intake ratio 
  TC  LDL-C  TAG
1 
P:S quartile Pro/Pro  Pro/Ala+Ala/Ala  P  Pro/Pro  Pro/Ala+Ala/Ala  P  Pro/Pro  Pro/Ala+Ala/Ala  P 
  Mean 
(95% CI) 
n   Mean  
(95% CI) 
n       Mean 
(95% CI) 
n   Mean 
(95% CI) 
 n       Mean 
(95% CI) 
n   Mean 
(95% CI) 
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0.37 
Data is presented for subjects for whom genotypic and phenotypic data was available (n = 322). Mean (95% CI), or 
1
GM mean (95% CI) values stratified 




Figure 4.1 Mean TAG concentrations with respect to quartiles of habitual dietary P:S 
ratio and PPARG Pro12Ala genotype. The numbers of genotyped subjects with 
measurements in each quartile of P:S ratio were as shown in Table 4.5. GM 
concentration of TAG is shown. Bars represent 95% CI. Dietary P:S ratio x 
genotype interaction determined by ANCOVA significantly influenced plasma TAG 
concentration (P = 0.02), after adjustment for BMI, gender and age.  There was a 
significant trend in reduction of plasma TAG concentration between P:S ratio 0.34 




4.3.5 Change in measured variables after dietary intervention  
Details on changes on blood lipids, Si and adiponectin after dietary intervention can be 
found in Section 3.3.7.  
 
 
4.3.6 PPARG Pro12Ala genotype associations with plasma lipid, adiponectin 
concentrations, insulin sensitivity and anthropometry measurement at 
baseline 
  
Table 4.6 shows plasma lipids concentrations, obesity measures, insulin sensitivity 
measures and adiponectin concentrations with respect to PPARG Pro12Ala genotype 
after the 4-week HS diet at baseline in White subjects. No significant differences in 
these variables were found between the two genotypes. The HS diet consumed during 
the 4-week run-in to baseline comprised 18% of energy SFA. The P:S intake ratio in 
White subjects at baseline was 0.35 i.e. in the second quartile of habitual P:S intake 
(0.34 – 0.47). At baseline, carriers of the Ala12-allele (n = 64) had higher plasma 
concentrations compared to non-carriers (n = 258) of TC, LDL-C and Apo B, but 




Table 4.6 Associations between PPARG Pro12Ala genotypes and phenotypes at 
baseline in White subjects 
  PPARG Pro12Ala genotype   
Phenotype Pro/Pro Pro/Ala + Ala/Ala   P 
Males n (%) 102 (40%) 35 (55%)  





 28.9 (28.3,29.4) 27.8 (26.8,28.9) 0.13 
Waist circumference (cm)
1
 98.4 (96.8,100.0) 97.6 (94.7,100.6) 0.23 
Body fat %
1
 34.2 (33.2,35.3) 31.4 (29.3,33.4) 0.19 
Insulin sensitivity (IVGTT)((mU/L)-1 min-1)
 2
  2.7 (2.5,3.0) 2.8 (2.5,3.2) 0.81 
Fasting insulin (pmol/L)
2
 59.0 (55.4,62.7) 54.4 (47.6,62.2) 0.49 
Fasting glucose (mmol/L) 5.7 (5.6,5.7) 5.8 (5.5,6.1) 0.26 
HOMA2-IR
2
 1.3 (1.2,1.4) 1.2 (1.1,1.3) 0.41 
Adiponectin (μg/mL) 2 10.4 (9.7,11.0) 9.8 (8.8,10.9) 0.74 
TC (mmol/L) 5.6 (5.5,5.7) 5.8 (5.6,6.1) 0.09 
TAG (mmol/L)
2
 1.3 (1.3,1.4) 1.4 (1.2,1.6) 0.64 
HDL-C (mmol/L)
 2
 1.4 (1.3,1.4) 1.3 (1.3,1.4) 0.81 
Apo A1 (g/L) 1.2 (1.2,1.2) 1.2 (1.2,1.3) 0.68 
LDL-C (mmol/L) 3.5 (3.4,3.6) 3.7 (3.5,3.9) 0.09 
Apo B (g/L) 0.95 (0.29,0.02) 1.03 (0.33,0.04) 0.12 
Values are mean (95% CI) or 
2
GM (95% CI) at baseline. P-values for ANCOVA on 
total sample are shown, adjusted for age, gender and BMI. 
1
P-values adjusted for gender 
and age.  
 
 
4.3.7 PPARG Pro12Ala genotype associations with change in plasma lipid 
concentrations after dietary intervention  
 
In order to investigate the effect of decrease in SFA without alteration in MUFA intake, 
we compared change in plasma lipid concentrations after continuation on the HS and 
switching to LF diet (18% versus 10% SFA), with respect to PPARG Pro12Ala 
genotype. Both diets contained the same proportion of PUFA. There was no significant 
difference in the change in either plasma TC, LDL-C or TAG concentration with respect 
to genotype (n =193), (P = 0.72, 0.60, 0.69 respectively after adjustment for change in 
BMI, age and gender as shown in Table 4.7). To examine the effect of increased intake 
of MUFA without alteration in SFA, we compared change in plasma lipid 
concentrations after the HM and LF diets (20% versus 11% MUFA), which also 
contained the same proportion of PUFA. There was no significant difference in the 
change in either plasma TC, LDL-C or TAG concentration with respect to genotype (n 
=268), P = 0.74, 0.94, 0.43 respectively after adjustments as shown in Table 4.7. 
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Table 4.7 Change in plasma lipid concentrations after dietary interventions with respect to PPARG Pro12Ala 
Phenotype   HS   LF   P diet x gene 
  Pro/Pro  Pro/Ala + Ala/Ala   Pro/Pro   Pro/Ala + Ala/Ala   
   (n = 47) (n =7) (n = 102  )  (n = 37) 
TC  Baseline 5.6 (5.3,5.8) 6.1 (5.4,6.8)  5.5 (5.3,5.7) 5.7 (5.4,6.1)   
 Follow-up 5.6 (5.3,5.9) 6.1 (5.3,6.9)  5.1 (5.0,5.3) 5.3 (5.0,5.6)   
 Change  -0.04 (-0.2,0.1) -0.04 (-0.5,0.4)  -0.4 (-0.5,-0.3) -0.5 (-0.7,-0.6)  0.72 
TAG Baseline 1.3 (1.2,1.5) 1.4 (1.1,1.9)  1.3 (1.2,1.4) 1.4 (1.2,1.6)   
 Follow-up 1.4 (1.2,1.6) 1.3 (1.0,1.8)  1.3 (1.2,1.4) 1.3 (1.1,1.5)   
 Change  0.04 (-0.04,0.11) -0.07 (-0.31,0.16)  -0.01 (-0.06,0.04) -0.06 (-0.16,0.05)  0.69 
LDL-C  Baseline 3.5 (3.2,3.7) 4.0 (3.4,4.6)  3.5 (3.3,3.6) 3.7 (3.4,3.9)   
 Follow-up 3.5 (3.2,3.7) 4.1 (3.5,4.8)  3.2 (3.0,3.3) 3.4 (3.1,3.6)   
  Change  -0.03 (-0.2,0.10) 0.1 (-0.3,0.5)   -0.3 (-0.4,-0.2) -0.3 (-0.4,-0.1)   0.6 
         
Phenotype  HM  LF  P diet x gene 
  Pro/Pro  Pro/Ala + Ala/Ala  Pro/Pro  Pro/Ala + Ala/Ala    
   (n = 109)  (n =20) (n = 102 ) (n = 37) 
TC  Baseline 5.7 (5.5,5.8) 5.9 (5.5,6.3)  5.5 (5.3,5.7) 5.7 (5.4,6.1)   
 Follow-up 5.3 (5.2,5.5) 5.5 (5.1,5.9)  5.1 (5.0,5.3) 5.3 (5.0,5.6)   
 Change  -0.3 (-0.4,-0.2) -0.4 (-0.6,-0.1)  -0.4 (-0.5,-0.3) -0.5 (-0.6,-0.3)  0.74 
TAG Baseline 1.3 (1.3,1.4) 1.4 (1.3,1.5)  1.3 (1.2,1.4) 1.4 (1.2,1.6)   
 Follow-up 1.4 (1.3,1.5) 1.4 (1.2,1.8)  1.3 (1.2,1.4) 1.3 (1.1,1.5)   
 Change  -0.01 (-0.06,0.04) 0.00 (-0.14,0.14)  -0.01 (-0.06,0.04) -0.06 (-0.15,0.04)  0.43 
LDL-C  Baseline 3.6 (3.5,3.7) 3.7 (3.4,4.0)  3.5 (3.3,3.6) 3.7 (3.4,3.9)   
 Follow-up 3.3 (3.2,3.4) 3.5 (3.1,3.8)  3.2 (3.0,3.3) 3.4 (3.1,3.6)   
  Change  -0.3 (-0.4,-0.2) -0.3 (-0.6,-0.1)   -0.3 (-0.4,-0.2) -0.3 (-0.4,-0.1)   0.94 
Baseline, follow-up and change in mean plasma TC and LDL-C and mean GM TAG concentrations (95% CI) (mmol/L) after dietary 
interventions, stratified by PPARG Pro12Ala genotypes are shown. P-values adjusted for change in BMI, age and gender.  
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4.4 Discussion:  
In this cohort of mainly overweight men and women, we have shown interaction 
between the habitual P:S ratio and PPARG Pro12Ala genotype influencing plasma TC 
and LDL-C  and TAG concentrations. At low P:S ratio (≤0.33), mean TC and LDL-C 
concentrations in Ala12-allele carriers were significantly higher than in non-carriers. 
The trends for reduction in plasma TC and TAG concentrations with increasing P:S 
intake were significant in Ala12-allele carriers. Paired comparisons of outcomes after 
dietary intervention suggest that lower SFA intake was not responsible for the effect. A 
decrease in SFA intake after the HM and LF diets had no significant effect on either 
plasma TC, LDL-C or TAG concentrations. 
 
Numerous studies have investigated associations between PPARG Pro12Ala and risk of 
obesity and diabetes, with equivocal outcomes. One meta-analysis of studies of T2D has 
found a significant increase in risk with the Pro12-allele (Altshuler et al, 2000) but 
another revealed no significant effect on related traits (Tonjes et al, 2006). Contrary 
findings of associations with obesity have also been reported (Masud & Ye 2003). 
These inconsistencies suggest that environmental modifiers of the effects of genetic 
variation in PPARγ2 may be involved. We have investigated associations between 
PPARG Pro12Ala genotype and concentrations of adiponectin, plasma lipid, obesity 
measures, fasting insulin and glucose and insulin sensitivity in subjects at risk of the 
metabolic syndrome, following habitual intake and dietary interventions differing in 
proportions of saturated and unsaturated fatty acids.  
 
 
4.4.1 SNP associations at recruitment:  
After the habitual diet, we found no significant differences in TC, LDL-C, HDL-C, 
TAG concentrations, fasting insulin, fasting glucose and HOMA-IR values. Pro/Pro 
homozygotes have higher BMI, waist circumference and percentage of body fat 
compared to Ala12-allele carriers (Table 4.4). However the difference did not reach a 
level of significance (P > 0.05). Contrary findings of associations between obesity and 
Pro12Ala have also been reported. Our findings concerning obesity measures are in line 
with the original study by Deeb et al. (1998), where Ala12-allele carriers have a 
significantly lower BMI, and there is no difference in insulin sensitivity between 
genotypes. The lower transcriptional activity of the Ala variant in vitro, might account 
for reduced adipogenesis in Ala12-allele carriers, through the reduction in C/EBPα 
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expression (Lowell, 1999). However, other studies have failed to yield consistent 
findings, with some demonstrating a modest increase in BMI in Ala12-allele carriers 
(Beamer et al, 1998).  
 
In White subjects, the dietary P:S ratio interacts with the genotype to influence 
concentrations of plasma TC and LDL-C and TAG (Table 4.5 and Figure 4.1). There is 
no significant interaction between PPARG Pro12Ala and dietary P:S ratio in 
determining HDL-C, fasting insulin, fasting glucose concentrations, HOMA-IR or 
measures of obesity. Memisoglu et al. (2003) found total fat intake was inversely 
correlated with plasma TC in Pro/Pro subjects but no effect among Ala12-allele carriers. 
They were the first to report an interaction between genotype and intake of MUFA, 
which was inversely
 
associated with BMI in Ala12-allele carriers, but not in Pro/Pro 
homozygotes. Thus, the responsiveness of Ala12-carriers to dietary manipulation only 
emerged when MUFA rather than total fat intake was analysed. Luan et al. (2001) had 
previously shown greater sensitivity of Ala12-allele carriers to dietary PUFA in 
determination of BMI and fasting insulin. Without reference to diet, genotype was not 
significantly
 
associated, but interaction between the
 
P:S ratio and genotype in 
determining BMI or fasting insulin was highly
 
significant (n = 592, P = 0.0038 and P = 
0.0097).  As the ratio of P:S increased, BMI and fasting insulin concentration  decreased 
and in Ala12-allele carriers but not in Pro/Pro homozygotes. Both of these findings are 
compatible with unsaturated fats acting as specific ligands for PPARγ (Xu et al, 1999) 
and lower transcriptional activity of the PPARγ-Ala variant reducing PPARγ-mediated 
adipogenesis (Deeb et al, 1998). 
 
Our study is the first to report significant interaction between the P:S ratio and PPARG 
Pro12Ala genotype influencing plasma TC and  LDL-C and TAG concentrations. At 
low (<0.33) ratio of P:S in habitual intake,  TC and LDL-C  concentrations in carriers of 
the less transcriptionally active PPARγ-Ala variant were significantly higher than in 
those homozygous for the normal PPARγ-Pro form. As the P:S ratio increased, the 
concentration of plasma TC and LDL-C fell in Ala12-allele carriers, with a significant 
trend seen in the former. When PUFA replaces SFA in the diet, the major portion of 
cholesterol lowering is seen in the LDL fraction (Jebb et al, 2010). Increased plasma 
LDL-C has been observed following TZD treatment (Ovalle & Bell, 2002).  The 
PPARγ-Ala12 form has lower transactivational ability than the wild-type (Deeb et al, 
1998). However a mechanistic link to PPARγ target gene activation, that might infer 
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association of the less active PPARγ-Ala form with lower LDL-C concentration, has not 
been established. 
 
Lipoprotein lipase activity is a rate-limiting determinant of TAG hydrolysis in plasma. 
Plasma TAG concentration in Ala12-allele carriers fell consistently beyond the second 
P:S quartile. It is well known that n-3 fatty acids decrease the concentration of serum 
TAG (Harris, 1997). PPARγ may mediate this effect, since PUFAs are PPARγ ligands 
(Xu et al, 1999) and LPL is a PPARγ target gene (Schoonjans et al, 1996). Lindi et al. 
(2003) found a significantly greater decrease in serum TAG concentration in healthy 
Ala12-allele carriers than in Pro/Pro homozygotes in response to n-3 fatty acid 
supplementation, when the total dietary fat intake was below 37% energy intake or the 
intake of SFA was below 10%. This is consistent with our finding of a fall in plasma 
TAG concentration in Ala12-allele carriers as P:S intake increased. However, both 
results suggest that the Ala12-allele is associated with increased LPL activity in the 
presence of high PUFA and by implication, higher transactivation of the LPL gene by 
the PPARγ Ala12- variant, contrary to findings in vitro (Deeb et al, 1998; Masugi et al, 
2000). These functional studies suggest that the PPARγ Ala12-variant has a lower 
binding affinity to PPRE and consequently reduced transactivation ability. Lindi et al. 
(2003) found no difference in post-heparin plasma LPL activity following placebo or 
fatty acid supplementation, suggesting that any change in LPL expression elicited by 
PPARγ was not functionally significant. An explanation of the genotype x diet 
interaction which significantly influenced plasma TAG concentration is not evident at 
present.  
 
We were not able to replicate Luan’s findings in 2001, which reported a significant 
association between P:S ratio and PPARG Pro12Ala in determining BMI or fasting 
insulin. A meta-analysis in 2007 reported that the protective effects of the Ala12 allele 
in insulin resistance were stronger in individuals with a lower BMI (Ludovico et al, 
2007); hence the higher BMI of the RISCK subjects (28.3 kg/m
2





4.4.2 SNP associations at baseline: 
The HS diet consumed during the 4-week run-in to baseline comprised 18% of energy 
SFA. The P:S intake ratio in White subjects at baseline was 0.35 i.e. in the second 
quartile of habitual P:S intake (0.34 – 0.47). At baseline, carriers of the Ala12-allele had 
higher concentrations of TC, LDL-C and Apo B and lower concentration of adiponectin 
compared to non-carriers, but differences were not significant after adjustment for BMI, 
gender and age. In the most recent meta-analysis including 52,998 subjects, only male 
Ala12-allele carriers had significantly increased plasma TC compared to non-carriers 
(Huang et al, 2011). 
 
At recruitment and baseline, Ala12-allele carriers are more insulin sensitive when 
measured according to HOMA-IR, Si or HOMA2-IR, compared to Pro/Pro 
homozygotes. However, the differences did not reach significant (P > 0.05). These 
findings are in line with recent meta-analysis of findings, which report a protective 
effect of the Ala12-allele against T2DM (Huguenin & Rosa, 2010), but contradict 
others (Rhee et al, 2006). Carriers of Ala12-allele are reported to have higher serum 
adiponectin concentration (Yamamoto et al,2002; Mousavinasab et al,2005) and a lower 
β-cell function index, lower insulin secretion and higher levels of Haemoglobin A1C 
(Hba1c) (Mori et al, 2001). The later study evaluates the effect of PPARG Pro12Ala 
among a large number of Japanese individuals (n = 3413). Thus, the small sample size 
of our study is inadequate for detecting such a significant association 
 
 
4.4.3 SNP associations after dietary intervention 
In order to establish whether effects of interaction between with the P:S ratio of habitual 
intake and genotype that we had observed were related to increased  PUFA, as  distinct 
from decreased SFA, we first compared change in plasma lipid concentrations after HS 
and LF diets, in which SFA was reduced and MUFA remained constant. Carriage of the 
Ala12-allele was not significantly associated with change in either plasma TC, LDL-C 
or TAG concentrations, so the decrease in SFA had no significant effect. We obtained 
the same results when we compared changes in lipids after HM and LF diets, in which 
MUFA was raised and SFA remained constant. An increase in MUFA might have been 
expected to have had an effect, but they are weaker PPARγ activators than PUFAs (Xu 
et al, 1999). Therefore we cannot confirm that the interaction between the P:S ratio of 
habitual intake and PPARG Pro12Ala genotype in determining plasma TC, LDL-C, and 
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TAG concentrations depends specifically on an increase in consumption of PUFA, but it 
seems not to depend on a decrease in SFA. 
 
Adiponectin gene expression is regulated by PPARγ and PUFAs which have been found 
to enhance the expression of adiponectin mRNA in adipose tissue and to dramatically 
increase plasma concentration of adiponectin (Maeda et al, 2001) (Section 1.6.3). There 
was no significant difference in changes of adiponectin after HF, HM or LF diets with 
respect to PPARG Pro12Ala (Appendix 5.2). In comparison with PUFAs, MUFAs are 
weaker activators for PPARγ. Adiponectin concentrations at screening were not 
available. Therefore, we were not able to examine the interaction of P:S ratio of habitual 
intake and PPARG Pro12Ala as determinant of  adiponectin concentration. 
 
 
4.5 Limitations and conclusion  
Limitations of our study include a relatively small number of genotyped subjects with 
plasma lipid measurements (n = 367) and the small observed changes in plasma lipid 
concentrations. To demonstrate a significant difference in LDL-C concentration in 
Ala12-allele carriers or non-carriers across all P:S quartiles, a total sample size of 1600 
would be required for alpha = 0.05 and a power of 0.95. For TAG concentration, the 
equivalent sample size would be 1800. The significance of the effect of dietary P:S x 
gene interactions on plasma cholesterol and TAG concentrations should be treated with 
caution, as they were of modest significance in mainly overweight subjects. If 
substantiated in a larger cohort, a recommendation to Ala12-allele carriers to maintain a 
high dietary intake of PUFA: SFA, to reduce plasma concentrations of atherogenic 
cholesterol and TAG, would be justified. Identification of individuals who are
 
genetically more likely to respond to particular dietary changes
 
may be important for 












Chapter 5  
 
The Effect of Interaction between PPARG Pro12Ala and 




5.1 Introduction  
The peroxisome proliferator-activated receptors, members of the nuclear hormone 
receptor superfamily, are master transcriptional regulators of lipid and carbohydrate 
metabolism (Ferré, 2004). The major natural ligands of PPARγ and PPARα are PUFAs 
and prostanoids (Desvergne & Wahli 1999; Xu et al, 1999). PPARα responds to several 
fatty acids, suggesting roles in transducing nutritional into metabolic signals (Semple et 
al, 2006). PPARα plays an important role in liver, where it controls metabolism of 
lipoproteins and fatty acids, as well as glucose homeostasis (Lefebvre et al, 2006). 
Activation of PPARα by several fatty acids increases uptake and activates expression of 
genes involved in peroxisomal and mitochondrial fatty acid β-oxidation (Pyper et al, 
2010), reducing the lipotoxic threat to insulin sensitivity. The PPARs are thus major 
regulators of lipid and glucose metabolism, allowing adaptation to nutritional status. 
 
PPARA Leu162Val polymorphism involves a substitution of valine for leucine at codon 
162 and has been associated with lipids and apolipoprotein concentrations (Vohl et al, 
2000; Flavell et al, 2000). Other findings have suggested that the associations of the 
lipid profile with PPARA Leu162Val can be modulated by dietary fat intake (Robitaille 
et al, 2004). These inconsistencies suggest that environmental influences or gene-gene 
interaction may influence the outcome. Numerous studies have investigated associations 
between PPARG Pro12Ala and components of the metabolic syndrome alone or in 
interaction with dietary fat as previously explained in (Section 4.1). In vitro studies 
have shown that compared to the wild types, PPARγ-Ala12 form has lower binding 
affinity for PPREs (Deeb et al, 1998) and the PPARα-Val162 form has  lower 
transcriptional activation in transfectants activated with ω-fatty acids (Rudkowska et al, 
2009), thus both variants will reduce transactivational ability of the receptors. 
 
We hypothesised that availability of the unsaturated fatty acid ligands of dietary origin 
might influence phenotypic outcomes based on carriage of the PPARG Pro12Ala and 
PPARA Leu162Val variants.  
 
We aimed to test the following in RISCK study participants 
1- Association between PPARA Leu162Val genotypes and mean quantitative 
phenotypes, including plasma lipids, adiponectin, fasting glucose and insulin,  
measures of obesity and insulin sensitivity at baseline. And to test this 
126 
 
association after a HS fat diet and after 24 weeks of dietary intervention in 
White subjects at risk of the metabolic syndrome. 
 
2- Interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes at 
baseline and their interaction with dietary fat in determining mean quantitative 
phenotypes at follow-up. 
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5.2 Subjects and methods 
5.2.1 Subjects  
This investigation was based on the participants of the RISCK study (Section 2.1.1). 
 
 
5.2.2 Study design  
Description of RISCK study design is given in Section 2.1.1. 
 
 
5.2.3 Blood analytic methods and anthropometry measurement 
For blood lipids, insulin sensitivity and anthropometric measurement are given in 
Sections 2.3.1.2, 2.3.1.3 and 2.3.2 respectively.  
 
 
5.2.4 DNA extraction and SNP genotyping  
Details on methods for DNA extraction from buffy coats are given in Section 2.3.4.  
PPARA Leu162Val (rs1800206) was genotyped in the 466 participants for whom DNA 
was available and who had consented to genetic analysis using by Pyrosequencing. 
Primers and PCR conditions for genotyping are given in Section 2.3.7. Genotyping 
accuracy was 98% and success rate was 97%. The PPARG Pro12Ala SNP (rs1801282) 
was genotyped by KBiosciences (Hoddesdon, UK) (Section 4.2.4). 
 
 
5.2.5 Statistical analyses  
All genotype distributions were tested for deviation from the Hardy-Weinberg 
equilibrium by a χ2 test with 1 df (P > 0.05). Statistical analyses were carried out using 
the SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Values for Si, 
HOMA2-IR, adiponectin, insulin, TAG and HDL-C were log transformed to obtain 
better approximations of the normal distribution prior to analysis. Data were analysed 
using ANCOVA, regressing follow-up measures against baseline measures. Outliers 
were excluded from the ANCOVA and were defined as points > 2.5 times the 
interquartile range from the median on the transformed scale at baseline, follow-up, or 
change from baseline. All data presented in text and tables are expressed
 
as means or 
GM ± SD or 95% CI.
 
The effect of each diet is expressed as the follow-up value above 
the baseline with 95% CI. Statistical significance was taken at P < 0.05. ANCOVA was 
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used to test the interaction between genotypes and intervention diets. In this model, the 
dependant variable was the analysed follow-up plasma lipid; fixed factors were the 
combined genotypes and dietary intake of fat (HS, LF and HM). Baseline values, BMI, 
age and gender were the covariates. Figures were drawn using Prism version 5 
(GraphPad software, Inc., California, and USA). 
 
 
5.3 Results  
5.3.1 Baseline characteristics of subjects 
Section 3.3.1 and Table 3.1 describe the characteristics of subjects who completed the 
study (n = 548). Section 4.3.1 and Table 4.1 describe the characteristics of subjects for 
whom DNA samples were available (n = 466). 
 
 
5.3.2 Pyrosequencing template PCR optimisation 
By comparing intensity of the bands produced by gel electrophoresis of the PPARA 
Leu162Val template PCR Figure 5.1, both optimal annealing temperature and MgCl2 
concentrations were determined. The expected length of the PCR product was 59 bp. 
Using the selected primers, an optimum PCR product was obtained with annealing 





Figure 5.1 Gel electrophoresis of PPARA Leu162Val template PCR; bands of a specific 
length (59 bp) were produced at different anneal temperatures using 1.5mM, 2.0mM 
and 2.5mM  MgCl2, however strong bands were only produced at a concentration of 1.5 
Mm MgCl2. It appeared that the strongest band was produced at 54.0˚C.  
  



















5.3.3 Genotyping by Pyrosequencing 
Pyrograms for the three PPARA Leu162Val genotypes are shown below (Figure 5.2). 




Figure 5.2 Pyrograms for Leu162Val genotypes Yellow blocks indicate the peaks for 




5.3.4 SNP allele and genotype frequencies 
Table 5.1 shows the allele and genotype frequencies for PPARA Leu162Val in the 466 
RISCK subjects. Genotype distributions did not deviate from Hardy-Weinberg
 
expectations. In comparison to MAFs listed on the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/snp build 132 accessed 01/09/11), the PPARA Val162 
allele was also more frequent in RISCK White subjects (0.042 in HapMap-CEU) and 
absent in Blacks, as in HapMap-YRI trios. There is no comparative data available for 
the S. Asian subjects.  
 
Table 5.1 PPARA Leu162Val allele and genotype frequency 
  Ethnic group
1
 
 S. Asian Black African        White European       Other All 
[n (%)] [n (%)]  [n (%)] [n (%)] [n (%)] 
  44 (9) 38 (8) 367 (79) 17(4) 466 (100) 
MAF 0.05 0.0 0.06 0.03 0.06 
Leu/Leu 39 (91) 37 (100) 310 (87) 16 (94) 402 (89%) 
Leu/Val 4 (9) 0 (0) 46 (13) 1 (6) 51 (11%) 
Val/Val 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Total  43 (9.5) 37 (8.2) 356 (78.6) 17 (3.7) 453 (100) 
All subjects for whom DNA samples were available were genotyped (n = 466); n (%) is 
number of each ethnic group genotyped, as % of total.  Total with genotype data (n = 
453); n (%) refers to number of each genotype obtained, with % genotype frequency. 
1
Self-reported ethnicity.  
 
PPARG Pro12Ala allele and genotype frequency data in RISCK subjects were shown 
previously (Section 4.3.2 and Table 4.3). In view of the small sample size of the S. 
Asian and other ancestries and absence of the PPARG Pro12Ala and PPARA Leu162Val 




5.3.5 Independent associations of genotypes with concentrations of plasma lipids, 
adiponectin, fasting glucose and insulin, measures of obesity, and insulin 
sensitivity at baseline 
 
Association between PPARG Pro12Ala genotypes and phenotypes can be found in 
Section 4.3.6 and Table 4.6. Table 5.2 shows plasma lipids, adiponectin, fasting 
glucose and insulin, measures of obesity and insulin sensitivity at baseline, stratified 
PPARA Leu162Val genotypes. Carriers of Val126-allele have significantly higher BMI 
after adjusting for age and gender. They also have higher body fat % and waist 
circumference; however the differences did not achieve significant levels. There were 
no significant associations of PPARA Leu162Val genotype with plasma lipid 
concentrations, fasting glucose and insulin, Si or HOMA2-IR.  
Table 5.2 Associations between PPARA Leu162Val genotypes and phenotypes at 
baseline in White subjects  
Phenotype PPARA  Leu162Val genotype   
  Leu/Leu Leu/Val  P 
Males n (%) 131(42%) 20(43%)  
Females n (%) 179(58%) 26 (57%)  
BMI
1
 28.6 (28.1,29.1) 30.0 (28.6,31.4) 0.05 
Waist circumference (cm)
1
 98.2 (96.8,99.6) 99.5 (95.8,103.1) 0.54 
Body fat %
1
 33.7 (32.7,34.7) 34.6 (32.0,37.1) 0.49 
Insulin sensitivity (IVGTT)((mU/L)-1 min-1)
2
  2.6 (2.4,2.9) 3.1 (2.2,3.8) 0.07 
Fasting insulin (pmol/L)
2
 59.2 (55.5,63.0) 57.7 (49.0,68.0) 0.19 
Fasting glucose (mmol/L) 5.7 (5.6,5.7) 5.9 (5.6,6.1) 0.29 
HOMA2-IR
2
 1.3 (1.2,1.3) 1.2 (1.1,1.4) 0.24 
Adiponectin (μg/mL) 2 10.2 (9.6,10.7) 10.0 (8.5,11.9) 0.98 
TC (mmol/L) 5.7 (5.6,5.8) 5.5 (5.2,5.8) 0.05 
TAG (mmol/L)
2
 1.4 (1.3,1.5) 1.3 (1.2,1.5) 0.20 
HDL-C(mmol/L)
2
 1.4 (1.3,1.4) 1.3 (1.3,1.4) 0.68 
Apo A1 (mg/dL) 1.2 (1.2,1.3) 1.3 (1.2,1.3) 0.42 
LDL-C (mmol/L) 3.6 (3.5,3.7) 3.5 (3.2,3.7) 0.09 
Proportion of sdLDL (%) 24.9 (23.0,26.9) 24.4 (19.3,29.5) 0.58 
Apol B (mg/dL) 1.0 (1.0,1.0) 1.0 (0.9,1.0) 0.43 
Values are mean (95% CI) or 
2
GM (95% CI) at baseline. P-values for ANCOVA on 
total sample are shown, adjusted for age, gender and BMI. 
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5.3.6 Effect of interaction between PPARG Pro12Ala and PPARA Leu162Val 
genotypes on concentrations of plasma lipids, adiponectin, fasting glucose 
and insulin, measures of obesity and insulin sensitivity at baseline in White 
subjects 
 
Subjects for whom PPARG Pro12Ala and PPARA Leu162Val genotype data was 
available (n = 310) were divided into four genotype groups defined by presence or 
absence of the variant alleles. Mean plasma lipids, adiponectin concentrations, fasting 
glucose and insulin, insulin sensitivity and obesity measures with respect to genotype 
combinations are shown in Table 5.3. There was a significant interaction between 
genotypes as determinants of TC and TAG after adjustment for BMI, gender and age. 
Co-carriers of PPARG Ala12 and PPARA Val162 alleles were associated with higher 




Table 5.3 Effect of interaction of PPARA Leu162Val and PPARG Pro12Ala on plasma lipid concentrations, obesity measures, fasting insulin 
and glucose, insulin sensitivity measures and in White subjects 
  PPARA Leu162Val / PPARG Pro12Ala  genotypes P 
Phenotype LL/PP                 
(n = 215) 
LL/PA+AA                     
(n = 56) 
LV /PP                                  
(n = 32) 
LV /PA+AA             










 28.7 (28.1,29.4) 27.8 (26.6,29.1) 30.0 (28.4,31.6) 28.0 (24.5,31.5) 0.12 0.17 0.21 
Waist circumference (cm)
1
 98.2 (96.6,99.9) 97.6 (94.3,100.9) 100.1 (95.7,104.5) 97.2 (88.0,106.4) 0.23 0.71 0.58 
Body fat %
1
 34.2 (33.1,35.4) 31.6 (29.4,33.9) 34.3 (31.2,37.3) 30.1 (23.1,37.0) 0.17 0.62 0.57 
Insulin sensitivity Si (IVGTT)((mU/L)-1 min-1)
2
  2.7 (2.5,2.9) 2.8 (2.4,3.3) 3.1 (2.5,3.8) 2.8 (1.8,4.3) 0.9 0.06 0.27 
HOMA2-IR
2
 1.3 (1.2,1.4) 1.2(1.0,1.3) 1.2(1.0,1.4) 1.5 (1.0,2.2) 0.33 0.95 0.43 
Adiponectin (μg/mL) 2 10.3 (9.6,11.0) 10.2(9.1,11.3) 10.6(8.5,13.2) 7.4 (4.4,12.6) 0.74 0.55 0.58 
Fasting insulin (pmol/L)
2
 4.1 (4.0,4.2) 4.0 (3.8,4.1) 3.9 (3.8,4.1) 4.4 (3.5,4.8) 0.63 0.17 0.13 
Fasting glucose (mmol/L) 5.6 (5.5,5.7) 5.8 (5.6,6.0) 5.9 (5.6,6.2) 5.7 (5.1,6.3) 0.24 0.42 0.36 
TC (mmol/L) 5.6 (5.5,5.8) 5.8 (5.6,6.1) 5.3 (4.9,5.6) 5.8 (5.1,6.5) 0.14 0.03 0.04 
TAG (mmol/L)
2
 1.4 (1.3,1.5) 1.4 (1.2,1.5) 1.2 (1.0,1.4) 1.8 (1.3,2.5) 0.67 0.07 0.03 
LDL-C(mmol/L) 3.6 (3.5,3.7) 3.7 (3.5,3.9) 3.3 (3.1,3.6) 3.7 (3.1,4.3) 0.13 0.08 0.12 
Proportion of sdLDL (%) 24.6 (22.2,27.0) 25.6 (20.9,30.3) 23.9 (17.7,30.1) 34.4 (21.2,47.6) 0.74 0.78 0.7 
Apo B (g/L) 0.97 (0.93,1.01) 1.02 (0.94,1.09) 0.87 (0.77,0.98) 1.08 (0.86,1.30) 0.18 0.14 0.15 
HDL-C (mmol/L)
2
 1.4 (1.3,1.4) 1.4 (1.3,1.4) 1.3 (1.2,1.4) 1.2 (1.1,1.5) 0.83 0.71 0.95 
Apo A1 (g/L) 1.2 (1.2,1.3) 1.2 (1.2,1.3) 1.2 (1.1,1.3) 1.3 (1.2,1.5) 0.74 0.46 0.54 
Values are mean (95% CI) or 
2
GM (95% CI) at baseline. All data and P-values for ANCOVA adjusted for age, gender and BMI, based on subjects for whom 
PPARG Pro12Ala and PPARA Leu162Val genotype data was available (n = 310). PP represents subjects homozygous for the PPARG Pro12 allele and PA + AA 
carriers of the Ala12 allele. LL represents subjects homozygous for the PPARA Leu162 allele and LV carriers of the Val162 allele.
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5.3.7 Change in concentrations of measured variables after dietary intervention 
Details on changes on plasma lipids and insulin sensitivity after dietary intervention can 
be found in Section 3.3.7.  
 
 
5.3.8 Effect of interaction between genotypes on concentrations of plasma lipids 
after dietary intervention 
 
Independent associations of PPARG Pro12Ala or PPARA Leu162Val genotypes with 
changes in concentrations of plasma lipids, adiponectin, fasting glucose and insulin, 
measures of obesity and insulin sensitivity measures with respect to baseline were not 
significant after randomisation to HM, LF or HS diets (Appendix 5.1, 5.2, 5.3 and 5.4).  
 
Investigation of genotype interaction was based on subjects genotyped for both SNPs, 
with measured variables after HM (n =127) and LF (n =135) diets. There was a 
significant interaction between PPARG Pro12Ala and PPARA Leu162Val genotypes as 
determinants of plasma LDL-C, (P = 0.004) and sdLDL as a proportion of LDL (P = 
0.012), after adjustment for change in BMI, age and gender. Co-carriers of the PPARG 
Ala12 and PPARA Val162 alleles had 47.2% lower LDL and 62.6% lower sdLDL as a 
proportion of LDL after the HM diet, compared to the LF diet. We did not test for an 
interaction after the parallel SFA diet, as there were no subjects carrying both PPARG 
Ala12 and PPARA Val162 alleles in this group. Figure 5.2 shows the follow-up 
concentration of plasma LDL-C and sdLDL as a proportion of LDL-C after the HM and 
LF diets, adjusted for baseline concentrations, with respect to PPARG Pro12Ala and 
PPARA Leu162Val genotype combinations. We then analysed the data by excluding 
homozygous Ala/Ala subjects (n = 3), to ensure they did not skew the results when 
added to the heterozygote group. The interaction between diet and PPARG Pro12Ala 
and PPARA Leu162Val genotypes remained significant for LDL-C and sdLDL (P = 




Figure 5.3 Interaction between PPARG Pro12Ala and PPARA Leu162Val genotype 
groups after dietary treatments influences plasma LDL-C concentration and sdLDL 
as proportion of LDL. Interaction between PPARG Pro12Ala and PPARA 
Leu162Val genotypes was a significant determinant of plasma concentrations of (A) 
LDL-C (P = 0.004) and (B) sdLDL as proportion of LDL (P = 0.012) after HM and 
LF diets, after adjustment for baseline values, change in BMI, age and gender using 
3-way ANOVA. PP represents subjects homozygous for the PPARG Pro12 allele 
and PA + AA carriers of the Ala12 allele. LL represents subjects homozygous for 
the PPARA Leu162 allele and LV + VV carriers of the Val162 allele. Mean follow-
up concentrations of LDL-C (mmol/L) and sdLDL (%) adjusted for baseline values 
after 24 weeks on HM or LF diets are shown. Bars indicate 95% CI. The figure is 
based on subjects with genotypes for both SNPs and measurements of plasma lipids 
after HM and LF diets.  In HM diet, LL/PP n = 91, LL/LP+AA n =17, LV /PP n =16 
and LV /PA+AA n =3. In LF diet LL/PP n = 89, LL/LP+AA n = 33, LV /PP n = 9 





Studies have reported that simultaneous activation of PPARα and PPARγ might alter 
the fatty acid distribution in liver, adipose tissues and skeletal muscle (Fiévet et al, 
2006). PPARα activation will increase hepatic oxidation of fatty acids, reduce synthesis 
and secretion of TAG, decrease VLDL secretion, and lower VLDL delivery to 
peripheral tissues (Fiévet et al, 2006). Here we have shown independent and interactive 
effects of PPARγ2 gene PPARG Pro12Ala and PPARα gene PPARA Leu162Val 
genotypes in determination of plasma lipid concentrations, after diets lowering intake of 
SFA by replacement with MUFA or carbohydrate. 
 
 
5.4.1 Independent associations of PPARA Leu162Val and PPARG ProAla12 
genotypes with concentrations of plasma lipids, fasting glucose and insulin, 
measures of obesity and insulin sensitivity measures at baseline 
 
After the 4 week HS diet, the PPARA Leu162Val genotype was not associated with 
adiponectin concentrations, insulin sensitivity or concentrations of plasma lipids at 
baseline. Others have reported similarly (Silbernagel et al, 2009; Doney et al, 2005), but 
associations of Val162 with higher (Sparsø et al, 2007) and lower (Nielsen et al, 2003) 
levels of plasma TAG have also been found. Others have also reported associations of 
Val162 with higher levels of Apo B and LDL-C (Vohl et al 2000; Tai et al, 2002) and 
HDL-C (Flavell et al, 2000). Some reports found a significant association of the Val162 
with lower BMI (Evans et al, 2001). In our study Val162-allele carriers had 
significantly higher BMI compared to non-carriers. Animal studies showed that 
treatment with fibrate decreased body weight gain (Chaput et al, 2000). For PPARG 
Pro12Ala association at baseline refer to Section 4.4.2.  
 
 
5.4.2 Interaction between genotypes on concentrations of plasma lipids, 
adiponectin, fasting glucose and insulin, measures of obesity and insulin 
sensitivity measures measurements at baseline 
 
Co-carriers of PPARG Ala12 and PPARA Val162 alleles were associated with higher 
concentrations of plasma TC and TAG compared to other genotype group at baseline. 
One other investigation found no significant interaction between PPARA Leu162Val 
and PPARG Pro12Ala in determination of plasma lipid concentrations in obese subjects 
(Aberle et al, 2006). A shift from a mean ~13% of energy SFA in the habitual intake 
(Moore et al, 2009) to ~18% of energy SFA on the HS diet would be expected to 
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increase plasma cholesterol and TAG. As SFAs bind to PPARγ and PPARα with less 
affinity than PUFAs (Xu et al, 1999), increasing SFA would reduce activation of the 
receptors. In vitro studies have shown that compared to the wild types, PPARγ-Ala12 
form has lower binding affinity for PPREs (Deeb et al, 1998) and the PPARα-Val162 
form has  lower transcriptional activation in transfectants activated with ω-fatty acids 




5.4.3 Effect of interaction between genotypes on concentrations of plasma lipids, 
insulin sensitivity measures and obesity measures after dietary intervention 
 
In mice, an increase in PPARγ mRNA in adipose tissue (Vidal-Puig et al, 1996), and 
increased hepatic PPARα mRNA and expression of PPARα target genes (Patsouris et al, 
2006) after a high-fat diet, suggests that intake might influence expression of genes 
induced by both receptors in humans. Neither PPARG Pro12Ala nor PPARA Leu162Val 
genotypes were independently associated with changes in concentrations of plasma 
lipids, adiponectin concentration, obesity measures or insulin sensitivity measures after 
intervention. However, after randomisation, the power to detect significant changes was 
reduced. Various dietary interactions with Pro12Ala have been reported (Memisoglu et 
al, 2003; Luan et al, 2001); both findings are compatible with unsaturated fatty acids 
acting as specific ligands for PPARγ (Xu et al, 1999) and lower transcriptional activity 
of the PPARγ-Ala variant (Deeb et al, 1998) reducing adipogenesis. Reports of PPARA 
Leu162Val interaction with fatty acid intake in determination of plasma lipids are 
inconsistent, including no interaction with dietary fat (Robitialle et al, 2004), Val162 
allele association with higher TC, LDL-C and Apo A1 after a high-PUFA diet (Paradis 
et al, 2005) and lower TAG and apoCII after high PUFA intake (Tai et al, 2005). 
Robitialle et al. (2004) reported a significant diet- gene interaction; with an increase in 
waist circumference in Leu162 homozygotes following high intake of dietary fat, no 
significant interaction was found in determining plasma lipids.   
 
Our study is the first to report significant interaction between PPARG Pro12Ala and 
PPARA Leu162Val genotypes as a determinant of plasma concentrations of LDL-C 
concentration and proportion as sdLDL. After the HM diet there was a significantly 
larger reduction in plasma LDL-C concentration and proportion as sdLDL concentration 




Fibrates and TZDs are agonists of PPARα and PPARγ respectively (Lefebvre et al, 
2006; Belfort et al, 2006). In rats, insulin-induced gene INSIG1, the key regulator of 
SREBP activity, is up-regulated by activation of PPARγ in adipose tissue by 
rosiglitazone (Kast-Woelbern et al, 2004) and by activation of PPARα in liver by 
clofibrate (König et al, 2007). PPARγ activation by troglitazone has been shown to 
reduce nuclear SREBP-2 (Klopotek et al, 2006). mRNA concentration of the SREBP-2 
target LDL receptor gene LDLR (Hua et al, 1993) is reduced after treatment with 
clofibrate (König et al, 2007). PPARγ activation by troglitazone has also been shown to 
down-regulate LDL clearance from plasma by the liver LDL receptor (Klopotek et al, 
2006). If the same events were to be evoked by endogenous MUFA ligands in humans, 
activities of PPARγ and PPARα would tend to increase circulating LDL-C 
concentration. 
 
Compared to wild-types, the PPARγ-Ala12 form has lower binding affinity for PPREs 
(Deeb et al, 1998) and the PPARα-Val162 form has lower transcriptional activation in 
transfectants activated with ω-fatty acids (Rudkowska et al, 2009). If both variants 
bound to the INSIG1 PPRE with lower affinity, co-carriers of PPARG Ala12 and 
PPARA Val162 would express less Insig-1, SREBP-2 activity would be higher, and 
upregulation of the LDLR gene would lead to the maximum increase in LDL-C 
clearance from the plasma. There were no significant differences in concentrations 
between the other genotype combinations.  
 
PPARG Ala12 carriers in the general Japanese population had a significantly higher 
proportion of sdLDL fractions 4-7, independent of lipid concentration (Hamada et al, 
2007). We, however, found no independent association of Ala12 with sdLDL 
proportion, and the interaction with PPARA Val162 after the HM diet was associated 
with a reduction rather than an increase in sdLDL particles. Several studies have 
investigated the effects of different nutritional interventions on LDL particle size. 
Krauss & Dreon. (1995) investigated healthy men consuming high (46%) fat and low 
(24%) fat diets for 6 weeks in random order. After the high fat diet, 83% of subjects had 
predominantly large, buoyant LDL (>255 Å, the cut-off for sdLDL (Lamarche et al, 
1999)), (pattern A), whereas the remainder had primarily smaller, denser LDL (pattern 
B). After the low fat diet, 41% with pattern A changed to B, i.e. the low fat diet 
increased the proportion of LDL as smaller, denser particles in some but not all 
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subjects, a variability that may reflect a genetic basis. In other studies, switching from a 
baseline diet rich in saturated fat to diets rich in MUFA, PUFA or a combination also 
reduced LDL particle size (Kratz et al, 2002). However, we found no significant change 
in the proportion of LDL-C as sdLDL after the switch from HS to HM or LF diets. 
 
Bouchard-Mercier et al. (2011) found no significant change in LDL peak particle 
diameter (LDL-PPD) in PPARG Pro12 homozygotes or Ala12-allele carriers after high 
SFA intake, but a significant increase in LDL-PPD in Ala12-allele carriers after high 
intake of PUFA, which unlike SFA are PPARγ activators (Xu et al, 1999). We, 
however, found no independent association of Ala12 with sdLDL proportion either at 
baseline after run-in on HS diet, or after 24 weeks on HM or LF diets. Bouchard-
Mercier et al. (2011) demonstrated dietary interaction with PPARA Leu162Val as a 
determinant of LDL-PPD. In agreement with reports of reduced LDL particle size on 
switching from SFA-rich to MUFA-rich diets (Kratz et al, 2002) they found in Leu162 
homozygotes that LDL-PPD was larger after high SFA intakes than low. However, 
contrary to the overall trend, among Val162 carriers, subjects with higher SFA intakes 
had smaller LDL-PPD i.e. a higher proportion of sdLDL, than those with lower intakes. 
Fibrate ligands of PPARα can reduce production of VLDL (Shah et al, 2010) and lower 
sdLDL (Caslake et al, 1993), so in carriers of the less-active PPARα-Val form, 
activation by dietary ligands could result in a shift to a higher proportion of sdLDL. We 
found no significant reduction in the proportion of sdLDL in Val162 carriers compared 
to Leu162 homozygotes after dietary intervention, but a significant reduction in the 
proportion of sdLDL in carriers of both PPARA Val162 and PPARG Ala12 alleles after 
the HM diet. This cannot be explained by reduced activity of both variants, because as 
indicated above, this would be expected to lead to a higher proportion of sdLDL. 
 
Only one other study has examined PPARG Pro12Ala and PPARA Leu162Val 
interaction after dietary intervention. After 2.5 years of low energy diet, in non-diabetic 
obese women there were significant favourable changes in lipid profile, but no 
significant interactive effects on anthropometric or biochemical characteristics at 





5.5 Limitation and conclusion 
Limitations include reduced power after randomisation to dietary treatments, compared 
to that at baseline, with small numbers carrying both variants (n =7). However, our 
ANOVA model used the variability of the whole dataset to measure the background 
variation and produced evidence of a significant effect of gene-gene interaction on 
LDL-C and proportion as sdLDL. The significance should nevertheless be treated with 
caution and confirmation awaits replication in a larger sample. Replication in another 
study with maximal correspondence in ethnic origin, age, and gender would be required 









Chapter 6  
 
The Effect of PPARG Pro12Ala and PPARA Leu162Val and 




6.1 Introduction  
Fish oil contains long-chain PUFA (LCP) which may act as physiological ligands for 
PPARγ and PPARα, suggesting roles in transducing nutritional into metabolic signals 
(Semple et al, 2006). Plasma TAG concentrations are lowered by increased intakes of n-
3 LCP in a dose-dependent manner in the MARINA study (Sanders et al, 2011). Both 
EPA and DHA are known ligands for PPARα and PPARγ (Deckelbaum et al, 2006). 
Binding of n-3 fatty acids to PPARα and PPARγ induces β-oxidation and adipogenesis 
(Deckelbaum et al, 2006, Yu et al, 2011).  In vitro studies have shown that both PPARγ-
Ala12 and PPARα-Val162 variants are associated with reduced transactivational ability 
of the receptors (Deeb et al, 1998; Rudkowska et al, 2009). 
 
The present study investigated the independent interaction of PPARG Pro12Ala and 
PPARA Leu162Val genotypes and dietary intake of n-3 PUFAs as determinants of 
plasma lipids in healthy participants of the MARINA study. It was hypothesised that 
PPARG Pro12Ala and PPARA Leu162Val genotypes interact with dietary intake of (n-
3) LCPs EPA and DHA from fish, to influence concentrations of plasma lipids. We 
investigated the independent association between PPARG Pro12Ala and PPARA 
Leu162Val genotypes and mean quantitative phenotypes, including plasma lipids and 
BMI after a 4 week run-in on normal diet with placebo supplement, and after 12 months 




6.2 Subjects and Methods 
6.2.1 Subjects  
This investigation was based on participation in the MARINA study (Section 2.1.2). 
 
 
6.2.2 Study design 
Description of MARINA study design is given in Section 2.1.2. 
 
 
6.2.3 Blood analytic methods:  
Methods of blood lipid analysis are given in Sections 2.3.1.2. 
 
 
6.2.4 DNA extraction and SNP genotyping 
Details on methods for DNA extraction from buffy coats are given in Section 2.3.4. 
Genotyping by Pyrosequencing was performed on the 310 participants for whom DNA 
was available and who had consented to genetic analysis. Primers and PCR PPARA 
Leu162Val (rs1800206) genotyping are given in Section 2.3.7. Genotyping success rate 
was 93.8%. The PPARG Pro12Ala SNP (rs1801282) was genotyped by KBiosciences 
(Hoddesdon, UK) using the KASPar system. Genotype accuracy as assessed by 
inclusion of duplicates in the array was 98%, and negative controls (water blanks) were 
included on each plate. Genotyping success rate was 89%. 
 
 
6.2.5 Statistical analyses 
All genotype distributions were tested for deviation from the Hardy-Weinberg 
equilibrium by a χ2 test with 1 df (P > 0.05). Statistical analyses were carried out using 
the SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). TAG data were log 
transformed to obtain better approximations of the normal distribution prior to analysis.  
Data were analysed using ANCOVA, adjusting for baseline values as well as for age, 
gender and BMI. All data presented in the text and tables are expressed as means or GM 




6.3 Results  
6.3.1 Baseline characteristics of subjects 
Out of 367 participants randomized to treatment, data was available for analysis on 312. 
The characteristics of all subjects who completed the study at baseline after a run-in on 
placebo supplement are shown in Appendix 6.1. The number of participants allocated 
to each of the four treatment groups did not significantly differ, nor did drop-out rates 
(Sanders et al, 2011). There were more women than men and most of the women were 
postmenopausal. About one-fifth of the study population was non-White with similar 
proportions of Asian and Black participants. The average BMI (25.6 kg/m
2
) was above 
the desirable range (20-25 kg/m
2
) and the mean waist circumference was greater than 
the cut-offs used to indicate risk of metabolic syndrome (94 cm in men and 80 cm in 
women) (Sanders et al, 2011). Table 6.1 shows the characteristics of all subjects for 
whom DNA was available (n = 310) at baseline after a run-in on placebo supplement. 
There was no significant difference in all measured variables between the four treatment 
groups.  
 
Table 6.1 Characteristics of all subjects at baseline by randomized treatment (n = 310) 
  Placebo 0.45 g/day 0.9 g/day 1.8 g/day 
  n = 70 n = 80 n = 80 n = 80 
Male 30 (42.8%) 30 (37.5%) 30 (37.5%) 29 (36.3%) 
Female 40 (57.2%) 50 (62.5%) 50 (62.5%) 51 (63.7%) 
Age (y) 55.4 (53.7,57.0) 55.1 (53.6,56.6) 55.2 (53.7,56.6) 55.1 (53.6,56.6) 
BMI (kg/m
2
) 26.1 (25.2,27.0) 25.2 (24.3,26.0) 26.2 (25.3,27.1) 25.1 (24.4,25.9) 
TC:HDL-C
1
 3.6 (3.4,3.8) 3.6 (3.4,3.8) 3.4 (3.2,3.6) 3.4 (3.2,3.7) 
TC (mmol/L) 5.4 (5.2,5.7) 5.4 (5.1,5.6) 5.4 (5.2,5.6) 5.4 (5.2,5.6) 
TAG(mmol/L)
2
 1.14 (1.03,1.28) 1.14 (1.03,1.27) 1.13 (1.04,1.23) 1.12 (1.00,1.24) 
HDL-C(mmol/L) 1.6 (1.5,1.7) 1.6 (1.5,1.6) 1.7 (1.5,1.8) 1.7 (1.6,1.8) 
LDL-C(mmol/L) 3.3 (3.1,3.5) 3.2 (3.0,3.4) 3.2 (3.0,3.4) 3.2 (3.0,3.3) 
Measurements made at baseline after a 4-week run-in on normal diet with placebo supplement  
and with (n-3) LCPs at the daily doses shown. Values are n (%) or mean or 
2
GM (95% CI) and 
 do not differ by treatment allocation.
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6.3.2 SNP minor allele and genotype frequencies 
Table 6.2 shows the allele and genotype frequencies for PPARG Pro12Ala and PPARA 
Leu162Val in all subjects who completed the study, and for whom DNA was available 
(n = 310). Genotype distributions did not deviate from Hardy-Weinberg expectations. 
Minor allele frequencies in MARINA subjects were in close agreement with those listed 
for Europeans on the NCBI SNP database (Internet: http://www.ncbi.nlm.nih.gov/snp; 
build 132  accessed 15/04/11): HapMap-CEU: PPARG Ala12 0.13 and PPARA Val162 
0.05. 
 
Table 6.2  PPARG Pro12Ala and PPARA Leu162Val allele and genotype frequencies. 





the number of each ethnic group genotyped, as % of total of number of each genotype 
obtained, with % genotype frequency.  
 
In view of the absence of the PPARA Leu162Val in Blacks and Asians and PPARG 
Pro12Ala in Blacks we chose to focus our genetic investigation on the White subjects 
only. We also presented the data for all subjects. 
  Ethnic group
1
 
 Far East 
 [n (%)]
2 
 S. Asian 
 [n (%)] 
Black African  
[n (%)] 
White  European  
[n (%)] 
Other 
 [n (%)] 
All 
 [n (%)] 
9 (3) 18 (6) 16(5) 254(82) 13(4) 310(100) 
PPARG Pro12Ala             
MAF
 
0.0556 0.25 0 0.1127 0.125 0.1141 
Pro/Pro 8 (89) 9 (56) 13 (100) 167 (78) 9 (75) 206 (78) 
Pro/Ala 1 (11) 6 (38) 0 (0) 44 (21) 3 (25) 54 (21) 
Ala/Ala 0 (0) 1 (6) 0 (0) 2 (1) 0 (0) 3 (1) 
Total  9 (100) 16 (100) 13 (100) 213 (100) 12 (100) 263 (100) 
PPARA Leu162Val        
MAF 0 0 0 0.05 0 0.411 
Leu/Leu 8 (100) 17 (100) 15 (100) 217 (90) 12 (100) 269 (92) 
Leu/Val 0 (0) 0 (0) 0 (0) 22 (9) 0 (0) 22 (7) 
Val/Val 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 1 (1) 
Total 8 (100) 17 (100) 15 (100) 240 (100) 12 (100) 292 (100) 
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6.3.3 Change in measured variables after dietary intervention 
Erythrocyte fatty acid composition was determined to measure compliance to the 
dietary intervention. Capsule counts indicated 88.5% of the participants consumed more 
than 90% of the capsules provided. There were no statistically significant differences in 
the reported capsule intakes between treatment groups. The proportions of EPA and 
DHA in erythrocyte lipids increased in a dose-dependent manner, compared with 
placebo (P < 0.001 for trends), indicating long-term compliance to the intervention 
(Sanders et al, 2011). 
 
No significant changes in the concentration of plasma TC or HDL-C were observed. 
However, plasma TAG concentrations were reduced by n-3 LCP consumption, 
compared to the placebo. The reduction in plasma TAG concentrations in all subjects 
and in males did not reach significance levels (Sanders et al, 2011). Among the female 
participants, there was a clear dose-response relationship (n = 192; P = 0.002 for trend) 
(Sanders et al, 2011). Plasma TAG concentrations were significantly lower following 
the highest dose (1.8 g/d) compared with the placebo and lower doses. The 
proportionate changes in females were -5.3% (95% CI -17.8, 7.3), -10.1% (95% CI-
22.8, 2.5) and -24.0 % (95% CI -31.6, -11.3) for 0.45 g/d, 0.9 g/d and 1.8g/d (n-3) LCP 
respectively (Sanders et al, 2011). 
 
 
6.3.4 Independent associations of genotypes with concentrations of plasma lipids 
and BMI at baseline 
 
Table 6.3 and table 6.4 show plasma lipid measurements and BMI at baseline stratified 
by PPARG Pro12Ala and PPARA Leu162Val genotypes in all subjects and in White 
subjects only. After a 4-week run-in on normal diet with placebo supplement, there 
were no significant associations of PPARG Pro12Ala or PPARA Leu162Val genotypes 
with BMI or plasma lipid concentrations. These findings are in line with the RISCK 
findings, where no significant differences were found with lipid profile. 
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Table 6. 3 Associations between PPARG Pro12Ala and PPARA Leu162Val genotypes and phenotypes at baseline in all subjects 
Phenotype PPARG Pro12Ala   PPARA Leu162Val   
  Pro/Pro Pro/Ala +Ala/Ala P Leu/leu Leu/Val + Val/Val P 
Males n 75 28  107 8  





 25.5 (25.0,26.0) 26.5 (25.6,27.5) 0.11 25.7 (25.2,26.2) 25.6 (23.9,27.4) 0.99 
TC (mmol/L) 5.4 (5.2,5.5) 5.6 (5.3,5.9) 0.10 5.4 (5.3,5.5) 5.5 (5.1,5.9) 0.6 
TAG (mmol/L) 1.1 (1.1,1.2) 1.2 (1.1,1.4) 0.43 1.1 (1.1,1.2) 1.1 (0.9,1.4) 0.75 
HDL-C(mmol/L) 1.6 (1.6,1.7) 1.6 (1.5,1.7) 0.40 1.6 (1.6,1.7) 1.7 (1.5,1.9) 0.69 
LDL-C (mmol/L) 3.2 (3.1,3.3) 3.4 (3.2,3.6) 0.18 3.2 (3.1,3.3) 3.3 (3.0,3.6) 0.69 
TC:HDL 3.5 (3.4,3.6) 3.7 (3.5,3.9) 0.85 3.5 (3.4,3.6) 3.5 (3.1,3.8) 0.81 
                            Values are mean (95% CI) 
2
GM (95% CI) at baseline. P-values for ANCOVA on total sample are shown, adjusted  
                             for ethnicity, age, gender and BMI. 
1
P-values adjusted for gender, ethnicity and age. 
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Table 6. 4 Associations between PPARG Pro12Ala and PPARA Leu162Val genotypes and phenotypes at baseline in White subjects 
Phenotype PPARG Pro12Ala   PPARA Leu162Val   
  Pro/Pro Pro/Ala +Ala/Ala P Leu/leu Leu/Val + Val/Val P 
Males n 61 22  88 8  





 25.5 (24.9,26.1) 26.5 (25.4,27.5) 0.14 25.6 (25.1,26.1) 25.7 (23.9,27.4) 0.97 
TC (mmol/L) 5.4 (5.3,5.6) 5.5 (5.2,5.8) 0.49 5.4 (5.3,5.5) 5.5 (5.1,6.0) 0.92 
TAG (mmol/L)
2
 1.2 (1.1,1.2) 1.2 (1.0,1.4) 0.71 1.2 (1.1,1.2) 1.1 (0.9,1.4) 0.74 
HDL- C (mmol/L) 1.7 (1.6,1.7) 1.6 (1.4,1.7) 0.76 1.6 (1.6,1.7) 1.7 (1.5,1.8) 0.78 
LDL-C(mmol/L) 3.2 (3.1,3.3) 3.4 (3.1,3.6) 0.37 3.2 (3.1,3.3) 3.3 (2.9,3.7) 0.66 
TC:HDL 3.5 (3.3,3.6) 3.7 (3.5,4.0) 0.43 3.5 (3.4,3.6) 3.5 (3.1,3.8) 0.92 
                             Values are mean (95% CI) 
2
GM (95% CI) at baseline. P-values for ANCOVA on total sample are shown,  
                              adjusted for age, gender and BMI. 
1





6.3.5 Associations of PPARG Pro12Ala and PPARA Leu162Val genotypes with 
changes in plasma lipid concentrations after dietary intervention in White 
subjects 
 
Plasma lipid concentrations were measured in the four treatment groups (placebo and 
three n-3 LCP doses) at baseline and at 6 and 12 months after treatment. The average of 
the measurements at 6 and 12 months was then subtracted from those made at baseline 
to determine the average change. The treatment effect was then determined with respect 
to the average measurement obtained after the placebo, i.e. the difference between the 
average measure after each dose and the average after the placebo.  Interaction between 
treatment and PPARG Pro12Ala was not significant in determining any of the blood 
lipid variables, including TC, HDL-C or LDL-C (P>0.05) after adjustment for all and 
White subjects as shown in Appendices 6.2 and 6.3. No significant interaction between 
treatment and PPARA Leu162Val determined any of the blood lipid variables including 
TC, TAG, HDL-C or LDL-C (P>0.05) after adjustment for all and White subjects as 
shown in Appendices 6.4 and 6.5. 
 
Interaction between PPARA Leu162Val and treatment was a significant determinant of 
plasma TAG concentrations (P = 0.04) after adjusting for age, BMI and gender for 
White subjects and (P = 0.043) for all subjects after adjusting for age, BMI, gender and 
ethnicity. As shown in Tables 6.5 and 6.6, treatment lowered plasma TAG 
concentration significantly in Leu162 homozygotes, (P =0.001) but not in Val162-allele 
carriers (P =0.27). Increasing the dose of n-3 LCP (0.45 g/d to 1.8 g/d) and increasing 
the period of treatment (6 months to 12 months) caused a progressive decrease in 
plasma TAG concentrations. The same effect was seen in White subjects. No significant 
interaction between PPARG Pro12Ala and treatment was found in determining plasma 
TAG concentrations as shown in Tables 6.7 and 6.8. We then analysed the data by 
excluding homozygous Ala/Ala subjects (n = 2) and homozygous Val/Val subjects (n = 
1), to ensure they did not skew the results when added to the heterozygote group. The 
interaction between treatment and PPARA Leu162Val genotypes remained significant 
for TAG in all and White subjects only (P = 0.041 and 0.046 respectively), while the 






We were also interested to replicate the findings of the interaction between PPARG 
Pro12Ala and PPARA Leu162Val in the RISCK study. However, in the MARINA study 
only one subject proved to be the carrier of the minor variants of both SNPs, thus 
preventing us from looking at their interaction.  
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Table 6.5 Plasma TAG concentrations stratified by PPARA Leu162Val genotype after n-3 LCP treatment in all subjects 
PPARA Leu162Val TAG (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day P 
Leu162 homozygotes   n = 61 n = 73 n = 66 n = 69  
 Baseline 1.13 (1.00,1.27) 1.12 (1.00,1.24) 1.14 (1.04,1.25) 1.15 (1.03,1.28)  
 6 months 1.19 (1.08,1.31) 1.10 (0.97,1.24) 1.08 (0.98,1.20) 0.95 (0.86,1.06)  
 12 months 1.20 (1.08,1.34) 1.14 (1.04,1.25) 1.15 (1.05,1.25) 0.97 (0.87,1.08)  
 Average 1.21 (1.10,1.33) 1.14 (1.04,1.25) 1.12 (1.03,1.23) 0.97 (0.88,1.07)  
 Change 0.07 (-0.05,0.10) 0.02 (-0.10,0.07) -0.02 (-0.23,-0.07) -0.15 (-0.06,0.02)  
  Treatment effect 0.000 [Reference] -0.054 (-0.184,0.077) -0.071 (-0.205,0.063) -0.217 (-0.350,-0.084)
 *
 <0.001 
Val162 carriers   n = 6 n = 4 n = 7 n = 6  
 Baseline 1.31 (1.00,1.73) 1.43 (0.68,3.01) 1.28 (0.80,2.06) 0.74 (0.41,1.32)  
 6 months 0.98 (0.61,1.57) 1.58 (0.52,4.79) 1.39 (0.88,2.20) 0.84 (0.52,1.36)  
 12 months 1.18 (0.89,1.57) 1.58 (0.67,3.71) 1.44 (0.89,2.34) 0.70 (0.56,0.88)  
 Average 1.13 (0.85,1.49) 1.59 (0.60,4.23) 1.44 (0.95,2.21) 0.78 (0.55,1.11)  
 Change -0.15 (-0.43,0.13) 0.11 (-0.18,0.39) 0.12 (-0.02,0.26) 0.06 (-0.22,0.33)  





Table 6.6 Plasma TAG concentrations stratified by PPARA Leu162Val genotype after n-3 LCP treatment in White subjects 
PPARA Leu162Val TAG (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day P 
Leu162 homozygotes  n = 49 n = 57 n = 52 n = 59  
 Baseline 1.17 (1.02,1.35) 1.09 (0.97,1.23) 1.19 (1.07,1.32) 1.18 (1.05,1.33)  
 6 months 1.21 (1.09,1.35) 1.12 (0.97,1.29) 1.09 (0.97,1.23) 0.96 (0.86,1.08)  
 12 months 1.21 (1.07,1.37) 1.17 (1.06,1.30) 1.17 (1.06,1.30) 0.99 (0.88,1.12)  
 Average 1.23 (1.10,1.36) 1.17 (1.06,1.30) 1.14 (1.03,1.26) 0.98 (0.88,1.10)  
 Change 0.05 (-0.06,0.15) 0.07 (-0.01,0.15) -0.04 (-0.14,0.06) -0.17 (-0.25,-0.08)  
  Treatment effect 0.000 [Reference] 0.023 (-0.11,0.15) -0.085 (-0.22,0.05) -0.212 (-0.34,-0.08)
*
 0.001 
Val162 carriers   n = 6 n = 4 n = 7 n = 6  
 Baseline 1.31 (1.00,1.73) 1.43 (0.68,3.01) 1.28 (0.80,2.06) 0.74 (0.41,1.32)  
 6 months 0.98 (0.61,1.57) 1.58 (0.52,4.79) 1.39 (0.88,2.20) 0.84 (0.52,1.36)  
 12 months 1.18 (0.89,1.57) 1.58 (0.67,3.71) 1.44 (0.89,2.34) 0.70 (0.56,0.88)  
 Average 1.13 (0.85,1.49) 1.59 (0.60,4.23) 1.44 (0.95,2.21) 0.78 (0.55,1.11)  
 Change -0.15 (-0.43,0.13) 0.11 (-0.18,0.39) 0.12 (-0.02,0.26) 0.06 (-0.22,0.33)  
  Treatment effect 0.000 [Reference] 0.260 (-0.04,0.56) 0.273 (0.01,0.53) 0.208 (-0.06,0.48) 0.27 
 For tables 6.5 and 6.6 Log plasma TAG concentrations (95% CI) (mmol/L) are shown. Data is presented for PPARA Leu162 homozygous and 
PPARA Val162-allele carrier in all and White subjects, for whom DNA samples and plasma TAG measurements were available. All variables 
were measured at baseline after a 4-week run-in on normal diet with a placebo supplement and after 6 and 12 months, during which normal diet 
was supplemented with n-3 LCP at the daily doses shown. The average of the measurements at 6 and 12 months was subtracted from those made 
at baseline to determine the average change. Treatment effects were determined by univariate ANCOVA. P-values derived from the GM values 
are presented. P-values are adjusted for BMI, age, ethnicity and gender for all subjects and P-values are adjusted for BMI, age and gender for 
White subjects  (nominally significant at P < 0.05).* significant difference between the highest dose of n-3 PUFA and placebo. Treatment x 
PPARA Leu162Val P=0.043 for all subjects and P=0.04 for White subjects. 
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Table 6.7 Plasma TAG concentrations stratified by PPARG Pro12Ala genotype after n-3 LCP treatment in all subjects 
PPARG Pro12Ala TAG (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day P 
Pro12 homozygotes    n = 46 n = 49 n = 54 n = 57  
 Baseline 1.11 (0.98,1.26) 1.16 (1.01,1.33) 1.12 (1.01,1.24) 1.13 (0.99,1.29)  
 6 months 1.19 (1.05,1.34) 1.10 (0.94,1.29) 1.05 (0.94,1.18) 0.95 (0.84,1.07)  
 12 months 1.17 (1.03,1.32) 1.16 (1.03,1.30) 1.17 (1.05,1.31) 0.96 (0.85,1.08)  
 Average 1.19 (1.06,1.33) 1.16 (1.03,1.30) 1.12 (1.01,1.25) 0.96 (0.86,1.07)  
 Change 0.07 (-0.09,0.08) 0.00 (-0.10,0.10) 0.00 (-0.24,-0.05) -0.15 (-0.07,0.02)  
  Treatment effect 0.000 [Reference] -0.028 (-0.191,0.134) -0.058 (-0.217,0.100) -0.214 (-0.372,-0.057) 0.025 
Ala12 carriers    n =13 n = 19 n = 9 n =16  
 Baseline 1.52 (1.14,2.02) 1.22 (0.94,1.57) 1.10 (0.87,1.38) 1.07 (0.83,1.38)  
 6 months 1.26 (1.02,1.55) 1.27 (0.98,1.63) 1.31 (1.00,1.73) 0.96 (0.76,1.22)  
 12 months 1.36 (1.12,1.65) 1.23 (0.98,1.53) 1.14 (0.80,1.63) 0.92 (0.71,1.20)  
 Average 1.32 (1.10,1.58) 1.26 (1.01,1.57) 1.23 (0.92,1.63) 0.96 (0.76,1.21)  
 Change -0.14 (-0.14,0.20) 0.03 (-0.16,0.38) 0.11 (-0.25,0.03) -0.11 (-0.12,0.06)  




Table 6. 8 Plasma TAG concentrations stratified by PPARG Pro12Ala genotype after n-3 LCP treatment in White subjects 
PPARG Pro12Ala TAG (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day P 
Pro12 homozygotes    n = 38 n = 39 n = 43 n = 47  
 Baseline 1.17 (1.01,1.34) 1.18 (1.01,1.37) 1.17 (1.03,1.32) 1.15 (0.99,1.32)  
 6 months 1.22 (1.06,1.40) 1.13 (0.93,1.37) 1.06 (0.93,1.22) 0.93 (0.81,1.06)  
 12 months 1.19 (1.04,1.36) 1.19 (1.05,1.35) 1.19 (1.05,1.35) 0.95 (0.83,1.08)  
 Average 1.22 (1.08,1.38) 1.19 (1.05,1.36) 1.14 (1.01,1.28) 0.94 (0.83,1.07)  
 Change 0.05 (-0.08,0.11) 0.02 (-0.14,0.09) -0.02 (-0.27,-0.07) -0.17 (-0.09,0.01)  
  Treatment effect 0.000 [Reference] -0.022 (-0.201,0.157) -0.070 (-0.245,0.104) -0.256 (-0.428,-0.084) 0.03 
Ala12 carriers    n =10 n = 14 n = 6 n =15  
 Baseline 1.55 (1.07,2.23) 1.18 (0.85,1.62) 1.10 (0.79,1.51) 1.09 (0.83,1.43)  
 6 months 1.23 (0.95,1.58) 1.31 (0.95,1.79) 1.37 (0.92,2.04) 0.98 (0.76,1.27)  
 12 months 1.36 (1.08,1.72) 1.29 (0.98,1.71) 1.27 (0.84,1.93) 0.95 (0.73,1.24)  
 Average 1.31 (1.05,1.63) 1.31 (0.99,1.74) 1.31 (0.91,1.89) 0.98 (0.78,1.25)  
 Change -0.17 (-0.09,0.31) 0.11 (-0.17,0.52) 0.18 (-0.25,0.04) -0.10 (-0.12,0.10)  
  Treatment effect 0.000 [Reference] 0.003 (-0.350,0.356) 0.001 (-0.419,0.421) -0.284 (-0.632,0.064) 0.41 
For tables 6.7 and 6.8 Log plasma TAG concentrations (95% CI) (mmol/L) are shown. Data is presented for PPARG Pro12 homozygous and PPARG 
Ala12-allele carrier in all and White subjects, for whom DNA samples and plasma TAG measurements were available. All variables were measured at 
baseline after a 4-week run-in on normal diet with a placebo supplement and after 6 and 12 months, during which normal diet was supplemented with 
n-3 LCP at the daily doses shown. The average of the measurements at 6 and 12 months was subtracted from those made at baseline to determine the 
average change. Treatment effects were determined by univariate ANCOVA. P-values are adjusted for BMI, age, ethnicity and gender for all subjects 
and P-values are adjusted for BMI, age and gender for White subjects  (nominally significant at P < 0.05) (nominally significant at P < 0.05). 




6.4 Discussion  
The MARINA study was designed to test the effects of three dose levels of n-3 long-
chain polyunsaturated fatty acids: n-3 LCPs, EPA and DHA versus placebo on variables 
associated with the risk of cardiovascular disease. Treatment caused a significant 
reduction in plasma TAG concentration in females, but not in males (Sanders et al, 
2011). We found a treatment effect related to genotype for SNP in the gene for PPARα. 
Plasma TAG concentration decreased in all subjects homozygous for the PPARA 
Leu162 alleles. A significant interaction between n-3 LCP treatment and genotypes of 
PPARA Leu162Val SNPs influenced plasma TAG concentration. 
 
The effects of fish oils rich in n-3 fatty acids in lowering TAGs are well known (Harris, 
1997). The n-3 LCPs EPA and DHA have a relatively potent effect on plasma lipids 
compared with other fatty acids, with effects noted with doses as low as 0.7 g/d 
(Theobald et al, 2007). After treatment, TAG concentration was significantly reduced in 
all MARINA subjects and particularly so in females, but did not reach significance in 
males. The highest dose lowered plasma TAG concentrations in women by 24%, with 
clear evidence of a dose-response relationship. The reduced effect in men may reflect 
the smaller number of participants. However, as we found no significant treatment x 
PPARA Leu162Val or PPARG ProAla12 x gender we did not test association in males 
and females separately.  
 
 
6.4.1 Independent associations of PPARA Leu162Val and PPARG ProAla12 
genotypes with concentrations of plasma lipids and obesity measures at 
baseline  
 
After a 4 week run-in on a normal diet with a placebo supplement, the PPARA 
Leu162Val genotype did not prove to be associated with concentrations of plasma lipids 
or BMI at baseline. Others have reported similar results to these (Silbernagel et al, 
2009; Doney et al, 2005). PPARG Pro12Ala was also not associated with lipid 
concentrations. Neither were we able to find an association with BMI. There is an 
insignificant trend for BMI to be higher in Ala12-allele carriers, which support the 




6.4.2 Independent associations of PPARA Leu162Val and PPARG ProAla12 
genotypes with concentrations of plasma lipids after dietary intervention  
 
We found no significant interaction between plasma lipid concentration and PPARG 
Pro12Ala genotypes, after 12 months of n-3 supplementation, in determining lipid 
profile. This was similar to our observation in the RISCK study, in which 6 months of 
high MUFA intake did not significantly interact with PPARG Pro12Ala to determine 
concentration of any of the plasma lipids (Section 5.3.8). We have reported a significant 
interaction between habitual P:S ratio and PPARG Pro12Ala genotype-influencing 
plasma LDL-C, TC and TAG concentrations. Recently, Lamri et al. (2011) reported a 
significant interaction between PPARG Pro12Ala and habitual intake of dietary fat in 
determining BMI. In this study, Ala12 homozygotes had significantly higher BMI than 
Pro-allele carriers among the high fat consumers. Their results are in line with Luan’s 
findings, where low habitual P:S ratio is associated with higher BMI in Ala12-allele 
carriers but nor Pro homozygotes (Luan et al, 2001). It seems that relatively long term 
exposure to PUFAs i.e. habitual intake is required in order to observe any change in 
plasma lipid concentrations or BMI with respect to PPARG Pro12Ala genotype. As 
reported previously (Section 4.1), the PPARγ2 Ala-variant exhibits modest impairment 
of transcriptional activation following treatment with pharmacological ligand TZDs 
(Deeb et al, 1998; Masugi et al, 2000). Ala12–allele carriers may be more responsive to 
long term intake of PUFAs rather than short term dietary manipulations. Low doses of 
n-3 LCPs (0.45, 0.9 or 1.8 g/d) used in the MARINA study may also affect the non-
significant interaction with PPARG Pro12Ala. Higher doses of 3.6 g n-3 fatty acids/day 
significantly decrease serum TAG concentration in healthy Ala12-allele carriers 
compared to Pro/Pro homozygotes (Lindi et al, 2003). The lack of effect of PPARG 
Pro12Ala is consistent with the fatty acids being weak ligands for PPARγ compared to 
PPARα (Xu et al, 1999). 
 
Reports of PPARA Leu162Val interaction with fatty acid intake in determining plasma 
lipids are inconsistent, including no interaction with PUFA (Tai et al, 2005), Val162- 
allele association with higher total and LDL-C after a high-PUFA diet (Paradis et al, 
2005), and higher TAG after low PUFA intake (Tai et al, 2005). We found that PPARA 
Leu162Val genotypes were not associated with changes in concentrations of plasma 
lipids after intervention in the RISCK study (Section 5.3.5). However, as PUFAs are 
stronger ligands of PPARα than MUFAs (Xu et al, 1999), this may account for 
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significant interaction between n-3 LCP treatment and genotypes of PPARA Leu162Val 
influencing plasma TAG concentration. Treatment lowered plasma TAG concentration 
significantly in Leu162 homozygotes, with significant increase between the highest 
dose compared to placebo but not in Val162-allele carriers. 
 
Most studies have found a reduced production rate of VLDL with n-3 LCP consumption 
in humans (Harris & Bulchandani, 2006), so part of the mechanism is likely to involve 
the inhibition of hepatic VLDL secretion. VLDL TAG synthesis can be reduced by 
decreasing fatty acid availability, secondary to an increase in β-oxidation, or by a 
decrease in lipogenesis (i.e. fatty acid synthesis). PPARα activation would suppress 
hormone sensitive lipase and decrease NEFA concentrations (Jia et al, 2011). An 
alternative mechanism through which n-3 LCPs could influence TAG concentration 
could be the potential enhancement of clearance by lipoprotein lipase. Park & Harris, 
(2003) have found EPA and DHA were equally effective in reducing postprandial TAG 
concentration and chylomicron triglyceride half-lives, while chylomicron particle sizes 
and lipoprotein lipase activity was increased. These results suggest that n-3 LCP 
supplementation accelerates chylomicron TAG clearance by increasing LPL activity. 
The LPL gene is responsive to PPARα activation (Schoonjans et al, 1996). Furthermore, 
after n-3 fatty acid dietary supplementation, Rudkowska et al, (2010) found LPL 
activity increased more in PPARA Leu162 homozygotes than in Val162-allele carriers 
and LPL activities were inversely related to plasma TAG concentration. Transcription 
was also found to be higher in Leu162- than Val162-constructs containing the LPL 
PPRE, after n-3 fatty acid transactivation (Rudkowska et al, 2009). These findings are 
compatible with the decreased TAG concentration we found in subjects homozygous for 
the more transcriptionally active Leu162 allele.  
 
 
6.5 Limitation and conclusion 
Limitations of our study include a relatively small number of genotyped subjects with 
plasma lipid measurements (n = 310) and the small observed changes in plasma lipid 
concentrations and relatively low doses of n- LCP used. Significant interactions 
between n-3 LCP treatment and genotypes of PPARA Leu162Val SNP were found to 
contribute to a reduction in plasma TAG concentration. The modulating effects of n-3 
LCP on plasma lipids were evident at doses of 0.45-1.8 g/d in the MARINA subjects. 
The discovery of significantly different responses to treatment in genetic subgroups 
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found in the current study has potential application in progress toward a personalized 










Chapter 7  
 





7.1 Introduction  
Numerous studies have investigated the effect of fish oils, especially DHA and EPA on 
risk factors for cardiovascular disease (Harris et al, 2008). However, fewer studies have 
investigated their differential effect of EPA versus. DHA. Animal studies suggest that 
both EPA and DHA taken individually exert an insulin-sensitising action (Murata et al, 
2001; Shimura et al, 1997), but the results from human feeding studies have been 
equivocal (Woodman et al, 2002; Griffin et al, 2006; Vessby et al, 2001; Egert et al, 
2008). A recent report from the LIPGENE investigators, suggested a beneficial effect of 
long chain n-3 supplementation on features metabolic syndrome (Paniagua et al, 2011). 
Some of the variability may be due to the differing proportions of EPA and DHA used 
in the studies.  
 
In mice, an improvement in insulin sensitivity and an increase in adiponectin 
concentrations with DHA but not EPA was noted (Vemuri et al, 2007). Furthermore, in 
3T3-L1 adipocytes, DHA, but not EPA, increases adiponectin concentration through a 
PPARγ pathway (Oster et al, 2010; Tishinsky et al, 2011). The in vitro and animal 
experimental data suggest that DHA will increase serum adiponectin concentrations. 
Long chain n-3 PUFA are known ligands for PPAR-γ (Maeda et al, 2001), while 
adiponectin gene expression is modulated by PPAR-γ (Iwaki et al, 2003). Fish oil was 
reported to increase adiponectin concentrations in human (Krebs et al, 2006) and animal 
studies (Hassanali et al, 2010; Kuda et al 2009; Duda et al, 2009; Higuchi et al, 2008). 
In PPARγ transgenic mice, fish oil rich in EPA and DHA markedly increased plasma 
adiponectin concentrations (Yu et al, 2011). However, a study in diabetic mice revealed 
that supplementation of EPA (1 g/kg body weight per day) or fish oil for 11 months had 
no effect on fasting adiponectin concentrations, fasting insulin or glucose (Cummings et 
al, 2010).  
 
In vitro, EPA exposure up-regulates the IRS-1 associated with the activation of PI3K 
and Akt kinase and down-regulates gluconeogenesis (Murata et al, 2001). In KK-Ay 
mice, DHA administration has been seen to significantly improve insulin sensitivity 
(Shimura et al, 1997). Studies have also found that PPARs play an important role in 
glucose metabolism (Wakutsu et al, 2010). Obese mice fed fish oil showed an 
improvement in glucose tolerance, and by administrating PPARs antagonists, glucose 
levels significantly increased (Wakutsu et al, 2010). A later study in PPARγ transgenic 
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mice, showed that fish oil supplemented diet significantly reduced blood glucose 
concentration by enhancing glucose metabolism genes such as GLUT-4 in the skeletal 
muscles (Yu et al, 2011). As n-3 PUFAs are known ligand for PPARα (Xu et al, 1999), 
in rats’ insulinoma cells, the expression of PPARα and RXR increased fatty acid uptake 
and oxidation and improved glucose-stimulated insulin secretion (Terauchi & 
Kadowaki, 2005). However, the effect of EPA and DHA on humans is largely 
controversial and needs to be further investigated.  As far as could be ascertained, no 
studies have compared the effects of supplementation with EPA versus. DHA on 
adiponectin concentrations. This study compared the effects of supplementation with 
DHA versus EPA (provided as fish oil concentrates) on adiponectin concentrations 
compared with a placebo (oleic acid, provided as refined olive oil) in healthy subjects. 
 




7.2 Study design and participants  
7.2.1 Study design  
A randomised, single-blind parallel study design was used to compare three treatments. 
The participants were healthy men (n = 48) who were randomly allocated to consume 
either and EPA (3g/d) rich concentrate, DHA (3g/d) rich concentration or placebo 
(equivalent volume of olive oil, British Pharmacopoeia specification). The primary 
outcome variable was a change in serum adiponectin concentration. Secondary 
outcomes included insulin sensitivity (HOMA-IR) and cardiovascular risk factors (lipid 
profile and blood pressure). The study protocol was reviewed and approved by the 




Figure 7.1 Outline of study protocol  
Each treatment comprised a 6-week intervention phase. Subjects were allocated to 
treatment using a randomisation plan from http://www.randomization.com. A parallel 
design has been chosen because of the duration of the intervention and the length of 
time taken for cell membrane fatty acid composition to return to baseline proportions 
following cessation of supplementation (approximately 3-4 months); a 6-week treatment 
period has been chosen since previous studies have indicated that this is a sufficient 
length of time to see significant changes in erythrocyte membrane composition (Sanders 
& Younger, 1981). In order to standardise intakes prior to the beginning of the study, 
the subjects underwent a 2-week run-in taking placebo capsules and avoiding the 
consumption of oily fish, fish oil supplements or other dietary supplements (restriction 
of oily fish and supplements was continued for the rest of the study). Thus, the total 
study time for each subject was 8 weeks.  
2 visits: 2-3h for all measurements 
Screening visit: 
45 min 
Start taking 5 
capsules a day 
Stop taking 
capsules 
2 weeks 6 weeks 




2-3 days prior to each visit: 24h urine 
collection and blood pressure recording 
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Following the run-in period, participants were asked to attend the metabolic unit on 2 
occasions for 2-3 hour study visits, separated by 6 weeks, during which time they took 
capsules containing their allocated treatment. Unused capsules returned by participants 
were counted and recorded. Compliance to the dietary intervention was assessed from 




7.2.2 Experimental capsules 
The experimental oils, 1 g of DHA, 0.5 g of EPA and 1 g of olive oil, were supplied by 
Croda Europe (Hull) and encapsulated by Power Health (Pocklington, UK). EPA, DHA 
rich oil and olive oil were provided in the form of triglycerides in soft gel capsules. 
Both EPA and DHA rich oil EPA and DHA were blended with olive oil, to at least 65% 
content of total n-3 PUFA, to provide 0.5 g of EPA and 1 g of DHA. EPA rich oil 
typically contains 58.4% of EPA and DHA rich oils contain 57.5% of DHA as shown in 
Table 7.1. Subjects who were assigned to the DHA or placebo treatment were asked to 
consume 5 capsules a day (1g/capsule), while those who were assigned to the EPA 
treatment were asked to consume 10 capsules per day (0.5g/capsule). Capsules
 
were 
stored at room temperature in a dry, dark room throughout the study. They were also 
packed in containers providing a 2-week supply for the run-in period (85 capsules) and 
a 6-week supply for the treatment (225 capsules for DHA or the placebo, and 450 
capsules for EPA). Three days’ extra capsules were added in the run-in and intervention 
periods and subjects were asked to bring the container back with the extra capsules after 
this time. The extra capsules were then counted and recorded to measure compliance. 
Table 7.2 shows the fatty acid analysis of the capsules, as certified by the manufacturer. 
The EPA and DHA blends consisted of blends of an EPA concentrate (TG7010, code 
SF06396, batch 213000) and a DHA concentrate (DHA700TG, code SF06405, batch 
213003) respectively and refined olive oil (batch 10813) 
 
Table 7.1 Composition of the dietary supplements and intakes provided with an intake 
of 5g/d 
Treatment   Composition  (mg/g) Daily intake (g/d) 
 Fat DHA EPA DHA EPA 
DHA 956 575 83 2.9 0.4 
EPA 956 584 88 2.9 0.4 








Table 7. 2 Fatty acids analysis of the capsules as certified by the manufacturer 
 
DHA EPA Refined olive oil 
Fatty Acid Content 
(%) 
Fatty Acid Content (%) Fatty Acid Content 
(%) 
C16:0 0.7 C14:0 0.5 16:00 10.9 
C16:1 0.3 C16:0 0.9 16:01 0.7 
C16:2 0.5 C16:1 0.7 16:02 Trace 
C16:3 0.1 C16:2 0.7 16:03 Trace 
C18:0 3.7 C16:3 0.5 18:00 3.2 
C18:1 6.9 C16:4 0.5 18:01 79.1 
C18:2 1.6 C18:0 0.4 18:02 4.4 
C18:3 n-6 0.5 C18:1 3.7 18:3n-3 0.5 
C18:3 n-3 0.2 C18:2 2.1 18:4n-3 - 
C18:4 n-3 0.3 C18:3 n-6 0.6 20:00 0.4 
C20:0 0.6 C18:3 n-3 1.1 20:01 0.2 
C20:1 2.2 C18:4 n-3 5.6 20:4n - 
C20:2 n-6 0.5 C20:0 0.5 20:5 n-3 (EPA) - 
C20:3 n-6 0.2 C20:1 0.2 22:01 - 
C20:4 n-6 2.8 C20:2 n-6 0.8 22:5n-3 - 
C20:4 n-3 0.7 C20:3 n-6 0.6 22:6n-3 ( DHA) - 
C22:0 0.3 C20:4 n-6 4.1 Others 0.6 
C20:5 n-3 EPA 8.3 C20:4 n-3 3.2 Total 100 
C22:1 0.9 C20:5 n-3 EPA 58.4 Total EPA+DHA wt% 0 
C21:5 n-3 0.5 C22:1 1.7 EPA + DHA g/d 0 
C22:4 n-6 0.6 C21:5 n-3 1.6 Target 0 
C22:5 n-6 4.6 C22:5 n-6 0.4   
C24:0 0.4 C22:5 n-3 1.5   
C22:5 n-3 3.1 C22:6 n-3 DHA 8.8   
C24:1 1.3 Others 0.9   
C22:6 n-3 DHA 57.5     
Others 0.7     




7.2.3 Participants and recruitment 
Healthy males, non-smokers, aged 18-45 years, were recruited from among staff and 
students at King’s College, London, UK by a circular email (approved by the Bromley 
Research Ethics Committee) and posters among King’s College London students and 
staff. Prior to entering the main study, participants were screened to ensure eligibility.  
 
 
7.2.3.1 Exclusion criteria:  
1. Reported history of CVD (myocardial infarction; angina, venous thrombosis; 
stroke, and dyslipidaemia); diabetes (or fasting glucose ≥ 6.1 mmol/L); cancer, 
and kidney, liver, or bowel disease. 
2. Presence of gastrointestinal disorder or use of a drug likely to alter 
gastrointestinal motility or nutrient absorption. 
3. Current smokers; history of substance abuse or alcoholism (previous weekly 
alcohol intake >60 units/men or 50 units/women); current self-reported weekly 
alcohol intake exceeding 28 units.  
4. Recent use of hypolipidaemic, antihypertensive, antiplatelet or antithrombotic 
medication. 
5. Platelet count above or below the normal range, or any history indicative of a 
congenital or acquired platelet, or haemostatic defect. 
6. Allergy or intolerance to any component of the study capsules.  
7. Unwillingness to restrict consumption of any source of fish oil for the length of 
the study. 
8. Subjects reporting consumption of >1 portion of oily fish per week. 
9. Weight change of >3kg in preceding 2 months; BMI <18 and >32 kg/m2. 
10. Blood pressure>160/90mmHg. 




Volunteers were initially sent an email explaining the study (Appendix 7.1). Those who 
responded were initially interviewed via a questionnaire (Appendix 7.2), administered 
either over the telephone or via email, to assess whether they were suitable for the 
study. Volunteers who met the inclusion criteria were then invited to attend a screening 
session. We anticipated that it would be necessary to invite ~80 people for the screening 
visit to get 60 subjects recruited onto the study, allowing for 10 drop-outs to achieve a 
final sample size of 50 subjects. We also included a run-in period which was meant to 





Figure 7.2 Methodology of recruitment 
  
No further action is taken 
Volunteer responds to advert by e-mail or telephone 
Volunteer is given more information verbally and 
completes screening questionnaire over the telephone 
Volunteer receives information sheet at least 3 days 
before starting the screening session 
No further action is taken 
Eligible 
Non eligible 
Volunteer attends screening session and information 
sheet is explained in more detail. 
 If volunteer is willing to take part in the study, the 
consent form is signed. 
Screening: height, weight, blood samples, body fat 
percentage and BP 
Volunteer is accepted as a subject on the study 






7.3 Equipment, consumables and supplements 
7.3.1 List of equipment: 
Item  Supplier  
Centrifuge Jouan CR4.12 for blood handling  DJB Labcare Ltd., Buckinghamshire, UK 
Calibrated automated BP monitor  Omron 7051T, Omron Healthcare Europe BV 
Bioelectrical impedance analysis equipment  BC-418 MA, Tanita UK Ltd., Middlesex, UK 
Ambulatory BP  TM-3430, A&D Instrument Ltd, Abingdon, UK 
Digital Volume Pulse DVP; Pulse Trace PCA 2, Micro Medical Ltd 





7.3.2 Consumables (Venous blood collection tubes): 
Item  Supplier  
4.5 mL EDTA lavender tubes Becton Dickinson; cat.no. 367654, UK 
4 mL fluoride/oxalate (FX) grey tubes Becton Dickinson; cat.no. 367922, UK 
8.5 mL gold tubes with clot activator and gel for 
serum separation  
6 mL gold tubes with clot activator and gel for 
serum separation  
Becton Dickinson; cat no. 367953, UK 
 
Becton Dickinson; cat no. 367953, UK 




Item  Supplier  
0.5g EPA-rich oil soft gel capsules Incromega EPA500TG SR, Croda Chemicals 
Europe Ltd, Goole, UK 
1g DHA-rich oil soft gel capsules  Incromega EPA500TG SR, Croda Chemicals 
Europe Ltd, Goole, UK 
1g olive oil soft gel capsules  Incromega EPA500TG SR, Croda Chemicals 




7.4 Screening procedure 
Potential participants arrived between 8.30 and 10.00 am and were  briefed on what the 
study involved. They were provided with a copy of the 'Information sheet for 
participants' (Appendix 7.3). A more detailed study booklet was also provided to them 
with additional information regarding study dates (Appendix 7.4). The participants 
were provided with a list of oily fish to avoid during the 8 weeks of intervention 
(Appendix 7.5). They were then  required to sign the consent form (Appendix 7.6). All 
required information was documented on a standard screening record sheet. After 
consent had been obtained, waist and hip circumferences were measured to the nearest 
0.1 cm using a plastic tape measure. Height was measured using a stadiometer. 
Percentage body fat was estimated using bioelectrical impedance and seated BP was 
measured with the OMRON 705 CPII auto upper arm BP monitor. In addition, a fasting 
venous blood sample was obtained. 
Participants were requested to select an 8-week regime, during which they were able to 
take 5 or 10 capsules a day and attend the metabolic unit twice for a 2-hour visit after 2 
and 8 weeks of intervention. A light breakfast was provided for the participants before 
leaving the screening session. 
 
 
7.4.1 Screening samples and blood handling  
Following the 10-12 hour overnight fast, venous blood samples were collected by Miss 
Sarah Cottin using butterfly needles into evacuated tubes with the minimum 
compression necessary to display the vein. Standard procedures are discussed in 
Appendix 7.7, according to the blood collection protocol outlined in Appendix 7.8. 
Miss Cottin is a qualified phlebotomist. Blood samples were handled according to the 
protocols.  
 
Blood was screened for haematology, glucose, lipid profile and liver function. Blood for 
haematology was collected into 4.5 mL tubes containing EDTA, for plasma glucose, 
into 4mL fluoride/oxalate grey tubes and for serum lipids and liver function, into a 6 
mL tube with no anticoagulant. All apart from the EDTA tube (whole blood) were then 
centrifuged at 3000 rpm for 15 min at 2-4º C and samples were then dispatched by 
motorcycle courier on the day of collection for same day analysis to Dr. Roy Sherwood, 
Department of Clinical Biochemistry at King's College Hospital, London, which is a 
171 
 
Clinical Pathology Accreditation Ltd. (CPA) laboratory (CPA 1245). Full blood counts 
were analysed through routine chemistry using a SYSMEX counter (Sysmex UK Ltd., 
Milton Keynes, UK). Plasma glucose was determined by the glucose oxidase method on 
the ADVIA 1650 automated chemistry analyser (Bayer Diagnostics). Assays for liver 
function and lipids were carried out using the ADVIA 1650 automated chemistry 
analyser (Bayer Diagnostics, Berkshire, UK). Total protein was measured using the 
Biuret reaction; albumin with bromocresol green; bilirubin through sulphanilic acid 
diazotisation; alkaline phosphatase using p-nitrophenol phosphate as substrate; aspartate 
aminotransferase using aspartate to glutamate conversion, monitored by UV, and 
gamma glutamyl transpeptidase, using γ-glutamyl-4 nitroanilide as a substrate. TC 
concentrations were measured using cholesterol oxidase and 4-aminoantipyrene; TAG 
was measured using lipoprotein lipase, and 4-aminoantipyrine. HDL-C was measured as 
for TC after the addition of an antibody, which binds LDL-C, VLDL and IDL 
cholesterol. LDL-C was calculated using the Friedewald formula (LDL-C = TC – HDL-
C – TAG / 2.2; in mmol/L) (Friedewald et al, 1972).  
 
 
7.5 Instructions prior to visits  
Three to four days before each visit, participants were asked to attend the metabolic unit 
for short visits (20-30 minutes). On this visit, the participants were shown how to use 
the BP monitor and instructed on the 24-hour urine collection. Written instructions for 
both procedures and a diary card, where the subject was asked to record his activities 
during the 24- hour BP monitoring, were provided (Appendix 7.9 and 7.10). Two to 
three days prior to each visit, participants were asked to record their BP and collect their 
urine for 24 hours. 
 
The day prior to the visit, participants were asked to avoid certain foods/drinks and 
activities due to their effects on vascular function and BP, i.e.  foods high in fat; 
alcohol; caffeine from midday (Hartley et al, 2004), and vigorous exercise. They were 
also asked to refrain from oily fish consumption for 2 weeks prior to the first visit. They 
were further asked to fast overnight and instructed to avoid eating or drinking anything, 
except water, for 12 hours before the time of their scheduled study visit and to avoid 
exercise on the morning of the study. An emailed reminder (Appendix 7.11) was sent 
out on the morning before the study day, summarising all instructions.  
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7.6 On the study day: 
A maximum of 2 subjects were booked each day. Participants arrived between 8 and 11 
am the following morning. The subjects’ record sheet was completed (Appendix 7.12) 
their weight, body composition and seated BP were measured; a 24-hour urine sample 
and the 24-hour BP monitor reading were collected. Subjects were allowed to rest 
quietly in a supine position for 15 minutes prior to the start of vascular measurements. 
Temperature was recorded before and after measurements, all of which were carried out 
on the left arm, while BP was measured on the right arm. Finally, a fasting blood 




Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. waist 
circumference was measured to the nearest 0.1 cm in the standing position with arms to 
the side, shoulder-width apart, and weight equally distributed on each leg. The 
measurements were standardised as the mid-point between the lower rib margin and the 
iliac crest. Where possible, measurements of participants were taken with their waists 
uncovered or else without heavy outer garments. Participants were asked to breathe 
normally and the reading was taken at the end of a normal exhalation. Body 
composition was assessed using a Tanita BC-418 segmental body composition analyser. 
 
 
7.6.2 Seated BP  
BP and heart rate were taken using an OMRON 705CPII, or equivalent, auto upper arm 
BP monitor. These measurements were taken while the participant was seated and after 
10 minutes of rest. When taking a BP measurement, the volunteer was calm and 
relaxed, sitting quietly with legs uncrossed and feet flat on the floor. At the same time, 
the arm from which the measurement was being taken was supported. A cuff of 
appropriate size was selected and wrapped snugly around the upper arm with space for a 
finger between the volunteer and cuff. The cuff was also appropriately aligned with the 
brachial artery, following the instructions contained in the equipment manual. 
Measurements of systolic and diastolic BP, as well as heart rate were made. The BP 
measurements were repeated at least three times at two-minute intervals. The value for 
the first reading was discarded and the mean of the two following readings was taken 





7.6.3 Ambulatory BP (to be used for another study) 
A&D TM-2430 ambulatory blood pressure (ABP) monitoring devices were used. These 
have been given A/A grading and have been approved for clinical use by the British 
Hypertension Society (Williams et al, 2004). Measurements were made in accordance 
with British Hypertension Society guidelines. The participants were shown how to use 
the ABP monitors. Triplicate measurements of clinic-based BP using an automated BP 
monitor were taken on the right and left arm, to ensure there were no differences in BP 
between arms. Participants were then provided with a suitably sized cuff (small, 
medium or large), as well as a brief instruction card and a diary card.  The diary card 
was completed by the participant following each measurement, in order for them to 
report what activity they were doing immediately prior to the measurement. The ABP 
was programmed to take measurements every 30 minutes during the day (0700 h -22:00 
h and hourly at night (22:00 h-07:00 h). The data was analysed using TM-2430-13 
Doctor Pro Software and checked for accuracy.  The first 3 readings following fitting 
the monitor were discarded. A minimum of 24 awake and 4 night-time readings was 
required. If unsatisfactory readings were obtained, the participant was requested to 
repeat the 24-hour BP monitoring. 
 
 
7.6.4 Vascular functions (to be used for another study) 
Peripheral arterial tone (DVP) was measured by using the forefinger on the radial pulse 
to obtain a reflection index (RI), stiffness index (SI), and pulse wave analysis (PWA), to 
obtain the peripheral augmentation index (PAIx). Supine BP was measured 
concurrently. These vascular measures were made in triplicate, according to the 
following sequence: (1) a single DVP measured on the left index finger, followed by (2) 
a BP measurement of the right brachial artery using a calibrated automated BP monitor, 
and finally (3) a PWA carried out on the left radial artery. Vascular functions were 
conducted by the author and Miss Sarah Cottin. At the end of the visit, blood was 





7.6.5 Blood sample collection, handling and analysis  
Venous blood samples for the analysis of plasma glucose, insulin, TAG, TC, LDL-C, 
HDL-C, Apo B100, NEFA, adiponectin were collected into evacuated tubes with the 
minimal compression necessary to display the vein. The blood for glucose analysis was 
collected into 4 ml fluoride oxalate. Blood for insulin analysis was collected into 4 ml 
lithium heparin tubes and blood for serum TAG, TC, LDL-C, HDL-C, Apo -B100, and 
NEFA was collected into 8.5 mL serum tubes, containing a clot activator and gel for 
serum separation. Blood for serum adiponectin was also collected into 8.5 mL serum 
tubes containing a clot activator and gel for serum separation. Tubes were then 
centrifuged at 3000 rpm for 15 minutes at 4ºC and plasma samples, glucose and insulin 





At the end of the 2-hour visit, the participants were provided with a light meal to 
consume before leaving the metabolic unit.  
 
 
7.7 Determination of measured variables  
7.7.1 Determination of plasma glucose: 
Determination of plasma glucose, insulin, TAG, TC, LDL-C, HDL-C, Apo B100, 
NEFA and adiponectin were analysed by the author in the Clinical Chemistry 
laboratories at King’s College Hospital with the guidance from Tracy Dew.  
Sample requirements 
The sample was taken into a fluoride-oxalate tube. The ADVIA 2400 used 3.4 µl of 
sample in the test. 
Method 
Glucose reagent was supplied by Siemens Healthcare Diagnostics Ltd, Newton House, 
Sir William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD. 
Glucose in the sample was phosphorylated by the transfer of phosphate from adenosine 
triphophosphate (ATP), via the action of hexokinase. Glucose-6-phosphate formed in 
this reaction was oxidised by glucose-6-phosphate dehydrogenase. This was 
accompanied by the reduction of NAD+ to NADH, which resulted in an increase in 
absorbance at 340 nm, proportional to the glucose concentration in the sample. The 
increase in absorbance was converted to glucose concentration by reference to a 
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previously determined calibrator and reagent blank. The effect of any interfering 
substances was reduced by blanking each sample using reagent 1 (buffer and co-factors) 
before the addition of reagent 2 (enzymes). Inter-assay CV was 1.6% and intra-assay 
CV was 0.6 %.  
 
 
7.7.2 Determination of plasma insulin: 
Sample requirements 
To assay the sample in duplicate, 50 L was used. However, the sample tube contained 
a volume of 250 L to account for dead volume and dilution. 
Method 
Insulin reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton House, Sir 
William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD. 
The Siemens Advia Centaur assay is a two-site sandwich immunoassay using direct 
chemiluminometric technology, through the application of constant amounts of two 
antibodies. The sample was incubated with two insulin-specific antibodies. The first 
was in the Lite Reagent, which is a monoclonal mouse anti-insulin antibody labelled 
with acridinium ester. The second antibody, in the solid phase, is a monoclonal mouse 
anti-insulin antibody, which was covalently coupled to paramagnetic particles. Insulin 
formed a sandwich between the two antibodies. After incubation, a magnetic field was 
applied, bringing about the solid phase (including the sandwich) held at the site of the 
reaction cuvette, while the liquid phase was aspirated. The cuvette was then washed 
with deionised water. Next, acid reagent (containing hydrogen peroxide) was added to 
the cuvette to begin a light emission reaction with the acridinium ester. The cuvette was 
then moved to the luminometer and base reagent was added to enhance the light 
reaction. Light intensity was measured immediately and converted to relative light units. 
This had a direct proportional relationship with insulin concentration. Inter-assay CV 




7.7.3 Determination of serum cholesterol: 
Sample requirements 
Serum sample was used. The ADVIA 2400 used 2 µl of sample in the test. 
Method 
Cholesterol reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton House, 
Sir William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD. 
Serum cholesterol was determined using an enzymatic method. Cholesterol esterase 
completely hydrolyses cholesterol esters in serum to free cholesterol, which is in turn 
oxidised by cholesterol oxidase to generate hydrogen peroxide. The hydrogen peroxide 
formed combines with 4-aminophenazone and a phenol to form a red quinone amine 
dye, measured as an endpoint reaction at 505/694 nm. The increase in dye absorbance 
here was directly proportional to the concentration of cholesterol in the sample, when 
compared to a previous calibration assay. Inter-assay CV was 1.1% and intra-assay CV 
was 0.6 %.  
 
 
7.7.4 Determination of HDL-C: 
Sample requirements 
The ADVIA 2400 used 2 µl of sample in the test. 
Method 
HDL–C reagents supplied by Siemens Healthcare Diagnostics Ltd, Newton House, Sir 
William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD. 
The Siemens Advia Direct HDL-C method is a two-step automated procedure. In the 
first step, cholesterol esterase and cholesterol oxidase react to remove non-HDL-C from 
the sample. The hydrogen peroxide produced is then removed by the enzyme catalase. 
The absence of detergent in this first reaction prevents HDL-C from reacting with the 
enzymes. In Stage 2, detergent is added to allow HDL-C to react with the enzyme 
system. Sodium azide inhibits the reaction of the hydrogen peroxide formed with 
catalase. The hydrogen peroxide acts with 4-aninoantipyrine to produce a quinoneimine 
pigment measured at 596 nm. Here, the inter-assay CV was 2.2% and intra-assay CV 






7.7.5 Determination of serum Apo B: 
Sample requirements The ADVIA 2400 used 2 µl of sample in the test. 
Method Apo B reagent supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD. 
The apolipoprotein method is a polyethylene glycol enhanced immunoturbidimetric 
assay. A sample containing human Apo B and specific antiserum was found to form an 
insoluble complex measured turbidimetrically at 340/694nm. By constructing a standard 
curve from the absorbance of standards, the concentration of Apo B was determined. 
Inter-assay CV was 3.3% and intra-assay CV was 1.6 %. 
 
 
7.7.6 Determination of serum NEFA: 
Method 
NEFA Assay kit is supplied by WAKO Chemicals Gmbh, Fuggerstrasse 12, D-41468 
Neuss, Germany. 
In the sample, NEFA was converted to acyl coenzyme A, AMP and pyrophosphoric 
acid by the action of ACS, under coexistence with coenzyme A (CoA) and ATP. The 
acyl coenzyme A obtained was oxidised and yielded 2,3-trans-Enoyl-CoA and hydrogen 
peroxide through the action of acyl coenzyme A oxidase In the presence of peroxide, 
the hydrogen peroxide formed yielded a blue-purple pigment via quantitative oxidation 
condensation with 3-Methyl-N-Ethyl-N-(ß-Hydroxyethyl)-Aniline (MEHA) and 4-
amino-antipyrine (4-AA). Non-esterified fatty acid concentration was obtained by 
measuring the absorbance of the blue-purple colour. Inter-assay CV was <1.5% and 
intra-assay CV was <1.5 %. 
 
 
7.7.7 Determination of serum TAG 
Sample requirements The ADVIA 2400 used 2 µL of sample in the test. 
Method TAG reagents supplied by Siemens Healthcare Diagnostics Ltd, Newton 
House, Sir William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD.  
The Siemens Advia method for the measurement of TAG is an enzymatic assay. TAGs 
are converted to glycerol and free fatty acids by lipase. Here, the glycerol was then 
converted to glycerol-3-phosphate by glycerol kinase, followed by its conversion 
through the action of glycerol-3-phosphate-oxidase to hydrogen peroxide. A coloured 
complex was formed from hydrogen peroxide, 4-aminophenazone and 4-chlorophenol 
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under the catalytic influence of peroxidase. The absorbance of the complex was 
measured as an endpoint reaction at 505/694 nm. Inter-assay CV was 0.033% and intra-
assay CV was 0.6 %. 
 
 
7.7.8 Determination of serum adiponectin 
Sample requirements 
To assay the sample in duplicate, a 50 L was required. However, the sample tube 
should contain at least a volume of 250 L to account for dead volume and dilution. All 
samples were pre-diluted 1/100 before being assayed. 
Method 
Kit used was Quantikine Adiponectin ELISA  distributed by R & D Systems Europe, 19 
Barton Lane, Abingdon Science Park, Abingdon, Oxon, OX14 3NB. 
This assay contains NSO-expressed recombinant human adiponectin and has been 
shown to accurately quantitate the recombinant factor. This assay measures total (low, 
middle, and high molecular weight) adiponectin. 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for adiponectin was pre-coated onto a microplate. 
Standards and samples were pipetted into the wells and any adiponectin present was 
bound by the immobilised antibody. After washing away any unbound substances, an 
enzyme-linked monoclonal antibody specific for adiponectin was added to the wells. 
Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
solution was added to the wells and colour developed in proportion to the amount of 
adiponectin bound in the initial step. The colour development was stopped and the 
colour intensity measured. Inter-assay CV was 6.8% and intra-assay CV was 2.5%. 
Linearity 
Any results above the concentration 250.0 ng/mL were reported as >250. If necessary, 
the samples can be diluted at 1:5 using the appropriate calibrator diluent and repeated in 
the subsequent batch. The results obtained from the assay were multiplied by the 





7.7.9 Erythrocyte lipid fatty acid composition 
Erythrocyte membrane phospholipid fatty acid composition was conducted by Miss 
Sarah Cottin. For detailed methodology refer to Appendix 7.14.  
7.8 Statistical analyses  
Power calculations were conducted using adiponectin as the primary endpoint. Using 
StatMate (GraphPad.com) gave 80% power at P < 0.05 to detect a 1 SD unit difference 
in adiponectin between treatments. Therefore, the study aimed to recruit a total of 48 
subjects. Data were tested for normality and analysed on an intention to treat basis using 
SPSS version 17.0 (SPSS Inc., Chicago, IL). Data were log-transformed for plasma 
TAG, HDL-C, adiponectin, insulin and HOMA-IR to render their distribution normal 
before statistical analysis. Baseline, follow-up means, and mean changes from baseline 
were analysed using the ANCOVA model, with treatment as a factor, follow-up values 
as dependant variable, and baseline values, age, BMI and ethnicity as covariates. All 
data presented in text and tables are expressed
 
as means or geometric means ± SD or 




7.9 Results  
7.9.1 Subjects 
Recruitment onto the trial commenced in June 2009 and was completed in May 2010. In 
response to the recruitment campaigns, an approximate total of 70 people expressed an 
interest in the study and were provided with the study information sheet. From those, 57 
individuals expressed further interest and were interviewed using the telephone 
questionnaire. Of these, one subject did not meet the inclusion criteria. Six decided not 
to participate, and were excluded after the screening visit prior to randomisation. Thus, 
12.3% (n = 7) of potential participants were excluded during the recruitment screening 
process leaving 49 who were randomised to treatment. Out of these, (n = 1) dropped out 





Figure 7.3 The Consort Flow Chart 
  
Excluded (n = 7) 
- Decided not to participate (n = 6) 
- Did not meet the inclusion criteria (n = 1) 
Screened (n = 57) 
Enrolled (n = 49) 
Completed (n = 48) 
Excluded (n = 1) 




7.9.2 Baseline characteristics of subjects 
A total of 48 subjects completed the study. The ethnic mix of subjects was 
predominantly White. In fact, White subjects made up 62.5% (n = 30), Black Africans: 
10.4% (n = 5), Indians and Middle-Eastern individuals: 16.7% (n = 8), and Chinese and 
East Asians: 10.4 % (n = 5). Their characteristics at recruitment with respect to 
treatment allocation are presented in Table 7.3. There were no significant differences in 
measured variables between subjects in treatment allocated groups. Fasting glucose was 
slightly higher in the DHA group compared to the EPA and olive oil groups.  The 
average BMI was within the desirable range (20-25 kg/m
2
) and the mean waist 
circumference were lower than the cut-offs used to indicate risk of metabolic syndrome 
(94 cm in men). Body weights were stable and there were no differences in changes in 
BMI, body fat percentage, systolic and diastolic BP, or heart rate between treatments, as 
shown in Table 7.4. 
 
Table 7. 3 Characteristics of subjects at baseline by randomised treatment 
  Treatment group  
Phenotype  Olive oil (n = 16) DHA (n = 16) EPA (n = 16) 
Age (years) 25.8 ±7.4 27.9 ±8.0 25.8 ±7.5 
Clinic Systolic BP (mm Hg) 119 ±10 125 ±10 119 ±14 
Clinic Diastolic BP(mm Hg) 67 ±6 72 ±8 68 ±12 
Heart rate (beats/min) 59 ±6 66 ±10 67 ±10 
Height (m) 1.76 ±0.07 1.75 ±0.08 1.79 ±0.08 
Weight (kg) 73.0 ±12.2 72.1 ±12.5 73.5 ±11.2 
BMI (kg/m
2
) 23.6 ±3.4 23.3 ±2.9 22.9 ±3.0 
Waist (cm) 81.7 ±10.2 82.5 ±10.3 80.6 ±8.3 
Hip circumference (cm) 99.3 ±8.7 99.8 ±8.6 98.7 ±8.0 
Waist:/Hip ratio 0.8 ±0.0 0.8 ±0.1 0.8 ±0.1 
Body fat (%) 16.6 ±5.5 14.4 ±4.5 13.5 ±4.5 
Fat mass (kg) 12.5 ±6.1 10.8 ±4.9 10.2 ±4.0 
Plasma glucose
1 
4.9± 0.3 5.3± 0.4 5.1± 0.3 
TC (mmol/L) 4.6 ± 0.6 4.4 ± 0.7 4.5 ± 0.7 
TAG (mmol/L)
2 
0.8 ± 0.3 0.8 ± 0.3 0.9 ± 0.5 
HDL-C (mmol/L)
2 
1.4 ± 0.4 1.3 ± 0.3 1.3 ± 0.2 
LDL-C(mmol/L) 2.7 ± 0.5 2.7 ± 0.6 2.7± 0.6 
TC:HDL-C ratio 3.2 ± 0.7 3.5 ± 0.8 3.4 ± 0.8  
Measurements made at the allocation of treatment: placebo, DHA or EPA.  Values are 
mean ± SD and do not differ by treatment allocation.  Association was tested by 
ANOVA 
1
Significant difference between groups. 
2




Table 7. 4 BMI, body fat %, clinic BP and heart rate at baseline and after 6 weeks of 
supplementation with the placebo, DHA or EPA. 
  Olive oil (n =16) DHA (n = 16) EPA (n = 16) P value 





    
Baseline 23.5 (21.3, 25.7) 21.1 (16.8, 25.3) 21.5 (18.6, 24.5)  
Follow-up 23.4 (21.3, 25.6) 23.6 (21.8, 25.4) 21.8 (19.1, 24.5)  
Change 0.0 (-0.2, 0.2) 0.7 (-0.4, 1.9) 0.3 (-0.2, 0.7) 0.26 
Treatment effect 0.000 [Reference] 0.69 (-1.6, 0.2) 0.06 (-1.1, 1.0)  
Body fat %
1 
    
Baseline 16.6 (13.8, 19.4) 15.0 (12.8, 17.1) 13.7 (11.3, 16.1)  
Follow-up 16.5 (13.6, 19.3) 14.2 (12.2, 16.2) 13.9 (11.5, 16.3)  
Change -0.2 (-1.2, 0.9) -0.5 (-1.9, 0.9) 0.2 (-0.8, 1.2) 0.70 
Treatment effect 0.000 [Reference] -0.58 (-0.9, 2.1) 0.01 (-1.5, 1.5)   
Systolic BP (mm Hg)     
Baseline 121 (116, 125) 122 (117, 126) 118 (113, 122)  
Follow-up 119 (114, 124) 121 (115, 126) 116 (110, 121)  
Change -2.0 (-5.6, 1.6) -1.1 (-4.7, 2.5) -2.3 (-5.9, 1.3) 0.88 
Treatment effect 0.000 [Reference] 1.05 (-4.0, 6.1) -0.69 (-5.8, 4.4)  
Diastolic BP (mm Hg)     
Baseline 67 (63, 71) 69 (65, 74) 69 (64, 73)  
Follow-up 66 (61, 70) 68 (64, 73) 66 (61, 70)  
Change -1.4 (-4.2, 1.5) -1.1 (-3.9, 1.8) -2.7 (-5.5, 0.1) 0.86 
Treatment effect 0.000 [Reference] 0.70 (-3.2, 4.6) -1.04 (-5.0, 2.9)  
Heart rate (beats/min)     
Baseline 63 (58, 69) 66 (61, 72) 66 (60, 71)  
Follow-up 65 (59, 70) 65 (60, 71) 65 (60, 71)  
Change 1.4 (-4.3, 7.2) -0.9 (-6.7, 4.8) -0.6 (-6.3, 5.2) 0.99 
Treatment effect 0.000 [Reference] 0.80 (-6.2, 7.8) 0.67 (-6.3, 7.6)  
Measurements made at baseline after a 2-week run-in with placebo supplements and after 6 
weeks with placebo, DHA or EPA supplements at daily doses of 3 g. Association was tested 
by ANCOVA with baseline values as covariate. P values are adjusted for age, BMI and 
ethnicity.  Values are means (95% CI). 
1




7.9.3 Compliance with taking the supplements  
Compliance to the dietary intervention was assessed from capsule counts and by 
measuring changes in the proportions of EPA and DHA in erythrocyte lipids. Out of the 
48 subjects, 32 returned the remaining capsules. Of these a total of 3 (6.2%) were 
estimated to have consumed less than 90% of the capsules and were classified as poor 
compliers.  There were no statistically significant differences in the reported capsule 
intakes between treatment groups. Table 7.5 shows erythrocyte fatty acid composition 
(%) at baseline and after EPA, DHA or placebo 3g/d. Compared to placebo, both EPA 
and DHA increased total n-3 PUFA by 4.5 % (95% CI: 2.9, 6.1) and 2.0 % (95% CI: 
0.5, 3.6) respectively. DHA treatment had no effect on EPA or docosapentaenoic acid 
(22:5n-6 DPA) DPA levels but significantly increased DHA levels by 1.7 % (95% CI: 
0.6, 2.8). EPA treatment significantly increased both EPA and DPA levels by 3.0% 
(95% CI: 2.4, 3.7) and 1.0 % (95% CI: 0.6, 1.3) respectively. Neither EPA nor DHA 
affected total SFA, MUFA or PUFA levels. Compared to placebo, both EPA and DHA 
decreased n-6 PUFA, however, this decrease was only significant with EPA treatment -
5.4% (-7.3,-3.5).  EPA and DHA significantly increased omega-3 index by 3.5% (95% 
CI: 2.0, 5.1) and 2.1% (95% CI: 0.6, 3.7). Generally, compliance to the supplements 
appeared good except in one subject allocated to the DHA who had a low DHA 




Table 7. 5 Erythrocyte fatty acid composition (%) at baseline and after EPA, DHA or 
placebo 
 Placebo DHA EPA  P 
 Baseline  Follow-up Baseline  Follow-up Baseline  Follow-up   
Total SFA 33.0 ± 2.8 32.8 ± 3.9 31.0 ± 5.5 32.3 ± 4.9 32.8 ± 3.5 34.1 ± 2.7 0.06 
16:0 17.5 ± 2.0 17.5 ± 3.1 16.1 ± 3.7 17.0 ± 3.1 17.4 ± 2.6 18.4 ± 1.6 0.15 
18:0 15.6 ± 1.2 15.2 ± 1.1 14.8 ± 2.0 15.2 ± 1.9 15.4 ± 1.2 15.7 ± 1.3 0.26 
Total MUFA 16.4 ± 1.0 16.7 ± 1.1 16.9 ± 1.5 16.9 ± 1.3 16.7 ± 1.2 16.2 ± 1.3 0.07 
16:1 0.4 ± 0.2 0.4 ± 0.5 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.96 
18:1 trans  0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.94 
18:1n-9 14.5 ± 1.0 14.8 ± 1.1 15.2 ± 1.4 15.3 ± 1.4 14.9 ± 1.2 14.6 ± 1.3 0.12 
18:1n-7 1.2 ± 0.1 1.3 ± 0.1 1.2 ± 0.2 1.2 ± 0.2 1.3 ± 0.1 1.2 ± 0.1 0.08 
Total PUFA 46.1 ± 2.6 46.3 ± 4.3 46.4 ± 5.2 46.8 ± 4.5 45.7 ± 4.2 45.2 ± 2.2 0.37 
Total n-6 PUFA 35.8 ± 2.7 35.8 ± 4.6 35.7 ± 3.3 34.2 ± 5.1 35.6 ± 3.8 30.3 ± 3.8* <0.001 
18:2n-6 12.3 ± 1.2 12.2 ± 1.6 11.9 ± 0.8 11.3 ± 1.3 12.1 ± 1.2 10.4 ± 1.7* 0.002 
20:3n-6 2.1 ± 0.4 2.3 ± 1.0 2.2 ± 0.6 2.0 ± 0.7 2.4 ± 0.7 1.7 ± 0.4* 0.006 
20:4n-6 17.2 ± 1.8 17.1 ± 2.2 17.6 ± 2.4 16.9 ± 2.9 17.1 ± 2.3 15.1 ± 1.8* 0.001 
22:4n-6 3.6 ± 0.7 3.6 ± 0.8 3.7 ± 1.0 3.4 ± 1.1 3.5 ± 0.9 2.7 ± 0.9* 0.002 
22:5n-6 0.6 ± 0.1 0.5 ± 0.2 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.4 ± 0.1* <0.001 
Total n-3 PUFA 10.3 ± 1.7 10.5 ± 1.5 10.7 ± 2.6 12.6 ± 2.3* 10.1 ± 2.1 14.9 ± 2.5* <0.001 
18:3n-3 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.61 
20:5n-3 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.5 1.6 ± 0.6 1.1 ± 0.4 4.2 ± 1.4* <0.001 
22:5n-3 3.2 ± 0.5 3.2 ± 0.6 3.4 ± 0.5 3.1 ± 0.6 3.4 ± 0.7 4.2 ± 0.4* <0.001 
22:6n-3 5.8 ± 1.3 6.0 ± 1.3 6.0 ± 1.8 7.7 ± 2.0* 5.4 ± 1.6 6.3 ± 1.2 0.01 
n3 index 6.9 ± 1.5 7.1 ± 1.5 7.2 ± 2.2 9.3 ± 2.5* 6.6 ± 1.9 10.5 ± 2.4* <0.001 
ration-6:n-3 3.6 ± 0.7 3.5 ± 0.8 3.5 ± 0.7 2.8 ± 0.9* 3.7 ± 0.9 2.2 ± 0.8* <0.001 
Data is presented as mean ± SD and expressed in % of total erythrocyte fatty acid composition. 
Differences between the three treatments were tested by ANOVA. When comparing the follow up 
values to placebo, association was tested by ANCOVA with baseline values as covariate. *P-values 





7.9.4 Fasting serum lipid concentrations:  
Table 7.6 shows the results for fasting serum lipids and NEFA concentrations. There 
was a treatment effect for plasma NEFA (P = 0.05) but none of the individual 
comparisons between treatments achieved significance using Bonferroni’s multiple 
comparison test. There were no other statistical significant differences. TAG values 
were low in all groups and showed a small decline following all treatments. Plasma Apo 
B concentrations showed a tendency to increase following DHA compared with the 




Table 7. 6 Plasma lipids at baseline and after 6 weeks of supplementation with the 
placebo, DHA or EPA. 
Phenotype  Treatment group    
 Olive oil (n = 16) DHA ( n = 16) EPA (n = 16)    P  
  (Mean, 95 % CI) (Mean, 95 % CI) (Mean, 95 % CI)  value 
TC (mmol/L)
1     
Baseline 4.7 (4.3, 5.1) 4.4 (4.0, 4.8) 4.6 (4.2, 5.0)  
Follow-up 4.6 (4.2, 5.0) 4.6 (4.2, 5.0) 4.6 (4.2, 5.0)  
Change -0.1 (-0.5, 0.2) 0.2 (-0.1, 0.5) 0.0 (-0.3, 0.3) 0.74 
Treatment effect 0.000 [Reference] 0.03 (-0.1, 0.1) 0.02 (-0.1, 0.1)  
Apo B (g/L)     
Baseline 0.88 (0.77, 0.99) 0.80 (0.69, 0.92) 0.90 (0.79, 1.01)  
Follow-up 0.81 (0.70, 0.92) 0.88 (0.77, 0.99) 0.84 (0.74, 0.95)  
Change -0.07 (-0.17, 0.04) 0.08 (-0.02, 0.18) -0.06 (-0.16, 0.04) 0.24 
Treatment effect 0.000 [Reference] 0.11 (0.0, 0.2) 0.02 (-0.1, 0.1)  
LDL-C (mmol/L)     
Baseline 2.9 (2.6, 3.2) 2.7 (2.4, 3.0) 2.8 (2.5, 3.1)  
Follow-up 2.8 (2.5, 3.1) 2.9 (2.5, 3.2) 2.8 (2.4, 3.1)  
Change -0.1 (-0.3, 0.2) 0.2 (-0.1, 0.4) 0.0 (-0.3, 0.2) 0.38 
Treatment effect 0.000 [Reference] 0.21 (-0.5,0.1) 0.01 (-0.3,0.3)  
HDL-C (mmol/L)
1     
Baseline 1.5 (1.3, 1.6) 1.4 (1.2, 1.5) 1.5 (1.3, 1.6)  
Follow-up 1.5 (1.3, 1.7) 1.4 (1.2, 1.6) 1.6 (1.4, 1.8)  
Change 0.0 (-0.1, 0.2) 0.1 (-0.1, 0.2) 0.2 (0.0, 0.3) 0.59 
Treatment effect 0.000 [Reference] 0.02 (-0.1, 0.1) 0.07 (-0.2, 0.0)  
TC:HDL-C
     
Baseline 3.3 (3.0, 3.7) 3.4 (3.0, 3.8) 3.3 (2.9, 3.7)  
Follow-up 3.2 (2.9, 3.6) 3.3 (3.0, 3.7) 3.1 (2.7, 3.4)  
Change -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.1) -0.2 (-0.4, 0.0) 0.96 
Treatment effect 0.000 [Reference] 0.08 (-0.3, 0.2) -0.12 (-0.4, 0.1)  
TAG (mmol/L)
1     
Baseline 0.8 (0.7, 1.0) 0.8 (0.6, 1.0) 0.9 (0.7, 1.1)  
Follow-up 0.7 (0.6, 0.8) 0.7 (0.6, 0.9) 0.7 (0.6, 0.8)  
Change -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.0) -0.3 (-0.4, -0.1) 0.35 
Treatment effect 0.000 [Reference] 0.04 (-0.2, 0.2) -0.10 (-0.3, 0.1)  
 NEFA (mmol/L)     
Baseline 0.3 (0.2, 0.4) 0.4 (0.3, 0.5) 0.4 (0.3, 0.5)  
Follow-up 0.4 (0.3, 0.4) 0.3 (0.2, 0.4) 0.3 (0.2, 0.4)  
Change 0.06 (-0.03, 0.15) -0.09 (-0.18, 0.00) -0.09 (-0.18, 0.00) 0.05 





Measurements made at baseline after a 2-week run-in with placebo supplements and after 6    weeks 
with the placebo, DHA or EPA supplements at daily doses of 3 g.  Association was tested by 
ANCOVA with baseline values as covariate. P values are adjusted for age, BMI and ethnicity. 
Values are means   (95% CI). 
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7.9.5 Serum adiponectin concentration 
Table 7.7 shows that there was a tendency for adiponectin concentrations to rise 
following placebo treatment but it remained unchanged on DHA or EPA treatments. 
There were no significant differences between EPA and DHA when compared with 
placebo. 
Table 7. 7 Serum adiponectin concentration at baseline and after 6 weeks of 
supplementation with the placebo, DHA or EPA 
Phenotype  Treatment group    
 Olive oil (n = 16) DHA (n = 16) EPA (n = 16) P value 
  (Mean, 95% CI) (Mean, 95% CI) (Mean, 95% CI)   
Adiponectin (μg/L)1     
Baseline 6.1 (4.7, 8.0) 6.7 (5.1, 8.8) 6.3 (4.8, 8.2)  
Follow-up 7.4 (5.6, 9.9) 6.7 (5.0, 8.9) 6.3 (4.8, 8.4)  
Change 1.4 (0.6, 0.2) 0.0 (0.6, -1.2) 0.7 (0.6, -0.6) 0.08 
Treatment effect 0.000 [Reference] -0.19 (-0.4, 0.0) -0.18 (-0.4, 0.0)  
Measurements made at baseline after a 2-week run-in with placebo supplements and after 6 
weeks with the placebo, DHA or EPA supplements at daily doses of 3 g. Association was 
tested by ANCOVA with baseline values as covariate. P values are adjusted for age, BMI 






7.9.6 Insulin homeostatic variables 
The results for plasma glucose, insulin concentrations and HOMA-IR are shown in 
Table 7.8. There was no evidence of any changes in plasma glucose but fasting insulin 
values tended to be greater on follow-up on all treatments. There were no differences 
between treatments in insulin or in HOMA, which an index of insulin sensitivity. 
 
Table 7. 8 Plasma glucose, insulin and HOMA-IR at baseline and after 6 weeks of 
supplementation with the placebo, DHA or EPA 
Phenotype  Treatment group    
 Olive oil (n = 16) DHA (n = 16) EPA (n = 16) P value 
  (Mean, 95% CI) (Mean, 95% CI) (Mean, 95% CI)   
Fasting glucose (mmol/L)     
Baseline 5.0 (4.8, 5.1) 5.3 (5.1, 5.4) 5.2 (5.0, 5.4)  
Follow-up 5.1 (4.8, 5.4) 5.2 (5.0, 5.5) 5.2 (4.9, 5.5)  
Change 0.1 (-0.2, 0.4) 0.0 (-0.3, 0.3) 0.0 (-0.3, 0.2) 0.95 
Treatment effect 0.000 [Reference] -0.04 (-0.4, 0.4) -0.08 (-0.5, 0.3)  
Fasting  insulin (mU/L)
1 
    
Baseline 5.4 (4.2, 7.0) 6.4 (5.0, 8.2) 5.6 (4.3, 7.2)  
Follow-up 6.7 (5.2, 8.7) 6.7 (5.1, 8.7) 6.1 (4.7, 7.9)  
Change 1.2 (1.0, 1.6) 1.0 (0.8, 1.3) 1.1 (0.9, 1.4) 0.72 
Treatment effect 0.000 [Reference] -0.11 (-0.4, 0.2) -0.12 (-0.4, 0.2)  
HOMA-IR 
1 
    
Baseline 1.2 (0.9, 1.6) 1.5 (1.1, 2.0) 1.3 (1.0, 1.6)  
Follow-up 1.5 (1.2, 2.0) 1.5 (1.1, 2.2) 1.4 (1.0, 1.8)  
Change 0.2 (0.0, 0.5) 0.0 (-0.2, 0.2) 0.1 (-0.2, 0.4) 0.68 
Treatment effect 0.000 [Reference] -0.12 (-0.4, 0.2) -0.14 (-0.5, 0.2)  
Measurements made at baseline after a 2-week run-in with placebo supplements and after 6 
weeks with the placebo, DHA or EPA supplements at daily doses of 3 g. Association was 
tested by ANCOVA with baseline values as covariate. P values are adjusted for age, BMI 
and ethnicity Values are mean (95% CI). 
1




7.10 Discussion  
The present study was conducted in men rather than women in order to avoid 
confounding effects of changes in the menstrual cycle.  
 
 
7.10.1 Adiponectin and insulin sensitivity  
The primary outcome of the study was to test whether relatively high intakes of EPA or 
DHA influenced serum adiponectin concentrations. The amounts provided by the 
supplements would be equivalent to amounts provided by large servings of oily fish. 
Compliance to the dietary supplements appeared to be good as indicated by capsules 
counts. There also were increases in the proportions of EPA and DHA in erythrocyte 
lipids. However, the increase in DHA in erythrocytes, however, was not possibly as 
great as reported in some previous studies and the expected fall in serum TAG was not 
observed. For example, Sanders et al. (2006) reported that a daily intake of 1.5g DHA 
for 6 weeks increased erythrocyte DHA from 6.1% to 7.6%, whereas in the present 
study, which provided 3g DHA, the increase in DHA was 6.0 to 7.7 %. The MARINA 
study (Sanders et al, 2011) reported that EPA and DHA increased by 1.3% to 3.6% and 
6.5% to 8.3% respectively after 6 months supplementation with 1.8g of a mixture of 
EPA and DHA (with a ratio of EPA:DHA of 1.51). The increases in EPA and DHA in 
the present study were from 1.1% to 4.2% and 6.0 to 7.7% respectively.  
The present study was unable to demonstrate any change in adiponectin following EPA 
or DHA compared with control. Indeed, the tendency was a reduction rather than an 
increase in adiponectin compared with placebo. The present study measured total 
adiponectin, rather than HMW adiponectin, which has been shown to be at its most 
active when mediating the adiponectin metabolic effect (Kobayashi et al, 2004). 
We were unable to find any significant changes in fasting insulin, glucose or HOMA-IR 
after EPA or DHA supplementation. These findings are in line with the findings of the 
Hartweg meta-analysis, where 9 weeks of 3.5 g/d n-3 PUFA had no effect on fasting 
insulin or glycaemic control (Hartweg et al, 2008). However, in hyperlipidaemic men, 
EPA and DHA taken individually increased fasting insulin but only EPA increased 
fasting glucose (Mori et al, 2000). A limitation of the present study is that the 





7.10.2 Blood lipids 
n-3 fatty acids regulate PPARs and SREBPs, which regulate the expression of lipid 
homeostasis genes (Deckelbaum et al, 2006; Yu et al, 2011) and increase the expression 
of the lipolytic genes (Yu et al, 2011). DHA, uniquely among PUFAs, controls SREBP-
1 nuclear abundance through 26S proteasomal degradation, and suppression of SREBP-
1, which in turn suppresses lipogenesis (Jump et al, 2008). Several studies have 
investigated the differential effect of EPA and DHA in blood lipids (Harris et al, 2008; 
Harris, 1989), which suggested that both EPA and DHA contribute to the TAG lowering 
effect. Using lipoprotein turnover studies with labelled substrate it has been 
demonstrated that the TAG lowering effect following EPA and DHA consumption is 
primarily mediated by a substantial decrease in hepatic TAG synthesis and VLDL TAG 
secretion (Harris et al, 1990; Sanders et al, 1985; Nestel et al, 1984) without any effect 
on catabolic rate. However, there are limited studies indicating increased clearance rates 
of VLDL (Bordin et al, 1998). DHA was found to lower TAG concentration in healthy 
subjects (Grimsgaard et al, 1997; Agren et al, 1996); in hypertensive diabetic patients 
(Woodman et al, 2002), and in dyslipidaemic subjects (Nestel et al, 2002; Mori et al, 
2000; Kelley et al, 2007). However, Theobald et al. (2004) and Sanders et al. (2006) 
were unable to show significant TAG lowering effects of 0.7g and 1.5g DHA/d. The 
present study which provided doses of ~3g/d was unable to demonstrate any significant 
changes in blood lipids. However, basal fasting TAG was low and it is known that the 
plasma TAG lowering effect is more evident in individuals with raised plasma TAG. 
There was a tendency for Apo B concentrations to be slightly greater following DHA 
which is in agreement with previous studies using algal DHA (Theobald et al, 2004; 
Sanders et al, 2006; Kelley et al, 2007). A limitation of the present study in this respect 
is the small sample size for a parallel design. 
 
 
7.11 Limitations and conclusion 
This study was conducted in young healthy men and so the results cannot be 
extrapolated to women or to older men and women especially as adiponectin 















8.1 Discussion  
This thesis set out to test the hypothesis the type of fatty acids in the diet would 
influence adiponectin concentrations and this may be influenced by common 
polymorphism in ADIPOQ, PPARG, and PPARA genes. It was found that adiponectin 
was positively correlated with age and negatively with BMI. Adiponectin was 
significantly higher in White Europeans than in South Asians and Black Africans. The 
ethnic differences are consistent with other reports but do not appear to be due to 
difference in dietary fatty acid intakes between groups. Serum adiponectin 
concentrations were significantly higher in females than males. The effects of four 
SNPs (-11391 G/A, -10066 G/A, -7734 C/A and +276 G/T) in the ADIPOQ gene and 
adiponectin concentrations in RISCK White subjects were investigated. The selected 
SNPs were previously showed to have the strongest replicated associations with serum 
adiponectin (Kyriakou et al, 2008). There was a small effect of diet high in MUFA and -
10066 G/A. After HM diet, GG subjects showed a 3.8% increase and GA+AA subjects 
a 2.6% decrease in serum adiponectin. The switch from SFA to MUFA could lead to 
increased expression of the ADIPOQ gene and serum adiponectin concentration through 
increased availability of PPARγ-activating ligands. The PPRE lies in a 1.3 kb linkage 
disequilibrium block (Heid et al, 2006). If the -10066A-allele was in LD with a variant 
in the PPRE reducing affinity for the receptor, this could account for higher serum 
adiponectin in response to MUFA in GG homozygotes and the lower concentration in 
A-allele carriers. This effect appeared to become exaggerated with increasing age. In -
10066 GG homozygotes over 40 years of age, adiponectin concentration increased 
progressively after the HM diet and decreased after the LF diet. The difference in % 
change in serum adiponectin between GG subjects on HM and LF diets in the oldest 61-
70 year age group achieved statistical significance. In -10066  A-allele carriers there 
was little change in serum adiponectin concentration compared to baseline with 
increasing age, after HM or LF diet. The major limitation is the small number of 
subjects; thus it is important in replicating the findings in a larger cohort of older 
subjects and robust evidence would be provided from repeated measures from 
prospective studies. 
 
The reasons for this apparent increase in adiponectin with age are uncertain. The 
analyses for the current study were corrected for adiposity; therefore changes in 
adiposity with increasing age might not be the reason. Fetal programming and early 
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development may have an effect on adiponectin expression in later life and this may 
also explain some of the differences between ethnic groups (Bansal et al, 2011). It is 
possible that there are developmental effects on pre-adiposites in early life that affect 
the capacity to synthesis adiponectin in later life in response to adipose tissue 
accumulation. 
 
In the RISCK cohort, substituting high saturated diet with either high MUFA diet or 
carbohydrate (low fat diet) has no effect on serum adiponectin concentrations. All three 
diets contained the same proportion of PUFA. The lack of effect of replacing MUFA 
with carbohydrate is in contrast to a report from the OMNIHEART investigators 
(Yeung et al, 2010). They reported that a MUFA diet maintained a higher level of both 
HMW and total adiponectin concentrations than either a carbohydrate rich low fat diet 
(HMW: +6.8%, P = 0.02; total: +4.5%, P = 0.001) or a protein rich diet (HMW: +8.4%, 
P = 0.003; total: +5.6%, P < 0.001) diets. The duration of the intervention in that study 
was only 6 weeks as opposed to six months in the RISCK study.  However, the findings 
are broadly in agreement with the findings in participants with the -10066 GG genotype 
in RISCK. Therefore, we conducted a dietary intervention trial investigating the effect 
of LC PUFAs on adiponectin concentrations. The amounts provided by the supplements 
would be equivalent to amounts provided by large servings of oily fish. This had no 
effect on serum adiponectin concentrations. Therefore, it is unlikely that lower amounts 
of LC PUFA found in a typical diet (< 1g/d) would have any effect on adiponectin in 
adult life. A limitation of this study was that it was conducted in young healthy men and 
so the results cannot be extrapolated to women or to older men and women. Further 
research could involve measuring changes in serum adiponectin in the MARINA study 
according to genotype. 
 
These findings suggest that age, gender, BMI and ethnicity are major determinant of 
adiponectin concentration. We reported a modest effect of diet and -10066 G/A, which 
exaggerated with increasing age. High intake of LC PUFAs has no effect of adiponectin 
concentrations in healthy males.  
 
Cross sectional analysis confirms the association between P:S ratio and PPARG 
Pro12Ala as previously reported by Luan et al.(2001). An analysis of White subjects in 
the RISCK study, showed that at the lowest P:S intake, carriage of the less active 
PPAR-γ Ala12 isoform was associated with higher plasma TC and LDL-C. Significant 
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trends in the reduction of plasma TC and TAG in Ala12-allele carriers as the P:S ratio 
increased. Thioglitazone decreases the release of NEFA from adipose tissue, reducing 
TAG synthesis in the liver and decreasing VLDL synthesis, which in turn has an effect 
on LDL-C, but has a greater effect in raising HDL-C (Belfort et al, 2006). The PPARγ-
Ala12 form has lower transactivational ability than the wild-type (Deeb et al, 1998). 
However a mechanistic link to PPARγ target gene activation, that might infer 
association of the less active PPARγ-Ala form with lower LDL-C concentration, has not 
been established. The decrease in TAG concentration in Ala12 carriers as the P:S ratio 
increase is consistent with Lindi’s findings in 2003. The former study found 
significantly greater decrease in serum TAG concentration in Ala12 carriers than in 
Pro12 homozygotes in response to n-3 fatty acid supplementation, when the intake of 
SFA was below 10%, i.e. at high P:S intake. However, both studies are inconsistent 
with reduced lipoprotein lipase activity associated with a less-active PPARγ-Ala 
isoform.  
 
In this study, we also showed that the significant interaction between P:S and PPARG 
Pro12Ala as a determinant of plasma lipids did not depend on decrease SFA intake. 
However, in the MARINA study no significant interaction between PPARG Pro12Ala 
and LC PUFA as determinate of plasma lipids concentrations was found. The difference 
between the participants in MARINA and RISCK study were mainly in BMI. PPARγ 
undoubtedly plays an important role in insulin sensitivity and influence ADIPOQ gene 
expression.  However, the findings in this thesis do not provide evidence for an effect of 
LC PUFAs or saturated fatty acids on PPARγ. Adiponectin, insulin and glucose 
concentrations have yet to be analysed in the MARINA study. This will enable us to test 
the interaction between PPARG Pro12Ala and LC PUFA as determent of HOMA-IR 
and adiponectin concentrations.  
 
The role of PPARα is primarily to activate the peroxysomal beta-oxidation of fatty acids 
in the liver, particularly C20-22 unsaturated fatty acids and branched chain fatty acids so 
that they can be reduced to sufficient size to form carnitine esters that can enter the 
mitochondrial for oxidation. This redirection of fatty acids from TAG synthesis to 
oxidation explains the reduction in VLDL TAG synthesis and secretion that occurs 
following the feeding of n-3 LCP, but does not occur with linolenic acid. PPARα may 
also have an additional role as activators of LPL activation. There is little evidence for 
an increase in fractional catabolic rate of VLDL from human feeding studies with 
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increased intakes of n-3 LCP, which would suggest that the main effect is on synthetic 
rate. In the MARINA study, we found a significant interaction n-3 PUFAs 
supplementation and PPARA Leu162Val as determinant of plasma TAG concentration. 
n-3 PUFAs supplementation lowered plasma TAG concentration significantly in 
PPARA Leu162 homozygotes, with significant increase between the highest dose 
compared to placebo but not in Val162-allele carriers. The LPL gene is responsive to 
PPARα activation (Schoonjans et al, 1996). Transcription of LPL was found to be 
higher in Leu162- than Val162-constructs containing the LPL PPRE, after n-3 fatty acid 
transactivation (Rudkowska et al, 2009). This is compatible with the decreased TAG 
concentration we found in subjects homozygous for the more transcriptionally active 
Leu162 allele.  
 
A novel finding of the thesis is the potential interaction between PPARG Pro12Ala and 
PPARA Leu162 Val and dietary intake of fat as determinant of plasma lipid. We 
reported a significant interaction between the two genotypes as determinants of plasma 
LDL-C concentration and sdLDL as a proportion of LDL after adjustment for change in 
BMI, age and gender. Carriage of both variant alleles (PPARA Val162 and PPARG 
Ala12) was associated with a greater reduction in LDL-cholesterol and proportion as 
sdLDL after HM diet than after LF diet. PPARγ-Ala12 and PPARα-Val162 forms have 
lower transactivational ability than the wild-types (Deeb et al, 1998; Rudkowska et al, 
2009).  
 
At baseline, after a 4-week run-in on the HS diet, we found no significant independent 
association between PPARA Leu162Val or PPARG Pro12Ala and proportion of sdLDL. 
Similarly, Bouchard-Mercier et al. (2011) found no significant change in LDL-PPD in 
PPARG Pro12 homozygotes or Ala12-allaele carriers after high SFA intake, but a 
significant increase in LDL-PPD in Ala12 carriers after high intake of PUFA. In 
contrast to our findings, they found that high SFA intake associated with larger LDL 
particle size in PPARA Leu162 homozygotes, but with a higher proportion of sdLDL in 
Val162 carriers. We found no significant change in the proportion of sdLDL in carriers 
of PPARG Ala12 or PPARA Val162 on switching from the HS diet at baseline to the 
HM or LF diets, but a significant reduction in the proportion of sdLDL in carriers of 
both PPARA Val162 and PPARG Ala12 alleles after the HM diet. This cannot be 
explained by reduced activity of both variants, but would be expected to lead to a higher 
proportion of sdLDL. The concentration of sdLDL is more dependent on VLDL TAG 
196 
 
concentrations because TAG is transferred by cholesterol ester transfer protein from 
VLDL to LDL, which in turn can be converted to sdLDL by hepatic lipase (Sanders & 
Emery, 2003). A high carbohydrate low fat diet would be expected to increase VLDL-
TAG. However, in the RISCK study there were no differences in fasting TAG, possibly 
because subjects received a standardised low fat meal on the day preceding blood 
collection.  
 
A major limitation of this study that only 7 subjects were carriers of both PPARA 
162Val and in PPARG Ala12 variants and these showed a significant reduction in 
plasma LDL-C and its proportion as sdLDL after the HM diet, as compared to the LF 
diet. In the MARINA study only one subject proved to be the carrier of the minor 
variants of both SNPs. A larger sample is required to confirm this association, which 
may be achieved by recruiting subjects based on the presence of both variants and 
randomising them to either the HM or LF diet.  
 
 
8.2 Concluding remarks, limitation and implications for further research 
The strength of the RISCK and MARINA studies lies in their design as randomised 
tightly controlled feeding trials with high adherence and retention rates and diets with 
practical relevance to the general population. Limitations to these SNP association 
studies include relatively small sample sizes and reduced power after randomisation to 
dietary treatments, in comparison with measurements at baseline. In the RISCK and 
MARINA studies, we focused our genetic analysis on White subjects. Replicating the 
findings in other ethnic group populations is required. Replication of all our findings in 
other studies with maximal correspondence in ethnic origin, age, and gender would be 
required to minimise the risk of false positive or negative gene-diet associations. 
Substantiated effects of common SNPs in modifying the outcome of dietary intervention 
studies in larger samples should help in the
 
identification of individuals at risk of 
complex disease who would
 




The major problem with genome wide association studies is that very high levels of 
statistical significance are required to allow for multiple comparisons. This means that 
real diet x genetic interactions may be missed. A promising approach would be to using 
a global risk scoring system to reduce the penalties incurred by multiple comparison 
testing For example, Walker et al. (2011) have used such an approach in examine risk 
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allele for serum cholesterol and insulin resistance. This study set out to examine 
whether variations in dietary fat influenced adiponectin concentrations. The findings 
presented in this thesis suggest no effect of EPA or DHA on adiponectin but a modest 
of MUFA compared to low fat, which appeared to be specific to a specific genotype. 
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Appendix 2.1 MARINA study experimental oils 
The experimental oils were supplied by Croda Europe (Hull, UK) and encapsulated by 
Powerhealth (Pocklington, UK). Blends of the test fat with 0.1 wt % peppermint oil to 
disguise the fish taste of the EPA and DHA were supplied. The placebo contained 
refined olive oil plus 0.1% peppermint oil. The EPA and DHA blends consisted of 
blends of an EPA concentrate (TG7010, code SF06396, batch 213000) and a DHA 
concentrate (DHA700TG, code SF06405, batch 213003) and refined olive oil (batch 
10813). These were blended to provide to provide to 1.8g, 0.9 and 0.46g EPA+DHA 
(with an EPA/DHA ratio of 1.51). The capsules (1g fill) were analyzed by the quality 




Appendix 2.2 Analysis of serum adiponectin: 
AutoDELFIA -based-time-resolved-fluorescence based assay is a method used for 
detecting human total serum adiponectin (low, middle, and high molecular
 
weight). In 
this method surface of wells in microtite plates is coated with mouse antibody to capture 
a target antigen (adiponectin) which are then further bound by europium (Eu) labeled 
antibodies that therefore, detect  the presence of adiponectin .  
Materials  
PerkinElmer Victor 2 multilabel counter 
PerkinElmer AutoDELFIA 1235 automatic immunoassay system 
PerkinElmer DELFIA platewasher 1296-026 
PerkinElmer Plateshaker 1296-003  
Perkin Elmer Assay Buffer (1244-111) 
Perkin Elmer Enhancement Solution (1244-105) 
Perkin Elmer wash concentrate (1244-114) 
Perkin Elmer Tracer Stability Buffer (CR84-100) 
96 well high binding fluoroNunc solid flat-bottomed microplates 
 
Note: All reagents and serum samples were thawed, mixed and brought to room 
temperature before analysis.  
 
Figure 2.1 AutoDELFIA (Perkin Elmer) is an automated fluorescent immunoassay 
system that is specifically designed to perform all sample and reagent handling 
Into each well of the microtitre plate, mouse antibody was absorbed. Plates were 
washed this is followed by adding 100 μl serum Adiponectin to the wells in duplicate, 
with 1/10000 dilution in Perkin Elmer DELFIA assay buffer.  Adiponectin present is 
captured by antibody and unbound protein is washed away after the first incubation 
period. Into each well 100 μl biotinlylated detection antibody added to each well. Then 
plates were further washed and 100 μl streptavidin Eu conjugate added (europium 
labelled antibody) to each well and were incubated again. Plated were then washed 6 
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times and 200 μl enhancement solution was added to each well. The plated were then 
incubated for 5 minutes before reading via a multi analyte detection system, set up for 
the detection for free Eu that detects the adiponectin. 
 
 
Appendix 2.3 Insulin resistance (Si)  
Glucose in the form of a 50% solution (0.3 g/kg) and regular human insulin (0.03 
units/kg) were injected through an intravenous cannula at 0 and 20 minutes respectively. 
Blood was collected at –10, -5, 0, 2, 4, 8, 19, 22, 30, 40, 50, 70, 100 and 180 min for 
measurement of plasma glucose and insulin concentrations. Si was calculated by 
mathematical modelling methods using the MINMOD Millennium programme (Version 
6.02). From the model, coefficients were obtained which may be interpreted as the 
acceleration of glucose disposal due to an incremental change in plasma glucose 
(glucose effectiveness, Sg), and the contribution attributable to an incremental rise in 
plasma insulin (Si). Sg and Si can therefore be taken as indices of insulin-independent 
and insulin-assisted glucose disposal respectively.  In addition, the area under the 
plasma insulin curve in the early stages of the test was computed and used as an 
indicator of the degree of endogenous insulin secretion in response to the glucose 
challenge (AIRG).  This term was combined with Si to give the disposition index (DI), 
which is a quantitative measure of the amount of glucose disposed, by the insulin-




Appendix 2.4 Anthropometry  
Weight was measured after an overnight fast to the nearest 0.1 kg using digital scales. 
Measurements were made with participants wearing light clothing and without shoes. 
Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. Waist 
circumference was measured to the nearest 0.1 cm in the standing position with arms to 
the side, shoulders-width apart and weight equally distributed on each leg. The 
measurement was standardised as the mid-point between the lower rib margin and the 
iliac crest and, where possible, was taken on participants with their waist uncovered or 
else without heavy outer garments. Participants were asked to breathe normally and the 
reading was taken at the end of a normal exhalation. Body composition was assessed 
using a Tanita BC-418 segmental body composition analyser (Tanita Corporation of 
America, Inc., Illinois USA). 
 
 
Appendix 2.5 Seated blood pressure  
Blood pressure and heart rate was taken using an OMRON 705CPII or equivalent auto 
upper arm blood pressure monitor. These measures were taken while the participant is 
seated and after 10 minutes of rest. When taking a blood pressure measurement the 
volunteer was calm and relaxed, sitting quietly with their legs uncrossed and feet flat on 
the floor the arm that the measurement was being taken from needs was supported. A 
cuff of appropriate size was selected and placed around upper arm wrapped snugly 
around the arm with space for a finger between volunteer and cuff. The cuff was 
appropriately aligned with the brachial artery following the instructions contained in the 
equipment manual. Measures of systolic and diastolic blood pressure and heart rate 
were made. The blood pressure measurements were repeated at least three times at two 
minute intervals. The value for the first reading was discarded and the mean for the two 




Appendix 3.1: Table 3.1 Characteristics of RISCK study subjects at baseline 
 Phenotype All Women Men  P 
 (n= 448)  ( n= 184) (n=264 ) 
Ethnicity
1
     
    South Asia 44(9.8) 19(10.3) 25(9.4)  
    Black African 38(8.5) 10(5.4) 28(10.6)  
    White European 366(81.7) 155(84.3) 211(80)  
Age (y) 52.5 ± 9.9 51.8 ± 9.5 53.6 ± 10.2  0.05 
BMI  (kg/m
2
) 28.8 ± 4.7 28.9 ± 5.2 28.5 ± 3.9  0.43 
Fasting insulin (pmol/L)
2 60.4 ± 52.1 58.2 ± 58.7 63.4 ± 40.8  0.1 
Fasting glucose (mmol/L) 5.7 ± 0.8 5.5 ± 0.6 5.9 ± 0.9 <0.001 
Insulin sensitivity IVGTT)((mU/L)-1 min-1)
2 2.7 ± 2.7 2.9 ± 3.1 2.4 ± 1.9  0.001 
HOMA2-IR
2 1.3 ± 0.7 1.3 ± 0.7 1.3 ± 0.8  0.54 
Adiponectin (μg/mL)2 9.6+5.9 11.1+6.3 7.7+4.1 <0.001 
TAG (mmol/L)
2 1.4+0.7 1.3+0.6 1.5+0.8 <0.001 
TC (mmol/L) 5.6+1.0 5.6+1.0 5.6+1.0  0.56 
HDL-C (mmol/L) 1.4+0.3 1.5+0.3 1.3+0.3 <0.001 
ApoA1 (g/L) 1.2+0.2 1.2+0.2 1.2+0.2  0.003 
LDL-C (mmol/L) 3.5+0.8 3.5+0.8 3.6+0.8  0.16 
Apo B (g/L) 1.0+0.3 1.0+0.3 1.0+0.3  0.11 
Systolic BP (mm Hg) 129.6+15.9 125.7+15.2 135.2+15.3 <0.001 
Diastolic BP (mm Hg) 79.6+9.5 77.3+9.1 82.9+9.1 <0.001 
Data is presented for subjects which DNA samples were available (n = 448). Mean ± 
SD, or 
2
geometric mean ± SD values for insulin, Si, HOMA2-IR, adiponectin, TAG 
and HDL-C are shown. All variables were measured at baseline after 4-wk run-in on 
reference HS diet. 
1
Self-reported ethnicity. Significance of differences between 




Appendix 3.2 Genotyping by Pyrosequencing 
Pyrograms for the three ADIPOQ -7734 C/A, 11391 G/A and. +276 G/T genotypes are 
shown below  
 
 
Figure 3.1 Pyrograms for ADIPOQ -7734 C/A genotypes Yellow blocks indicate the 







Figure 3.2 Pyrograms for ADIPOQ 11391 G/A genotypes Yellow blocks indicate the peaks 











Appendix 5.1: Table 5.1 Effect of Interaction between fat intake and PPARA Leu162Val genotypes in determining changes in obesity measures, 
insulin sensitivity measures and plasma lipids and adiponectin in White subjects  
  HS HM LF   
Phenotype LL (n = 45 ) LV (n = 7 ) LL (n = 128 ) LV (n = 22 ) LL (n = 137) LV (n = 17) p 
  Change (95%CI) Change (95%CI) Change (95%CI) Change (95%CI) Change (95%CI) Change (95%CI) diet x gene 
BMI (kg/m2)
1
 0.1 (-0.2,0.4) 0.5 (0.0,1.1) 0.0 (-0.2,0.1) -0.1 (-0.5,0.3) -0.4 (-0.6,-0.2) -0.3 (-1.0,0.4) 0.45 
Waist circumference (cm)
1
 -0.6 (-1.9,0.7) -0.3 (-3.6,3.1) 0.1 (-0.7,0.8) -1.1 (-3.5,1.4) -1.4 (-2.2,-0.6) -0.4 (-2.7,1.9) 0.33 
Body fat %
1
 0.3 (-0.3,1.0) 1.2 (-0.4,2.8) -0.3 (-0.7,0.0) 0.2 (-0.9,1.2) -0.5 (-0.9,-0.1) -0.1 (-1.4,1.3) 0.92 
Insulin sensitivity IVGTT)((mU/L)-1 min-1)
 2
 -0.02 (-0.1,0.1) -0.1 (-0.36,0.21) -0.04 (-0.1,0.1) 0.0 (-0.18,0.21) 0.02 (-0.1,0.1) -0.1 (-0.31,0.12) 0.58 
Fasting insulin (pmol/L) -2.9 (-3.2,-2.7) -3.2 (-4.1,-2.3) -3.4 (-3.6,-3.1) -2.9 (-3.4,-2.4) -2.9 (-3.1,-2.8) -3.2 (-3.7,-2.6) 0.11 
Fasting glucose (mmol/L)
 2
 -0.05 (-0.16,0.06) 0.04 (-0.43,0.51) -0.10 (-0.16,-0.03) -0.30 (-0.95,0.36) -0.16 (-0.27,-0.05) -0.21 (-0.45,0.02) 0.58 
HOMA2-IR
2
 0.04 (-0.07,0.15) 0.13 (-0.22,0.49) 0.05 (-0.03,0.13) -0.01 (-0.22,0.19) 0.00 (-0.09,0.08) 0.03 (-0.22,0.29) 0.68 
NEFA (μmol/L) -61.3 (-130.6,8.0) -109.2 (-304.4,86.0) -34.3 (-77.3,8.7) -10.4 (-167.6,146.7) 3.4 (-36.8,43.6) 3.6 (-91.6,98.9) 0.84 
Total cholesterol (mmol/L) -0.05 (-0.22,0.12) 0.09 (-0.24,0.41) -0.37 (-0.47,-0.27) -0.38 (-0.69,-0.07) -0.40 (-0.49,-0.31) -0.42 (-0.69,-0.15) 0.92 
TAG (mmol/L)
 2
 0.00 (-0.10,0.09) 0.09 (-0.30,0.49) -0.04 (-0.09,0.01) 0.00 (-0.17,0.18) -0.01 (-0.05,0.03) 0.01 (-0.15,0.17) 0.94 
HDL Cholesterol (mmol/L)
 2
 -0.05 (-0.12,0.02) -0.07 (-0.30,0.15) -0.04 (-0.07,-0.01) -0.07 (-0.15,0.01) -0.11 (-0.14,-0.08) -0.10 (-0.19,-0.01) 0.85 
Apolipoprotein A1 (mg/dL) -0.02 (-0.07,0.02) 0.03 (-0.13,0.20) -0.01 (-0.04,0.01) -0.05 (-0.13,0.03) -0.07 (-0.10,-0.04) -0.08 (-0.21,0.04) 0.76 
LDL Cholesterol (mmol/L) 0.01 (-0.14,0.16) 0.00 (-0.34,0.34) -0.29 (-0.37,-0.22) -0.35 (-0.63,-0.06) -0.28 (-0.36,-0.20) -0.31 (-0.49,-0.12) 0.98 
Apolipoprotein B (mg/dL) 0.03 (-0.02,0.08) 0.05 (-0.14,0.24) -0.06 (-0.09,-0.03) -0.11 (-0.19,-0.03) -0.07 (-0.11,-0.04) -0.08 (-0.18,0.02) 0.75 
















Values are mean change (95% CI) or 
2
GM (95% CI. All data and P-values for ANCOVA adjusted for age, gender and BMI, based on subjects for whom PPARA Leu162Val 
genotype data was available (n = 356). LL represents subjects homozygous for the PPARA Leu162 allele and LV carriers of the Val162 allele.
1





Appendix 5.2 Table 5.2 Effect of Interaction between fat intake PPARG Pro12Ala genotypes and changes in obesity measures, insulin 
sensitivity measures and plasma lipids and adiponectin concentrations in White subjects 
  HS HM LF   
Phenotype PP (n = 47 ) PA+AA (n = 7 ) PP (n = 109 ) PA + AA  (n = 20 ) PP (n = 109 ) PA + AA (n = 37) p 
  Change (95%CI) Change (95%CI) Change (95%CI) Change (95%CI) Change (95%CI) Change (95%CI) diet x gene 
BMI (kg/m2)
1
 0.1 (-0.1,0.4) 0.3 (-0.3,0.9) -0.1 (-0.2,0.1) -0.1 (-0.6,0.3) -0.5 (-0.7,-0.3) -0.2 (-0.5,0.2) 0.42 
Waist circumference (cm)
1
 -0.5 (-1.7,0.7) -1.5 (-6.1,3.1) -0.3 (-1.1,0.6) -0.2 (-2.3,1.9) -1.5 (-2.4,-0.6) -1.2 (-2.6,0.1) 0.81 
Body fat %
1
 0.5 (-0.2,1.1) 1.0 (-0.5,2.6) -0.2 (-0.6,0.2) 0.0 (-0.8,0.8) -0.4 (-0.9,0.0) -0.2 (-1.1,0.6) 0.94 
Insulin sensitivity IVGTT)((mU/L)-1 min-1)
 2
 -0.08 (-0.2,0.1) 0.0 (-0.31,0.38) -0.05 (-0.2,0.1) -0.1 (-0.26,0.06) 0.02 (-0.1,0.1) 0.1 (-0.09,0.21) 0.75 
Fasting insulin (pmol/L)
2 
-3.0 (-3.3,-2.7) -2.9 (-3.5,-2.3) -3.3 (-3.6,-3.0) -3.3 (-3.6,-3.0) -3.1 (-3.3,-2.9) -2.8 (-3.2,-2.4) 0.81 
Fasting glucose (mmol/L) -0.05 (-0.15,0.05) -0.05 (-0.38,0.27) -0.13 (-0.28,0.01) -0.08 (-0.23,0.08) -0.12 (-0.19,-0.06) -0.32 (-0.70,0.07) 0.41 
HOMA2-IR
2
 0.01 (-0.10,0.12) 0.01 (-0.31,0.34) 0.02 (-0.06,0.10) 0.08 (-0.08,0.24) 0.04 (-0.05,0.13) -0.06 (-0.23,0.11) 0.62 
NEFA (μmol/L) -68.8 (-138.6,1.0) -95.7 (-301.3,110.0) -8.1 (-52.9,36.6) -4.6 (-157.3,148.0) -25.4 (-72.9,22.1) 85.5 (18.1,153.0) 0.24 
Total cholesterol (mmol/L) -0.04 (-0.20,0.12) -0.04 (-0.65,0.57) -0.33 (-0.44,-0.21) -0.38 (-0.56,-0.21) -0.38 (-0.48,-0.29) -0.46 (-0.66,-0.25) 0.92 
Triglycerides (mmol/L)
 2
 0.04 (-0.05,0.12) -0.07 (-0.45,0.31) -0.01 (-0.07,0.05) 0.00 (-0.15,0.15) -0.01 (-0.06,0.04) -0.06 (-0.15,0.04) 0.55 
HDL Cholesterol (mmol/L)
 2
 -0.04 (-0.11,0.02) -0.03 (-0.14,0.09) -0.05 (-0.08,-0.02) -0.04 (-0.11,0.04) -0.10 (-0.14,-0.07) -0.14 (-0.19,-0.08) 0.64 
Apolipoprotein A1 (g/L) 0.01 (-0.04,0.06) -0.07 (-0.20,0.05) -0.01 (-0.04,0.01) -0.04 (-0.11,0.04) -0.05 (-0.09,-0.02) -0.10 (-0.16,-0.04) 0.56 
LDL Cholesterol (mmol/L) -0.03 (-0.18,0.13) 0.09 (-0.26,0.43) -0.29 (-0.38,-0.20) -0.32 (-0.54,-0.09) -0.27 (-0.35,-0.19) -0.27 (-0.44,-0.10) 0.8 
Proportion of sdLDL (%) 2.38 (-0.80,5.56) -1.07 (-5.28,3.15) 2.66 (0.72,4.59) -2.30 (-7.10,2.49) 1.72 (0.39,3.06) 1.78 (-1.68,5.25) 0.31 
Apolipoprotein B (g/L) 0.04 (-0.01,0.09) -0.04 (-0.22,0.14) -0.06 (-0.09,-0.03) -0.06 (-0.13,0.01) -0.07 (-0.10,-0.03) -0.08 (-0.16,0.00) 0.94 
Adiponectin  (μg/mL) 0.02 (-0.03,0.08) -0.08 (-0.15,-0.01) -0.01 (-0.04,0.02) 0.03 (-0.03,0.09) 0.00 (-0.02,0.03) -0.03 (-0.09,0.03) 0.16 
Values are mean change (95% CI) or 
2
GM (95% CI). All data and P-values for ANCOVA adjusted for age, gender and BMI, based on subjects for whom PPARG Pro12Ala    
genotype data was available (n = 329). PP represents subjects homozygous for the PPARG Pro12 allele and PA + AA carriers of the Ala12 allele.
1







Appendix 5.3: Table 5.3 Effect of Interaction between fat intake and PPARA Leu162Val genotypes in determining obesity measures, insulin 
sensitivity measures and plasma lipids and adiponectin in White subjects 
Values are follow-up values adjusted for baseline values (95% CI) or 
2
GM (95% CI.). LL represents subjects homozygous for the PPARA Leu162 allele and 
LV carriers of the Val162 allele.   
  HS HM LF 
Phenotype LL (n = 45 ) LV (n = 7 ) LL (n = 128 ) LV (n = 22 ) LL (n = 137) LV (n = 17) 
  Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) 
BMI (kg/m2) 28.7 (28.4,29.0) 30.5 (29.7,31.4) 28.6 (28.4,28.7) 29.9 (29.4,30.4) 28.2 (28.0,28.3) 29.7 (29.2,30.2) 
Waist circumference (cm) 97.6 (96.4,98.9) 99.2 (95.5,102.9) 98.3 (97.6,99.0) 98.4 (96.3,100.6) 96.8 (96.1,97.5) 99.1 (96.6,101.5) 
Body fat % 34.0 (33.3,34.7) 36.0 (34.3,37.8) 33.4 (33.0,33.8) 34.8 (33.8,35.8) 33.1 (32.8,33.5) 34.3 (33.1,35.5) 
Insulin sensitivity IVGTT)((mU/L)-1 min-1)
 2
 2.8 (2.4,3.1) 2.8 (2.0,3.8) 2.6 (2.4,2.8) 3.1 (2.6,3.7) 2.8 (2.6,3.1) 2.7 (2.2,3.3) 
Fasting insulin (pmol/L) 96.8 (46.3,93.3) 72.9 (58.9,86.8) 77.7 (63.6,91.7) 72.1 (64.2,80.0) 61.5 (48.0,74.9) 65.9 (56.9,74.8) 
Fasting glucose (mmol/L)
 2
 5.6 (5.5,5.7) 5.7 (5.3,6.2) 5.6 (5.5,5.6) 5.6 (5.3,5.8) 5.5 (5.4,5.6) 5.6 (5.4,5.9) 
HOMA2-IR
2
 1.2 (1.1,1.4) 1.1 (0.9,1.5) 1.3 (1.2,1.4) 1.2 (1.0,1.4) 1.2 (1.2,1.3) 1.3 (1.1,1.5) 
NEFA (μmol/L) 633.6 (573.7,693.5) 649.0 (480.1,817.9) 661.4 (625.9,696.9) 668.9 (573.1,764.8) 691.9 (657.5,726.2) 650.2 (542.9,757.5) 
Total cholesterol (mmol/L) 5.7 (5.5,5.8) 5.6 (5.1,6.0) 5.4 (5.3,5.5) 5.1 (4.8,5.3) 5.3 (5.2,5.4) 5.1 (4.8,5.4) 
TAG (mmol/L)
 2
 1.4 (1.3,1.5) 1.5 (1.1,1.9) 1.4 (1.3,1.4) 1.3 (1.1,1.6) 1.4 (1.3,1.4) 1.3 (1.1,1.6) 
HDL Cholesterol (mmol/L)
 2
 1.4 (1.3,1.4) 1.3 (1.2,1.5) 1.4 (1.3,1.4) 1.3 (1.2,1.4) 1.3 (1.3,1.3) 1.3 (1.2,1.4) 
Apolipoprotein A1 (mg/dL) 1.2 (1.2,1.3) 1.3 (1.1,1.4) 1.2 (1.2,1.2) 1.2 (1.1,1.3) 1.2 (1.1,1.2) 1.2 (1.1,1.3) 
LDL Cholesterol (mmol/L) 3.6 (3.5,3.7) 3.4 (3.1,3.8) 3.3 (3.3,3.4) 3.1 (2.9,3.3) 3.3 (3.3,3.4) 3.2 (3.0,3.5) 
Apolipoprotein B (mg/dL) 1.03 (0.97,1.08) 0.98 (0.84,1.12) 0.94 (0.90,0.97) 0.85 (0.77,0.93) 0.91 (0.88,0.94) 0.89 (0.80,0.98) 
Proportion of sdLDL (%) 26.1 (22.5,29.7) 31.7 (21.4,42.0) 26.2 (24.1,28.3) 20.3 (14.5,26.0) 24.4 (22.4,26.5) 26.1 (19.6,32.7) 
Adiponectin (μg/mL) 10.5 (10.1,11.0) 9.8 (8.6,11.2) 10.0 (9.7,10.3) 11.0 (10.2,11.8) 10.1 (9.8,10.4) 10.0 (9.1,10.9) 
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Appendix 5.4: Table 5.4: Effect of Interaction between fat intake PPARG Pro12Ala genotypes and obesity measures, insulin sensitivity 
measures and plasma lipids and adiponectin concentrations in White subjects 
  HS HM LF 
Phenotype PP (n = 47 ) PA+AA (n = 7 ) PP (n = 109 ) PA + AA  (n = 20 ) PP (n = 109 ) PA + AA (n = 37) 
 Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) Follow-up (95%CI) 
BMI (kg/m2) 29.0 (28.7,29.2) 28.2 (27.4,28.9) 28.8 (28.6,29.0) 27.7 (27.3,28.2) 28.4 (28.2,28.5) 27.7 (27.3,28.0) 
Waist circumference (cm) 97.9 (96.7,99.2) 96.0 (92.8,99.2) 98.2 (97.3,99.0) 97.4 (95.5,99.3) 97.0 (96.1,97.8) 96.4 (95.0,97.8) 
Body fat %
1
 34.7 (34.1,35.3) 32.1 (30.4,33.8) 34.0 (33.6,34.4) 31.3 (30.2,32.4) 33.8 (33.4,34.2) 30.9 (30.2,31.7) 
Insulin sensitivity IVGTT)((mU/L)-1 min-1)
 2
 2.6 (2.3,3.0) 2.9 (2.2,3.9) 2.6 (2.3,2.8) 2.5 (2.1,3.0) 2.8 (2.6,3.1) 3.0 (2.6,3.4) 
Fasting insulin (pmol/L)
2
 68.8 (44.1,93.5) 68.3(50.4,86.1) 82.8 (66.5,99.1) 62.1 (51.5,72.7) 59.0 (42.2,74.8) 64.0 (56.3,71.8) 
Fasting glucose (mmol/L) 5.6 (5.5,5.7) 5.7 (5.3,6.0) 5.6 (5.5,5.6) 5.7 (5.5,5.9) 5.5 (5.4,5.6) 5.5 (5.4,5.7) 
HOMA2-IR
2
 1.3 (1.1,1.4) 1.2 (0.9,1.7) 1.3 (1.2,1.4) 1.3 (1.1,1.6) 1.3 (1.2,1.4) 1.1 (1.0,1.3) 
NEFA (μmol/L) 652.5 (595.6,709.5) 584.6 (416.2,752.9) 683.0 (645.5,720.6) 686.3 (585.5,787.2) 678.1 (639.6,716.7) 717.2 (643.2,791.2) 
Total cholesterol (mmol/L) 5.5 (5.4,5.7) 5.8 (5.4,6.2) 5.3 (5.2,5.4) 5.4 (5.2,5.7) 5.2 (5.1,5.3) 5.3 (5.2,5.5) 
Triglycerides (mmol/L)
 2
 1.4 (1.3,1.5) 1.3 (1.0,1.6) 1.3 (1.3,1.4) 1.4 (1.2,1.6) 1.3 (1.3,1.4) 1.3 (1.2,1.5) 
HDL Cholesterol (mmol/L)
 2
 1.4 (1.3,1.4) 1.3 (1.2,1.4) 1.3 (1.3,1.4) 1.3 (1.3,1.4) 1.3 (1.3,1.3) 1.2 (1.2,1.3) 
Apolipoprotein A1 (g/L) 1.2 (1.2,1.3) 1.2 (1.0,1.3) 1.2 (1.2,1.2) 1.2 (1.1,1.3) 1.2 (1.1,1.2) 1.1 (1.1,1.2) 
LDL Cholesterol (mmol/L) 3.5 (3.4,3.6) 3.9 (3.6,4.2) 3.2 (3.2,3.3) 3.4 (3.2,3.7) 3.2 (3.2,3.3) 3.5 (3.3,3.6) 
Proportion of sdLDL (%) 0.99 (0.94,1.04) 1.04 (0.88,1.19) 0.90 (0.86,0.93) 0.96 (0.87,1.05) 0.89 (0.85,0.92) 0.94 (0.88,1.01) 
Apolipoprotein B (g/L) 26.3 (23.2,29.5) 26.1 (18.1,34.0) 24.9 (22.8,27.0) 23.1 (18.4,27.8) 23.8 (21.7,26.0) 25.3 (21.9,28.8) 
Adiponectin  (μg/mL) 10.6 (10.2,11.1) 9.1 (8.0,10.2) 10.3 (10.0,10.6) 10.1 (9.4,10.9) 10.4 (10.1,10.7) 9.5 (9.0,10.0) 
Values are follow-up values adjusted for baseline values (95% CI) or 
2
GM (95% CI.). PP represents subjects homozygous for the PPARG Pro12 allele and PA 
+ AA carriers of the Ala12 allele.  
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Appendix 6.1: Characteristics of subjects at baseline by randomized treatment 
                   Table 6.1 Characteristics of subjects at baseline by randomized treatment 
  Placebo 0.45 g/day 0.9 g/day 1.8 g/day 
  n=88 n=94 n=93 n=92 
Male 34 (38.6%) 36 (38.3%) 36 (38.7%) 36 (39.1%) 
Female 54 (61.4%) 58 (61.7%) 57 (61.3%) 56 (60.9%) 
Age (y) 55 (54 to 57) 55 (53 to 56) 55 (54 to 56) 55 (54 to 57) 
Ethnicity
1
     
White 68 (77.3%) 76 (80.9%) 73 (78.5%) 79 (85.9%) 
Black 9 (10.2%) 4 (4.3%) 6 (6.5%) 1 (1.1%) 
Asian
2
 6 (6.8%) 6 (6.4%) 10 (10.8%) 2 (2.2%) 
Far Eastern 2 (2.3%) 4 (4.3%) 0 (0.0%) 4 (4.3%) 
Other 3 (3.4%) 4 (4.3%) 4 (4.3%) 6 (6.5%) 
BMI (kg/m
2
) 26.2 (25.3,27.1) 25.1 (24.3,25.9) 26.2 (25.3,27.0) 25.1 (24.3,26.0) 
Total-C:HDL-C
2
 3.59 (3.40, 3.79) 3.53 (3.35 , 3.73) 3.43 (3.26 , 3.62) 3.47 (3.28 , 3.68) 
TC (mmol/L) 5.6 (5.4 , 5.7) 5.5 (5.3 , 5.7) 5.4 (5.2 , 5.6) 5.5 (5.4 , 5.7) 
TAG(mmol/L)
3 
1.2 (1.0,1.3) 1.1 (1.0,1.3) 1.1 (1.0,1.2) 1.1 (1.0,1.2) 
HDL-C(mmol/L) 1.53 (1.44 , 1.61) 1.54 (1.47 , 1.61) 1.56 (1.48 , 1.64) 1.58 (1.48 , 1.68) 
LDL-C(mmol/L) 3.5 (3.3 , 3.6) 3.4 (3.2 , 3.6) 3.3 (3.2 , 3.5) 3.4 (3.2 , 3.5) 
Systolic BP (mmHg ) 126 (123,129) 122 (119,125) 126 (123,129) 121 (119,124) 
Diastolic BP (mmHg ) 76 (75,78) 73 (71,74) 76 (74,77) 73 (72,75) 
Measurements made at baseline after a 4-week run-in on normal diet with placebo supplement and after 6 
and 12 months during which normal diet was supplemented with (n-3) LCP at the daily doses shown. 












Appendix 6.2 Plasma LDL concentrations stratified by PPARG Pro12Ala after n-3 LCP treatment  
Table 6.2 Plasma LDL-C concentrations stratified by PPARG Pro12Ala after n-3 LCP treatment in all subjects 
PPARG Pro12Ala LDL-C(mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day 
Pro12 homozygotes    n = 46 n = 49 n = 54 n = 57 
 Baseline 3.3 (3.0,3.5) 3.2 (3.0,3.4) 3.2 (3.0,3.4) 3.1 (2.9,3.3) 
 6 months 3.5 (3.2,3.7) 3.5 (3.2,3.8) 3.4 (3.2,3.6) 3.3 (3.1,3.5) 
 12 months 3.4 (3.1,3.6) 3.4 (3.2,3.7) 3.4 (3.2,3.6) 3.3 (3.1,3.6) 
 Average 3.4 (3.2,3.6) 3.5 (3.2,3.7) 3.4 (3.2,3.6) 3.3 (3.1,3.5) 
 Change 0.17 (0.03,0.32) 0.28 (0.09,0.47) 0.17 (0.03,0.31) 0.19 (0.06,0.32) 
  Treatment effect 0.000 [Reference] 0.093 (-0.105,0.292) 0.108 (-0.081,0.296) -0.014 (-0.207,0.178) 
Ala12 carriers   n =13 n = 19 n = 9 n =16 
 Baseline 3.3 (2.7,3.9) 3.6 (3.3,4.0) 3.2 (2.6,3.9) 3.3 (3.0,3.7) 
 6 months 3.6 (3.2,4.0) 3.8 (3.4,4.1) 3.4 (2.4,4.3) 3.5 (3.2,3.9) 
 12 months 3.5 (3.1,4.0) 3.7 (3.3,4.1) 3.2 (2.5,3.8) 3.8 (3.4,4.2) 
 Average 3.6 (3.2,4.0) 3.7 (3.4,4.1) 3.2 (2.5,3.9) 3.7 (3.3,4.0) 
 Change 0.31 (-0.14,0.76) 0.08 (-0.18,0.35) 0.01 (-0.34,0.35) 0.35 (-0.07,0.77) 





Table 6.3 Plasma LDL-C concentrations stratified by PPARG Pro12Ala after n-3 LCP treatment in White subjects 
PPARG Pro12Ala LDL-C (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day 
Pro12 homozygotes    n = 38 n = 39 n = 43 n = 47 
 Baseline 3.3 (3.1,3.6) 3.3 (3.1,3.6) 3.2 (2.9,3.4) 3.1 (2.9,3.3) 
 6 months 3.4 (3.2,3.7) 3.7 (3.4,4.1) 3.4 (3.1,3.6) 3.3 (3.1,3.5) 
 12 months 3.3 (3.1,3.6) 3.6 (3.3,3.9) 3.4 (3.1,3.6) 3.3 (3.1,3.6) 
 Average 3.4 (3.2,3.6) 3.7 (3.4,4.0) 3.4 (3.1,3.6) 3.3 (3.1,3.5) 
 Change 0.07 (-0.07,0.21) 0.35 (0.13,0.57) 0.19 (0.03,0.35) 0.23 (0.10,0.37) 
  Treatment effect 0.000 [Reference] 0.279 (0.061,0.497) 0.178 (-0.031,0.388) 0.101 (-0.110,0.311) 
Ala12 carriers    n =10 n = 14 n = 7 n =15 
 Baseline 3.1 (2.4,3.8) 3.6 (3.1,4.0) 3.4 (2.5,4.2) 3.4 (3.0,3.7) 
 6 months 3.5 (3.0,4.0) 3.6 (3.2,4.0) 3.6 (2.3,4.9) 3.6 (3.2,4.0) 
 12 months 3.6 (3.0,4.2) 3.6 (3.3,4.0) 3.4 (2.6,4.2) 3.8 (3.4,4.3) 
 Average 3.6 (3.0,4.1) 3.6 (3.3,4.0) 3.4 (2.5,4.3) 3.7 (3.3,4.1) 
 Change 0.45 (-0.11,1.01) 0.07 (-0.20,0.34) 0.05 (-0.42,0.52) 0.33 (-0.11,0.78) 
  Treatment effect 0.000 [Reference] -0.184 (-0.682,0.313) -0.188 (-0.627,0.251) 0.003 (-0.481,0.488) 
For tables 6.2 and 6.3 plasma LDL-C concentrations (95% CI) (mmol/L) are shown. Data is presented for PPARG Pro12 homozygous and PPARG 
Ala12-allele carriers for all and White subjects, for whom DNA samples and plasma LDL-C measurements were available. All variables were 
measured at baseline after a 4-week run-in on normal diet with a placebo supplement and after 6 and 12 months, during which normal diet was 
supplemented with n-3 LCP at the daily doses shown. The average of the measurements at 6 and 12 months was subtracted from those made at baseline 
to determine the average change. Treatment effects were determined by univariate ANCOVA. P-values are adjusted for BMI, age, ethnicity and gender 
for all subjects and P-values are adjusted for BMI, age and gender for Whites  (nominally significant at P < 0.05) (nominally significant at P < 0.05. 




Appendix 6.3 Plasma HDL concentrations stratified by PPARG Pro12Ala after n-3 LCP treatment  
Table 6.4 Plasma HDL-C concentrations stratified by PPARG Pro12Ala after n-3 LCP treatment in all subjects 
PPARG Pro12Ala HDL-
C(mmol/L) 
Placebo 0.45g/day 0.9g/day 1.8g/day 
Pro12 homozygotes   n = 46 n = 49 n = 54 n = 57 
 Baseline 1.5 (1.4,1.7) 1.6 (1.4,1.7) 1.7 (1.5,1.8) 1.7 (1.6,1.9) 
 6 months 1.5 (1.4,1.6) 1.6 (1.5,1.7) 1.6 (1.5,1.8) 1.7 (1.5,1.8) 
 12 months 1.5 (1.4,1.6) 1.6 (1.5,1.7) 1.7 (1.5,1.8) 1.7 (1.6,1.9) 
 Average 1.5 (1.4,1.6) 1.6 (1.5,1.7) 1.7 (1.5,1.8) 1.7 (1.6,1.8) 
 Change -0.03 (-0.12,0.05) 0.02 (-0.05,0.09) -0.03 (-0.10,0.05) 0.01 (-0.06,0.08) 
  Treatment effect 0.000 [Reference] 0.064 (-0.033,0.160) -0.029 (-0.122,0.063) 0.093 (-0.001,0.187) 
Ala12 carriers   n =13 n = 19 n = 9 n =16 
 Baseline 1.6 (1.4,1.8) 1.6 (1.4,1.8) 1.7 (1.3,2.2) 1.5 (1.3,1.8) 
 6 months 1.5 (1.4,1.7) 1.6 (1.4,1.7) 1.6 (1.2,1.9) 1.6 (1.3,1.8) 
 12 months 1.6 (1.4,1.9) 1.5 (1.4,1.7) 1.6 (1.3,1.9) 1.5 (1.3,1.7) 
 Average 1.6 (1.4,1.8) 1.5 (1.4,1.7) 1.6 (1.3,1.9) 1.5 (1.3,1.7) 
 Change -0.01 (-0.09,0.07) -0.04 (-0.15,0.07) -0.16 (-0.50,0.17) -0.01 (-0.13,0.12) 






Table 6.5 Plasma HDL concentrations stratified by PPARG Pro12Ala after n-3 LCP treatment in White subjects 
PPARG Pro12Ala HDL-C 
(mmol/L) 
Placebo 0.45g/day 0.9g/day 1.8g/day 
Pro12 homozygotes    n = 38 n = 39 n = 43 n = 47 
 Baseline 1.5 (1.4,1.7) 1.6 (1.5,1.8) 1.7 (1.6,1.9) 1.7 (1.5,1.9) 
 6 months 1.5 (1.3,1.6) 1.6 (1.5,1.8) 1.7 (1.6,1.8) 1.7 (1.5,1.8) 
 12 months 1.5 (1.4,1.6) 1.6 (1.5,1.8) 1.7 (1.6,1.8) 1.8 (1.6,1.9) 
 Average 1.5 (1.4,1.6) 1.6 (1.5,1.8) 1.7 (1.6,1.8) 1.7 (1.6,1.9) 
 Change -0.02 (-0.12,0.08) 0.01 (-0.07,0.09) -0.03 (-0.11,0.05) 0.02 (-0.06,0.10) 
  Treatment effect 0.000 [Reference] 0.062 (-0.046,0.171) -0.030 (-0.133,0.074) 0.092 (-0.013,0.197) 
Ala12 carriers   n =10 n = 14 n = 7 n =15 
 Baseline 1.6 (1.3,1.8) 1.5 (1.3,1.7) 1.7 (1.2,2.2) 1.5 (1.3,1.8) 
 6 months 1.5 (1.3,1.8) 1.5 (1.4,1.7) 1.5 (1.2,1.8) 1.5 (1.3,1.7) 
 12 months 1.7 (1.4,1.9) 1.5 (1.3,1.6) 1.6 (1.2,2.0) 1.5 (1.3,1.7) 
 Average 1.6 (1.3,1.8) 1.5 (1.3,1.6) 1.5 (1.3,1.8) 1.5 (1.3,1.7) 
 Change 0.01 (-0.08,0.10) -0.03 (-0.16,0.10) -0.18 (-0.63,0.27) -0.03 (-0.16,0.10) 
  Treatment effect 0.000 [Reference] -0.067 (-0.242,0.108) -0.012 (-0.169,0.145) -0.055 (-0.227,0.118) 
For tables 6.4 and 6.5 plasma HDL-C concentrations (95% CI) (mmol/L) are shown. Data is presented for PPARG Pro12 homozygous and PPARG 
Ala12-allele carriers for all and White subjects, for whom DNA samples and plasma HDL-C measurements were available. All variables were 
measured at baseline after a 4-week run-in on normal diet with a placebo supplement and after 6 and 12 months, during which normal diet was 
supplemented with n-3 LCP at the daily doses shown. The average of the measurements at 6 and 12 months was subtracted from those made at baseline 
to determine the average change. Treatment effects were determined by univariate ANCOVA. P-values are adjusted for BMI, age, ethnicity and gender 
for all subjects and P-values are adjusted for BMI, age and gender for Whites  (nominally significant at P < 0.05) (nominally significant at P < 0.05. 
Treatment x PPARG Pro12Ala P=0.61 for all subjects and P=0.44 for White subjects.
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Appendix 6.4 Plasma HDL-C concentrations stratified by PPARA Leu162Val after n-3 LCP 
Table 6.6 Plasma HDL-C concentrations stratified by PPARA Leu162Val after n-3 LCP treatment in all subjects 
PPARA Leu162Val HDL-C(mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day 
Leu162 homozygotes    n = 61 n = 73 n = 66 n = 69 
 Baseline 1.6 (1.5,1.7) 1.6 (1.5,1.7) 1.7 (1.6,1.8) 1.6 (1.5,1.8) 
 6 months 1.5 (1.4,1.6) 1.6 (1.5,1.7) 1.6 (1.5,1.8) 1.6 (1.5,1.7) 
 12 months 1.5 (1.4,1.6) 1.6 (1.5,1.7) 1.6 (1.5,1.7) 1.7 (1.6,1.8) 
 Average 1.5 (1.4,1.6) 1.6 (1.5,1.7) 1.6 (1.5,1.7) 1.7 (1.5,1.8) 
 Change -0.04 (-0.11,0.03) 0.02 (-0.05,0.08) -0.04 (-0.12,0.04) 0.02 (-0.04,0.08) 
  Treatment effect 0.000 [Reference] 0.051 (-0.032,0.133) -0.022 (-0.102,0.059) 0.072 (-0.012,0.156) 
Val162 carriers    n =6 n = 4 n = 7 n =6 
 Baseline 1.7 (1.4,2.1) 1.6 (1.0,2.1) 1.6 (1.2,1.9) 1.8 (1.2,2.4) 
 6 months 1.6 (1.2,1.9) 1.6 (1.1,2.1) 1.5 (1.1,1.9) 1.9 (1.7,2.2) 
 12 months 1.6 (1.4,1.9) 1.6 (0.9,2.3) 1.5 (1.3,1.7) 2.0 (1.6,2.3) 
 Average 1.6 (1.4,1.8) 1.6 (1.0,2.2) 1.5 (1.2,1.8) 2.0 (1.7,2.2) 
 Change -0.13 (-0.35,0.10) 0.03 (-0.32,0.37) -0.05 (-0.20,0.10) 0.15 (-0.25,0.55) 





Table 6.7 Plasma HDL-C concentrations stratified by PPARA Leu162Val after n-3 LCP treatment in White subjects 
PPARA Leu161Val HDL-C (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day 
Leu162 homozygotes    n = 49 n = 57 n = 52 n = 59 
 Baseline 1.6 (1.5,1.7) 1.6 (1.5,1.7) 1.7 (1.6,1.8) 1.6 (1.5,1.8) 
 6 months 1.6 (1.4,1.7) 1.6 (1.5,1.7) 1.7 (1.5,1.8) 1.6 (1.5,1.7) 
 12 months 1.6 (1.5,1.7) 1.6 (1.5,1.7) 1.7 (1.5,1.8) 1.7 (1.5,1.8) 
 Average 1.6 (1.5,1.7) 1.6 (1.5,1.7) 1.7 (1.5,1.8) 1.6 (1.5,1.8) 
 Change -0.02 (-0.11,0.06) 0.02 (-0.06,0.09) -0.05 (-0.13,0.04) 0.01 (-0.05,0.08) 
  Treatment effect 0.000 [Reference] 0.044 (-0.051,0.139) -0.008 (-0.099,0.083) 0.052 (-0.043,0.147) 
Val162 carriers    n =6 n = 4 n = 7 n =6 
 Baseline 1.7 (1.4,2.1) 1.6 (1.0,2.1) 1.6 (1.2,1.9) 1.8 (1.2,2.4) 
 6 months 1.6 (1.2,1.9) 1.6 (1.1,2.1) 1.5 (1.1,1.9) 1.9 (1.7,2.2) 
 12 months 1.6 (1.4,1.9) 1.6 (0.9,2.3) 1.5 (1.3,1.7) 2.0 (1.6,2.3) 
 Average 1.6 (1.4,1.8) 1.6 (1.0,2.2) 1.5 (1.2,1.8) 2.0 (1.7,2.2) 
 Change -0.13 (-0.35,0.10) 0.03 (-0.32,0.37) -0.05 (-0.20,0.10) 0.15 (-0.25,0.55) 
  Treatment effect 0.000 [Reference] 0.078 (-0.151,0.306) -0.228 (-0.458,0.002) 0.306 (0.103,0.508) 
For tables 6.6 and 6.7 plasma HDL-C concentrations (95% CI) (mmol/L) are shown. Data is presented for PPARA Leu162 homozygotes homozygous 
and PPARA Val162 carriers for all and White subjects, for whom DNA samples and plasma HDL-C measurements were available. All variables were 
measured at baseline after a 4-week run-in on normal diet with a placebo supplement and after 6 and 12 months, during which normal diet was 
supplemented with n-3 LCP at the daily doses shown. The average of the measurements at 6 and 12 months was subtracted from those made at baseline 
to determine the average change. Treatment effects were determined by univariate ANCOVA. P-values are adjusted for BMI, age, ethnicity and gender 
for all subjects and P-values are adjusted for BMI, age and gender for Whites  (nominally significant at P < 0.05),nominally significant at P < 0.05. 




Appendix 6.5 Plasma LDL-C concentrations stratified by PPARA Leu162Val after n-3 LCP 
Table 6.8 Plasma LDL-C concentrations stratified by PPARA Leu162Val after n-3 LCP treatment in all subjects 
PPARA Leu162Val LDL-C(mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day 
Leu162 homozygotes    n = 61 n = 73 n = 66 n = 69 
 Baseline 3.2 (3.0,3.5) 3.3 (3.1,3.5) 3.2 (3.0,3.4) 3.1 (3.0,3.3) 
 6 months 3.5 (3.3,3.7) 3.5 (3.3,3.7) 3.4 (3.2,3.6) 3.3 (3.2,3.5) 
 12 months 3.4 (3.2,3.6) 3.5 (3.3,3.7) 3.3 (3.1,3.5) 3.5 (3.3,3.7) 
 Average 3.4 (3.3,3.6) 3.5 (3.3,3.7) 3.3 (3.1,3.5) 3.4 (3.2,3.6) 
 Change 0.19 (0.05,0.33) 0.23 (0.10,0.37) 0.12 (0.00,0.24) 0.24 (0.11,0.38) 
  Treatment effect 0.000 [Reference] 0.050 (-0.119,0.219) 0.025 (-0.140,0.189) 0.026 (-0.146,0.198) 
Val162 carriers    n =6 n = 4 n = 7 n =6 
 Baseline 3.9 (3.1,4.7) 2.9 (1.7,4.1) 3.3 (2.6,4.0) 3.0 (1.8,4.1) 
 6 months 3.3 (2.8,3.8) 3.2 (1.7,4.6) 3.4 (2.9,3.9) 3.7 (2.8,4.5) 
 12 months 4.0 (3.3,4.6) 3.2 (2.0,4.3) 3.5 (3.0,4.0) 3.4 (2.4,4.5) 
 Average 3.8 (3.2,4.3) 3.2 (2.0,4.3) 3.4 (3.0,3.9) 3.6 (2.7,4.4) 
 Change -0.13 (-0.60,0.33) 0.25 (-0.68,1.18) 0.14 (-0.30,0.58) 0.60 (0.03,1.17) 





Table 6.9 Plasma LDL-C concentrations stratified by PPARA Leu162Val after n-3 LCP treatment in White subjects 
PPARA Leu161Val LDL-C (mmol/L) Placebo 0.45g/day 0.9g/day 1.8g/day 
Leu162 homozygotes    n = 49 n = 57 n = 52 n = 59 
 Baseline 3.3 (3.0,3.5) 3.3 (3.1,3.5) 3.2 (2.9,3.4) 3.1 (3.0,3.3) 
 6 months 3.5 (3.2,3.7) 3.6 (3.4,3.9) 3.4 (3.1,3.6) 3.3 (3.2,3.5) 
 12 months 3.4 (3.1,3.6) 3.6 (3.4,3.8) 3.2 (3.0,3.5) 3.5 (3.3,3.7) 
 Average 3.4 (3.2,3.6) 3.6 (3.4,3.8) 3.3 (3.1,3.5) 3.4 (3.2,3.6) 
 Change 0.14 (-0.01,0.29) 0.28 (0.13,0.43) 0.13 (0.00,0.26) 0.27 (0.12,0.41) 
  Treatment effect 0.000 [Reference] 0.158 (-0.029,0.345) 0.066 (-0.114,0.246) 0.092 (-0.095,0.278) 
Val162 carriers   n =6 n = 4 n = 7 n =6 
 Baseline 3.9 (3.1,4.7) 2.9 (1.7,4.1) 3.3 (2.6,4.0) 3.0 (1.8,4.1) 
 6 months 3.3 (2.8,3.8) 3.2 (1.7,4.6) 3.4 (2.9,3.9) 3.7 (2.8,4.5) 
 12 months 4.0 (3.3,4.6) 3.2 (2.0,4.3) 3.5 (3.0,4.0) 3.4 (2.4,4.5) 
 Average 3.8 (3.2,4.3) 3.2 (2.0,4.3) 3.4 (3.0,3.9) 3.6 (2.7,4.4) 
 Change -0.13 (-0.60,0.33) 0.25 (-0.68,1.18) 0.14 (-0.30,0.58) 0.60 (0.03,1.17) 
  Treatment effect 0.000 [Reference] 0.027 (-0.571,0.625) -0.359 (-0.913,0.195) 0.386 (-0.156,0.928) 
For tables 6.8 and 6.9 plasma LDL-C concentrations (95% CI) (mmol/L) are shown. Data is presented for PPARA Leu162 homozygotes homozygous 
and PPARA Val162 carriers for all and White subjects, for whom DNA samples and plasma LDL-C measurements were available. All variables were 
measured at baseline after a 4-week run-in on normal diet with a placebo supplement and after 6 and 12 months, during which normal diet was 
supplemented with n-3 LCP at the daily doses shown. The average of the measurements at 6 and 12 months was subtracted from those made at baseline 
to determine the average change. Treatment effects were determined by univariate ANCOVA. P-values are adjusted for BMI, age, ethnicity and gender 
for all subjects and P-values are adjusted for BMI, age and gender for Whites  (nominally significant at P < 0.05) (nominally significant at P < 0.05. 
Treatment x PPARA Leu162Val P=0.46 for all subjects and P=0.43 for White subjects  
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Appendix 7.1 EDT circular email  
Circular e-mail for use for recruitment of volunteers for study ref. 08/H0805/2, 
approved by Bromley Research Ethics Committee. This project contributes to the 
College's role in conducting research, and teaching research methods. You are under no 
obligation to reply to this email, however if you choose to, participation in this research 
is voluntary and you may withdraw at any time 
 
INVESTIGATION INTO INCORPORATION OF (N−3) POLYUNSATURATED 
FATTY ACIDS, EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC 
ACID, INTO ERYTHROCYTE MEMBRANES AND EFFECTS ON NOVEL 
MARKERS OF CARDIOVASCULAR RISK 
 
Short title: The EPA and DHA Trial 
 
We need you to help us investigate how two different types of omega-3 fatty acids, 
present in fish oils (eicosapentaenoic acid, abbreviated to EPA, and docosahexaenoic 
acid, abbreviated to DHA)  affect the health of your blood vessels. 
 
If you are a healthy male, non-smoker and aged between 18 and 45 years, not allergic to 
fish and not receiving any medication for blood pressure or blood cholesterol then you 
may be able to help us. By taking part in this research you will get information about 
your cardiovascular health. 
 
If you decide to take part you need to attend 3 visits as follows: 
 
- SCREENING VISIT (approximately 45 min). You will be asked to attend the 
Nutritional Sciences Division (King's College London) for a screening visit. You will be 
provided with an information sheet and you will be given the opportunity to ask any 
questions you may have before proceeding. We will then ask you questions about your 
medical history and dietary habits, and will measure your height, weight, body fat, 
waist/hip circumference and blood pressure. We will take a small blood sample (16.5 ml 
/ ~3 teaspoons) to assess your suitability for the study. You will be shown how to fit the 
24 h blood pressure monitor which you will use to record your blood pressure for 24 h 
prior to each of the study visits. Breakfast will be provided afterwards. 
 
- STUDY VISITS (approximately 2-3 h). Should you be suitable to take part, you 
would be asked to take 5 g of oil per day in the form of capsules which either contain 
olive oil or fish oil for the whole duration of the study (8 weeks). You will be asked to 
attend the Nutritional Sciences Division (King's College London) for a total of 2 
occasions: after 2 weeks of taking the capsules (study visit 1) and at the end of the 8 
weeks (study visit 2). 2-3 days before each visit we shall ask you to collect a urine 
sample for 24 h, and to be fitted with a blood pressure monitor which measures your 
blood pressure for 24 h. On the day before each of these visits, we shall ask you to 
avoid any strenuous exercise, to avoid foods high in fat and to fast overnight. On the 
day of your study visits 1 and 2, we shall weigh you and estimate your body fat content. 
After resting for 15 minutes, we will measure your pulse with external probes on your 
wrist and finger, and measure the small blood vessels in your finger using a special 
microscope camera. Following this we shall collect a small blood sample (47 ml / ~9 
teaspoons) from a vein in your arm to measure changes in blood fats and other 




We shall take 111 ml of blood in total over the course of the study (including the 
screening visit) – this is equivalent to about 22 teaspoons of blood. We shall provide 
you with capsules to consume for two weeks before your first study visit (after the 
initial screening visit), and then you will be provided with more capsules to consume 
every day for the next 6 weeks until your final study visit. 
 
The risk associated with the blood collection is small, but there may be a small amount 
of bruising. The capsules contain pure oils (either olive oil or fish oil), which are 
commonly found in the diet. There is no risk associated with the consumption of these 
capsules. You will be compensated for your time on completion of the study. The study 
has been approved by the Bromley National Research Ethics Committee (Reference No. 
08/H0805/2) and will take place from July 2009 to December 2009. 
 
Thank you for your interest. For further information please contact Sarah or Aseel 
(contact details below). We will provide you with a detailed information sheet and 
answer any question you have regarding the study. 
 
Sarah Cottin    sarah.cottin@kcl.ac.uk          Aseel Al Saleh  aseel.a.alsaleh@kcl.ac.uk 




Appendix 7.2 EDT study questionnaire  
The EPA and DHA Trial  
 
Please complete this questionnaire and return by email to sarah.cottin@kcl.ac.uk or 
aseel.alsaleh@kcl.ac.uk,  
School of Biomedical and Health Sciences, King’s College London, Franklin-Wilkins 
Building Room 4.46A, 150 Stamford Street  
London SE1 9NN 
 
































Have you recently taken part in any other trial? 
 
YES / NO* 
Do you smoke? 
 
YES / NO* 
 
Do you drink alcohol? 
 
If so, how many units per /week? 
1 unit = glass of wine, shot of spirits,  
             1/2 pint of beer 
 
 
YES / NO* 
 
 
……………. Units day / week* 
 
 
Do you suffer from any allergies? 
 
If so please give details: 
 YES / NO* 
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Do you suffer from any medical problems? 
 
If so please describe: 
 
 
YES / NO* 
 
Are you taking any medication? 
 
If so please give details: 
 
 





Do you take any dietary supplements? 
 
 
YES / NO* 
 
 
How frequently do you consume oily fish? 
(explain what oily fish are) 
 
>1 portion per wk/1 portion  
per wk/<1 portion per wk 
 
 
Do you have a history of any of the following? 
 












YES / NO* 
 
YES / NO* 
 
   YES / NO* 
 
 
YES / NO* 
 
YES / NO* 
 
 
Are you receiving medication for any of the following? 
 
Raised blood cholesterol 
 
High blood pressure 
 
Immune system (anti-histamines, anti-inflammatory drugs) 
 
 
Do you have any special dietary requirements? 
 
Lacto-ovo vegetarian/vegan/other (specify) 
 






YES / NO* 
 
YES / NO* 
 





YES / NO* 
 
YES / NO* 
 





Do you suffer from any medical problems? 
 
If so please describe: 
 
 YES / NO* 
Suitability  
 
Suitable                                           Yes       No 
 
If Yes, book screening visit  
 
Date …………………….  Time……………………… 
 
ID code EDT  
 
Investigator Signature …………………………………… Date ……………….. 
 
Relevant information added to database  
 
 





Appendix 7.3 Information sheet for participants  
REC Protocol Number   08/H0805/2 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
The EPA and DHA trial 
We would like to invite you to participate in this original research project.  You should 
only participate if you want to; choosing not to take part will not disadvantage you in 
any way. Before you decide whether you want to take part, it is important for you to 
understand why the research is being done and what your participation will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more 
information.  
What is the purpose of this study? 
The omega-3 fatty acids found in oily fish are of great interest as a higher dietary intake 
of these omega-3 fatty acids has been shown to decrease the risk of fatal coronary heart 
disease (CHD) and stroke. The mechanisms by which omega-3 fatty acids found in oily 
fish may offer protection are yet to be explained, and it is not known whether the 
different types of omega-3 fatty acids differ in their effects in the body or whether they 
act in the same way. The main types of omega-3 fatty acids found in oily fish are 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). This research project is 
a randomised controlled trial that compares capsule intakes of different mixtures of 
omega-3 fatty acids equivalent to 6 portions of oily fish each week on measurements 
that are related to cardiovascular disease risk. Study participants will be aged 18-45 
years.  
Why have I been chosen? 
You have been contacted as you have expressed an interest in our research. In order to 
participate in this study you need to be able to say ‘Yes’ to the following:  
 I am male 
 I am aged between 18 and 45 years 
 I do not smoke 
 I have never had a heart attack, stroke, high blood pressure (>160/90mm Hg), liver 
diseases, diabetes, chronic gastrointestinal disorder or cancer  
 I do not have a history of excess alcohol intake or substance abuse  
 I am prepared to take 5 capsules a day for 8 weeks 
 
What will happen to me if I take part? 
If you would like to participate you would first need to complete a screening 
questionnaire with us over the telephone (approx. 10 mins.), after which potentially 
eligible volunteers will be invited to attend a clinic screening appointment (approx. 45 
mins) in the Metabolic Unit on 4th Floor, Corridor B, Franklin-Wilkins Building, 
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Stamford Street, SE1 9NH. Volunteers will need to attend this visit after an overnight 
fast. 
The study will be explained in detail and you will be able to ask any questions you may 
have to ensure you will be giving fully informed consent. Following the signing of the 
consent form, your height, weight, waist/hip circumference and percentage body fat 
measurements will be recorded, and a fasting blood sample (approx. 16.5mls/ ~3 
teaspoons) will be taken to determine whether liver function, haematology, blood 
glucose and blood lipids are within normal ranges. Seated blood pressure will be 
measured using an automated sphygmomanometer (blood pressure monitor) that 
conforms to the recommendation of British Hypertension Society. Refreshments will be 
provided once all samples and measurements have been made. 
Eligible subjects will be asked to complete an 8-week period taking 5g oil each day in 
capsules (either 10 x 500mg or 5 x 1g) whilst following dietary advice to avoid oily fish 
intake (e.g. salmon, herring, fresh tuna, mackerel, trout, or sardines) as well as fish 
oil/cod liver oil supplements. You can still eat as much white fish (e.g. cod, plaice, 
hake, etc.), tinned tuna and shellfish as you choose. We will give you a detailed list of 
types of fish to avoid. You will be randomly allocated to 1 of 3 groups: 1 group will 
take olive oil capsules, 1 group will take fish oil capsules which contain more EPA than 
DHA, and the other group will take fish oil capsules which contain more DHA than 
EPA. You will have an equal chance of being allocated to any one of these groups.  
During the intervention, you will be asked to attend the Metabolic Unit at the Franklin-
Wilkins Building twice, after 2 weeks and in the end of the intervention. The week 
before each visit, you will be given urine bottles and an ambulatory blood pressure 
monitor to use 2 or 3 days before your next study visit; and we will explain in detail 
how to collect your urine for 24 h and how to use the blood pressure monitor. 
 
At the end of the 2-week period you will attend the Metabolic Unit at the Franklin-
Wilkins Building for your first study visit, bringing with you the collected urine and 
blood pressure monitor which you will have used over 24 h. We will make 
measurements to assess the functioning of the large and small blood vessels in your 
wrist and finger and take a blood sample (approx. 47 ml/ ~9 teaspoons. This visit lasts 2 
to 3 h and will be repeated at the end of the intervention period. See figure 1 for an 
outline of these visits. To standardise everyone before these visits you will be asked to 
avoid strenuous physical activity, foods high in fat, caffeine or alcohol on the day 
before the visit. We will give you a list of foods to avoid and a list of suggested evening 
meals to help you with this. Only water will be allowed for 12 h before the scheduled 
study visit.  
 





Figure 1. Study outline. 
 
Screening visit:  
1) You should avoid eating or drinking anything, except water, for 12 h before your 
scheduled screening visit.  
2) The visit will last approximately 45 min. 
3) We will give you a copy of this information sheet, explain to you all the details 
of the study and answer any questions you have. If you are still happy to take 
part in the study, you will be asked to sign a consent form.  
4) We shall ask you questions about your medical history, your food habits through 
a Food Frequency Questionnaire and measure your weight, height, percentage 
body fat, blood pressure and waist and hip circumference.  
5) We will need to take a small blood sample (16.5 ml /~ 3 teaspoons) to check that 
your blood chemistry is normal.  
6) Then you will be provided with breakfast.  
7) The results of the screening blood test will be given to you. If any abnormal 
results are found we will inform you immediately and we will provide you with 
a letter for your GP, which we will advise you to give to your GP.  
Main study: 
1) Following screening, if your results comply with the study inclusion criteria you 
will be invited to attend the Metabolic Unit in the Franklin-Wilkins Building on 2 
further occasions; each of these visits will take approximately 2-3 h each. 
2) We shall ask you to avoid eating oily fish and consuming fish oil supplements for 
2 weeks prior to the start of the study and during the study. We will provide you 
with study capsules containing a test oil and ask you to consume 5 of these 
capsules per day. We will also ask you to avoid fatty foods, drinking alcohol, and 
any strenuous exercise the day prior to each visit to the Department of Nutrition 
& Dietetics.  
3) We shall also ask you not to consume caffeine from midday the day before each 
visit and to avoid eating or drinking anything, except water, for 12 h before your 
scheduled study visit.  







2 weeks 6 weeks 
Total duration: 8 weeks 
Questionnaire 
through the 
phone (10 min) 
2-3 days prior to each visit: 24h urine 
collection and blood pressure recording 
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4) 2 to 3 days prior to each of the 2 remaining visits, you will be asked to collect 
urine samples and to record your blood pressure (using the ambulatory blood 
pressure monitor) for 24 h. 
5) You will be asked to report to the Metabolic Unit in the Department of Nutrition 
& Dietetics between 08:00 h and 11:00 h, in the fasted state (i.e. without having 
consumed breakfast and without having consumed any food or drink for 12 h, 
apart from water).  Make sure you drink some water on the morning of the study 
to avoid dehydration. 
6) At each of the 2 visits (at 2 wk and 8 wk), we will then measure your blood 
pressure and the function of your large and small blood vessels. We shall make 
measurements of blood pressure using a sphygmomanometer, in which a cuff 
will be placed around your arm and will be inflated. The cuff causes a tingling 
sensation in your arm, but does not cause pain. The measurements we make to 
assess the function of your larger blood vessels are carried out using probes that 
are gently placed on your wrist and finger to determine the elasticity or tone of 
your arteries. The measurement of small blood vessel function involves you 
placing the top of your finger under a camera which can image individual 
capillaries (the smallest type of blood vessel) to monitor the capillary blood flow 
before and after inflation of a cuff placed around your forearm. All of these 
measurements are non-invasive and will not cause any discomfort. In the end of 
the visit, we will take a small sample of blood: 47 ml /~9 teaspoons.  
 
7) Finally, following these measurements you will be offered refreshments.  
After the second visit (at 2 wk), you will be provided with more oil capsules for the 
remainder of the study and you will continue to take 5 capsules per day for 6 weeks. 
You will be advised to avoid oily fish and to abstain from taking fish oil supplements or 
cod liver oil for the duration of the study (8 weeks in total). 
Will my participation be kept confidential? 
Any information collected about you during this research will be kept strictly 
confidential. Your GP will not be told that you are taking part in the study, unless you 
request us to do so. Subject confidentiality and anonymity will be observed throughout 
the study by use of subject codes in place of names, and the storage of subject details in 
a secure place. Only the investigators have access to this data. Should you wish to find 
out the results of this study you are welcome to contact Dr Wendy Hall (details below) 
for a copy of the final report once the study is finished. 
What will happen to my study results? 
We hope to publish the results of the whole study in a scientific journal. You will not be 
identified in any publication. We will be happy to discuss the overall results with you 
when the study is completed, and will let you know how you can get a copy of the 





Who is organising and funding the study? 
The study is organised and funded by the Nutritional Sciences Division, Kings College 
London. In recognition of your time commitment, you will be paid an honorarium of 
£50 upon completion of the study.  
Do I have to take part? 
It is up to you to decide whether to take part or not. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. You 
can withdraw from the study at any time by informing one of the researchers and you 
are not obliged to give a reason. A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
If you decide to take part, please let us know if you have been involved in any other 
study in the last year. 
If this study has harmed you in any way you can contact King's College London using 
the details below for further advice and information:  
Thank you for your interest. 
 
For further information, please contact: 
Sarah Cottin,   email: sarah.cottin@kcl.ac.uk  
or Aseel Al Saleh, email:  aseel.a.alsaleh@kcl.ac.uk  
 
Nutritional Sciences Division, King’s College London, Franklin Wilkins Building, 150 
Stamford Street, London, SE1 9NH        
Chief Investigator: Dr Wendy Hall Tel. 020 7848 4197 wendy.hall@kcl.ac.uk 
Co-investigators: Prof Tom Sanders Tel. 020 7848 4273 tom.sanders@kcl.ac.uk; Dr 




Appendix 7.4 EDT booklet  
The EPA and DHA trial 
A high intake of fish oils, as observed in the Inuit population, is associated to a reduced 
risk of heart diseases and insulin resistance. Fish oils are composed of two types of 
omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 
The beneficial effects of fish oils have been well established and omega 3 supplements 
have flourished on the market over the past decade. However, it remains unclear if EPA, 
DHA or a combination of both are required to improve insulin sensitivity and 
cardiovascular health.  
 
  
    
 
This study aims at comparing the effect of EPA and DHA on different biological 
processes involved in the development of cardiovascular diseases, including 
inflammation, thrombosis and endothelial function. 
STUDY OUTLINE 
The nutritional intervention (outlined below) lasts 8 weeks during which you will be 
asked to take 5g of oil per day in the form of capsules containing one type of fat (either 
EPA, DHA or olive oil as a placebo). You will be required to attend the Metabolic Unit 
at the Franklin-Wilkins Building, Waterloo Campus, of King’s College London on 3 
different occasions: one before (screening) and 2 during the intervention. 
 
THE DAY BEFORE THE VISITS 







2 weeks 6 weeks 
Total duration: 8 weeks 
Questionnaire 
through the 
phone (10 min) 
2-3 days prior to each visit: 24h urine 
collection and blood pressure recording 
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Prior to each of the 3 visits (screening or intervention) you should avoid having caffeine 
from midday, and also avoid doing exercise and drinking alcohol for 24h. You will be 
asked to have a low fat meal in the evening (instructions will be given) fast overnight 
(no food or drink, except water, from 10pm, and no breakfast on the study day). You 
will then attend the Metabolic Unit at a pre-arranged time between 8.30 and 10.30 am. It 
is important that you drink water before attending.  
FIRST VISIT: SCREENING (45 min) 
The purpose of this screening session is to determine whether you are suitable to 
participate in our study. This involves measurement of your height, weight, waist 
circumference, body fat and blood pressure. It also involves the collection of a blood 
sample to determine your blood fats and glucose levels. We will give you more 
information and answer any question you might have regarding the study. Breakfast will 
be provided In the end of the screening session. 
2 VISITS DURING THE INTERVENTION (2-3H) 
You will be required to attend the Metabolic Unit at the Franklin-Wilkins Building, 
Waterloo Campus, of King’s College London after 2 weeks and in the end of the 
intervention (8 weeks). 
2 or 3 days prior to each visit, you will be asked to collect your urine and to record your 
blood pressure for 24h: A cuff will be put on your left arm and inflate every half an 
hour during the day and every hour at night. 
Each visit will consist in non-invasive vascular measurement (sensors will be placed on 
your finger and your wrist) and blood taking. Lunch will be provided in the end of each 
visit. 
FISH OILS RESTRICTION 
We shall ask you to avoid eating oily fish, such as salmon, trout or mackerel, and 
consuming fish oil supplements for the 8 week intervention period. However, you will 
still be allowed to eat non oily fish such as cod, haddock or sea bass. A more detailed 
list of fishes allowed/to avoid will be provided. 
STUDY DATES 
Please choose the date you will start the intervention, taking into account your availability for 
the 2 following visits. 
 Date Time 
Day starting taking capsules (time 0)  - 
2 week point   





WHAT YOU WILL GET BY TAKING PART 
 Information on your blood fats and glucose levels 
 A full biochemical screening 
 Information on your body composition, physical measurements, vascular health and 
blood pressure 
 £50 for your time 
By participating in our study you will provide us with valuable information.  Your commitment 





Aseel Alsaleh aseel.alsaleh@kcl.ac.uk, 
Sarah Cottin sarah.cottin@kcl.ac.uk, 
020 7848 4594 
Department of Nutrition and Dietetics, King’s College London, 
Franklin-Wilkins Building, 150 Stamford Street, London. SE1 9NH 
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Appendix 7.5 List of oily fishes to avoid during the 8 weeks of intervention  
Restriction in oily fish consumption 
You are required to avoid any source of fish oils, including supplements and oily fishes 
(left of the table below) during the 8 week intervention period 

















Jack fish  
Katla  










































Appendix 7.6 EDT consent form  
CONSENT FORM FOR PARTICIPANTS IN A NUTRITIONAL STUDY 
Please complete this form after you have read the Information Sheet 
and you are satisfied that the research has been fully explained. 
Title of Study: The EPA and DHA Trial 
Research Ethics Committee Ref: 08/H0805/2 
Thank you for considering taking part in this research. The person organizing the research must 
explain the project to you before you agree to take part. 
If you have any questions arising from the Information Sheet or explanation already given to 
you, please ask the researcher before you decide whether to participate. You will be given a 
copy of this Consent Form to keep and refer to at any time. 
 I confirm that I fit into the following criteria 
 
 I understand that if I decide at any other time during the research that I no longer wish 
to participate in this project, I can notify the researchers involved and be withdrawn 
from it immediately. 
 I consent to the processing of my personal information for the purposes of this research 
study. I understand that such information will be treated as strictly confidential and 
handled in accordance with the provisions of the Data Protection Act 1998. 
 I agree that the research team may use my data for future research and understand that 
any such use of identifiable data would be reviewed and approved by a research ethics 
committee. Please note that in such cases, as with this project, confidentiality and 





agree that the research project named above has been explained to me to my satisfaction and I 
agree to take part in the study. I have read both the notes written above and the Information 
Sheet about the project, and understand what the research study involves. 






 I am a male aged between 18 and 45 years and do not smoke 
 I do not have a history of heart disease, stroke, high blood pressure, diabetes, 
thrombosis, liver disease, chronic gastrointestinal disorders or a cancer diagnosis 
(except basal cell carcinoma)  






confirm that I have carefully explained the nature, demands and any foreseeable risks (where 
applicable) of the proposed research to the volunteer. 




Appendix 7.7 KCL standard venepuncture procedure 
Before taking a sample, ensure the volunteer understands the procedure and is in a comfortable 
position. Be aware if the volunteer has ever felt faint when giving blood on previous occasions. 
Only appropriately trained personnel may perform venepuncture. Prior to starting the procedure, 
ensure that adequate hand washing takes place. Place the tourniquet around the arm, and then 
clean the selected site with an antiseptic swab to decontaminate the skin.  
The vacutainer method (Beckton-Dickinson) is used when smaller blood volumes are required, 
as it reduces the risk of spillages. Screw the needle into the disposable vacutainer holder, 
unsheathe the needle and then insert the needle into the brachial vein with minimal pressure. 
Attach the vacutainer, and release the tourniquet once blood begins to flow into the vacutainer. 
This will facilitate a natural flow as the blood sampling progresses. Extra care should be taken 
when using a needle and syringe to avoid spillages when decanting into the blood tubes.  
Serum samples should be collected first, followed by citrate samples (for haemostatic factors) 
followed by remaining samples with anticoagulants. A minimal use of the tourniquet (released 
during filling off the first vacutainer) is crucial to avoid platelet activation. Therefore, the last 
sample to be collected should be the citrate 4.5 ml, as it will be used for platelet-monocyte 
aggregation technique. After removing the needle, the volunteer should be asked to apply 
pressure to the site with a cotton wool ball, until such time that the bleeding stops. Before 
applying a plaster to the site, check that the volunteer is not allergic to them.  
Needles must never be re-sheathed and after use they should immediately be discarded into a 
sharps bin.  
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SAMPLE TUBES ICE/ 
RT 
CENTRIFUGE SEPARATION ANALYTES Labels ANALYSIS STORAGE/ 
TRANSPORT 
ul / vial vials 




ICE 15m X 1300g @ 
4OC 
3 1 Glucose Glc KCL– 
ILAB 
-40 o C 
3 1 Spare Sp   -40 o C 
1 8.5 8.5 ml 
serum  
RT 15m X 1300g @ 
4OC 
200 1 Adiponectin Adpn KCH -80 o C 
200 1 CRP CRP KCH -40 o C 
200 1 Resistin Res KCH -40 o C 
200 1 spare Sp1   -40 o C 
            
2 8.5 8.5 ml 
serum  
RT 15m X 1300g @ 
4OC 
200 1 sdLDL sdLDL   -80 o C 
200 1 TAG, NEFA, 
cholesterol, HDL 
FLIP KCL - 
ILAB 
-80 o C 
200 1 MMP-9 MMP9   -80 o C 
500 1 NOx  NOx  KCL -80 o C 
200 2 Infl markers (IL-6, 
IL-1...) 
IF   -80 o C 
200 2 Spare Serum 
Sp2,3 
  -80 o C 
200 1 Apolipoprotein B100 ApoB100 KCH -80 o C 
200 1 Apolipoprotein A1 ApoA1   -80 o C 
            





SAMPLE TUBES ICE/ 
RT 




4OC 300 1 Spare Sp   -40 o C 
8 4.5 4.5 ml 
EDTA  
ICE 15m X 1300g @ 
4OC 
500 1 PFA PFA KCL - GLC -40 o C 
600 1 prostacyclin PGI2 KCL -80 o C 
200 2 spare EDTA 
Sp1,2 
  -80 o C 
            




~1000   EPC EPC KCL Fresh WB 
15m X 1300g @ 
4OC 
pellet   Erythrocyte lipids + 
spare 
Er Lip1,2   Fresh cells/ -
80 
500 1 spare EDTA 
Sp3 
  -80 o C 
            
5,6,9 13.5 3 *4.5 ml 
Citrate 
(blue) 
ICE 15m X 1300g @ 
21OC 
2000 1 isoprostane IsoPs KCL -80 o C 
2000 1 Spare CitSp1   -80 o C 
RT Before 
centrifugation 
~500   PMA PMA KCL Fresh WB 
15m X 1300g @ 
21OC 
500 2 spare CitSp2,3   -80 o C 






Appendix 7.9 Instructions for taking a 24-hour urine collection 
2 days prior to each intervention please collect all urine passed during a period of 24 hours. We 
will provide you with some plastic containers and plastic bags to keep the containers in. After 
you have made the 24-hour collection, keep it in a cool place until your appointment. 
Please follow these instructions: 
On the first morning when you awake, empty your bladder into the toilet. Please make a note on 
the collection container of the date and time you did this.  After this, collect and store in the 
container all urine you pass during the day and the following night. 
When you feel the need to have a bowel movement, first try to pass urine into the container (that 
is, try not to pass urine directly into the toilet with a bowel motion). 
The following morning when you awake, at the same time as on the previous day (that is 24 
hours after you started) complete the collection by emptying your bladder into the container. 
Make a note of the time you complete the collection, if this is not exactly 24 hours later don’t 
worry. 
Keep the top of the collection container closed, and keep the container in the plastic bag 
provided in the fridge. If you pass urine but forget to collect it, please tell us when you hand 
your collection in, and if possible try to estimate how much was lost. You can do this by noting 
how much you collect in the jug on the next occasion. Some people find it useful to pin their 
pants to their outer clothes with a safety pin as a reminder to make a collection each time they 
go to the toilet.  
Please ask us if you have any queries and let us know if you have any difficulties in making the 
collection. 
Note: Please empty your bladder in the morning before you make the first collection and please 
ensure you collect urine when you empty your bladder the following morning.  
 
Contact Sarah Cottin, Email: sarah.cottin@kcl.ac.uk or Aseel Al-Saleh, Email: 
aseel.alsaleh@kcl.ac.uk, 




Appendix 7.10 24 hour Blood Pressure Monitoring - Subject Information Sheet 
The aim of this test is to monitor what is happening to your blood pressure over a 24 hour 
period. Please make your measurement 2 or 3 days before your visit to FWB. Please try to make 
the measurement over 25h, as the first hour when you are getting used to wearing the monitor 
does not always give us a representative reading. You will be asked to do your measurement at 
approximately the same time before each visit. 
We will provide you with a diary card to fill in on the day of measurements, please fill in your 
activity level at the time of measurement, the time you go to bed, the time you get up and any 
unusual circumstances. 
Procedure 
Night and day; the blood pressure cuff has two settings; a day time setting and a night time 
setting. The monitor will automatically change to night time settings at 10pm and day time 
settings at 7am.Frequency of cuff inflation; During the day time the cuff will inflate every 30 
minutes, during the night time the cuff will inflate every 1 hr.  
During a measurement 
To avoid incorrect results the arm must be kept still during measurements. 
If you are standing; let your arm hang loosely, whilst keeping it still. 
If you are sitting; rest your arm loosely on a table or let your arm hang loosely, whilst keeping it 
still. 
Avoid opening and closing your hand during the measurement, and do not move your fingers. 
Ensure the air tube is not kinked while the measurement is being taken. 
If you are driving when a measurement starts, continue to drive normally and do not worry 
about keeping the arm still (please make a note on the diary card if this happens), or turn the 
monitor off whilst you are driving. 
While you are asleep, place the recorder on its side so that the air tube will not kink. 
In the event of failed measurements the monitor will repeat the measurement. 
 
Between measurements:  
Engage in normal activities. 
Check that the yellow mark is still in position as the cuff may move during the day. 
Using the blood pressure monitor 
How to put the cuff on upper arm 
Put the cuff on the upper left arm so that the position of the yellow marking of the cuff is on the 
artery; the opposite side to your elbow. The cuff should be wrapped on the arm tightly, but still 
allow a finger to slide between the cuff and the arm. 
How to turn the monitor on and off 
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To start the 24-hr measurement press and hold the black ‘AUTO ON/OFF’ button until it bleeps 
and the letter ‘A’ appears on the display.  
To turn the monitor off or pause it when you take the cuff off (during bathing or exercise) press 
and hold down the ‘AUTO ON/OFF’ button until the letter ‘A’ is no longer on the display. 
When you want to restart it press and hold the black ‘AUTO ON/OFF’ button until it bleeps and 
the letter ‘A’ appears on the display.  
To deflate the cuff or terminate a recording press the red START/STOP button.  
If the letter ‘E’ appears on the display at any time this means that there is an error and you will 
need to contact Aseel or Sarah. If the letter ‘B’ appears on the display at any time this means 
that the batteries need replacing. 
If water gets into the unit, please remove the cuff and do not continue using the recorder. Turn 
off the unit and remove the batteries. 
If the letter ‘E’ appears on the display at any time this means that there is an error and you will 
need to contact Aseel or Sarah. If the letter ‘B’ appears on the display at any time this means 
that the batteries need replacing. 
 
If water gets into the unit, please remove the cuff and do not continue using the recorder. Turn 
off the unit and remove the batteries. 






A - This is displayed when the unit is in automatic measurement mode 
B – This is displayed when battery capacity is low 




In case of any problems please call Aseel or Sarah on 020 7848 4594 or in  
For emergency 07789002228 or 07964919960. 
IF YOU EXPERIENCE ANY PAIN OR AN EXTREMELY UNPLEASANT SENSATION DURING 
MEASUREMENTS PLEASE TURN OFF THE UNIT IMMEDIATELY, USING THE ON/OFF KEY 
AND REMOVE THE CUFF. 
A S 
B 
Red START/STOP button - can be used during a 
measurement to terminate a measurement and deflate 
the cuff 
Black AUTO ON/OFF button – this will switch the 
monitor on to automatic mode (press for 3 seconds, 
until the letter ‘A’ appears on the display) or to 
cancel automatic mode (press again for 3 seconds, 




Name:      Date:   
Please fill in your activity level at the time of measurement, the time you go to bed, the time 
you get up and any unusual circumstances. 
 
Time you go to sleep…………  Time you wake up…………..... 
 
Did you take any exercise Y / N  If Yes at what time…………....  
Time Activity level (please circle) Other 
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
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 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
Time Activity level Other 
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
 Lying down  Sitting Walking  
 Lying down Sitting Walking  
 Lying down Sitting Walking  
Notes: 
 
Brief Instructions: Refer to the 24 hour Blood Pressure Monitoring - Subject Information 
Sheet for full instructions.  During the day time (7am – 10pm), the cuff will inflate every 30 
minutes and during the night time (10pm-7am) every 1 hr. Between measurements engage in 
normal activities, also check that the yellow mark is still in position as the cuff may move 
during the day. The arm must be kept still during measurements. To start the 24-hr measurement 
press and hold the black ‘AUTO ON/OFF’ button until it bleeps and the letter ‘A’ appears on 
the display. To turn the monitor off or pause it whilst bathing etc. press and hold down the 
‘AUTO ON/OFF’ button until the letter ‘A’ is no longer on the display. To deflate the cuff or 
terminate a recording press the red START/STOP button.  
In case of any problems please call Aseel or Sarah on 020 7848 4594. 
  IF YOU EXPERIENCE ANY PAIN OR AN EXTREMELY UNPLEASANT 
SENSATION DURING MEASUREMENTS PLEASE TURN OFF THE UNIT 
IMMEDIATELY, USING THE ON/OFF KEY AND REMOVE THE CUFF. 
271 
 
Appendix 7.11 Reminder e-mail  
Dear …., 
 
This is a reminder that your screening appointment for the following study is at …am 
tomorrow morning. 
 
You will need to arrive at the metabolic unit on the 4
th
 floor of Franklin-Wilkins 
building at the time stated above. There will be arrow signs on the 4
th
 floor to guide you. 
Please use the phone at the end of corridor A to ring the unit on extension 4304 and 
4612 when you arrive, and we will come and get you. 
 
Please remember to arrive fasted, having not consumed any food or drink, except water, 
from 10pm tonight. We strongly advice that you drink water before you arrive to avoid 
dehydration. 
 
Thank you again for participating in the study, we will look forward to seeing you 
tomorrow.  





Appendix 7.12 Participant record sheet  
PARTICIPANT CODE  
PARTICIPANT NAME  
D.O.B.  
DATE  TIME  






                                                                                              YES / NO 
CHECK Low fat meal last night (< 10 g fat)                                        YES / NO 
Fasted since 10 pm last night                                                YES / NO 
No caffeine since midday yesterday                                      YES / NO 
No alcohol all day yesterday                                                  YES / NO 
No exercise all day yesterday and today                               YES / NO 
No medications taken since the beginning of the study        YES / NO 
No supplements taken since the beginning of the study       YES / NO 
Compliance to oily fish consumption restriction                    YES / NO 
Compliance to capsules intake 5/d                                       YES / NO 
Advise to sip water 
Blood taken 
47ml 
                                                                                              YES / NO 
Order of draw: 
1. 8.5 ml serum (Adpn...) 
2. 8.5 ml serum (sdLDL, Nox, IF...) 
3. 4 ml LH 
4. 4 ml LX 
5. 4.5 ml Citrate (IsoP) 
6. 4.5 ml Citrate (IsoP) 
7. 4.5 ml EDTA (EPC) – RELEASE TOURNIQUET 
8. 4.5 ml EDTA (PGI2) 
9. 4.5 ml Citrate (PMA) 
Urine sample collected                                                                                              YES / NO 
24h Blood pressure and 
diary card 
Collected:                                                                          YES / NO 
Data transferred:                                                               YES / NO 
Start:     … : …                                                           Finish:   … : …    
Sleep:   … : …   to   … : …    
Seated blood pressure 
(mmHg) 
 
To be taken at 2-5 minute 
intervals 
Reading 1:      (S) Pulse: 
                        (D) 
Reading 2:      (S) Pulse: 
                        (D) 
Reading 3:      (S) Pulse: 
                        (D) 
Average of reading 2 & 3:     (S)        Pulse: 






DVP 1 2 3 Average 
HR (bpm)     
SI (m/s)     
RI (%)     
PPT (ms)     
 
PWA 1 2 3 Average 
SBP(mmHg)     
DBP(mmHg)     
MAP     
HR(bpm)     
CSp(mmHg)     
CDp(mmHg)     
Peripheral AIx %     
Central AIx %     
P1 (mmHg)     
T1 (ms)     
 
CAM1 
ALL PICTURES AND VIDEOS HAVE TO BE RECORDED, CALCULATIONS MAY BE 
DONE LATER IN THE DAY 
1. Pictures 1, 2, 3 
Save as: yymmdd_CodeSubject_pic1 to 5 (ex: 090810_EDT01DLV1_pic1) 
 Pic1 Pic2 Pic3 Pic4 Pic5 Average 
CD (%)       
 
2. Videos 1, 2, 3 (far from the nail fold) ~10s: 
Save as: yymmdd_CodeSubject_video1 to 3 (ex: 090810_EDT01DLV1_video1) 
 Video 1 Video 2 Video 3 Average 
FCD (%)     
FCF     
 
3. Doppler 
Save as: yymmdd_CodeSubject_doppler1 to 6 (ex: 090810_EDT01DLV1_doppler1) 
 Doppler 1 Doppler 2 Doppler 3 Average 
RBCV rest – far 
(um/s) 
    
RBCV rest – 
close (um/s) 





4. Videos 4, 5, 6A (next to the nail fold) ~10s: 
Save as: yymmdd_CodeSubject_video4, 5, and 6A (ex: 090810_EDT01DLV1_video6A) 





















    
FCD (%)     
FCF (mm/s)     
1. RBCV (mm/s)     
2. RBCV (mm/s)     
3. RBCV (mm/s)     
 
5. Video 6B (post occlusion) ~20s 
SAMEA AREA AND CAPILLARIES AS VIDEO 6A 
Save as: yymmdd_CodeSubject_video6B (ex: 090810_EDT01DLV1_video6B) 
 Video 6A 
FCD (%)  
FCF (mm/s)  
     1.   RBCV (mm/s)  
     2.   RBCV (mm/s)  
     3.   RBCV (mm/s)  
 





Appendix 7.13 Step by step for taking a DVP and PWA measurements: 
Select or enter a new patient: 
For subjects on their first visits, touch the “patient” icon to enter the patient database 
then touch “Add” to enter the new subject’s details. 
For subjects on their second visit, search for this subject by adding the ID or name. 
Once selected, the patient’s name will appear at the bottom of the screen. 
Take a DVP measurement: 
From the main menu, select the protocol, by touching the icon and click OK to start the 
test. The spot check test screen will be displayed. The signal displayed might be small at 
first but they will gradually increase. The unit will automatically perform three tests and 
display the averaged results. If the tests are outside of 20 per cent of their average, you 
will be asked either to repeat a particular test, or to repeat the protocol if the all the tests 
were very variable. Select “Accept” or “Reject” and save the data.  
Step by step for taking a PWA measurement: 
1-Select or enter a new patient: 
For subjects on their first visits, open the subject screen by clicking on the “patient” 
button. This screen will allow you to create a new subject entry by clicking the “Create 
New” button and enter the subject’s details.  
For subjects on their second visit, select an existing subject from the database by 
scrolling down the list of subjects and click on the row to select the subject. When the 
subject is selected the subject name is highlighted.  
Take a PWA measurement: 
- While still in the “patient screen” open the study screen by clicking on “study” 
button. The screen will allow you enter the study details and to proceed to 
“Capture data” 
- Click the “radial” check box 
- Enter the diastolic and systolic blood pressure values that have been obtained 
from the cuff automated sphygmomanometer 
- Click on the “Capture Data” button  
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- The tonometer should be placed perpendicular to the wrist and adjustments to 
the position should be made until a strong, accurate and reproducible waveform 
is displayed in the “Signal detail” window.  
- When you are satisfied that you have a good reading, press the “Space Bar” on 
the key board. 
You must have a minimum of 12 seconds of signal for the data to be captured. The last 
2 seconds of waveforms will be deleted, allowing sufficient time to remove the 
tonometer for the wrist to activate the capture of data.   
Examine the report for quality control: 
After you have completed the data capture, the “report screen” will be automatically 
displayed. Two types of “Report Screen” are available, Clinical and detailed Screen, 
and each may be selected by clicking on the “clinical” or “detailed” tab. It is important 
to check the quality control to ensure that your measurement has been recorded with 
sufficient quality. The quality control indices are provided on the “detailed” report 
screen”. When the figures appear in green they are within the limits set using the 
configuration setting. When they appear in red they are outside theses limits. The 
measurement will be accepted if they are 2 red figures or less on the detailed screen.   
For DVP, the indices recorded were heart rate (HR), reflective index (RI), stiffness 
index (SI) and peak-to-peak time (PPT). For PWA, the indices recorded were peripheral 
systolic (SBP), diastolic (DBP) and mean (MBP) blood pressure, heart rate, peripheral 
augmentation index (PAIx), central systolic (CSp) and diastolic blood pressure (CDp), 
central augmentation index (CAIx), Pressure at T1 (P1) and time to first peak (T1). The 






Appendix 7.14 Erythrocyte lipids 
Erythrocyte lipids were measured in order to determine the omega-3 index as a sensitive 
marker of CV risk, as well as compliance, in addition to the capsules count. Blood was 
collected in 4.5 ml EDTA tubes and centrifuged at 1300 g, 4ºC for 15 min .The pellet 
(erythrocytes) was kept in the fridge 3 to 5 days before being treated according to the 
following protocol:. 
Lipid extraction 
Erythrocytes lipids: The buffy coat was removed, and the erythrocytes washed three 
times with 5 volumes of cold saline (0.89%)  for 10 min at 900 g, 4ºC. 0.5 ml 
erythrocytes were pipetted into large 25 ml glass-stoppered centrifuge tubes and 0.5 ml 
distilled water added. The contents were vortex-mixed to haemolyse the erythrocytes. 
5.5 ml chilled isopropanol were then added slowly, and the tube was vortexed 
thoroughly again. After 15 min storage at 4ºC, 3.5 ml chilled chloroform were added 
and the contents mixed thoroughly. At the end of another 30 min at 4ºC, the samples 
were centrifuged at 1500 g for 15 min at 4ºC. The supernatant was collected and stored 
in glass tubes at -40ºC until GC analysis. 
Methyl ester preparation 
Lipid extracts were treated in 3 batches; lipid extracts from the same subjects were 
treated at the same time. 
Approximately 1 ml of each thawed lipid extract was transferred to a labelled GC vial 
and evaporated in an Eppendorff concentrator at 45 ºC for ~1 h. Each extract was then 
re-dissolved in 100 µl hexane, and 50 µl NaOCH3 added to neutralise acidity. The 
content was thoroughly mixed and 1 ml hexane was added. CaCl2 was then added in 
order to absorb any remaining water and the vials were covered and allowed to stand 1 h 
at RT. Samples were transferred to new GC vials, and evaporated for 20 min at RT. The 
final extracts were re-dissolved in 50 µl hexane and transferred to inserts in GC 
microvials for GC analysis. 
GC conditions 
Fatty acid methyl esters were separated on an Agilent 6890 Gas Chromatograph 
(Agilent Technologies) fitted with a flame ionization detector with a 25 m BP75 
capillary column. The injection volume was 2 μL, the temperature was 160ºC for 4 min 
and then rose to 200ºC in 10 min (gradient of 12ºC/min).  
 
